US20070179114A1 - Novel 2'-C methyl nucleoside derivatives - Google Patents
Novel 2'-C methyl nucleoside derivatives Download PDFInfo
- Publication number
- US20070179114A1 US20070179114A1 US11/593,381 US59338106A US2007179114A1 US 20070179114 A1 US20070179114 A1 US 20070179114A1 US 59338106 A US59338106 A US 59338106A US 2007179114 A1 US2007179114 A1 US 2007179114A1
- Authority
- US
- United States
- Prior art keywords
- group
- alkyl
- compound
- phenyl
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 methyl nucleoside derivatives Chemical class 0.000 title claims description 159
- 150000001875 compounds Chemical class 0.000 claims abstract description 207
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 229910052721 tungsten Inorganic materials 0.000 claims description 138
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 97
- 125000003118 aryl group Chemical group 0.000 claims description 93
- 125000005842 heteroatom Chemical group 0.000 claims description 89
- 229910052739 hydrogen Inorganic materials 0.000 claims description 84
- 125000004122 cyclic group Chemical group 0.000 claims description 82
- 239000001257 hydrogen Substances 0.000 claims description 81
- 125000001424 substituent group Chemical group 0.000 claims description 72
- 125000000217 alkyl group Chemical group 0.000 claims description 70
- 125000004429 atom Chemical group 0.000 claims description 70
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 60
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 54
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 49
- 229910052760 oxygen Inorganic materials 0.000 claims description 48
- 125000001246 bromo group Chemical group Br* 0.000 claims description 47
- 229910052717 sulfur Inorganic materials 0.000 claims description 47
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 46
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 45
- 125000002252 acyl group Chemical group 0.000 claims description 41
- 229910052698 phosphorus Inorganic materials 0.000 claims description 38
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 35
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 35
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 35
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 35
- 229910052757 nitrogen Inorganic materials 0.000 claims description 35
- 229910052736 halogen Inorganic materials 0.000 claims description 32
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 29
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims description 28
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 26
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- 239000011574 phosphorus Substances 0.000 claims description 26
- 150000002148 esters Chemical class 0.000 claims description 24
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 22
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 20
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 20
- 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 claims description 19
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 19
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 229910052720 vanadium Inorganic materials 0.000 claims description 17
- 125000004076 pyridyl group Chemical group 0.000 claims description 16
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 15
- 125000002541 furyl group Chemical group 0.000 claims description 14
- 125000001544 thienyl group Chemical group 0.000 claims description 14
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- 125000003342 alkenyl group Chemical group 0.000 claims description 10
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 9
- 150000008575 L-amino acids Chemical class 0.000 claims description 8
- 229910052727 yttrium Inorganic materials 0.000 claims description 8
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 7
- 150000005676 cyclic carbonates Chemical class 0.000 claims description 7
- 150000002431 hydrogen Chemical group 0.000 claims description 7
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 6
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 6
- 125000002877 alkyl aryl group Chemical group 0.000 claims description 6
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims description 6
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 125000005704 oxymethylene group Chemical group [H]C([H])([*:2])O[*:1] 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 239000011593 sulfur Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 2
- 229910052711 selenium Inorganic materials 0.000 claims description 2
- 239000011669 selenium Substances 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 239000000651 prodrug Substances 0.000 abstract description 150
- 229940002612 prodrug Drugs 0.000 abstract description 150
- 238000002360 preparation method Methods 0.000 abstract description 40
- 230000009385 viral infection Effects 0.000 abstract description 25
- 208000036142 Viral infection Diseases 0.000 abstract description 22
- 238000011282 treatment Methods 0.000 abstract description 15
- 208000005176 Hepatitis C Diseases 0.000 abstract description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 339
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 233
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 224
- 230000015572 biosynthetic process Effects 0.000 description 154
- 238000003786 synthesis reaction Methods 0.000 description 139
- 239000000243 solution Substances 0.000 description 121
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 111
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 105
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 99
- 238000006243 chemical reaction Methods 0.000 description 97
- 239000000203 mixture Substances 0.000 description 93
- 235000019439 ethyl acetate Nutrition 0.000 description 87
- 239000002777 nucleoside Substances 0.000 description 83
- 238000000034 method Methods 0.000 description 80
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 60
- 238000007792 addition Methods 0.000 description 59
- 229910019142 PO4 Inorganic materials 0.000 description 55
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 52
- 239000010452 phosphate Substances 0.000 description 51
- 229940093499 ethyl acetate Drugs 0.000 description 47
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 44
- 150000003833 nucleoside derivatives Chemical class 0.000 description 44
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 39
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 39
- 238000005160 1H NMR spectroscopy Methods 0.000 description 38
- 239000003814 drug Substances 0.000 description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 35
- 229940086542 triethylamine Drugs 0.000 description 33
- 125000002947 alkylene group Chemical group 0.000 description 32
- 239000003795 chemical substances by application Substances 0.000 description 32
- 125000003835 nucleoside group Chemical group 0.000 description 32
- 230000002829 reductive effect Effects 0.000 description 32
- 239000007787 solid Substances 0.000 description 32
- 229940079593 drug Drugs 0.000 description 31
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 30
- 239000011541 reaction mixture Substances 0.000 description 30
- 238000006317 isomerization reaction Methods 0.000 description 26
- 210000004185 liver Anatomy 0.000 description 26
- 238000006366 phosphorylation reaction Methods 0.000 description 26
- 235000021317 phosphate Nutrition 0.000 description 25
- 230000026731 phosphorylation Effects 0.000 description 24
- 230000004913 activation Effects 0.000 description 23
- 238000003756 stirring Methods 0.000 description 22
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 21
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 21
- 150000002009 diols Chemical class 0.000 description 21
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- 238000004128 high performance liquid chromatography Methods 0.000 description 20
- 239000000543 intermediate Substances 0.000 description 20
- 239000003921 oil Substances 0.000 description 20
- 239000012071 phase Substances 0.000 description 20
- 239000002243 precursor Substances 0.000 description 20
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 19
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 19
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 19
- 235000019198 oils Nutrition 0.000 description 19
- 210000001853 liver microsome Anatomy 0.000 description 18
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 18
- 238000009472 formulation Methods 0.000 description 17
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 16
- 239000004480 active ingredient Substances 0.000 description 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 150000000185 1,3-diols Chemical class 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 15
- 230000000865 phosphorylative effect Effects 0.000 description 15
- 230000009467 reduction Effects 0.000 description 15
- 238000006722 reduction reaction Methods 0.000 description 15
- 239000000725 suspension Substances 0.000 description 15
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 14
- 238000001816 cooling Methods 0.000 description 14
- 239000000284 extract Substances 0.000 description 13
- 239000002904 solvent Substances 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 241000700159 Rattus Species 0.000 description 12
- 238000004440 column chromatography Methods 0.000 description 12
- 230000008878 coupling Effects 0.000 description 12
- 238000010168 coupling process Methods 0.000 description 12
- 238000005859 coupling reaction Methods 0.000 description 12
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 12
- 239000010410 layer Substances 0.000 description 12
- 230000014759 maintenance of location Effects 0.000 description 12
- 125000006413 ring segment Chemical group 0.000 description 12
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000002253 acid Substances 0.000 description 10
- ITVPBBDAZKBMRP-UHFFFAOYSA-N chloro-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound OP(O)(Cl)=O ITVPBBDAZKBMRP-UHFFFAOYSA-N 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 238000011067 equilibration Methods 0.000 description 10
- 125000005843 halogen group Chemical group 0.000 description 10
- 210000003494 hepatocyte Anatomy 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 238000006467 substitution reaction Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 9
- 239000008346 aqueous phase Substances 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000012043 crude product Substances 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 9
- 125000006239 protecting group Chemical group 0.000 description 9
- 229960000329 ribavirin Drugs 0.000 description 9
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 229940035437 1,3-propanediol Drugs 0.000 description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 8
- 238000010438 heat treatment Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000003647 oxidation Effects 0.000 description 8
- 238000007254 oxidation reaction Methods 0.000 description 8
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000010076 replication Effects 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 150000001298 alcohols Chemical class 0.000 description 7
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 7
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 7
- 239000012258 stirred mixture Substances 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 230000029812 viral genome replication Effects 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 238000010626 work up procedure Methods 0.000 description 7
- VJGRFGFLZJIODS-VIFPVBQESA-N (1s)-1-(3-chlorophenyl)propane-1,3-diol Chemical compound OCC[C@H](O)C1=CC=CC(Cl)=C1 VJGRFGFLZJIODS-VIFPVBQESA-N 0.000 description 6
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 108010047761 Interferon-alpha Proteins 0.000 description 6
- 102000006992 Interferon-alpha Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 6
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 6
- 239000004305 biphenyl Substances 0.000 description 6
- 235000010290 biphenyl Nutrition 0.000 description 6
- 238000009833 condensation Methods 0.000 description 6
- 230000005494 condensation Effects 0.000 description 6
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 235000011007 phosphoric acid Nutrition 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000003765 sweetening agent Substances 0.000 description 6
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 238000000825 ultraviolet detection Methods 0.000 description 6
- IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 description 5
- MMMZJMRWWRQXJM-UHFFFAOYSA-N 1-chlorophospholane Chemical group ClP1CCCC1 MMMZJMRWWRQXJM-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 239000003443 antiviral agent Substances 0.000 description 5
- 239000007900 aqueous suspension Substances 0.000 description 5
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 5
- 239000012267 brine Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000006227 byproduct Substances 0.000 description 5
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 238000006555 catalytic reaction Methods 0.000 description 5
- 238000004296 chiral HPLC Methods 0.000 description 5
- 239000007859 condensation product Substances 0.000 description 5
- 239000002270 dispersing agent Substances 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 239000000839 emulsion Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000003599 food sweetener Nutrition 0.000 description 5
- 238000006206 glycosylation reaction Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 5
- 229910000103 lithium hydride Inorganic materials 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- VJGRFGFLZJIODS-SECBINFHSA-N (1r)-1-(3-chlorophenyl)propane-1,3-diol Chemical compound OCC[C@@H](O)C1=CC=CC(Cl)=C1 VJGRFGFLZJIODS-SECBINFHSA-N 0.000 description 4
- PASOFFRBGIVJET-YRKGHMEHSA-N (2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 PASOFFRBGIVJET-YRKGHMEHSA-N 0.000 description 4
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 108010024636 Glutathione Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 239000007836 KH2PO4 Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000005917 acylation reaction Methods 0.000 description 4
- 150000001414 amino alcohols Chemical class 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 230000003197 catalytic effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003086 colorant Substances 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 4
- 229940043279 diisopropylamine Drugs 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 229960003180 glutathione Drugs 0.000 description 4
- 230000013595 glycosylation Effects 0.000 description 4
- 150000004795 grignard reagents Chemical class 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 4
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 4
- 150000008300 phosphoramidites Chemical class 0.000 description 4
- 125000004437 phosphorous atom Chemical group 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000012312 sodium hydride Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- CURNJKLCYZZBNJ-UHFFFAOYSA-M sodium;4-nitrophenolate Chemical compound [Na+].[O-]C1=CC=C([N+]([O-])=O)C=C1 CURNJKLCYZZBNJ-UHFFFAOYSA-M 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 229960004295 valine Drugs 0.000 description 4
- 239000004474 valine Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- SUGIWOQOKKWXRH-QMMMGPOBSA-N (3s)-3-(3-chlorophenyl)-3-hydroxypropanoic acid Chemical compound OC(=O)C[C@H](O)C1=CC=CC(Cl)=C1 SUGIWOQOKKWXRH-QMMMGPOBSA-N 0.000 description 3
- YXTVVUBNUSBKNH-UHFFFAOYSA-N 1-(3-bromophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=CC(Br)=C1 YXTVVUBNUSBKNH-UHFFFAOYSA-N 0.000 description 3
- VJGRFGFLZJIODS-UHFFFAOYSA-N 1-(3-chlorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=CC(Cl)=C1 VJGRFGFLZJIODS-UHFFFAOYSA-N 0.000 description 3
- NCPBESHYZRJICR-UHFFFAOYSA-N 1-dichlorophosphoryloxy-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(OP(Cl)(Cl)=O)C=C1 NCPBESHYZRJICR-UHFFFAOYSA-N 0.000 description 3
- NVKAMPJSWMHVDK-GITKWUPZSA-N 2-amino-9-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-3h-purin-6-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(N)=NC(O)=C2N=C1 NVKAMPJSWMHVDK-GITKWUPZSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 239000004593 Epoxy Substances 0.000 description 3
- 108090000371 Esterases Proteins 0.000 description 3
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 3
- 241000710781 Flaviviridae Species 0.000 description 3
- PNKUSGQVOMIXLU-UHFFFAOYSA-N Formamidine Chemical class NC=N PNKUSGQVOMIXLU-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 239000004471 Glycine Substances 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 3
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 150000003934 aromatic aldehydes Chemical class 0.000 description 3
- 229960000074 biopharmaceutical Drugs 0.000 description 3
- 229910000085 borane Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 150000004985 diamines Chemical class 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- DWYMPOCYEZONEA-UHFFFAOYSA-L fluoridophosphate Chemical compound [O-]P([O-])(F)=O DWYMPOCYEZONEA-UHFFFAOYSA-L 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 208000010710 hepatitis C virus infection Diseases 0.000 description 3
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 150000001261 hydroxy acids Chemical class 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 229960003136 leucine Drugs 0.000 description 3
- 229940057995 liquid paraffin Drugs 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- CQRPUKWAZPZXTO-UHFFFAOYSA-M magnesium;2-methylpropane;chloride Chemical compound [Mg+2].[Cl-].C[C-](C)C CQRPUKWAZPZXTO-UHFFFAOYSA-M 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- 150000003014 phosphoric acid esters Chemical class 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- 229960002429 proline Drugs 0.000 description 3
- 235000019260 propionic acid Nutrition 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 235000011152 sodium sulphate Nutrition 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 description 3
- 229950006081 taribavirin Drugs 0.000 description 3
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 3
- 238000006276 transfer reaction Methods 0.000 description 3
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- NFLGAXVYCFJBMK-BDAKNGLRSA-N (-)-menthone Chemical compound CC(C)[C@@H]1CC[C@@H](C)CC1=O NFLGAXVYCFJBMK-BDAKNGLRSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- XBYRXGNBTIDIKZ-GAJNKVMBSA-N (2r,3r,4r,5r)-2-(4-azidopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N=[N+]=[N-])=C2C=C1 XBYRXGNBTIDIKZ-GAJNKVMBSA-N 0.000 description 2
- YNVCLSAXHSBSTK-GAJNKVMBSA-N (2r,3r,4r,5r)-2-(4-chloropyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(Cl)=C2C=C1 YNVCLSAXHSBSTK-GAJNKVMBSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- UUWJBXKHMMQDED-UHFFFAOYSA-N 1-(3-chlorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(Cl)=C1 UUWJBXKHMMQDED-UHFFFAOYSA-N 0.000 description 2
- GZVMFSAUHKADTG-UHFFFAOYSA-N 1-(3-chlorophenyl)prop-2-en-1-one Chemical compound ClC1=CC=CC(C(=O)C=C)=C1 GZVMFSAUHKADTG-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IWYHWZTYVNIDAE-UHFFFAOYSA-N 1h-benzimidazol-1-ium;trifluoromethanesulfonate Chemical compound OS(=O)(=O)C(F)(F)F.C1=CC=C2NC=NC2=C1 IWYHWZTYVNIDAE-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- HDAKKFUBVLXOCP-UHFFFAOYSA-N 3-(3-chlorophenyl)-3-oxopropanoic acid Chemical compound OC(=O)CC(=O)C1=CC=CC(Cl)=C1 HDAKKFUBVLXOCP-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- HSJKGGMUJITCBW-UHFFFAOYSA-N 3-hydroxybutanal Chemical compound CC(O)CC=O HSJKGGMUJITCBW-UHFFFAOYSA-N 0.000 description 2
- IZZXPXZRVVXKFU-UHFFFAOYSA-N 3-methyl-1-phenylbutane-1,3-diol Chemical compound CC(C)(O)CC(O)C1=CC=CC=C1 IZZXPXZRVVXKFU-UHFFFAOYSA-N 0.000 description 2
- ANSYAMHYCYOWAW-UHFFFAOYSA-N 3-phenylmethoxypropanal Chemical compound O=CCCOCC1=CC=CC=C1 ANSYAMHYCYOWAW-UHFFFAOYSA-N 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- 235000006491 Acacia senegal Nutrition 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 102000055025 Adenosine deaminases Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 2
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 102100040018 Interferon alpha-2 Human genes 0.000 description 2
- 108010079944 Interferon-alpha2b Proteins 0.000 description 2
- 241000764238 Isis Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ZUKPVRWZDMRIEO-VKHMYHEASA-N L-cysteinylglycine Chemical compound SC[C@H]([NH3+])C(=O)NCC([O-])=O ZUKPVRWZDMRIEO-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- WUMZLKDCOINBEA-UHFFFAOYSA-N Lamivudine-monophosphate Chemical compound O=C1N=C(N)C=CN1C1OC(COP(O)(O)=O)SC1 WUMZLKDCOINBEA-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000006751 Mitsunobu reaction Methods 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 241000709664 Picornaviridae Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 102000012479 Serine Proteases Human genes 0.000 description 2
- 108010022999 Serine Proteases Proteins 0.000 description 2
- 101800001838 Serine protease/helicase NS3 Proteins 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 108700042768 University of Wisconsin-lactobionate solution Proteins 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- JBPUGFODGPKTDW-SFHVURJKSA-N [(3s)-oxolan-3-yl] n-[[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]methyl]carbamate Chemical compound C=1C=C(C=2OC=NC=2)C(OC)=CC=1NC(=O)NC(C=1)=CC=CC=1CNC(=O)O[C@H]1CCOC1 JBPUGFODGPKTDW-SFHVURJKSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- 125000005354 acylalkyl group Chemical group 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 150000004703 alkoxides Chemical class 0.000 description 2
- XXROGKLTLUQVRX-UHFFFAOYSA-N allyl alcohol Chemical compound OCC=C XXROGKLTLUQVRX-UHFFFAOYSA-N 0.000 description 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 2
- 125000001769 aryl amino group Chemical group 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 description 2
- 125000005841 biaryl group Chemical group 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 150000001728 carbonyl compounds Chemical class 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- PDXRQENMIVHKPI-UHFFFAOYSA-N cyclohexane-1,1-diol Chemical class OC1(O)CCCCC1 PDXRQENMIVHKPI-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 229960002433 cysteine Drugs 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 108010016616 cysteinylglycine Proteins 0.000 description 2
- 230000009615 deamination Effects 0.000 description 2
- 238000006481 deamination reaction Methods 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- WVPKAWVFTPWPDB-UHFFFAOYSA-M dichlorophosphinate Chemical compound [O-]P(Cl)(Cl)=O WVPKAWVFTPWPDB-UHFFFAOYSA-M 0.000 description 2
- IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000006735 epoxidation reaction Methods 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 125000005343 heterocyclic alkyl group Chemical group 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- 150000002429 hydrazines Chemical class 0.000 description 2
- 150000004678 hydrides Chemical class 0.000 description 2
- 238000006197 hydroboration reaction Methods 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 229960004452 methionine Drugs 0.000 description 2
- ORLUVKRBTHGREP-UHFFFAOYSA-N methyl 3-(1,3-dihydroxypropyl)benzoate Chemical compound COC(=O)C1=CC=CC(C(O)CCO)=C1 ORLUVKRBTHGREP-UHFFFAOYSA-N 0.000 description 2
- MDZSDWBDIPJXKR-UHFFFAOYSA-N methyl 3-(3-chlorophenyl)-3-oxopropanoate Chemical compound COC(=O)CC(=O)C1=CC=CC(Cl)=C1 MDZSDWBDIPJXKR-UHFFFAOYSA-N 0.000 description 2
- MSTNSVUBJIOYNN-UHFFFAOYSA-N methyl 4-(1,3-dihydroxypropyl)benzoate Chemical compound COC(=O)C1=CC=C(C(O)CCO)C=C1 MSTNSVUBJIOYNN-UHFFFAOYSA-N 0.000 description 2
- 229940102396 methyl bromide Drugs 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 229940127073 nucleoside analogue Drugs 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000012053 oil suspension Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- HFPZCAJZSCWRBC-UHFFFAOYSA-N p-cymene Natural products CC(C)C1=CC=C(C)C=C1 HFPZCAJZSCWRBC-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- ALQHHUFONRFGMF-UHFFFAOYSA-N phosphinan-2-one Chemical group O=C1CCCCP1 ALQHHUFONRFGMF-UHFFFAOYSA-N 0.000 description 2
- AQSJGOWTSHOLKH-UHFFFAOYSA-N phosphite(3-) Chemical class [O-]P([O-])[O-] AQSJGOWTSHOLKH-UHFFFAOYSA-N 0.000 description 2
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 description 2
- 235000011009 potassium phosphates Nutrition 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 238000011533 pre-incubation Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 150000003219 pyrazolines Chemical class 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000002342 ribonucleoside Substances 0.000 description 2
- 150000003335 secondary amines Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 229960001153 serine Drugs 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000000707 stereoselective effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- BBAWEDCPNXPBQM-GDEBMMAJSA-N telaprevir Chemical compound N([C@H](C(=O)N[C@H](C(=O)N1C[C@@H]2CCC[C@@H]2[C@H]1C(=O)N[C@@H](CCC)C(=O)C(=O)NC1CC1)C(C)(C)C)C1CCCCC1)C(=O)C1=CN=CC=N1 BBAWEDCPNXPBQM-GDEBMMAJSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 229960002898 threonine Drugs 0.000 description 2
- 235000008521 threonine Nutrition 0.000 description 2
- VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229910052723 transition metal Inorganic materials 0.000 description 2
- 150000003624 transition metals Chemical class 0.000 description 2
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical compound C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- AXEFIGHWTZPXOH-DLGLCQKISA-N (+-)-7,7-dimethyl-2-oxobicyclo(2.2.1)heptane-1-methanesulfonic acid Chemical compound C1N(C2)CN3CN1CN2C3.C1C[C@@]2(CS(O)(=O)=O)C(=O)CC1C2(C)C AXEFIGHWTZPXOH-DLGLCQKISA-N 0.000 description 1
- QDPWSASGSYTONB-QMMMGPOBSA-N (1s)-1-pyridin-4-ylpropane-1,3-diol Chemical compound OCC[C@H](O)C1=CC=NC=C1 QDPWSASGSYTONB-QMMMGPOBSA-N 0.000 description 1
- KHPCBZYTDJCPHW-GITKWUPZSA-N (2r,3r,4r,5r)-2-(2,6-diaminopurin-9-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC(N)=NC(N)=C2N=C1 KHPCBZYTDJCPHW-GITKWUPZSA-N 0.000 description 1
- IRZRJANZDIOOIF-GAJNKVMBSA-N (2r,3r,4r,5r)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2C=C1 IRZRJANZDIOOIF-GAJNKVMBSA-N 0.000 description 1
- KACXPNWIOCRYCS-GJDHVLDNSA-N (2r,3r,4r,5r)-2-(6-aminopurin-9-yl)-5-[[4-(3-chlorophenyl)-2-oxo-1,3,2$l^{5}-dioxaphosphinan-2-yl]oxymethyl]-3-methyloxolane-3,4-diol Chemical compound C([C@@H]1[C@@H](O)[C@]([C@@H](O1)N1C2=NC=NC(N)=C2N=C1)(O)C)OP(O1)(=O)OCCC1C1=CC=CC(Cl)=C1 KACXPNWIOCRYCS-GJDHVLDNSA-N 0.000 description 1
- MXYRZDAGKTVQIL-IOSLPCCCSA-N (2r,3r,4s,5r)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)-2-methyloxolane-3,4-diol Chemical compound C1=NC2=C(N)N=CN=C2N1[C@]1(C)O[C@H](CO)[C@@H](O)[C@H]1O MXYRZDAGKTVQIL-IOSLPCCCSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- HKSUSEMODQDQMJ-JRQMZCAUSA-N (4s)-2-(4-nitrophenoxy)-4-pyridin-4-yl-1,3,2$l^{5}-dioxaphosphinane 2-oxide Chemical compound C1=CC([N+](=O)[O-])=CC=C1OP1(=O)O[C@H](C=2C=CN=CC=2)CCO1 HKSUSEMODQDQMJ-JRQMZCAUSA-N 0.000 description 1
- PTNZGHXUZDHMIQ-CVHRZJFOSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride Chemical compound Cl.C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O PTNZGHXUZDHMIQ-CVHRZJFOSA-N 0.000 description 1
- MGAXYKDBRBNWKT-UHFFFAOYSA-N (5-oxooxolan-2-yl)methyl 4-methylbenzenesulfonate Chemical class C1=CC(C)=CC=C1S(=O)(=O)OCC1OC(=O)CC1 MGAXYKDBRBNWKT-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- WKUYJSAYZXQXSD-DUXPYHPUSA-N (e)-3-(3-chlorophenyl)prop-2-en-1-ol Chemical compound OC\C=C\C1=CC=CC(Cl)=C1 WKUYJSAYZXQXSD-DUXPYHPUSA-N 0.000 description 1
- FFKGOJWPSXRALK-SNAWJCMRSA-N (e)-3-(3-chlorophenyl)prop-2-enoic acid Chemical compound OC(=O)\C=C\C1=CC=CC(Cl)=C1 FFKGOJWPSXRALK-SNAWJCMRSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- LABRPRANVKSMGP-UHFFFAOYSA-N 1,3,2-dioxaphosphinane Chemical compound C1COPOC1 LABRPRANVKSMGP-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- GBUNDIKOLPTDHU-UHFFFAOYSA-N 1-(2,3,5,6-tetrafluorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=C(F)C(F)=CC(F)=C1F GBUNDIKOLPTDHU-UHFFFAOYSA-N 0.000 description 1
- CQZLBRSOWNNENC-UHFFFAOYSA-N 1-(2,3,5-trichlorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC(Cl)=CC(Cl)=C1Cl CQZLBRSOWNNENC-UHFFFAOYSA-N 0.000 description 1
- ULJGPJGEPINESL-UHFFFAOYSA-N 1-(2,3,6-trifluorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=C(F)C=CC(F)=C1F ULJGPJGEPINESL-UHFFFAOYSA-N 0.000 description 1
- LHAXIXAUNQSVNH-UHFFFAOYSA-N 1-(2,3-dichlorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=CC(Cl)=C1Cl LHAXIXAUNQSVNH-UHFFFAOYSA-N 0.000 description 1
- SCPSSMPKRBJSLT-UHFFFAOYSA-N 1-(2,3-dihydro-1,4-benzodioxin-6-yl)propane-1,3-diol Chemical compound O1CCOC2=CC(C(O)CCO)=CC=C21 SCPSSMPKRBJSLT-UHFFFAOYSA-N 0.000 description 1
- MOOQBDRRMRDOHO-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=C(Cl)C=C1Cl MOOQBDRRMRDOHO-UHFFFAOYSA-N 0.000 description 1
- UHLNSIIVUPVMTP-UHFFFAOYSA-N 1-(2,4-difluorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=C(F)C=C1F UHLNSIIVUPVMTP-UHFFFAOYSA-N 0.000 description 1
- JJWDEUXKQSUBIG-UHFFFAOYSA-N 1-(2,5-difluorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC(F)=CC=C1F JJWDEUXKQSUBIG-UHFFFAOYSA-N 0.000 description 1
- IQZSMBLXVQXOTO-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=C(Cl)C=CC=C1Cl IQZSMBLXVQXOTO-UHFFFAOYSA-N 0.000 description 1
- GVNFVCLLALBZPE-UHFFFAOYSA-N 1-(2-bromo-5-chlorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC(Cl)=CC=C1Br GVNFVCLLALBZPE-UHFFFAOYSA-N 0.000 description 1
- GMDZXLGJGQLAGC-UHFFFAOYSA-N 1-(2-bromophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=CC=C1Br GMDZXLGJGQLAGC-UHFFFAOYSA-N 0.000 description 1
- FZDSULCYDIFJPE-UHFFFAOYSA-N 1-(2-chlorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=CC=C1Cl FZDSULCYDIFJPE-UHFFFAOYSA-N 0.000 description 1
- ZABWTCYMJWFIDW-UHFFFAOYSA-N 1-(2-fluoro-5-methoxyphenyl)propane-1,3-diol Chemical compound COC1=CC=C(F)C(C(O)CCO)=C1 ZABWTCYMJWFIDW-UHFFFAOYSA-N 0.000 description 1
- ABMQTSSUMOCJQL-UHFFFAOYSA-N 1-(2-fluorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=CC=C1F ABMQTSSUMOCJQL-UHFFFAOYSA-N 0.000 description 1
- NZJFYJOALNQRNQ-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=C(Cl)C(Cl)=C1 NZJFYJOALNQRNQ-UHFFFAOYSA-N 0.000 description 1
- NWVCINURMYBGFG-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC(Cl)=CC(Cl)=C1 NWVCINURMYBGFG-UHFFFAOYSA-N 0.000 description 1
- JFDWTDQXUURDCM-UHFFFAOYSA-N 1-(3,5-dimethoxyphenyl)propane-1,3-diol Chemical compound COC1=CC(OC)=CC(C(O)CCO)=C1 JFDWTDQXUURDCM-UHFFFAOYSA-N 0.000 description 1
- IEDYPHVLGZOFOL-UHFFFAOYSA-N 1-(3,5-dimethylphenyl)propane-1,3-diol Chemical compound CC1=CC(C)=CC(C(O)CCO)=C1 IEDYPHVLGZOFOL-UHFFFAOYSA-N 0.000 description 1
- AFRLUMQCUGPCOO-UHFFFAOYSA-N 1-(3-bromo-4-fluorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=C(F)C(Br)=C1 AFRLUMQCUGPCOO-UHFFFAOYSA-N 0.000 description 1
- NMEPPHLIGWPQPO-UHFFFAOYSA-N 1-(3-bromo-5-ethoxyphenyl)propane-1,3-diol Chemical compound CCOC1=CC(Br)=CC(C(O)CCO)=C1 NMEPPHLIGWPQPO-UHFFFAOYSA-N 0.000 description 1
- LELUJZZNZXCYIN-UHFFFAOYSA-N 1-(3-chloro-4-fluorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=C(F)C(Cl)=C1 LELUJZZNZXCYIN-UHFFFAOYSA-N 0.000 description 1
- NNSRZZIDIQCCOS-UHFFFAOYSA-N 1-(3-fluorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=CC(F)=C1 NNSRZZIDIQCCOS-UHFFFAOYSA-N 0.000 description 1
- UZOYKBBAMVVEMJ-UHFFFAOYSA-N 1-(3-methylphenyl)propane-1,3-diol Chemical compound CC1=CC=CC(C(O)CCO)=C1 UZOYKBBAMVVEMJ-UHFFFAOYSA-N 0.000 description 1
- NLJQVEQPZXOUOM-UHFFFAOYSA-N 1-(4-bromophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=C(Br)C=C1 NLJQVEQPZXOUOM-UHFFFAOYSA-N 0.000 description 1
- HEVAQXKXYWWEQS-UHFFFAOYSA-N 1-(4-chloro-2-fluorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=C(Cl)C=C1F HEVAQXKXYWWEQS-UHFFFAOYSA-N 0.000 description 1
- IYZLUGCBNLJQIQ-UHFFFAOYSA-N 1-(4-chloro-3-fluorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=C(Cl)C(F)=C1 IYZLUGCBNLJQIQ-UHFFFAOYSA-N 0.000 description 1
- LXYVQNOBTVGBGC-UHFFFAOYSA-N 1-(4-chlorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=C(Cl)C=C1 LXYVQNOBTVGBGC-UHFFFAOYSA-N 0.000 description 1
- GEWDSLKGMMEOAZ-UHFFFAOYSA-N 1-(4-fluorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC=C(F)C=C1 GEWDSLKGMMEOAZ-UHFFFAOYSA-N 0.000 description 1
- PTXIOWUPCBAQBY-UHFFFAOYSA-N 1-(4-methylphenyl)propane-1,3-diol Chemical compound CC1=CC=C(C(O)CCO)C=C1 PTXIOWUPCBAQBY-UHFFFAOYSA-N 0.000 description 1
- RQWAIGYNWMBBKY-UHFFFAOYSA-N 1-(4-tert-butylphenyl)propane-1,3-diol Chemical compound CC(C)(C)C1=CC=C(C(O)CCO)C=C1 RQWAIGYNWMBBKY-UHFFFAOYSA-N 0.000 description 1
- KQVJFDRUAXIIKS-UHFFFAOYSA-N 1-(5-bromo-2-fluorophenyl)propane-1,3-diol Chemical compound OCCC(O)C1=CC(Br)=CC=C1F KQVJFDRUAXIIKS-UHFFFAOYSA-N 0.000 description 1
- XPZSAAVZPDKDKB-UHFFFAOYSA-N 1-(5-bromopyridin-3-yl)propane-1,3-diol Chemical compound OCCC(O)C1=CN=CC(Br)=C1 XPZSAAVZPDKDKB-UHFFFAOYSA-N 0.000 description 1
- SRCFLSHXORAAFT-UHFFFAOYSA-N 1-(furan-3-yl)propane-1,3-diol Chemical compound OCCC(O)C=1C=COC=1 SRCFLSHXORAAFT-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
- NBKORJKMMVZAOZ-VPCXQMTMSA-N 1-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidine-2,4-dione Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 NBKORJKMMVZAOZ-VPCXQMTMSA-N 0.000 description 1
- ROMLWXASPCWWKX-UHFFFAOYSA-N 1-[2-(trifluoromethyl)phenyl]propane-1,3-diol Chemical compound OCCC(O)C1=CC=CC=C1C(F)(F)F ROMLWXASPCWWKX-UHFFFAOYSA-N 0.000 description 1
- HBPXPGOMVUBYKO-UHFFFAOYSA-N 1-[3-(trifluoromethyl)phenyl]propane-1,3-diol Chemical compound OCCC(O)C1=CC=CC(C(F)(F)F)=C1 HBPXPGOMVUBYKO-UHFFFAOYSA-N 0.000 description 1
- ZQEHLOVPFIDWMC-UHFFFAOYSA-N 1-[4-(4-chlorophenoxy)phenyl]propane-1,3-diol Chemical compound C1=CC(C(O)CCO)=CC=C1OC1=CC=C(Cl)C=C1 ZQEHLOVPFIDWMC-UHFFFAOYSA-N 0.000 description 1
- LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OOQQYCLGKYLFED-UHFFFAOYSA-N 1-pyridin-2-ylpropane-1,3-diol Chemical compound OCCC(O)C1=CC=CC=N1 OOQQYCLGKYLFED-UHFFFAOYSA-N 0.000 description 1
- WMQUKDQWMMOHSA-UHFFFAOYSA-N 1-pyridin-4-ylethanone Chemical compound CC(=O)C1=CC=NC=C1 WMQUKDQWMMOHSA-UHFFFAOYSA-N 0.000 description 1
- QDPWSASGSYTONB-UHFFFAOYSA-N 1-pyridin-4-ylpropane-1,3-diol Chemical compound OCCC(O)C1=CC=NC=C1 QDPWSASGSYTONB-UHFFFAOYSA-N 0.000 description 1
- OMOCPVDLPNCZMW-UHFFFAOYSA-N 1-thiophen-3-ylpropane-1,3-diol Chemical compound OCCC(O)C=1C=CSC=1 OMOCPVDLPNCZMW-UHFFFAOYSA-N 0.000 description 1
- NYSZLKQMKGHQKC-QPJJXVBHSA-N 2,2,2-trichloro-n-[(e)-3-phenylprop-2-enyl]acetamide Chemical compound ClC(Cl)(Cl)C(=O)NC\C=C\C1=CC=CC=C1 NYSZLKQMKGHQKC-QPJJXVBHSA-N 0.000 description 1
- SFRDXVJWXWOTEW-UHFFFAOYSA-N 2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(CO)CO SFRDXVJWXWOTEW-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- MDVRYDOLQHKVSZ-NBYAQTDISA-N 2-amino-7-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=C(N)NC2=O)=C2C=C1 MDVRYDOLQHKVSZ-NBYAQTDISA-N 0.000 description 1
- OGHAROSJZRTIOK-KQYNXXCUSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-methylpurin-9-ium-6-olate Chemical compound C12=NC(N)=NC([O-])=C2N(C)C=[N+]1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical compound O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 1
- RXMVFKJGHWRWCA-UHFFFAOYSA-N 2h-benzotriazol-4-yloxy-tris(dimethylamino)phosphanium Chemical class CN(C)[P+](N(C)C)(N(C)C)OC1=CC=CC2=C1N=NN2 RXMVFKJGHWRWCA-UHFFFAOYSA-N 0.000 description 1
- AKXKFZDCRYJKTF-UHFFFAOYSA-N 3-Hydroxypropionaldehyde Chemical compound OCCC=O AKXKFZDCRYJKTF-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- KTJRGPZVSKWRTJ-UHFFFAOYSA-N 3-chloro-1-phenylpropan-1-one Chemical compound ClCCC(=O)C1=CC=CC=C1 KTJRGPZVSKWRTJ-UHFFFAOYSA-N 0.000 description 1
- SRWILAKSARHZPR-UHFFFAOYSA-N 3-chlorobenzaldehyde Chemical compound ClC1=CC=CC(C=O)=C1 SRWILAKSARHZPR-UHFFFAOYSA-N 0.000 description 1
- WHIHIKVIWVIIER-UHFFFAOYSA-N 3-chlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=CC(Cl)=C1 WHIHIKVIWVIIER-UHFFFAOYSA-N 0.000 description 1
- XILHWPXWDWFBTK-UHFFFAOYSA-N 3-isoquinolin-1-ylpropan-1-ol Chemical class C1=CC=C2C(CCCO)=NC=CC2=C1 XILHWPXWDWFBTK-UHFFFAOYSA-N 0.000 description 1
- PINRUEQFGKWBTO-UHFFFAOYSA-N 3-methyl-5-phenyl-1,3-oxazolidin-2-imine Chemical compound O1C(=N)N(C)CC1C1=CC=CC=C1 PINRUEQFGKWBTO-UHFFFAOYSA-N 0.000 description 1
- FUCYABRIJPUVAT-UHFFFAOYSA-N 3-phenylmethoxypropan-1-ol Chemical compound OCCCOCC1=CC=CC=C1 FUCYABRIJPUVAT-UHFFFAOYSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N 3-phenylprop-2-enal Chemical class O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- XYVMOLOUBJBNBF-UHFFFAOYSA-N 3h-1,3-oxazol-2-one Chemical compound OC1=NC=CO1 XYVMOLOUBJBNBF-UHFFFAOYSA-N 0.000 description 1
- LTBCYGZGEUORSW-UHFFFAOYSA-N 4-(3-chlorophenyl)-2-(4-nitrophenoxy)-1,3,2$l^{5}-dioxaphosphinane 2-oxide Chemical class C1=CC([N+](=O)[O-])=CC=C1OP1(=O)OC(C=2C=C(Cl)C=CC=2)CCO1 LTBCYGZGEUORSW-UHFFFAOYSA-N 0.000 description 1
- LMBFUMXVHAJSNJ-UHFFFAOYSA-N 4-(dimethylamino)cyclohexan-1-one Chemical compound CN(C)C1CCC(=O)CC1 LMBFUMXVHAJSNJ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- PPUDLEUZKVJXSZ-VPCXQMTMSA-N 4-amino-1-[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]pyrimidin-2-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(N)C=C1 PPUDLEUZKVJXSZ-VPCXQMTMSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- BTJIUGUIPKRLHP-UHFFFAOYSA-M 4-nitrophenolate Chemical compound [O-]C1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-M 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- GMVPRGQOIOIIMI-DODZYUBVSA-N 7-[(1R,2R,3R)-3-hydroxy-2-[(3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DODZYUBVSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108091023020 Aldehyde Oxidase Proteins 0.000 description 1
- 102100036826 Aldehyde oxidase Human genes 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241001536481 Banzi virus Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
- 208000007204 Brain death Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 238000005698 Diels-Alder reaction Methods 0.000 description 1
- OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
- YSAVZVORKRDODB-UHFFFAOYSA-N Diethyl tartrate Chemical compound CCOC(=O)C(O)C(O)C(=O)OCC YSAVZVORKRDODB-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000001263 FEMA 3042 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 238000003747 Grignard reaction Methods 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- 229940124771 HCV-NS3 protease inhibitor Drugs 0.000 description 1
- 238000007167 Hofmann rearrangement reaction Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical class O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 108010078049 Interferon alpha-2 Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108010011356 Nucleoside phosphotransferase Proteins 0.000 description 1
- BAULLJWMDGGPEA-UHFFFAOYSA-N OP(O)(=O)NN1CCCC1 Chemical compound OP(O)(=O)NN1CCCC1 BAULLJWMDGGPEA-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 101800001554 RNA-directed RNA polymerase Proteins 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- 206010061494 Rhinovirus infection Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical group O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010078233 Thymalfasin Proteins 0.000 description 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010057293 West Nile viral infection Diseases 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 208000003152 Yellow Fever Diseases 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- OFNKWWQSCLHVHZ-UHFFFAOYSA-N [O-][N+](C(C=C1)=CC=C1O[ClH]P(O)(Cl)=O)=O Chemical compound [O-][N+](C(C=C1)=CC=C1O[ClH]P(O)(Cl)=O)=O OFNKWWQSCLHVHZ-UHFFFAOYSA-N 0.000 description 1
- YLEQMGZZMCJKCN-NKWVEPMBSA-N [[(2r,5s)-5-(4-amino-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)SC1 YLEQMGZZMCJKCN-NKWVEPMBSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000005882 aldol condensation reaction Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004171 alkoxy aryl group Chemical group 0.000 description 1
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000004103 aminoalkyl group Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 238000005915 ammonolysis reaction Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 150000001491 aromatic compounds Chemical class 0.000 description 1
- 150000007860 aryl ester derivatives Chemical class 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960005261 aspartic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000009876 asymmetric hydrogenation reaction Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- ZJRCIQAMTAINCB-UHFFFAOYSA-N benzoylacetonitrile Chemical class N#CCC(=O)C1=CC=CC=C1 ZJRCIQAMTAINCB-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 150000004725 beta keto acid derivatives Chemical class 0.000 description 1
- 150000004718 beta keto acids Chemical class 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 125000005518 carboxamido group Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N chembl421 Chemical compound C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 229910001914 chlorine tetroxide Inorganic materials 0.000 description 1
- PJZPDFUUXKKDNB-KNINVFKUSA-N ciluprevir Chemical compound N([C@@H]1C(=O)N2[C@H](C(N[C@@]3(C[C@H]3\C=C/CCCCC1)C(O)=O)=O)C[C@H](C2)OC=1C2=CC=C(C=C2N=C(C=1)C=1N=C(NC(C)C)SC=1)OC)C(=O)OC1CCCC1 PJZPDFUUXKKDNB-KNINVFKUSA-N 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- FSDSKERRNURGGO-UHFFFAOYSA-N cyclohexane-1,3,5-triol Chemical compound OC1CC(O)CC(O)C1 FSDSKERRNURGGO-UHFFFAOYSA-N 0.000 description 1
- RLMGYIOTPQVQJR-UHFFFAOYSA-N cyclohexane-1,3-diol Chemical class OC1CCCC(O)C1 RLMGYIOTPQVQJR-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical compound [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- MHDVGSVTJDSBDK-UHFFFAOYSA-N dibenzyl ether Chemical compound C=1C=CC=CC=1COCC1=CC=CC=C1 MHDVGSVTJDSBDK-UHFFFAOYSA-N 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-N dichloropalladium;triphenylphosphanium Chemical compound Cl[Pd]Cl.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1[PH+](C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-N 0.000 description 1
- WVPKAWVFTPWPDB-UHFFFAOYSA-N dichlorophosphinic acid Chemical class OP(Cl)(Cl)=O WVPKAWVFTPWPDB-UHFFFAOYSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 1
- XEBCWEDRGPSHQH-UHFFFAOYSA-N diisopropyl tartrate Chemical compound CC(C)OC(=O)C(O)C(O)C(=O)OC(C)C XEBCWEDRGPSHQH-UHFFFAOYSA-N 0.000 description 1
- HWSUUGHIDOOOOJ-UHFFFAOYSA-N dioxaphosphinane Chemical compound C1COOPC1 HWSUUGHIDOOOOJ-UHFFFAOYSA-N 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000002359 drug metabolite Substances 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- ROEZPXRDTJGAAN-UHFFFAOYSA-N ethyl 3-(3-chlorophenyl)prop-2-enoate Chemical compound CCOC(=O)C=CC1=CC=CC(Cl)=C1 ROEZPXRDTJGAAN-UHFFFAOYSA-N 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 235000014304 histidine Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229950011479 hyclate Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- HXJZHJLLMIGFCM-UHFFFAOYSA-N hydroxy-imino-di(propan-2-yloxy)-$l^{5}-phosphane Chemical compound CC(C)OP(N)(=O)OC(C)C HXJZHJLLMIGFCM-UHFFFAOYSA-N 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229940090438 infergen Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 235000013902 inosinic acid Nutrition 0.000 description 1
- 108010010648 interferon alfacon-1 Proteins 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229940065638 intron a Drugs 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- UWCWSEMVQFWUHB-UHFFFAOYSA-N iodophosphonic acid Chemical compound OP(O)(I)=O UWCWSEMVQFWUHB-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002546 isoxazolidines Chemical class 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- RBIGAKKSHIRYNT-UHFFFAOYSA-M lithium;4-nitrophenolate Chemical compound [Li+].[O-]C1=CC=C([N+]([O-])=O)C=C1 RBIGAKKSHIRYNT-UHFFFAOYSA-M 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- IWCVDCOJSPWGRW-UHFFFAOYSA-M magnesium;benzene;chloride Chemical compound [Mg+2].[Cl-].C1=CC=[C-]C=C1 IWCVDCOJSPWGRW-UHFFFAOYSA-M 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- RMGJCSHZTFKPNO-UHFFFAOYSA-M magnesium;ethene;bromide Chemical compound [Mg+2].[Br-].[CH-]=C RMGJCSHZTFKPNO-UHFFFAOYSA-M 0.000 description 1
- BRKADVNLTRCLOW-UHFFFAOYSA-M magnesium;fluorobenzene;bromide Chemical compound [Mg+2].[Br-].FC1=CC=[C-]C=C1 BRKADVNLTRCLOW-UHFFFAOYSA-M 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical group N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
- 229950003168 merimepodib Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
- YVNZOWCPXSCKBU-VIFPVBQESA-N methyl (3s)-3-(3-chlorophenyl)-3-hydroxypropanoate Chemical compound COC(=O)C[C@H](O)C1=CC=CC(Cl)=C1 YVNZOWCPXSCKBU-VIFPVBQESA-N 0.000 description 1
- KJDIWFXVVDOKCM-UHFFFAOYSA-N methyl 3-oxo-3-pyridin-4-ylpropanoate Chemical compound COC(=O)CC(=O)C1=CC=NC=C1 KJDIWFXVVDOKCM-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-N methyl sulfate Chemical compound COS(O)(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-N 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000007932 molded tablet Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
- 229960004866 mycophenolate mofetil Drugs 0.000 description 1
- WJPHKKLZKLZWDB-UHFFFAOYSA-N n,n-diethylmethanimidamide Chemical compound CCN(CC)C=N WJPHKKLZKLZWDB-UHFFFAOYSA-N 0.000 description 1
- DSWNRHCOGVRDOE-UHFFFAOYSA-N n,n-dimethylmethanimidamide Chemical compound CN(C)C=N DSWNRHCOGVRDOE-UHFFFAOYSA-N 0.000 description 1
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical class ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000012705 nitroxide-mediated radical polymerization Methods 0.000 description 1
- 125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002900 organolithium compounds Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- ZOUWOGOTHLRRLS-UHFFFAOYSA-N palladium;phosphane Chemical class P.[Pd] ZOUWOGOTHLRRLS-UHFFFAOYSA-N 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- AFDMODCXODAXLC-UHFFFAOYSA-N phenylmethanimine Chemical group N=CC1=CC=CC=C1 AFDMODCXODAXLC-UHFFFAOYSA-N 0.000 description 1
- OTYNBGDFCPCPOU-UHFFFAOYSA-N phosphane sulfane Chemical compound S.P[H] OTYNBGDFCPCPOU-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 238000001394 phosphorus-31 nuclear magnetic resonance spectrum Methods 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 208000025223 poliovirus infection Diseases 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 229940074439 potassium sodium tartrate Drugs 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- JUYUYCIJACTHMK-UHFFFAOYSA-N quinoline-8-sulfonyl chloride Chemical compound C1=CN=C2C(S(=O)(=O)Cl)=CC=CC2=C1 JUYUYCIJACTHMK-UHFFFAOYSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000012066 reaction slurry Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 238000006894 reductive elimination reaction Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 238000002390 rotary evaporation Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 238000005870 sharpless asymmetric epoxidation reaction Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000010802 sludge Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000015523 tannic acid Nutrition 0.000 description 1
- 229940033123 tannic acid Drugs 0.000 description 1
- 229920002258 tannic acid Polymers 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- FGTJJHCZWOVVNH-UHFFFAOYSA-N tert-butyl-[tert-butyl(dimethyl)silyl]oxy-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)O[Si](C)(C)C(C)(C)C FGTJJHCZWOVVNH-UHFFFAOYSA-N 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 229960004231 thymalfasin Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- QHUNJMXHQHHWQP-UHFFFAOYSA-N trimethylsilyl acetate Chemical compound CC(=O)O[Si](C)(C)C QHUNJMXHQHHWQP-UHFFFAOYSA-N 0.000 description 1
- JSPLKZUTYZBBKA-UHFFFAOYSA-N trioxidane Chemical compound OOO JSPLKZUTYZBBKA-UHFFFAOYSA-N 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000013022 venting Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- PGOLTJPQCISRTO-UHFFFAOYSA-N vinyllithium Chemical compound [Li]C=C PGOLTJPQCISRTO-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Definitions
- the present invention is directed towards novel 2′-C-methyl nucleoside 5′-monophosphate derivatives, their preparation and their uses. More specifically, the novel compounds are useful to treat hepatitis C viral infections.
- Hepatitis C is a viral disease that causes inflammation of the liver that may lead to cirrhosis, primary liver cancer and other long-term complications.
- Nucleosides are a well-recognized class of compounds shown to be effective against a variety of viral infections, including hepatitis B, HIV, and herpes. A few nucleosides are reported to inhibit hepatitis C (HCV) virus replication, including ribavirin, which currently is marketed as a drug combination with various interferons, and nucleosides containing a 2′-C-methyl ribose sugar.
- HCV hepatitis C
- Nucleosides are generally effective as antiviral agents following conversion of the nucleoside to the corresponding nucleoside 5′-triphosphate (NTP). Conversion occurs inside cells through the action of various intracellular kinases.
- the first step i.e. conversion of the nucleoside to the 5′-monophosphate (NMP) is generally the slow step and involves a nucleoside kinase, which is encoded by either the virus or host.
- Conversion of the NMP to the NTP is generally catalyzed by host nucleotide kinases.
- the NTP interferes with viral replication through inhibition of viral polymerases and/or via incorporation into a growing strand of DNA or RNA followed by chain termination.
- nucleosides to treat viral liver infections are often complicated by one of two problems.
- the desired nucleoside is a good kinase substrate and accordingly produces NTP in the liver as well as other cells and tissues throughout the body. Since NTP production is often associated with toxicity, efficacy can be limited by extrahepatic toxicities.
- the desired nucleoside is a poor kinase substrate so is not efficiently converted into the NMP and ultimately into the NTP.
- B is selected from the group consisting of
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- W and W′ are independently selected from the group consisting of —R 2 , optionally substituted monocyclic aryl, and optionally substituted monocyclic heteroaryl;
- Z is selected from the group consisting of halogen, —CN, —COR 5 , —CONR 4 2 , —CO 2 R 5 , —SO 2 R 5 , —SO 2 NR 4 2 , —OR 4 , —SR 4 , —R 4 , —NR 4 2 , —OCOR 5 , —OCO 2 R 5 , —SCOR 5 , —SCO 2 R 5 , —NHCOR 4 , —NHCO 2 R 5 , —(CH 2 ) p —OR 6 , and —(CH 2 ) p —SR 6 ; or
- W and W′ are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms;
- the invention relates to compounds of Formula I, and pharmaceutically acceptable salts and prodrugs thereof:
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- W and W′ are independently selected from the group consisting of —R 2 , optionally substituted monocyclic aryl, and optionally substituted monocyclic heteroaryl;
- V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- W and W′ are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms;
- R 2 is selected from the group consisting of R 3 and hydrogen
- R 3 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R 4 is selected from the group consisting of R 5 and hydrogen
- R 6 is selected from the group consisting of hydrogen, and lower acyl
- R 12 is selected from the group consisting of hydrogen, and lower acyl
- p is an integer 2 or 3.
- Some of the compounds of Formula I have asymmetric centers where the stereochemistry is unspecified, and the diastereomeric mixtures of these compounds are included, as well as the individual stereoisomers when referring to a compound of Formula I generally.
- keto-enol tautomers may exist as tautomers such as keto-enol tautomers and imine-enamine tautomers.
- the individual tautomers as well as mixtures thereof are encompassed with compounds of Formula I.
- An example of keto-enol tautomers which are intended to be encompassed within the compounds of the present invention is illustrated below:
- Also provided are methods for inhibiting viral replication comprising the step of administering to a patient a therapeutically effective amount of a compound of Formula I, pharmaceutically acceptable salts or prodrugs thereof.
- Also provided are methods for inhibiting HCV replication comprising the step of administering to a patient a therapeutically effective amount of a compound of Formula I, pharmaceutically acceptable salts or prodrugs thereof.
- Also provided are methods for treating viral infections of the liver comprising the step of administering to a patient a therapeutically effective amount of a compound of Formula I,
- RNA-dependent RNA viral infection comprising the step of administering to a patient a therapeutically effective amount of a compound of Formula I, a pharmaceutically acceptable salts or prodrugs thereof.
- aryl refers to aromatic groups which have 5-14 ring atoms and at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted.
- the aryl group may be optionally substituted with 1-6 substituents.
- Heterocyclic aryl or heteroaryl groups are groups which have 5-14 ring atoms wherein 1 to 4 heteroatoms are ring atoms in the aromatic ring and the remainder of the ring atoms being carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen. Suitable heteroaryl groups include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolyl, pyridyl-N-oxide, pyrimidyl, pyrazinyl, imidazolyl, indolyl and the like, all optionally substituted.
- monocyclic aryl refers to aromatic groups which have 5-6 ring atoms and includes carbocyclic aryl and heterocyclic aryl. Suitable aryl groups include phenyl, furanyl, pyridyl, and thienyl. Aryl groups may be substituted.
- Substituted aryl and “substituted heteroaryl” refers to aryl and heteroaryl groups substituted with 1-6 substituents. These substituents are selected from the group consisting of lower alkyl, lower alkoxy, lower perhaloalkyl, halogen, hydroxy, cyano, and amino.
- alkylaryl- refers to an aryl group substituted with an alkyl group. “Lower alkylaryl-” refers to such groups where alkyl is lower alkyl. The aryl portion may have 5-14 ring atoms and the alkyl portion may have up to and including 10 carbon atoms. The term “lower” referred to herein in connection with organic radicals or compounds respectively defines such as with up to and including 10, in one aspect up to and including 6, and in another aspect one to four carbon atoms. Such groups may be straight chain, branched, or cyclic.
- arylamino (a), and “aralkylamino” (b), respectively, refer to the group —NRR′ wherein respectively, (a) R is aryl and R′ is hydrogen, alkyl, aralkyl, heterocycloalkyl, or aryl, and (b) R is aralkyl and R′ is hydrogen, aralkyl, aryl, alkyl or heterocycloalkyl.
- carboxy esters refers to —C(O)OR where R is alkyl, aryl, aralkyl, cyclic alkyl, or heterocycloalkyl, all optionally substituted.
- -sulphonylamido or “-sulfonylamido” refers to —S( ⁇ O) 2 NR 2 where each R is independently hydrogen or alkyl.
- halogen refers to —F, —Cl, —Br and —I.
- alkylaminoalkylcarboxy refers to the group alkyl-NR-alk-C(O)—O— where “alk” is an alkylene group, and R is a H or lower alkyl.
- sulphonate or “sulfonate” refers to —SO 2 OR, where R is —H, alkyl, aryl, aralkyl, or heterocycloalkyl.
- alkylene refers to a divalent straight chain, branched chain or cyclic saturated aliphatic group. In one aspect the alkylene group contains up to and including 10 atoms. In another aspect the alkylene chain contains up to and including 6 atoms. In a further aspect the alkylene groups contains up to and including 4 atoms.
- the alkylene group can be either straight, branched or cyclic. The alkylene may be optionally substituted with 1-3 substituents.
- acyloxy refers to the ester group —O—C(O)R, where R is H, alkyl, alkenyl, alkynyl, aryl, aralkyl, or heterocycloalkyl.
- alkylaminoaryl- refers to the group alkyl-NR-aryl- wherein “aryl” is a divalent group and R is —H, alkyl, aralkyl, or heterocycloalkyl. In “lower alkylaminoaryl-”, the alkyl group is lower alkyl.
- aryloxyalkyl- refers to an alkyl group substituted with an aryloxy group.
- alkoxy- or “alkyloxy-” refers to the group alkyl-O—.
- alkoxyalkyl- or “alkyloxyalkyl-” refer to the group alkyl-O-alk- wherein “alk” is an alkylene group. In “lower alkoxyalkyl-”, each alkyl and alkylene is lower alkyl and alkylene, respectively.
- alkylthio- refers to the group alkyl-S—.
- alkoxycarbonyloxy- refers to alkyl-O—C(O)—O—.
- aryloxycarbonyloxy- refers to aryl-O—C(O)—O—.
- alkylthiocarbonyloxy- refers to alkyl-S—C(O)—O—.
- carboxamidoalkylaryl and “carboxamidoaryl” refers to an aryl-alk-NR 1 —C(O), and ar-NR 1 —C(O)-alk-, respectively where “ar” is aryl, “alk” is alkylene, R 1 and R include H, alkyl, aryl, aralkyl, and heterocycloalkyl.
- nitro refers to —NO 2 .
- aminocarboxamidoalkyl- refers to the group NR 2 —C(O)—N(R)-alk- wherein R is an alkyl group or H and “alk” is an alkylene group. “Lower aminocarboxamidoalkyl-” refers to such groups wherein “alk” is lower alkylene.
- heterocyclic base B refers to
- R 14 is independently selected from the group consisting of H and NH 2 ; and X is selected from the group consisting of NH 2 , NHCH 3 , N(CH 3 ) 2 , OCH 3 , SCH 3 , OH, and SH.
- terapéuticaally effective amount means an amount of a compound or a combination of compounds that ameliorates, attenuates or eliminates one or more of the symptoms of a particular disease or condition or prevents, modifies, or delays the onset of one or more of the symptoms of a particular disease or condition.
- L-amino acid refers to those amino acids routinely found as components of proteinaceous molecules in nature, including alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine and histidine.
- this term is intended to encompass L-amino acids having only the amine and carboxylic acid as charged functional groups, i.e., alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine, glycine, serine, threonine, cysteine and tyrosine.
- they are alanine, valine, leucine, isoleucine, proline, phenylalanine, and glycine.
- it is valine.
- patient refers to an animal being treated including a mammal, such as a dog, a cat, a cow, a horse, a sheep, and a human. Another aspect includes a mammal, both male and female.
- prodrug refers to any compound that when administered to a biological system generates a biologically active compound as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), and/or metabolic chemical reaction(s), or a combination of each.
- Standard prodrugs are formed using groups attached to functionality, e.g. HO—, HS—, HOOC—, R 2 N—, associated with the drug, that cleave in vivo.
- Standard prodrugs include but are not limited to carboxylate esters where the group is alkyl, aryl, aralkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl as well as esters of hydroxyl, thiol and amines where the group attached is an acyl group, an alkoxycarbonyl, aminocarbonyl, phosphate or sulfate.
- the groups illustrated are exemplary, not exhaustive, and one skilled in the art could prepare other known varieties of prodrugs.
- Such prodrugs of the compounds of Formula I fall within this scope.
- Prodrugs must undergo some form of a chemical transformation to produce the compound that is biologically active or is a precursor of the biologically active compound.
- prodrug herein also includes but is not limited to esterase cleavable prodrugs of the 2′ and 3′-hydroxy groups of compounds of Formula I (Anastasi et al., Curr. Med. Chem., 2003, 10, 1825). Standard groups include acyl and alkoxycarbonyl groups, and esters of natural L-amino acid derivatives (Perry, et al., Drugs, 1996, 52, 754). Also included is a cyclic carbonate derivative formed by carbonylation of the 2′ and 3′-hydroxy groups, which upon activation by esterase activity in vivo results in compounds of Formula I.
- prodrugs are preferred at the 6-position of purine analogs. Such substitution may include H, halogen, amino, acetoxy or azido groups. Hydrogen substituted prodrugs at the 6-position of guanosine analogs undergo oxidation in vivo by aldehyde oxidase or xanthine oxidase to give the required functionality (Rashidi et al., Drug Metab. Dispos. 1997, 25, 805). While esterases unmask acetoxy groups, amine and halogen substituents are known to be substrates for deaminases. 6-Azido substituted compounds are also known to give the corresponding amino derivatives by the action of reductases (Koudriakova, et al., J. Med Chem., 1996, 39, 4676).
- V and Z are connected via 4 additional atoms.
- V aryl
- a spiro-fused cyclopropyl group for W and W′ spiro-fused cyclopropyl group for W and W′.
- trans stereochemistry refers to the spatial relationship of the V group and the substituent attached to the phosphorus atom via an exocyclic single bond on the six membered 2-oxo-phosphorinane ring.
- the structures C and D below show two possible trans-isomers of 2- and 4-substituted 2-oxo-phosphorinane. Structure C shows trans-isomer of (2S, 4S)— configuration whereas structure D shows trans-isomer of (2R, 4R)-configuration.
- liver refers to liver organ.
- enhancing refers to increasing or improving a specific property.
- liver specificity refers to the ratio: [ drug ⁇ ⁇ or ⁇ ⁇ a ⁇ ⁇ drug ⁇ ⁇ metabolite ⁇ ⁇ in ⁇ ⁇ liver ⁇ ⁇ tissue ] [ drug ⁇ ⁇ or ⁇ ⁇ a ⁇ ⁇ drug ⁇ ⁇ metabolite ⁇ ⁇ in ⁇ ⁇ blood ⁇ ⁇ or ⁇ ⁇ another ⁇ ⁇ tissue ] as measured in animals treated with the drug or a prodrug.
- the ratio can be determined by measuring tissue levels at a specific time or may represent an AUC based on values measured at three or more time points.
- increased or enhanced liver specificity refers to an increase in the liver specificity ratio in animals treated with the prodrug relative to animals treated with the parent drug.
- the term “enhanced oral bioavailability” refers to an increase of at least 50% of the absorption of the dose of the parent drug. In an additional aspect the increase in oral bioavailability of the prodrug (compared to the parent drug) is at least 100%, that is a doubling of the absorption. Measurement of oral bioavailability usually refers to measurements of the prodrug, drug, or drug metabolite in blood, plasma, tissues, or urine following oral administration compared to measurements following parenteral administration.
- therapeutic index refers to the ratio of the dose of a drug or prodrug that produces a therapeutically beneficial response relative to the dose that produces an undesired response such as death, an elevation of markers that are indicative of toxicity, and/or pharmacological side effects.
- sustained delivery refers to an increase in the period in which there is a prolongation of therapeutically-effective drug levels due to the presence of the prodrug.
- treating or “treatment” of a disease includes inhibiting the disease (slowing or arresting its development), providing relief from the symptoms or side-effects of the disease (including palliative treatment), and relieving the disease (causing regression of the disease).
- the present invention relates to compounds of Formula I, stereoisomers, pharmaceutically acceptable salts or prodrugs thereof or pharmaceutically acceptable salts of the prodrugs as represented by Formula I:
- B is selected from the group consisting of
- Z is selected from the group consisting of halogen, —CN, —COR 5 , —CONR 4 2 , —CO 2 R 5 , —SO 2 R 5 , —SO 2 NR 4 2 , —OR 4 , —SR 4 , —R 4 , —NR 4 2 , —OCOR 5 , —OCO 2 R 5 , —SCOR 5 , —SCO 2 R 5 , —NHCOR 4 , —NHCO 2 R 5 , —(CH 2 ) p —OR 6 , and —(CH 2 ) p —SR 6 ; or
- Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom;
- R 2 is selected from the group consisting of R 3 and hydrogen
- R 3 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R 12 is selected from the group consisting of hydrogen, and lower acyl
- p is an integer 2 or 3;
- W and W′ are independently selected from the group consisting of —R 2 , optionally substituted monocyclic aryl, and optionally substituted monocyclic heteroaryl;
- Z is selected from the group consisting of halogen, —CN, —COR 5 , —CONR 4 2 , —CO 2 R 5 , —SO 2 R 5 , —SO 2 NR 4 2 , —OR 4 , —SR 4 , —R 4 , —NR 4 2 , —OCOR 5 , —OCO 2 R 5 , —SCOR 5 , —SCO 2 R 5 , —NHCOR 4 , —NHCO 2 R 5 , —(CH 2 ) p —OR 6 , and —(CH 2 ) p —SR 6 ; or
- V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom;
- W and W′ are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms;
- R 2 is selected from the group consisting of R 3 and hydrogen
- R 4 is selected from the group consisting of R 5 and hydrogen
- R 5 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R 12 is selected from the group consisting of hydrogen, and lower acyl
- p is an integer 2 or 3;
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- W and W′ are independently selected from the group consisting of —R 2 , optionally substituted monocyclic aryl, and optionally substituted monocyclic heteroaryl;
- Z is selected from the group consisting of halogen, —CN, —COR 5 , —CONR 4 2 , —CO 2 R 5 , —SO 2 R 5 , —SO 2 NR 4 2 , —OR 4 , —SR 4 , —R 4 , —NR 4 2 , —OCOR 5 , —OCO 2 R 5 , —SCOR 5 , —SCO 2 R 5 , —NHCOR 4 , —NHCO 2 R 5 , —(CH 2 ) p —OR 6 , and —(CH 2 ) p —SR 6 ; or
- Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom;
- R 3 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R 4 is selected from the group consisting of R 5 and hydrogen
- R 5 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R 12 is selected from the group consisting of hydrogen, and lower acyl
- p is an integer 2 or 3;
- the invention comprises compounds of Formula I:
- V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom;
- R 2 is selected from the group consisting of R 3 and hydrogen
- R 3 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R 4 is selected from the group consisting of R 5 and hydrogen
- R 5 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R 12 is selected from the group consisting of hydrogen, and lower acyl
- p is an integer 2 or 3;
- W and W′ are independently selected from the group consisting of —R 2 , optionally substituted monocyclic aryl, and optionally substituted monocyclic heteroaryl;
- Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom;
- W and W′ are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms;
- V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; and R 3 is C 1 -C 6 alkyl.
- V is selected from the group consisting of phenyl, 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-bromo-4-fluorophenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.
- V is selected from the group consisting of 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-pyridyl, and 4-pyridyl.
- V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of —Cl, —Br, —F, C 1 -C 3 alkyl, —CF 3 , —COCH 3 , —OH, —OMe, —NH 2 , —NMe 2 , —OEt, —COOH, —CO 2 t-butyl, —CO 2 NH 2 , —SMe, —SO 2 Me, —SO 2 NH 2 and —CN; monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C 1 -C 3 alkyl, —CF 3 , —COCH 3 , —OH, —OMe, —NH 2 , —NMe 2 , —OEt, —COOH, —CO 2 t
- V and Z are connected via an additional 4 atoms to form a 6-membered ring that is fused to a phenyl or substituted phenyl at the beta and gamma position to the O attached to the phosphorus.
- Z is selected from the group consisting of —H, —OMe, —OEt, phenyl, C 1 -C 3 alkyl, —NR 4 2 , —SR 4 , —(CH 2 ) p —OR 6 , —(CH 2 ) p —SR 6 and —OCOR 5 ;
- R 4 is C 1 -C 4 alkyl;
- R 5 is selected from the group consisting of C 1 -C 4 alkyl, monocyclic aryl, and monocyclic aralkyl; and
- R 6 is C 1 -C 4 acyl.
- Z is selected from the group consisting of —H, —OMe, —OEt, and phenyl.
- V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- R 4 is C 1 -C 4 alkyl
- R 5 is selected from the group consisting of C 1 -C 4 alkyl, monocyclic aryl, and monocyclic aralkyl
- R 6 is C 1 -C 4 acyl.
- V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of halogen, C 1 -C 6 alkyl, —CF 3 , —OR 3 , —OR 12 , —COR 3 , —CO 2 R 3 , —NR 3 2 , —NR 12 2 , —CO 2 NR 2 2 , —SR 3 , —SO 2 R 3 , —SO 2 NR 2 2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of halogen, C 1 -C 6 alkyl, —CF 3 , —OR 3 , —OR 12 , —COR 3 , —CO 2 R 3 , —NR 3 2 , —NR 12 2 , —CO 2 NR 2 2 , —SR 3 , —SO 2 R 3 , —SO 2
- W and W′ are independently selected from the group consisting of —H, methyl, and V, or W and W′ are each methyl, with the proviso that when W is V, then W′ is H;
- Z is selected from the group consisting of —H, —OMe, —OEt, phenyl, C 1 -C 3 alkyl, —NR 4 2 , —SR 4 , —(CH 2 ) p —OR 6 , —(CH 2 ) p —SR 6 and —OCOR 5 ; or
- V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom;
- W and W′ are connected via an additional 2-5 atoms to form a cyclic group
- R 3 is C 1 -C 6 alkyl
- R 4 is C 1 -C 4 alkyl
- R 5 is selected from the group consisting of C 1 -C 4 alkyl, monocyclic aryl, and monocyclic aralkyl
- R 6 is C 1 -C 4 acyl.
- V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of —Cl, —Br, —F, C 1 -C 3 alkyl, —CF 3 , —COCH 3 , —OMe, —NMe 2 , —OEt, —CO 2 t-butyl, —CO 2 NH 2 , —SMe, —SO 2 Me, —SO 2 NH 2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C 1 -C 3 alkyl, —CF 3 , —COCH 3 , —OMe, —NMe 2 , —OEt, —CO 2 t-butyl, —CO 2 NH 2 , —SMe, —SO 2 Me, —SO 2 Me, —
- Z is selected from the group consisting of —H, —OMe, —OEt, phenyl, C 1 -C 3 alkyl, —NR 4 2 , —SR 4 , —(CH 2 ) p —OR 6 , —(CH 2 ) p —SR 6 and —OCOR 5 ; or
- Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom;
- W and W′ are connected via an additional 2-5 atoms to form a cyclic group
- R 4 is C 1 -C 4 alkyl
- R 5 is selected from the group consisting of C 1 -C 4 alkyl, monocyclic aryl, and monocyclic aralkyl
- R 6 is C 1 -C 4 acyl.
- W and W′ are independently selected from the group consisting of —H, methyl, and V, or W and W′ are each methyl, with the proviso that when W is V, then W′ is H;
- Z is selected from the group consisting of —H, —OMe, —OEt, phenyl, C 1 -C 3 alkyl, —NR 4 2 , —SR 4 , —(CH 2 ) p —OR 6 , —(CH 2 ) p —SR 6 and —OCOR 5 ; or
- W and W′ are connected via an additional 2-5 atoms to form a cyclic group
- R 4 is C 1 -C 4 alkyl
- R 5 is selected from the group consisting of C 1 -C 4 alkyl, monocyclic aryl, and monocyclic aralkyl
- R 6 is C 1 -C 4 acyl.
- V is selected from the group consisting of phenyl, 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-bromo-4-fluorophenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl; and
- Z is selected from the group consisting of —H, OMe, OEt, and phenyl
- W and W′ are independently selected from the group consisting of —H and phenyl, or W and W′ are each methyl.
- Z, W, and W′ are each —H.
- V and W are the same and each is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl.
- B is
- V is selected from the group consisting of 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, and 4-pyridyl; and Z, W, and W′ are each —H.
- B is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
- V is selected from the group consisting of 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, and 4-pyridyl; and Z, W, and W′ are each —H.
- B is
- V is selected from the group consisting of 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, and 4-pyridyl; and Z, W, and W′ are each —H.
- B is
- a further aspect of this invention includes compounds of Formula V:
- V and the 5′oxymethylene group of the ribose sugar moiety are cis to one another
- V and the 5′oxymethylene group of the ribose sugar moiety are cis to one another;
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl; or pharmaceutically acceptable prodrugs or salts thereof.
- V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of halogen, C 1 -C 6 alkyl, —CF 3 , —OR 3 , —OR 12 , —COR 3 , —CO 2 R 3 , —NR 3 2 , —NR 12 2 , —CO 2 NR 2 2 , —SR 3 , —SO 2 R 3 , —SO 2 NR 2 2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of halogen, C 1 -C 6 alkyl, —CF 3 , —OR 3 , —OR 12 , —COR 3 , —CO 2 R 3 , —NR 3 2 , —NR 12 2 , —CO 2 NR 2 2 2 , —SR 3 , —SO 2 R 3 , —SO
- V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of —Cl, —Br, —F, C 1 -C 3 alkyl, —CF 3 , —COCH 3 , —OMe, —NMe 2 , —OEt, —CO 2 t-butyl, —CO 2 NH 2 , —SMe, —SO 2 Me, —SO 2 NH 2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C 1 -C 3 alkyl, —CF 3 , —COCH 3 , —OMe, —NMe 2 , —OEt, —CO 2 t-butyl, —CO 2 NH 2 , —SMe, —SO 2 Me, —SO 2 Me, —
- V and Z are connected via an additional 4 atoms to form a 6-membered ring that is fused to a phenyl or substituted phenyl at the beta and gamma position to the O attached to the phosphorus.
- V is selected from the group consisting of phenyl; substituted phenyl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C 1 -C 3 alkyl, and —CF 3 ; pyridyl; substituted pyridyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C 1 -C 3 alkyl, and —CF 3 ; furanyl; substituted furanyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C 1 -C 3 alkyl, and —CF 3 ; thienyl; and substituted thienyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C 1 -C 3 alkyl, and —CF 3 .
- V is selected from the group consisting of phenyl, 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-bromo-4-fluorophenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.
- V is selected from the group consisting of 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-pyridyl, and 4-pyridyl.
- this invention includes compounds of Formula II:
- B is selected from the group consisting of:
- V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom;
- W and W′ are connected via an additional 2-5 atoms to form a cyclic group
- R 4 is C 1 -C 4 alkyl
- R 6 is C 1 -C 4 acyl
- R 7 and R 8 are independently selected from the group consisting of hydrogen, C 1 -C 4 acyl, C 1 -C 4 alkoxycarbonyl, and a naturally-occurring L-amino acid connected via its carbonyl group to form an ester; or
- R 7 and R 8 form a cyclic carbonate
- R 9 is selected from the group consisting of amino, azido, —N ⁇ CHN(R 4 ) 2 , —NHC(O)R 4 , and —NHC(O)OR 4 ;
- R 10 is selected from the group consisting of OR 6 , halogen, and H.
- the invention comprises compounds of Formula II:
- B is selected from the group consisting of
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- W and W′ are independently selected from the group consisting of —H, methyl, and V, or W and W′ are each methyl, with the proviso that when W is V, then W′ is H;
- V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom;
- R 4 is C 1 -C 4 alkyl
- R 5 is selected from the group consisting of C 1 -C 4 alkyl, monocyclic aryl, and monocyclic aralkyl;
- R 6 is C 1 -C 4 acyl
- R 7 and R 8 are independently selected from the group consisting of hydrogen, C 1 -C 4 acyl, C 1 -C 4 alkoxycarbonyl, and a naturally-occurring L-amino acid connected via its carbonyl group to form an ester; or
- a further aspect of the invention comprises compounds of Formula III:
- V and the 5′oxymethylene group of the ribose sugar moiety are cis to one another;
- B is selected from the group consisting of:
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- R 4 is C 1 -C 4 alkyl
- R 7 and R 8 are independently selected from the group consisting of hydrogen, C 1 -C 4 acyl, C 1 -C 4 alkoxycarbonyl, and a naturally-occurring L-amino acid connected via its carbonyl group to form an ester; or
- R 7 and R 8 form a cyclic carbonate
- V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of —Cl, —Br, —F, C 1 -C 3 alkyl, —CF 3 , —COCH 3 , —OMe, —NMe 2 , —OEt, —CO 2 t-butyl, —CO 2 NH 2 , —SMe, —SO 2 Me, —SO 2 NH 2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C 1 -C 3 alkyl, —CF 3 , —COCH 3 , —OMe, —NMe 2 , —OEt, —CO 2 t-butyl, —CO 2 NH 2 , —SMe, —SO 2 Me, —SO 2 t-but
- V is selected from the group consisting of phenyl, 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-bromo-4-fluorophenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.
- the invention comprises compounds of Formula III:
- B is selected from the group consisting of
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- R 4 is C 1 -C 4 alkyl
- R 6 is C 1 -C 4 acyl
- R 7 and R 8 are independently selected from the group consisting of hydrogen, C 1 -C 4 acyl, C 1 -C 4 alkoxycarbonyl, and a naturally-occurring L-amino acid connected via its carbonyl group to form an ester; or
- R 10 is selected from the group consisting of OR 4 , OR 6 , NH 2 , NHR 4 , halogen, and H.
- V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of —Cl, —Br, —F, C 1 -C 3 alkyl, —CF 3 , —COCH 3 , —OMe, —NMe 2 , —OEt, —CO 2 t-butyl, —CO 2 NH 2 , —SMe, —SO 2 Me, —SO 2 NH 2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C 1 -C 3 alkyl, —CF 3 , —COCH 3 , —OMe, —NMe 2 , —OEt, —CO 2 t-butyl, —CO 2 NH 2 , —SMe, —SO 2 Me, —SO 2 t-but
- V is selected from the group consisting of phenyl, 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-bromo-4-fluorophenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.
- the compounds of this invention are compounds of Formula VI:
- X is selected from the group consisting of NH 2 , NHCH 3 , N(CH 3 ) 2 , OCH 3 , and SCH 3 ;
- Y and Y′ are independently O or NH;
- V, W, and W′ are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkaryl, each of which is optionally substituted;
- Z is hydrogen, CHWOH, CHWOCOW′, SW, or CH 2 aryl.
- the invention comprises compounds of Formula VII:
- B is selected from the group consisting of:
- X is selected from the group consisting of NH 2 , NHCH 3 , N(CH 3 ) 2 , OCH 3 , SCH 3 , OH, and SH;
- Y and Y′ are independently O or NH;
- the heterocyclic base may be further substituted at any position on the heterocyclic base with a substituent of a molecular weight of less than 150 and selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, aryl, alkaryl, cycloalkyl, acyl, and alkoxy, and wherein said substituents may be coupled to the 6-position of the heterocyclic base via a carbon, sulfur, oxygen, or selenium;
- V, W, and W′ are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkaryl, each of which is optionally substituted;
- Z is hydrogen, CHWOH, CHWOCOW′, SW, or CH 2 aryl.
- B is selected from the group consisting of:
- B is selected from the groups consisting of:
- X is NH 2 .
- the invention comprises:
- the invention comprises:
- the invention comprises:
- the invention comprises:
- the invention comprises:
- the following compounds are included in the invention but the compounds are not limited to these illustrative compounds.
- M1 is a variable that represents nucleosides of Formula I which are attached via 5′-hydroxyl group that is phosphorylated with a group P(O)(O—CH(V)CH 2 CH 2 —O) to make compounds of Formula VI.
- V is an aryl or heteroaryl group that has 2 substituents, L1 and L2, at the designated positions. V may have additional substituents.
- Variable M1 Variable V: Group V1
- Preferred compounds are also compounds listed in Table 1 using variables M1 and V2 wherein the four digit number represents M1.V2.L1.L2.
- Preferred compounds are also compounds listed in Table 1 using variables M1 and V3 wherein the four digit number represents M1.V3.L1.L2. TABLE 1 1.1.1.1 1.1.1.2 1.1.1.3 1.1.1.4 1.1.1.5 1.1.1.6 1.1.1.7 1.1.1.8 1.1.1.9 1.1.2.1 1.1.2.2 1.1.2.3 1.1.2.4 1.1.2.5 1.1.2.6 1.1.2.7 1.1.2.8 1.1.2.9 1.1.3.1 1.1.3.2 1.1.3.3 1.1.3.4 1.1.3.5 1.1.3.6 1.1.3.7 1.1.3.8 1.1.3.9 1.1.4.1 1.1.4.2 1.1.4.3 1.1.4.4 1.1.4.5 1.1.4.6 1.1.4.7 1.1.4.8 1.1.4.9 1.1.5.1 1.1.5.2 1.1.5.3 1.1.5.4 1.1.5.5 1.1.5.6 1.1.5.7 1.1.5.8 1.1.5.9 1.1.6.1 1.1.6.2 1.1.6.3 1.1.6.4 1.1.6.5 1.1.6.6 1.1.6.7 1.1.6.8 1.1.6.9 1.1
- M1 is a variable that represents nucleosides of Formula I which are attached via 5′-hydroxyl group that is phosphorylated with a group P(O)(O—CH(V)CH(Z)C(WW′)—O) to make compounds of Formula I.
- variable M1 The structures for variable M1 are the same as described above.
- Preferred compounds are compounds listed in Table 2 using groups M1 and Group 1 of V/Z/W.
- the compound 1.3 therefore is 7-deaza-2′-methyladenosine with the P(O)(O—CH(4-pyridyl)CH(CH 3 )CH 2 O) attached to the primary hydroxyl.
- Preferred compounds are also compounds listed in Table 2 using groups M1 and Group 2 of V/Z/W.
- Preferred compounds are also compounds listed in Table 2 using groups M1 and Group 3 of V/Z/W. TABLE 2 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9
- Preferred compounds are also compounds of Tables 1 and 2 of formulae VI-VIII where R 7 is an L-valinyl group attached via a carbonyl and R 7 and R 8 form a 5-membered cyclic carbonate.
- the compounds of the present invention can be used for inhibiting viral replication.
- the compounds of this invention can be used for inhibiting RNA-dependent RNA viral replication.
- the compounds of this invention can be used for inhibiting HCV replication.
- the compounds of the present invention can be used for treating viral infections.
- compounds of this invention can be used for treating RNA-dependent RNA viral infection.
- compounds of this invention can be used for treating HCV infection.
- the compounds of the present invention can be used for treating viral infections of the liver.
- compounds of this invention can be used for treating RNA-dependent RNA viral infection in the liver.
- compounds of this invention can be used for treating HCV infection in the liver.
- inhibition of viral replication is measured in serum. Increased viral titer reduction is associated with decreased generation of viral mutants which are associated with drug resistance.
- the compounds of the present invention can be used for preventing the onset of symptoms associated with a viral infection.
- NMP nucleoside monophosphate
- NTP biologically active nucleoside triphosphate
- Drug elimination from the hepatocyte typically entails degradation of phosphorylated metabolites back to a species capable of being transported out of the hepatocyte and into the blood for elimination by the kidney or into the bile for biliary excretion.
- the phophorylated metabolites are dephosphorylated to the uncharged nucleoside.
- nucleosides that leak back into the systemic circulation result in systemic exposure. If the nucleoside is active systemically, e.g. through entry into virally infected cells and phosphorylation to the active species, escape of the nucleoside from the liver leads to biological activity outside of the liver (i.e. extrahepatic tissues, blood cells).
- prodrugs of the invention can be effective for treating diseases outside of the liver, e.g. viral infections. Since many nucleosides exhibit poor oral bioavailability due to breakdown in the gastrointestinal tract either enzymatically (e.g. deamination by adenosine deaminase) or chemically (e.g. acid instability), the prodrug can be used for oral drug delivery. Moreover, given that the prodrugs in some cases are broken down slowly relative to e.g. most ester based prodrugs, the prodrugs could advantageously result in slow, sustained systemic release of the nucleoside.
- nucleosides that are preferentially excreted through the bile or nucleosides that are unable to undergo phosphorylation in tissues or nucleosides that undergo rapid intrahepatic metabolism to a biologically inactive metabolite.
- Some enzymes in the hepatocyte are present that can degrade nucleosides and therefore minimize exposure (e.g. Phase I and Phase II enzymes).
- adenosine deaminase which can deaminate some adenosine-based nucleosides to produce the corresponding inosine analogue. Rapid intracellular deamination of the nucleoside following its dephosphorylation to the nucleoside limits systemic exposure to the nucleoside and diminishes the risk of toxicity.
- Example A-D Methods described in Examples A-D were used to test activation of compounds of this invention. Methods used in Example E were used to evaluate the ability of compounds of the invention to generate NTPs.
- HCV replication in human liver tissue was evaluated as in Example F.
- Liver specificity of the prodrugs relative to the nucleosides was measured by methods in Example G.
- Tissue distribution can be determined according to methods in Example H.
- Oral bioavailability was determined by methods described in Example I.
- the susceptibility of nucleoside analogs to metabolism can be determined as in Example J.
- the RNA-dependent RNA viral infection is a positive-sense single-stranded RNA-dependent viral infection.
- the positive-sense single-stranded RNA-dependent RNA viral infection is Flaviviridae viral infection or Picornaviridae viral infection.
- the Picornaviridae viral infection is rhinovirus infection, poliovirus infection, or hepatitis A virus infection.
- the Flaviviridae viral infection is selected from the group consisting of hepatitis C virus infection, yellow fever virus infection, dengue virus infection, West Nile virus infection, Japanese encephalitis virus infection, Banzi virus infection, and bovine viral diarrhea virus infection.
- the Flaviviridae viral infections hepatitis C virus infection.
- compounds of the present invention can be used to bypass drug resistance.
- compounds of the present invention can be used to treat cancer.
- Compounds of the invention are administered in a total daily dose of 0.01 to 1000 mg/kg. In one aspect the range is about 0.1 mg/kg to about 100 mg/kg. In another aspect the range is 0.5 to 20 mg/kg. The dose may be administered in as many divided doses as is convenient.
- Compounds of this invention when used in combination with other antiviral agents may be administered as a daily dose or an appropriate fraction of the daily dose (e.g., bid). Administration of the prodrug may occur at or near the time in which the other antiviral is administered or at a different time.
- the compounds of this invention may be used in a multidrug regimen, also known as combination or ‘cocktail’ therapy, wherein, multiple agents may be administered together, may be administered separately at the same time or at different intervals, or administered sequentially.
- the compounds of this invention may be administered after a course of treatment by another agent, during a course of therapy with another agent, administered as part of a therapeutic regimen, or may be administered prior to therapy by another agent in a treatment program.
- Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
- an inert solid diluent for example calcium phosphate or kaolin
- an oil medium such as peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
- excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monoo
- Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachid oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin.
- the oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol.
- Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation.
- These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
- Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives.
- a dispersing or wetting agent e.g., sodium tartrate
- suspending agent e.g., sodium EDTA
- preservatives e.g., sodium bicarbonate, sodium bicarbonate, sodium bicarbonate, sodium bicarbonate
- the pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions.
- the oily phase may be a vegetable oil, such as olive oil or arachid oil, a mineral oil, such as liquid paraffin, or a mixture of these.
- Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate.
- the emulsion may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
- sweetening agents such as glycerol, sorbitol or sucrose.
- Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
- compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension.
- a sterile injectable preparation such as a sterile injectable aqueous or oleaginous suspension.
- This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
- the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilized powder.
- the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
- sterile fixed oils may conventionally be employed as a solvent or suspending medium.
- any bland fixed oil may be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic
- a time-release formulation intended for oral administration to humans may contain 20 to 2000 ⁇ mol (approximately 10 to 1000 mg) of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions. It is preferred that the pharmaceutical composition be prepared which provides easily measurable amounts for administration.
- formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion.
- the active ingredient may also be administered as a bolus, electuary or paste.
- a tablet may be made by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free flowing form such as a powder or granules, optionally mixed with a binder (e.g., povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface active or dispersing agent.
- Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent.
- the tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropyl methylcellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach. This is particularly advantageous with the compounds of Formula I when such compounds are susceptible to acid hydrolysis.
- Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
- the formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
- Injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- Formulations suitable for parenteral administration may be administered in a continuous infusion manner via an indwelling pump or via a hospital bag.
- Continuous infusion includes the infusion by an external pump.
- the infusions may be done through a Hickman or PICC or any other suitable means of administering a formulation either parenterally or i.v.
- Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, or an appropriate fraction thereof, of a drug.
- the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs which have previously been administered; and the severity of the particular disease undergoing therapy, as is well understood by those skilled in the art.
- Another aspect of the present invention is concerned with a method of inhibiting HCV replication or treating HCV infection with a compound of the present invention in combination with one or more agents useful for treating HCV infection.
- agents active against HCV include, but are not limited to, ribavirin, levovirin, viramidine, thymosin alpha-1, interferon- ⁇ , interferon- ⁇ , pegylated interferon- ⁇ (peginterferon- ⁇ ), a combination of interferon- ⁇ and ribavirin, a combination of peginterferon- ⁇ and ribavirin, a combination of interferon- ⁇ and levovirin, and a combination of peginterferon- ⁇ and levovirin.
- Interferon- ⁇ includes, but is not limited to, recombinant interferon- ⁇ 2a (such as Roferon interferon available from Hoffmann-LaRoche, Nutley, N.J.), pegylated interferon- ⁇ 2a (PegasysTM), interferon- ⁇ 2b (such as Intron-A interferon available from Schering Corp., Kenilworth, N.J.), pegylated interferon- ⁇ 2b (PegIntronTM), a recombinant consensus interferon (such as interferon alphacon-1), and a purified interferon- ⁇ product.
- Amgen's recombinant consensus interferon has the brand name Infergen®.
- Levovirin is the L-enantiomer of ribavirin which has shown immunomodulatory activity similar to ribavirin.
- Viramidine is a liver-targeting prodrug analog of ribavirin disclosed in WO 01/60379 (assigned to ICN Pharmaceuticals).
- the individual components of the combination can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
- the instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment, and the term “administering” is to be interpreted accordingly.
- the scope of combinations of the compounds of this invention with other agents useful for treating HCV infection includes in principle any combination with any pharmaceutical composition for treating HCV infection.
- the dose of each compound may be either the same as or different from the dose when the compound is used alone.
- composition comprising a compound of Formula I or prodrug or pharmaceutically acceptable salt thereof and at least one agent useful for treating a viral infection, particularly an HCV infection.
- the compounds of the present invention may also be administered in combination with an agent that is an inhibitor of HCV NS3 serine protease.
- HCV NS3 serine protease is an essential viral enzyme and has been described to be an excellent target for inhibition of HCV replication.
- Both substrate and non-substrate based inhibitors of HCV NS3 protease inhibitors are disclosed in WO 98/22496, WO 98/46630, WO 99/07733, WO 99/07734, WO 99/38888, WO 99/50230, WO 99/64442, WO 00/09543, WO 00/59929, GB-2337262, WO 02/48116, WO 02/48172, U.S.
- NS3 protease inhibitors for combination with the compounds of the present invention are BILN 2061 (Boehringer Ingelheim) and VX-950/LY-570310.
- BILN 2061 Boehringer Ingelheim
- VX-950/LY-570310 VX-950/LY-570310.
- HCV NS3 protease as a target for the development of inhibitors of HCV replication and for the treatment of HCV infection is discussed in B. W. Dymock, “Emerging therapies for hepatitis C virus infection,” Emerging Drugs, 6: 13-42 (2001).
- Ribavirin, levovirin, and viramidine may exert their anti-HCV effects by modulating intracellular pools of guanine nucleotides via inhibition of the intracellular enzyme inosine monophosphate dehydrogenase (IMPDH).
- IMPDH inosine monophosphate dehydrogenase
- Ribavirin is readily phosphorylated intracellularly and the monophosphate derivative is an inhibitor of IMPDH.
- inhibition of IMPDH represents another useful target for the discovery of inhibitors of HCV replication.
- the compounds of the present invention may also be administered in combination with an inhibitor of IMPDH, such as VX-497 (merimepodib), which is disclosed in WO 97/41211 and WO 01/00622 (assigned to Vertex); another IMPDH inhibitor, such as that disclosed in WO 00/25780 (assigned to Bristol-Myers Squibb); or mycophenolate mofetil [see A. C. Allison and E. M. Eugui, Agents Action, 44 (Suppl.): 165 (1993)].
- an inhibitor of IMPDH such as VX-497 (merimepodib), which is disclosed in WO 97/41211 and WO 01/00622 (assigned to Vertex); another IMPDH inhibitor, such as that disclosed in WO 00/25780 (assigned to Bristol-Myers Squibb); or mycophenolate mofetil [see A. C. Allison and E. M. Eugui, Agents Action, 44 (Suppl.): 165 (1993
- the compounds of the present invention may also be administered in combination with the antiviral agent amantadine (1-aminoadamantane) and its hydrochloride salt [for a comprehensive description of this agent, see J. Kirschbaum, Anal. Profiles Drug Subs. 12: 1-36 (1983)].
- the compounds of the present invention may also be combined for the treatment of HCV infection with antiviral 1′-C, 2′-C-, or 3′-C-branched ribonucleosides disclosed in R. E. Harry-O'kuru, et al., J. Org. Chem., 62: 1754-1759 (1997); M. S. Wolfe, et al., Tetrahedron Lett., 36: 7611-7614 (1995); U.S. Pat. No. 3,480,613 (Nov. 25, 1969); International Publication Number WO 01/90121 (29 Nov. 2001); International Publication Number WO 01/92282 (6 Dec. 2001); and International Publication Number WO 02/32920 (25 Apr.
- Such branched ribonucleosides include, but are not limited to, 2′-C-methylcytidine, 2′-C-methyluridine, 2′-C-methyladenosine, 2′-C-methylguanosine, and 9-(2-C-methyl- ⁇ -D-ribofuranosyl)-2,6-diaminopurine, and prodrugs thereof.
- the compounds of the present invention may also be combined for the treatment of HCV infection with other nucleosides having anti-HCV properties, such as those disclosed in WO 02/51425 (4 Jul. 2002), assigned to Mitsubishi Pharma Corp.; WO 01/79246, WO 02/32920 (25 Apr. 2002), and WO 02/48165 (20 Jun. 2002), assigned to Pharmasset, Ltd.; WO 01/68663 (20 Sep. 2001), assigned to ICN Pharmaceuticals; WO 99/43691 (2 Sep. 1999); WO 02/18404 (7 Mar. 2002), assigned to Hoffmann-LaRoche; U.S. 2002/0019363 (14 Feb. 2002); WO 02/057287 (25 Jul. 2002), assigned to Merck & Co. and Isis Pharmaceuticals; and WO 02/057425 (25 Jul. 2002), assigned to Merck & Co. and Isis Pharmaceuticals.
- the compounds of the present invention may also be combined for the treatment of HCV infection with non-nucleoside inhibitors of HCV polymerase such as those disclosed in WO 01/77091 (18 Oct. 2001), assigned to Tularik, Inc.; WO 01/47883 (5 Jul. 2001), assigned to Japan Tobacco, Inc.; WO 02/04425 (17 Jan. 2002), assigned to Boehringer Ingelheim; WO 02/06246 (24 Jan. 2002), assigned to Istituto di Ricerche di Biologia Moleculare P. Angeletti S. P. A.; and WO 02/20497 (3 Mar. 2002).
- WO 01/47883 discloses a large number of benzimidazole derivatives, such as JTK-003, which is claimed to be an orally active inhibitor of NS5B that is currently undergoing clinical evaluation.
- NMP 5′-nucleoside monophosphate
- Synthesis of phosphorylation precursors is attained in two stages: 1. Synthesis of 1,3-diols and 2. Synthesis of phosphorylation precursor.
- V, W, Z groups of Formula I can be introduced or modified either during synthesis of diols or after the synthesis of prodrugs.
- 1,3-diols are divided into two types as following: 1) synthesis of racemic 1-(aryl)-propane-1,3-diols; 2) synthesis of enantioenriched 1-(aryl)-propane-1,3-diols.
- 1,3-Dihydroxy compounds can be synthesized by several well-known methods from the literature.
- Substituted aromatic aldehydes are utilized to synthesize racemic 1-(aryl)propane-1,3-diols via addition of lithium enolate of alkyl acetate followed by ester reduction (path A) (Turner, J. Org. Chem. 55:4744 (1990)).
- path A Li enolate of alkyl acetate followed by ester reduction
- aryl lithium or aryl Grignard additions to 1-hydroxy propan-3-al also give 1-(arylsubstituted)propane-1,3-diols (path B).
- This method will enable conversion of various substituted aryl halides to 1-(arylsubstituted)-1,3-propane diols (Coppi, et al., J. Org. Chem. 53:911 (1988)).
- Aryl halides can also be used to synthesize 1-substituted propane diols by Heck coupling of 1,3-diox-4-ene followed by reduction and hydrolysis (Sakamoto, et al., Tetrahedron Lett. 33:6845 (1992)).
- Pyridyl-, quinolyl-, isoquinolyl-propan-3-ol derivatives can be hydroxylated to 1-substituted-1,3-diols by N-oxide formation followed by rearrangement in the presence of acetic anhydride (path C) (Yamamoto, et al., Tetrahedron 37:1871 (1981)).
- a variety of aromatic aldehydes can also be converted to 1-substituted-1,3-diols by vinyl lithium or vinyl Grignard addition followed by hydroboration reaction (path D).
- the ⁇ -keto acid or ester substrates for high pressure hydrogenation or hydrogen transfer reactions may be prepared by a variety of methods such as condensation of acetophenone with dimethylcarbonate in the presence of a base (Chu, et al., J. Het Chem. 22:1033 (1985)), by ester condensation (Turner, et al., J. Org. Chem. 54:4229 (1989)) or from aryl halides (Kobayashi, et al., Tetrahedron Lett. 27:4745 (1986)).
- 1,3-diols of high enantiomeric purity can be obtained by enantioselective borane reduction of ⁇ -hydroxyethyl aryl ketone derivatives or ⁇ -keto acid derivatives (path B) (Ramachandran, et al., Tetrahedron Lett. 38:761 (1997)).
- path B ⁇ -hydroxyethyl aryl ketone derivatives or ⁇ -keto acid derivatives
- commercially available cinnamyl alcohols may be converted to epoxy alcohols under catalytic asymmetric epoxidation conditions. These epoxy alcohols are reduced by Red-Al to result in 1,3-diols with high ee's (path C) (Gao, et al., J. Org. Chem. 53:4081 (1980)).
- Enantioselective aldol condensation is another well-described method for synthesis of 1,3-oxygenated functionality with high ee's starting from aromatic aldehydes. (path D) (Mukaiyama, Org. React. 28:203 (1982)). Synthesis of 2-Substituted 1,3-Diols:
- Various 2-substituted-1,3-diols can be made from commercially available 2-(hydroxymethyl)-1,3-propane-diol.
- Pentaerythritol can be converted to triol via decarboxylation of diacid followed by reduction (path a) (Werle, et al., Liebigs. Ann. Chem., 1986, 944) or diol-monocarboxylic acid derivatives can also be obtained by decarboxylation under known conditions (Iwata, et. al., Tetrahedron Lett. 1987, 28, 3131).
- Nitrotriol is also known to give triol by reductive elimination (path b) (Latour, et.
- the triol can be derivatized by mono acylation or carbonate formation by treatment with alkanoyl chloride, or alkylchloroformate (path d) (Greene and Wuts, Protective groups in organic synthesis , John Wiley, New York, 1990).
- Aryl substitution can be affected by oxidation to aldehyde and aryl Grignard additions (path c).
- Aldehydes can also be converted to substituted amines by reductive animation reaction (path e). Synthesis of cyclic-1,3-diols:
- Compounds of Formula 1 where V-Z or V-W are fused by four carbons are made from cyclohexane diol derivatives.
- Commercially available cis, cis-1,3,5-cyclohexane-triol can be used as is or modified as described in case of 2-substituted propan-1,3-diols to give various analogues. These modifications can either be made before or after ester formation.
- Various 1,3-cyclohexane-diols can be made by Diels-Alder methodology using pyrone as diene (Posner, et. al., Tetrahedron Lett., 1991, 32, 5295).
- 1,3-Diols described in the earlier section can be converted selectively to either hydroxy amines or to corresponding diamines by converting hydroxy functionality to a leaving group and treating with anhydrous ammonia or required primary or secondary amines (Corey, et al., Tetrahedron Lett., 1989, 30, 5207: Gao, et al., J. Org. Chem., 1988, 53, 4081).
- a similar transformation may also be achieved directly from alcohols under Mitsunobu type of reaction conditions (Hughes, D. L., Org. React., 1992, 42).
- a general synthetic procedure for 3-aryl-3-hydroxy-propan-1-amine type of prodrug moiety involves aldol type condensation of aryl esters with alkyl nitrites followed by reduction of resulting substituted benzoylacetonitrile (Shih et al., Heterocycles, 1986, 24, 1599).
- the procedure can also be adapted for formation of 2-substituted aminopropanols by using substituted alkylnitrile.
- 3-aryl-3-amino-propan-1-ol type of prodrug groups are synthesized from aryl aldehydes by condensation of malonic acid in presence of ammonium acetate followed by reduction of resulting substituted ⁇ -amino acids.
- Chiral induction in 1,3-polar additions to form substituted isoxazolidines is also attained by chiral phosphine palladium complexes resulting in enantioselective formation of amino alcohols (Hori, et al., J. Org. Chem., 1999, 64, 5017).
- optically pure 1-aryl substituted amino alcohols are obtained by selective ring opening of corresponding chiral epoxy alcohols with desired amines (Canas et al., Tetrahedron Lett., 1991, 32, 6931).
- Diastereoselective formation of 1,3-aminoalcohols is also achieved by reductive amination of optically pure 3-hydroxy ketones (Haddad et al., Tetrahedron Lett., 1997, 38, 5981).
- 3-aminoketones are transformed to 1,3-disubstituted aminoalcohols in high stereoselectivity by a selective hydride reduction (Barluenga et al., J. Org. Chem., 1992, 57, 1219).
- Synthesis of phosphorylation precursors is divided in to two sections: a. synthesis of P(III) phosphorylation precursor, b. stereoselective synthesis of P(V) phosphorylation precursors. Synthesis of P(III) Phosphorylation Precursors:
- Phosphorylation of 5′-alcohol is achieved using cyclic 1′,3′-propanyl esters of phosphorylating agents where the agent is in the P(III) oxidation state.
- Appropriately substituted phosphoramidites can be prepared by reacting cyclic chlorophospholanes with N,N-dialkylamine (Perich, et al., Aust. J. Chem., 1990, 43, 1623. Perich, et al, Synthesis, 1988, 2, 142) or by reaction of commercially available dialkylaminophosphorochloridate with substituted propane-1,3-diols. Synthesis of P(V) Phosphorylation Precursors:
- the activated precursor can be prepared by several well known methods.
- Chlorophosphates useful for synthesis of the prodrugs are prepared from the substituted-1,3-propanediol (Wissner, et al, J. Med. Chem., 1992, 35, 1650). Chlorophosphates are made by oxidation of the corresponding chlorophospholanes (Anderson, et al, J. Org.
- chlorophosphate agent is made by treating substituted-1,3-diols with phosphorus oxychloride (Patois, et al, J. Chem. Soc. Perkin Trans. I, 1990, 1577).
- Chlorophosphate species may also be generated in situ from corresponding cyclic phosphites (Silverburg, et al., Tetrahedron Lett., 1996, 37, 771), which in turn can be either made from a chlorophospholane or phosphoramidate intermediate.
- Phosphorofluoridate intermediate prepared either from pyrophosphate or phosphoric acid may also act as precursor in preparation of cyclic prodrugs (Watanabe et al., Tetrahedron Lett., 1988, 29, 5763).
- Monoalkyl or dialkylphosphoramidate (Watanabe, et al, Chem Pharm Bull., 1990, 38, 562), triazolophosphoramidate (Yamakage, et al., Tetrahedron, 1989, 45, 5459) and pyrrolidinophosphoramidate (Nakayama, et al, J. Am. Chem. Soc., 1990, 112, 6936) are some of the known intermediates used for the preparation of phosphate esters.
- Another effective phosphorylating procedure is a metal catalyzed addition of cyclic chlorophosphate adduct of 2-oxazolone.
- This intermediate attains high selectivity in phosphorylation of primary hydroxy group in presence of secondary hydroxyl group (Nagamatsu, et al, Tetrahedron Lett., 1987, 28, 2375).
- These agents are obtained by reaction of a chlorophosphate with the amine or alternatively by formation of the corresponding phosphoramidite followed by oxidation.
- the enantioenriched activated phosphorylating agent is synthesized by phosphorylation of an enantioenriched 1-(V)-1,3-propanediol with phosphorodichloridates of formula L—P(O)Cl 2 in the presence of a base (Ferroni, et al., J. Org. Chem. 64(13), 4943 (1999)). Phosphorylation of an enantiomerically pure substituted diol with, for example, a commercially available phosphorodichloridate R—OP(O)Cl 2 , where RO is a leaving group, preferably aryl substituted with electron withdrawing groups, such as a nitro or a chloro, produces two diastereomeric intermediates.
- the relative configuration of the phosphorus atom is easily determined by comparison of the 31 P NMR spectra.
- the chemical shift of the equatorial phosphoryloxy moiety (trans-isomer) is always more upfield than the one of the axial isomer (cis-isomer) (Verkade, et al, J. Org. Chem., 1977, 42, 1549).
- These diastereomers can be further equilibrated to give a trans-2,4-substituted phosphorylating agents in presence of a base such as triethyl amine or DBU.
- the equilibration to complete inversion of 2,4-cis-diastereomer is also achieved in presence of appropriately substituted sodium phenoxide.
- the equilibration step results in greater than 95% ee of the isolated trans-phosphorylating agent.
- nucleoside moieties of Formula I are well described in the literature.
- 2′-C-methyl-adenosine and 2′-C-methyl-guanosine analogs are made by Lewis acid catalyzed reactions of the persilylated base and 1′-acetate or benzoate sugar intermediate (Walton et al., J. Am. Chem. Soc., 1966, 88, 4524; Harry-O'Kuru et al., J. Org. Chem., 1997, 62, 1754, WO01/90121).
- the 7-deaza analogs are made as described earlier from 1′-bromo sugar intermediate via reaction of sodium salt of the bases (US2002-0147160A1 or WO02/057827).
- the glycosylation products are subjected to deprotection and amination via ammonolysis reaction.
- nucleoside moieties and derivatives thereof of Formulae VI-VIII of the present invention may be synthesized by many well-established general methods described in the nucleoside literature. Several nucleosides analogs described herein are synthesized as illustrated in WO04/046331 and by the methods cited therein. These compounds of the present invention can also be made from a wide variety of commercial bases utilizing the 2′-methyl riboglycosylation precursor (US2002-0147160A1 or WO02/057827) via a range of well-known glycosylation reactions (Vorbruggen and Ruh-Pohlenz, Handbook of Nucleoside Synthesis , Wiley, New York, 2001).
- deaza and aza nucleoside analogs may be prepared utilizing the methods reported in the case of corresponding ribo-analogs by glycosylation with 2′-methyl glycosylation precursor (Robins, et al., Advances in Antiviral Drug Design, Vol. 1, p 39-85, De Clercq, ed., JAI Press, Greenwich, Conn., 1993).
- new base analogs of the nucleosides can be synthesized by modification of the available nucleosides or via synthesis of new bases followed by glycosylation ( Chemistry of Nucleosides and Nucleotides , Vols. 1-3, Townsend, ed., Plenum, New York, 1988 and Nucleic Acid Chemistry, Vols. 1-4, Townsend and Tipson Eds., Wiley, New York, 1986).
- prodrugs can be introduced at different stages of the synthesis. Most often they are made at a later stage, because of the general sensitivity of these groups to various reaction conditions.
- Optically pure prodrugs containing single isomer at phosphorus center are made by coupling of enantiomerically enriched activated phosphate intermediates.
- prodrugs are further organized into, 1) synthesis via P(III) intermediates, 2) synthesis via P(V) intermediates, and 3) miscellaneous methods. Synthesis of Prodrugs Via P(III) Intermediates: wherein Q is N or CH; and L is H and M is NH 2 or M is OH and L is NH 2 .
- Chlorophospholanes are used to phosphorylate alcohols on nucleosides in the presence of an organic base (e.g., triethylamine, pyridine).
- an organic base e.g., triethylamine, pyridine.
- the phosphite can be obtained by coupling the nucleoside with a phosphoramidate in the presence of a coupling promoter such as tetrazole or benzimidazolium triflate (Hayakawa et al., J. Org. Chem., 1996, 61, 7996).
- Phosphite diastereomers may be isolated by column chromatography or crystallization (Wang, et al, Tetrahedron Lett, 1997, 38, 3797; Bentridge et al., J. Am.
- the resulting phosphites are subsequently oxidized to the corresponding phosphate prodrugs using an oxidant such as molecular oxygen or t-butylhydroperoxide (Meier et al., Bioorg, Med. Chem. Lett., 1997, 7, 1577). Oxidation of optically pure phosphites is expected to stereoselectively provide optically active prodrugs (Mikolajczyk, et al., J. Org. Chem., 1978, 43, 2132. Cullis, P. M. J. Chem. Soc., Chem Commun., 1984, 1510, Verfurth, et al., Chem. Ber., 1991, 129, 1627).
- an oxidant such as molecular oxygen or t-butylhydroperoxide
- the prodrug moiety can be introduced at different stages of the synthesis. Most often the cyclic phosphates are introduced at a later stage, because of the general sensitivity of these groups to various reaction conditions.
- the synthesis can also proceed through using a protected or unprotected nucleoside or nucleoside analog depending on the reactivity of the functional groups present in the compound.
- Single stereoisomers of the cis-prodrugs can be made either by separation of the diastereoisomers/enantiomers by a combination of column chromatography and/or crystallization, or by enantiospecific or enantioselective synthesis using enantioenriched activated phosphate intermediates.
- the general procedure for the phosphorylation of protected nucleosides is accomplished by reacting a suitably protected nucleoside with a base and reacting the alkoxide generated with the phosphorylating reagent.
- the protected nucleoside can be prepared by one skilled in the art using one of the many procedures described for the protection of nucleosides (Greene T. W., Protective Groups in Organic Chemistry, John Wiley & Sons, New York (1999)).
- the nucleoside is protected in such a way as to expose the hydroxyl group on which to add the phosphate group while protecting all the remaining hydroxyls and other functional groups on the nucleoside that may interfere with the phosphorylation step or lead to regioisomers.
- the protecting groups selected are resistant to strong bases, e.g., ethers, silyl ethers and ketals.
- the protecting groups are optionally substituted MOM ethers, MEM ethers, trialkylsilyl ethers and symmetrical ketals.
- the protecting groups are t-butyldimethylsilyl ether and isopropylidene. Further protection entails masking of the amino group of the base moiety, if present, so as to eliminate any acidic protons.
- the selected N-protecting groups are selected from the groups of dialkyl formamidines, mono and dialkyl imines, mono and diaryl imines.
- the N-protecting groups are selected from the groups of dialkyl formamidines and mono-alkyl imine and mono aryl imine.
- the mono-alkyl imine is benzylimine and the mono-aryl imine is phenylimine.
- the N-protecting group is a symmetrical dialkyl formamidine selected from the group of dimethyl formamidine and diethyl formamidine.
- the alkoxide of the exposed hydroxyl group on the suitably protected nucleoside is accomplished with a base in an aprotic solvent that is not base sensitive such as THF, dialkyl and cyclic formamides, ether, toluene and mixtures of those solvents.
- the solvents are DMF, DMA, DEF, N-methylpyrrolidinone, THF, and mixture of those solvents.
- nucleosides and non-nucleoside compounds with cyclic and acyclic phosphorylating agents have been used for the phosphorylation of nucleosides and non-nucleoside compounds with cyclic and acyclic phosphorylating agents.
- trialkylamines such as triethylamine (Roodsari et al., J. Org. Chem. 64(21), 7727 (1999)) or N,N-diisopropylethylamine (Meek et al., J. Am. Chem. Soc. 110(7), 2317 (1988)
- nitrogen containing heterocyclic amines such as pyridine (Hoefler et al., Tetrahedron 56(11), 1485 (2000)), N-methylimidazole (Vankayalapati et al., J.
- Grignard reagents are alkyl and aryl Grignards.
- the Grignard reagents are t-butyl magnesium halides and phenyl magnesium halides.
- the Grignard reagents are t-butylmagnesium chloride and phenylmagnesium chloride.
- magnesium alkoxides are used to generate the magnesium 5′-alkoxide of the nucleoside.
- magnesium alkoxides are selected from the group of Mg(O-t-Bu) 2 , and Mg(O-iPr) 2 .
- deprotection reagents include fluoride salts to remove silyl protecting groups, mineral or organic acids to remove acid labile protecting groups such as silyl and/or ketals and N-protecting groups, if present.
- reagents are tetrabutylammonium fluoride (TBAF), hydrochloric acid solutions and aqueous TFA solutions. Isolation and purification of the final prodrugs, as well as all intermediates, are accomplished by a combination of column chromatography and/or crystallization.
- the sequence provides methods to synthesize single isomers of compounds of Formula I. Due to the presence of a stereogenic center at the carbon where V is attached on the cyclic phosphate reagent, this carbon atom can have two distinct orientations, namely R or S.
- the trans-phosphate reagent prepared from a racemic diol can exist as either the S-trans or R-trans configuration and results in a S-cis and R-cis prodrug mixture.
- the reaction of the C′-S-trans-phosphate reagent generates the C′-S-cis-prodrug of the nucleoside while reaction with the C′-R-trans-phosphate reagent generates the C′-R-cis-prodrug.
- Synthesis of 6-, 2′- and/or 3-′ substituted prodrugs of Formula II or III can be accomplished starting from compounds of Formula I.
- selective 3′-acylation of nucleoside monophosphate cyclic prodrugs of Formula I may be achieved by several methods as described in the literature ( Protective groups in organic synthesis , Greene and Wuts, John Wiley, New York, 1991). Additionally, selective 3′-acylation can be attained by various esterification methods in the presence of tertiary hydroxy functionality at the 2′-position without protection. Acylation may also be accomplished efficiently by utilizing amine protected amino acids as described earlier (WO 04/002422, Hanson et al., Bioorg. Med. Chem.
- Prodrugs at 6-position may be prepared from the corresponding halo derivatives of the nucleosides.
- the prodrug substitution is made at the nucleoside stage (before 5′-prodrug formation) from the corresponding chloro or hydroxy functionalities in case of compounds of Formula II or III where R 9 or R 10 is substituted (e.g., N 3 , H, —COR).
- R 9 or R 10 is substituted (e.g., N 3 , H, —COR).
- Synthesis of such nucleoside precursors are attained as described earlier (WO 02/057287).
- Preparation of these purine analogs by azido displacement (Aso et al., J. Chem Soc Perkin Trans II, 2000, 8 1637) or hydrogention (Freer et al., Tetrahedron, 2000, 56, 45) are well known methods.
- these prodrug functionality substituted nucleosides are transformed to corresponding monophosphate cyclic prodrugs of Formula II or
- Coupling of activated phosphates with alcohols is accomplished in the presence of an organic base.
- an organic base for example, chlorophosphates synthesized as described in the earlier section react with an alcohol in the presence of a base such as pyridine or N-methylimidazole.
- phosphorylation is enhanced by in situ generation of iodophosphate from chlorophosphate (Stomberg, et al., Nucleosides & Nucleotides., 1987, 5: 815).
- Phosphorofluoridate intermediates have also been used in phosphorylation reactions in the presence of a base such as CsF or n-BuLi to generate cyclic prodrugs (Watanabe et al., Tetrahedron Lett., 1988, 29, 5763). Phosphoramidate intermediates are known to couple by transition metal catalysis (Nagamatsu, et al., Tetrahedron Lett., 1987, 28, 2375).
- reaction of the optically pure diastereomer of phosphoramidate intermediate with the hydroxyl of nucleoside in the presence of an acid produces the optically pure phosphate prodrug by direct S N 2(P) reaction (Nakayama, et al., J. Am. Chem. Soc., 1990, 112, 6936).
- reaction of the optically pure phosphate precursor with a fluoride source preferably cesium fluoride or TBAF, produces the more reactive phosphorofluoridate which reacts with the hydroxyl of the nucleoside to give the optically pure prodrug by overall retention of configuration at the phosphorus atom (Ogilvie, et al., J. Am. Chem. Soc., 1977, 99, 1277).
- Prodrugs of Formula I are synthesized by reaction of the corresponding phosphodichloridate and an alcohol (Khamnei, et al., J. Med. Chem., 1996, 39: 4109). For example, the reaction of a phosphodichloridate with substituted 1,3-diols in the presence of base (such as pyridine and triethylamine) yields compounds of Formula I.
- base such as pyridine and triethylamine
- Such reactive dichloridate intermediates can be prepared from the corresponding acids and the chlorinating agents such as thionyl chloride (Starrett, et al, J. Med. Chem., 1994, 1857), oxalyl chloride (Stowell, et al., Tetrahedron Lett., 1990, 31: 3261), and phosphorus pentachloride (Quast, et al., Synthesis, 1974, 490).
- the chlorinating agents such as thionyl chloride (Starrett, et al, J. Med. Chem., 1994, 1857), oxalyl chloride (Stowell, et al., Tetrahedron Lett., 1990, 31: 3261), and phosphorus pentachloride (Quast, et al., Synthesis, 1974, 490).
- Phosphorylation of an alcohol is also achieved under Mitsunobu reaction conditions using the cyclic 1′,3′-propanyl ester of phosphoric acid in the presence of triphenylphosphine and diethyl azodicarboxylate (Kimura et al., Bull. Chem. Soc. Jpn., 1979, 52, 1191). The procedure can be extended to prepare enantiomerically pure phosphates from the corresponding phosphoric acids. Phosphate prodrugs are also prepared from the free acid by Mitsunobu reactions (Mitsunobu, Synthesis, 1981, 1; Campbell, J. Org.
- Cyclic-1,3-propanyl prodrugs of phosphates are also synthesized from NMP and substituted propane-1,3-diols using a coupling reagent such as 1,3-dicyclohexylcarbodiimide (DCC) in presence of a base (e.g., pyridine).
- a coupling reagent such as 1,3-dicyclohexylcarbodiimide (DCC) in presence of a base (e.g., pyridine).
- DCC 1,3-dicyclohexylcarbodiimide
- EDCI 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
- Phosphate prodrugs can be prepared by an alkylation reaction between the phosphate corresponding tetrabutylammonium salts and substituted-1,3-diiodopropanes made from 1,3-diols (Farquhar, et al., Tetrahedron Lett., 1995 36, 655). Furthermore, phosphate prodrugs can be made by conversion of nucleoside to the dichloridate intermediate with phosphoryl chloride in presence of triethylphosphite and quenching with substituted-1,3-propanediols (Farquhar et al., J. Org. Chem., 1983, 26, 1153).
- Phosphorylation can also be achieved by making the mixed anhydride of the cyclic diester of phosphoric acid and a sulfonyl chloride, preferably 8-quinolinesulfonyl chloride, and reacting the hydroxyl of the nucleoside in the presence of a base, preferably N-methylimidazole (Takaku, et al., J. Org. Chem., 1982, 47, 4937).
- a base preferably N-methylimidazole
- Step A ( J. Org. Chem. 53:911 (1988))
- Step A ( J. Org. Chem. 55:4744 (1990))
- the crude hydroxyester was dissolved in ether (2.8 mL/mmol), cooled to ice bath temperature, and lithium aluminum hydride (3 mmol) was added batch wise. The reaction was stirred allowing the cooling bath to melt and the reaction to reach room temperature. After stirring overnight at room temperature, the reaction was cooled back to ice bath temperature and quenched with ethyl acetate. Aqueous work up (0.5 M HCl) afforded the crude diol, which was purified either by chromatography or distillation.
- a pressure vessel was charged with 1-(3-bromophenyl)-1,3-propanediol (2 g, 8.6 mmol), methanol (30 mL), triethylamine (5 mL) and bis(triphenylphosphine)palladium dichloride (0.36 g, 05 mmol).
- the sealed vessel was pressurize with carbon monoxide at 55 psi and heated at 85° C. for 24 h.
- the cooled vessel was opened and the reaction mixture was filtered through Celite and rinsed with methanol.
- the combined filtrates were concentrated under reduced pressure and the residue was purified by column chromatography (silica gel, hexanes/ethyl acetate 1/1) to afford the title compound (1.2 g)
- Example 4 1-(4-bromophenyl)-1,3-propane diol was prepared as Example 4 and further derivatized as Example 4a.
- Racemic diols synthesized as in Examples 1-4 may be resolved to yield both enantiomers as described in the following procedure.
- the separated ketals were hydrolyzed by adding a catalytic amount of concentrated hydrochloric acid to a methanol (4.0 mmol) solution of each. After stirring overnight at room temperature, the methanol was removed under vacuum and the residue was subjected to aqueous work up. The resolved diols were further purified by either chromatography or distillation.
- Enantiomeric excesses were defined as diacetates (prepared by treatment of diols with acetic anhydride, triethylamine, cat.DMAP in dichloromethane) by HPLC ((S,S) Whelko-0, 250 cm ⁇ 4.0 mm ID purchased from Regis).
- (+)Diisopropyltartrate provided >96% ee in (R)-1-(3′-chlorophenyl)-1,3-dihydroxypropane.
- a 12 L, 3-neck round bottom flask was equipped with a mechanical stirrer, thermometer, addition funnel (500 mL) and nitrogen inlet (bubbler in-line).
- the flask was flushed with nitrogen and charged with formic acid (292 mL, 350 g).
- Triethylamine (422 mL, 306 g) was charged to the addition funnel, then added slowly with stirring, maintaining the temperature less than 45° C. After the addition was complete (1 h, 30 min), the solution was stirred with the ice bath applied for 20 min., then at ambient temperature for an additional 1 h.
- the flask was charged sequentially with methyl 3-(3-chlorophenyl)-3-oxo-propanoate (1260 g), DMF (2.77 L including rinsing volume) and (S,S)-Ts-DPEN-Ru—Cl-(p-cymene) (3.77 g).
- the flask was equipped with a heating mantle and the addition funnel was replaced with a condenser (5 C circulating coolant for condenser).
- the stirred reaction solution was slowly heated to 60° C. (90 min. to attain 60° C.) and the contents were maintained at 60° C. for 4.25 h. HPLC indicated 3% starting material remained.
- the solution was stirred at 60° C.
- the crude hydroxyester (10 mg, 0.046 mmol) was dissolved in dichloromethane (1 mL). Acetic anhydride (22 ⁇ L, 0.23 mmol) and 4-(dimethylamino)pyridine (22 mg, 0.18 mmol) were added and the solution was stirred at ambient temperature for 15 min. The solution was diluted with dichloromethane (10 mL) and washed with 1 M hydrochloric acid (3 ⁇ 3 mL). The organic phase was dried (MgSO 4 ), filtered and concentrated under reduced pressure.
- a 22 L, 3-neck round bottom flask was equipped with a mechanical stirrer, thermowell/thermometer and nitrogen inlet (outlet to bubbler).
- the flask was charged with 2 M borane-THF (3697 g, 4.2 L) and the stirred solution was cooled to 5° C.
- a solution of (S)-3-(3-chlorophenyl)-3-hydroxypropanoic acid (830 g) in THF (1245 mL) was prepared with stirring (slightly endothermic).
- the reaction flask was equipped with an addition funnel (1 L) and the hydroxyacid solution was slowly added to the stirred borane solution, maintaining the temperature ⁇ 16° C.
- the oil was purified by vacuum distillation and the fraction at 135-140° C./0.2 mm Hg was collected to provide 712.2 g of a colorless oil.
- a 50 L, 3-neck flask was equipped with an overhead stirrer, heating mantle, and nitrogen inlet.
- the flask was charged with THF (8 L), potassium t-butoxide (5 kg, 44.6 mol), and THF (18 L).
- 4-Acetylpyridine (2.5 kg, 20.6 mol) was added, followed by dimethylcarbonate (3.75 L, 44.5 mol).
- the reaction mixture was stirred without heating for 2.5 h then with heating to 57-60° C. for 3 h.
- the heat was turned off and the mixture cooled slowly overnight (15 h).
- the mixture was filtered through a 45 cm Buchner funnel.
- the solid was returned to the 50 L flask and diluted with aqueous acetic acid (3 L acetic acid in 15 L of water).
- the mixture was extracted with MTBE (1 ⁇ 16 L, 1 ⁇ 12 L).
- the combined organic layers were washed with aqueous Na 2 CO 3 (1750 g in 12.5 L water), saturated aqueous NaHCO 3 (8 L), and brine (8 L) then dried over MgSO 4 (500 g) overnight (15 h).
- the solution was filtered and the solvent removed by rotary evaporation to a mass of 6.4 kg.
- the resulting suspension was cooled in an ice bath with stirring for 2 h.
- the solid was collected by filtration, washed with MTBE (500 mL), and dried in a vacuum oven at 20° C. for 15 h, giving 2425 g of the keto ester as a pale yellow solid.
- the MTBE mother liquor was concentrated to approximately 1 L.
- the resulting suspension was cooled in an ice bath for 1 h.
- the solid was collected by filtration, washed with MTBE (2 ⁇ 150 mL), and dried in a vacuum oven to give 240 g of a second crop.
- Step B Synthesis of S-methyl-3-hydroxy-3-(pyridin-4-yl)-propanoate
- a 22 L, 3-neck round bottom flask was equipped with an overhead stirrer, thermowell/thermometer, addition funnel (1 L), and cooling vessel (empty).
- the flask was flushed with nitrogen, charged with formic acid (877 g) and cooled with an ice bath.
- Triethylamine (755 g) was charged to the addition funnel and added slowly over 50 min. to the stirred formic acid.
- the cooling bath was removed and the reaction solution was diluted with DMF (5.0 L).
- the ketoester (2648 g) was added in one portion, followed by an additional 0.5 L of DMF.
- the flask was equipped with a heating mantle and the stirred mixture was heated gradually to 16° C. to dissolve all solids.
- the catalyst (S,S)-Ts-DPEN-Ru—Cl-(p-cymene) (18.8 g) was added in one portion and the stirred mixture was heated to 55° C. over 1 h. The resulting dark solution was stirred at 55° C. for 16 h. TLC indicated the reaction was complete.
- the oil was dissolved in dichloromethane (10 L) and transferred to a 5 gal. stationary separatory funnel.
- the dark solution was washed with saturated sodium bicarbonate solution (3.0 L) and the aqueous phase was back extracted with dichloromethane (3.0 L).
- the combined dichloromethane extracts were dried over MgSO 4 (300 g), filtered, and concentrated under reduced pressure to provide 3362 g of a brown oil.
- a 22 L, 4-neck round bottom flask was equipped with an overhead stirrer, thermowell/thermometer, addition funnel (2 L), condenser and cooling vessel (empty).
- the flask was flushed with nitrogen and charged sequentially with sodium borohydride (467 g, 12.3 mol), 1-butanol (9.0 L), and water (148 mL, 8.23 mol)
- the crude hydroxyester was dissolved in 1-butanol (1.0 L) and the solution was charged to the addition funnel.
- the solution was added over 3.25 h, using cooling as necessary to keep the temperature below 62° C.
- the mixture was stirred for 0.5 h then the flask was equipped with a heating mantle and the stirred mixture was heated to 90° C.
- Acetonitrile (3 L) was fed into the evaporator flask and the solvent was evaporated under reduced pressure.
- a 12 L, 3-neck round bottom flask was equipped with a mechanical stirrer and addition funnel (2 L). The flask was flushed with nitrogen and charged with diisopropylamine (636 mL) and THF (1.80 L). A thermocouple probe was immersed in the reaction solution and the stirred contents were cooled to ⁇ 20° C. n-Butyllithium (1.81 L of a 2.5 M solution in hexanes) was charged to the addition funnel and added slowly with stirring, maintaining the temperature between ⁇ 20 and ⁇ 28° C. After the addition was complete (30 min), the addition funnel was rinsed with hexanes (30 mL) and the stirred solution was cooled to ⁇ 62° C.
- Trimethylsilyl acetate 300 g was added slowly with stirring, maintaining the temperature ⁇ 60° C. After the addition was complete (30 min), the solution was stirred at ⁇ 60° C. for 15 min.
- 3-Chlorobenzoyl chloride (295 mL) was added slowly with stirring, maintaining the temperature ⁇ 60° C. After the addition was complete (65 min), the cooling bath was removed and the reaction solution was stirred for 1.25 h, with gradual warming to 0° C.
- the reaction flask was cooled with an ice bath, then water (1.8 L) was added to the stirred solution. The reaction mixture was stirred for 10 min., then diluted with t-butyl methyl ether (1.0 L).
- the lower aqueous phase was separated and transferred to a 12 L, 3-neck round bottom flask equipped with a mechanical stirrer.
- t-Butyl methyl ether was added (1.8 L) and the stirred mixture was cooled to ⁇ 10° C. (ice bath).
- Concentrated HCl solution 300 mL of 12 M solution was added and the mixture was vigorously stirred.
- the layers were separated and aqueous phase was further acidified with con. HCl (30 mL) and extracted again with t-butyl methyl ether (1.0 L).
- the combined MTBE extracts were washed with brine (1 L), dried (MgSO4, 70 g), filtered and concentrated under reduced pressure to give 827 g of a yellow solid.
- a 12 L, 3-neck round bottom flask was equipped with a mechanical stirrer and addition funnel (1 L). The flask was flushed with nitrogen and charged with 3-(3-chlorophenyl)-3-oxo-propanoic acid (275.5 g) and dichloromethane (2.2 L). A thermocouple probe was immersed in the reaction slurry and the stirred contents were cooled to ⁇ 20° C. Triethylamine (211 mL) was added over 5 min. to the stirred slurry and all solids dissolved.
- Beta-ketoester starting material was synthesized as described in Example 7, step A.
- a solution containing beta-ketoester (1 mmol) in either methanol or ethanol (5-10 mL/mmol ketoester) was degassed through several pump/vent (N 2 ) cycles at room temperature.
- the degassed solution was moved into a glove bag and under an atmosphere of N 2 was poured into a stainless steel bomb containing a stir bar and 1.0 mole % Ru-BINAP catalyst.
- the bomb was sealed, removed from the glove bag and purged with H 2 prior to stirring 18-24 h at room temperature and 150 psi H 2 . After venting the hydrogen pressure, the bomb was opened and the reaction mixture was removed and concentrated.
- the crude beta-hydroxyester was used for hydrolysis.
- the reddish reaction mixture was cooled to room temperature and stirred at room temperature for 2 h then placed in the refrigerator overnight.
- the final ratio was determined by HPLC to be 96/4 trans/cis.
- the reaction mixture was quenched with a saturated solution of ammonium chloride and diluted with ethyl acetate. The layers were separated and the organics were washed 4 times with 0.3 N sodium hydroxide to remove the nitrophenol, then saturated sodium chloride and dried over sodium sulfate.
- Example 13a Same as Example 11.1 starting with 1-(2,3-dichlorophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and lithium hydride as in Example 13a.
- Example 11.1 Same as Example 11.1 starting with 1-(2,3,5-trichlorophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- Example 13a Same as Example 11.1 starting with 1-(2-chlorophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and lithium hydride as in Example 13a.
- Example 11.1 Same as Example 11.1 starting with 1-(3,5-dimethoxyphenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- Example 11.1 Same as Example 11.1 starting with 1-(2-bromophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13a.
- Example 11.1 Same as Example 11.1 starting with 1-(3-bromo-5-ethoxyphenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- Example 11.1 Same as Example 11.1 starting with 1-(2-trifluoromethylphenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- Example 11.1 Same as Example 11.1 starting with 1-(4-chlorophenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- Example 11.1 Same as Example 11.1 starting with 1-(3-methylphenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- Example 11.1 Same as Example 11.1 starting with 1-(4-fluorophenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- Example 11.1 Same as Example 11.1 starting with 1-(2-fluorophenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- Example 11.1 Same as Example 11.1 starting with 1-(3-fluorophenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- Example 11.1 Same as Example 11.1 starting with 1-[4-(4-chlorophenoxy)phenyl]-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- Example 11.1 Same as Example 11.1 starting with 1-(3-bromophenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- Example 11.1 Same as Example 11.1 starting with 1-(3,4-ethylenedioxyphenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- Example 11.1 Same as Example 11.1 starting with 1-(2-fluoro-4-chlorophenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- Example 11.1 Same as Example 11.1 starting with 1-(2,6-dichlorophenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- Example 11.1 Same as Example 11.1 starting with 1-(2-fluoro-5-methoxyphenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- Example 11.1 Same as Example 11.1 starting with 1-(3-fluoro-4-chlorophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- Example 11.1 Same as Example 11.1 starting with 1-(3-chloro-4-fluorophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- Example 11.1 Same as Example 11.1 starting with 1-(2,3,5,6-tetrafluorophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- Example 11.1 Same as Example 11.1 starting with 1-(2,3,6-trifluorophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- the 1,2-cis ketal (4.5 g, 17.5 mmol) was dissolved in 70% aq TFA (10 mL) and allowed to react overnight at room temperature. The reaction was diluted with acetonitrile (30 mL) and volatiles were removed under reduced pressure. The residue was dissolved in EtOAc (300 mL) and the organic layer was washed with saturated aq NaHCO 3 , water and dried (anhydrous Na 2 SO 4 ). The crude product was purified by column chromatography (1-5% MeOH—CH 2 Cl 2 ) to give 1,2-cis diol diastereomer (3.5 g).
- the 1,2-trans ketal diastereomer was also hydrolyzed following the above procedure to give 1,2-trans-diol diastereomer.
- 1,2-cis-diol diastereomer was subjected to phosphorylation using the procedure described in Example 11.1 without equilibration to give the following two isomers.
- Phosphorus oxychloride (3.4 mL, 36.3 mmol) was added to a solution of 1-(3-chlorophenyl)-1,3-propanediol in dichloromethane at 0° C. followed by triethylamine (10.2 mL, 73 mmol). After 2 h, sodium 4-nitrophenoxide (10.63 g, 66 mmol) was added to the solution of cis/trans phosphorochloridate reagent and the orange reaction mixture was heated at reflux for 1 h. The cooled solution was partitioned with ethyl acetate and a saturated solution of ammonium chloride. The organics were separated and dried over sodium sulfate, filtered and concentrated under reduced pressure.
- a cis/trans mixture of 4-(3-chlorophenyl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes was prepared as in Example 11, except that the cis and trans isomers were separated by column chromatography prior to the addition of 4-nitrophenol.
- Cis-4-(3-chlorophenyl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinane was isomerized to the trans isomer by adding a solution of the cis-isomer to a solution of 4-nitrophenoxide prepared with the following bases.
- Lithium hydride (19.4 mg, 2.44 mmol) was added to a solution of 4-nitrophenol in THF at room temperature. The yellow solution was stirred at room temperature for 30 min. A solution of cis-4-(3-chlorophenyl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinane (300 mg, 0.813 mmol) in THF was added to the solution of lithium 4-nitrophenoxide. The orange reaction mixture was stirred a room temperature. After 5 h the ratio was 92.9/5.4 trans/cis (HPLC determination).
- (+)-(R)-1-(3-chlorophenyl)-1,3-propanediol (3 g, 16.1 mmol) and triethylamine (6.03 ml, 59.6 mmol) in THF (80 mL) was added dropwise to a solution of 4-nitrophenoxyphosphorodichloridate (7.63 g, 29.8 mmol) in 150 mL of THF at 0° C. After about 2 h, the starting diol was consumed, with the formation of two isomeric 4-nitophenylphosphates, and additional triethylamine (8.31 mL) followed by of 4-nitrophenol (8.29 g, 59.6 mmol) were added.
- Example 11.1 Same as Example 11.1 starting with S-( ⁇ )-1-phenyl-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- a 1 liter 3-neck round bottom flask was equipped with a mechanical stirrer, addition funnel, a thermometer and a N 2 inlet.
- the flask is charged with S-( ⁇ )-1-(pyrid-4-yl)-propane-1,3-diol (25 g, 163.4 mmol) and ethyl acetate (250 mL) and the resulting suspension was treated slowly with a 4N HCl solution in dioxane (43 mL, 176 mmol) over a period of 15 min.
- 4-nitrophenylphosphorodichloridate 41.81 g, 163.4 mmol
- the internal temperature of the reaction mixture was adjusted to ⁇ 10° C. with the help of a dry ice-acetone cooling bath.
- a solution of triethylamine (79 mL, 572 mmol) in ethyl acetate (100 mL) was added maintaining the reaction temperature at ⁇ 5° C.
- the cooling bath was removed and the reaction mixture was stirred at room temperature for 1 h.
- the reaction mixture was filtered to remove triethylamine-hydrochloride salt, which is washed with ethyl acetate (3 ⁇ 30 mL) until the filtrate shows only faint absorption.
- the filtrate was evaporated down to a volume of 150-175 mL under reduced pressure.
Abstract
Description
- This application is a divisional of U.S. application Ser. No. 10/903,215 filed Jul. 29, 2004, which claims benefit of U.S. Provisional Application No. 60/544,743 filed Feb. 13, 2004 and which is incorporated by reference herein in its entirely, including figures.
- The present invention is directed towards novel 2′-C-methyl nucleoside 5′-monophosphate derivatives, their preparation and their uses. More specifically, the novel compounds are useful to treat hepatitis C viral infections.
- The following description of the background of the invention is provided to aid in understanding the invention, but is not admitted to be, or to describe, prior art to the invention. All publications are incorporated by reference in their entirety.
- Hepatitis C is a viral disease that causes inflammation of the liver that may lead to cirrhosis, primary liver cancer and other long-term complications. Nucleosides are a well-recognized class of compounds shown to be effective against a variety of viral infections, including hepatitis B, HIV, and herpes. A few nucleosides are reported to inhibit hepatitis C (HCV) virus replication, including ribavirin, which currently is marketed as a drug combination with various interferons, and nucleosides containing a 2′-C-methyl ribose sugar.
- Nucleosides are generally effective as antiviral agents following conversion of the nucleoside to the corresponding nucleoside 5′-triphosphate (NTP). Conversion occurs inside cells through the action of various intracellular kinases. The first step, i.e. conversion of the nucleoside to the 5′-monophosphate (NMP) is generally the slow step and involves a nucleoside kinase, which is encoded by either the virus or host. Conversion of the NMP to the NTP is generally catalyzed by host nucleotide kinases. The NTP interferes with viral replication through inhibition of viral polymerases and/or via incorporation into a growing strand of DNA or RNA followed by chain termination.
- Use of nucleosides to treat viral liver infections is often complicated by one of two problems. In some cases, the desired nucleoside is a good kinase substrate and accordingly produces NTP in the liver as well as other cells and tissues throughout the body. Since NTP production is often associated with toxicity, efficacy can be limited by extrahepatic toxicities. In other cases, the desired nucleoside is a poor kinase substrate so is not efficiently converted into the NMP and ultimately into the NTP.
- For instance, U.S. Pat. No. 6,312,662 discloses the use of certain phosphate prodrugs for the liver-specific delivery of various drugs including nucleosides for the treatment of patients with liver diseases such as hepatitis C, hepatitis B and hepatocellular carcinoma.
- The present invention is directed towards novel 2′-C-methyl nucleoside 5′-monophosphate derivatives, their preparation and their uses for the treatment of hepatitis C viral infections.
-
- wherein:
-
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- W and W′ are independently selected from the group consisting of —R2, optionally substituted monocyclic aryl, and optionally substituted monocyclic heteroaryl;
- Z is selected from the group consisting of halogen, —CN, —COR5, —CONR4 2, —CO2R5, —SO2R5, —SO2NR4 2, —OR4, —SR4, —R4, —NR4 2, —OCOR5, —OCO2R5, —SCOR5, —SCO2R5, —NHCOR4, —NHCO2R5, —(CH2)p—OR6, and —(CH2)p—SR6; or
- together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
- together W and W′ are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms;
- R2 is selected from the group consisting of R3 and hydrogen;
- R3 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R4 is selected from the group consisting of R3 and hydrogen;
- R5 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R6 is selected from the group consisting of hydrogen, and lower acyl;
- R12 is selected from the group consisting of hydrogen, and lower acyl; and
- p is an integer 2 or 3.
-
- wherein:
-
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- W and W′ are independently selected from the group consisting of —R2, optionally substituted monocyclic aryl, and optionally substituted monocyclic heteroaryl;
- Z is selected from the group consisting of halogen, —CN, —COR5, —CONR4 2, —CO2R5, —SO2R5, —SO2NR4 2, —OR4, —SR4, —R4, —NR4 2, —OCOR5, —OCO2R5, —SCOR5, —SCO2R5, —NHCOR4, —NHCO2R5, —(CH2)p—OR6, and —(CH2)p—SR6; or
- together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
- together W and W′ are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms;
- R2 is selected from the group consisting of R3 and hydrogen;
- R3 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R4 is selected from the group consisting of R5 and hydrogen;
- R5 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R6 is selected from the group consisting of hydrogen, and lower acyl;
- R12 is selected from the group consisting of hydrogen, and lower acyl; and
- p is an integer 2 or 3.
- Some of the compounds of Formula I have asymmetric centers where the stereochemistry is unspecified, and the diastereomeric mixtures of these compounds are included, as well as the individual stereoisomers when referring to a compound of Formula I generally.
- Some of the compounds described herein may exist as tautomers such as keto-enol tautomers and imine-enamine tautomers. The individual tautomers as well as mixtures thereof are encompassed with compounds of Formula I. An example of keto-enol tautomers which are intended to be encompassed within the compounds of the present invention is illustrated below:
-
- Also provided are pharmaceutical compositions comprising compounds of Formula I, pharmaceutically acceptable salts or prodrugs thereof; in association with pharmaceutically acceptable excipients or carriers.
- Also provided are methods for inhibiting viral replication comprising the step of administering to a patient a therapeutically effective amount of a compound of Formula I, pharmaceutically acceptable salts or prodrugs thereof.
- Also provided are methods for inhibiting RNA-dependent RNA viral replication comprising the step of administering to a patient a therapeutically effective amount of a compound of Formula I, or pharmaceutically acceptable salts or prodrugs thereof.
- Also provided are methods for inhibiting HCV replication comprising the step of administering to a patient a therapeutically effective amount of a compound of Formula I, pharmaceutically acceptable salts or prodrugs thereof.
- Also provided are methods for treating viral infections comprising the step of administering to a patient a therapeutically effective amount of a compound of Formula I, or pharmaceutically acceptable salts or prodrugs thereof.
- Also provided are methods for treating viral infections of the liver comprising the step of administering to a patient a therapeutically effective amount of a compound of Formula I,
- or pharmaceutically acceptable salts or prodrugs thereof.
- Also provided are methods for treating RNA-dependent RNA viral infection comprising the step of administering to a patient a therapeutically effective amount of a compound of Formula I, a pharmaceutically acceptable salts or prodrugs thereof.
- Also provided are methods for treating HCV infection comprising the step of administering to a patient a therapeutically effective amount of a compound of Formula I, pharmaceutically acceptable salts or prodrugs thereof.
- Also provided are methods for preparing compounds of Formula I, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof.
- In accordance with the present invention and as used herein, the following terms are defined with the following meanings, unless explicitly stated otherwise.
- The term “alkyl” refers to saturated aliphatic groups including straight-chain, branched chain and cyclic groups, up to and including 10 carbon atoms. Suitable alkyl groups include methyl, ethyl, n-propyl, isopropyl, and cyclopropyl. The alkyl may be optionally substituted with 1-3 substituents.
- The term “aryl” refers to aromatic groups which have 5-14 ring atoms and at least one ring having a conjugated pi electron system and includes carbocyclic aryl, heterocyclic aryl and biaryl groups, all of which may be optionally substituted. The aryl group may be optionally substituted with 1-6 substituents.
- Carbocyclic aryl groups are groups which have 6-14 ring atoms wherein the ring atoms on the aromatic ring are carbon atoms. Carbocyclic aryl groups include monocyclic carbocyclic aryl groups and polycyclic or fused compounds such as optionally substituted naphthyl groups.
- Heterocyclic aryl or heteroaryl groups are groups which have 5-14 ring atoms wherein 1 to 4 heteroatoms are ring atoms in the aromatic ring and the remainder of the ring atoms being carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen. Suitable heteroaryl groups include furanyl, thienyl, pyridyl, pyrrolyl, N-lower alkyl pyrrolyl, pyridyl-N-oxide, pyrimidyl, pyrazinyl, imidazolyl, indolyl and the like, all optionally substituted.
- The term “monocyclic aryl” refers to aromatic groups which have 5-6 ring atoms and includes carbocyclic aryl and heterocyclic aryl. Suitable aryl groups include phenyl, furanyl, pyridyl, and thienyl. Aryl groups may be substituted.
- The term “monocyclic heteroaryl” refers to aromatic groups which have 5-6 ring atoms wherein 1 to 4 heteroatoms are ring atoms in the aromatic ring and the remainder of the ring atoms being carbon atoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen.
- The term “biaryl” represents aryl groups which have 5-14 atoms containing more than one aromatic ring including both fused ring systems and aryl groups substituted with other aryl groups. Such groups may be optionally substituted. Suitable biaryl groups include naphthyl and biphenyl.
- The term “optionally substituted” or “substituted” includes groups substituted by one to four substituents, independently selected from lower alkyl, lower aryl, lower aralkyl, lower cyclic alkyl, lower heterocycloalkyl, hydroxy, lower alkoxy, lower aryloxy, perhaloalkoxy, aralkoxy, lower heteroaryl, lower heteroaryloxy, lower heteroarylalkyl, lower heteroaralkoxy, azido, amino, halogen, lower alkylthio, oxo, lower acylalkyl, lower carboxy esters, carboxyl, -carboxamido, nitro, lower acyloxy, lower aminoalkyl, lower alkylaminoaryl, lower alkylaryl, lower alkylaminoalkyl, lower alkoxyaryl, lower arylamino, lower aralkylamino, lower alkylsulfonyl, lower-carboxamidoalkylaryl, lower-carboxamidoaryl, lower hydroxyalkyl, lower haloalkyl, lower alkylaminoalkylcarboxy-, lower aminocarboxamidoalkyl-, cyano, lower alkoxyalkyl, lower perhaloalkyl, and lower arylalkyloxyalkyl. “Substituted aryl” and “substituted heteroaryl” refers to aryl and heteroaryl groups substituted with 1-6 substituents. These substituents are selected from the group consisting of lower alkyl, lower alkoxy, lower perhaloalkyl, halogen, hydroxy, cyano, and amino.
- The term “-aralkyl” refers to an alkylene group substituted with an aryl group. Suitable aralkyl groups include benzyl, picolyl, and the like, and may be optionally substituted. The aryl portion may have 5-14 ring atoms and the alkyl portion may have up to and including 10 carbon atoms. “Heteroarylalkyl” refers to an alkylene group substituted with a heteroaryl group.
- The term “alkylaryl-” refers to an aryl group substituted with an alkyl group. “Lower alkylaryl-” refers to such groups where alkyl is lower alkyl. The aryl portion may have 5-14 ring atoms and the alkyl portion may have up to and including 10 carbon atoms. The term “lower” referred to herein in connection with organic radicals or compounds respectively defines such as with up to and including 10, in one aspect up to and including 6, and in another aspect one to four carbon atoms. Such groups may be straight chain, branched, or cyclic.
- The term “cyclic alkyl” or “cycloalkyl” refers to alkyl groups that are cyclic of 3 to 10 carbon atoms, and in one aspect are 3 to 6 carbon atoms. Suitable cyclic groups include norbornyl and cyclopropyl. Such groups may be substituted.
- The term “heterocyclic”, “heterocyclic alkyl” or “heterocycloalkyl” refer to cyclic groups of 3 to 10 atoms, and in one aspect are 3 to 6 atoms, containing at least one heteroatom, in a further aspect are 1 to 3 heteroatoms. Suitable heteroatoms include oxygen, sulfur, and nitrogen. Heterocyclic groups may be attached through a nitrogen or through a carbon atom in the ring. The heterocyclic alkyl groups include unsaturated cyclic, fused cyclic and spirocyclic groups. Suitable heterocyclic groups include pyrrolidinyl, morpholino, morpholinoethyl, and pyridyl.
- The terms “arylamino” (a), and “aralkylamino” (b), respectively, refer to the group —NRR′ wherein respectively, (a) R is aryl and R′ is hydrogen, alkyl, aralkyl, heterocycloalkyl, or aryl, and (b) R is aralkyl and R′ is hydrogen, aralkyl, aryl, alkyl or heterocycloalkyl.
- The term “acyl” refers to —C(O)R where R is alkyl, heterocycloalkyl, or aryl. The term “lower acyl” refers to where R is lower alkyl. The term C1-C4 acyl refers to where R is C1-C4.
- The term “carboxy esters” refers to —C(O)OR where R is alkyl, aryl, aralkyl, cyclic alkyl, or heterocycloalkyl, all optionally substituted.
- The term “carboxyl” refers to —C(O)OH.
- The term “oxo” refers to ═O in an alkyl or heterocycloalkyl group.
- The term “amino” refers to —NRR′ where R and R′ are independently selected from hydrogen, alkyl, aryl, aralkyl and heterocycloalkyl, all except H are optionally substituted; and R and R′ can form a cyclic ring system.
- The term “-carboxylamido” refers to —CONR2 where each R is independently hydrogen or alkyl.
- The term “-sulphonylamido” or “-sulfonylamido” refers to —S(═O)2NR2 where each R is independently hydrogen or alkyl.
- The term “halogen” or “halo” refers to —F, —Cl, —Br and —I.
- The term “alkylaminoalkylcarboxy” refers to the group alkyl-NR-alk-C(O)—O— where “alk” is an alkylene group, and R is a H or lower alkyl.
- The term “sulphonyl” or “sulfonyl” refers to —SO2R, where R is H, alkyl, aryl, aralkyl, or heterocycloalkyl.
- The term “sulphonate” or “sulfonate” refers to —SO2OR, where R is —H, alkyl, aryl, aralkyl, or heterocycloalkyl.
- The term “alkenyl” refers to unsaturated groups which have 2 to 12 atoms and contain at least one carbon-carbon double bond and includes straight-chain, branched-chain and cyclic groups. Alkenyl groups may be optionally substituted. Suitable alkenyl groups include allyl. “1-Alkenyl” refers to alkenyl groups where the double bond is between the first and second carbon atom. If the 1-alkenyl group is attached to another group, e.g. it is a W substituent attached to the cyclic phosphate, it is attached at the first carbon.
- The term “alkynyl” refers to unsaturated groups which have 2 to 12 atoms and contain at least one carbon-carbon triple bond and includes straight-chain, branched-chain and cyclic groups. Alkynyl groups may be optionally substituted. Suitable alkynyl groups include ethynyl. “1-Alkynyl” refers to alkynyl groups where the triple bond is between the first and second carbon atom. If the 1-alkynyl group is attached to another group, e.g. it is a W substituent attached to the cyclic phosphate, it is attached at the first carbon.
- The term “alkylene” refers to a divalent straight chain, branched chain or cyclic saturated aliphatic group. In one aspect the alkylene group contains up to and including 10 atoms. In another aspect the alkylene chain contains up to and including 6 atoms. In a further aspect the alkylene groups contains up to and including 4 atoms. The alkylene group can be either straight, branched or cyclic. The alkylene may be optionally substituted with 1-3 substituents.
- The term “acyloxy” refers to the ester group —O—C(O)R, where R is H, alkyl, alkenyl, alkynyl, aryl, aralkyl, or heterocycloalkyl.
- The term “aminoalkyl-” refers to the group NR2-alk- wherein “alk” is an alkylene group and R is selected from —H, alkyl, aryl, aralkyl, and heterocycloalkyl.
- The term “alkylaminoalkyl-” refers to the group alkyl-NR-alk- wherein each “alk” is an independently selected alkylene, and R is H or lower alkyl. “Lower alkylaminoalkyl-” refers to groups where the alkyl and the alkylene group is lower alkyl and alkylene, respectively.
- The term “arylaminoalkyl-” refers to the group aryl-NR-alk- wherein “alk” is an alkylene group and R is —H, alkyl, aryl, aralkyl, or heterocycloalkyl. In “lower arylaminoalkyl-”, the alkylene group is lower alkylene.
- The term “alkylaminoaryl-” refers to the group alkyl-NR-aryl- wherein “aryl” is a divalent group and R is —H, alkyl, aralkyl, or heterocycloalkyl. In “lower alkylaminoaryl-”, the alkyl group is lower alkyl.
- The term “alkoxyaryl-” refers to an aryl group substituted with an alkyloxy group. In “lower alkyloxyaryl-”, the alkyl group is lower alkyl.
- The term “aryloxyalkyl-” refers to an alkyl group substituted with an aryloxy group.
- The term “aralkyloxyalkyl-” refers to the group aryl-alk-O-alk- wherein “alk” is an alkylene group. “Lower aralkyloxyalkyl-” refers to such groups where the alkylene groups are lower alkylene.
- The term “alkoxy-” or “alkyloxy-” refers to the group alkyl-O—.
- The term “alkoxyalkyl-” or “alkyloxyalkyl-” refer to the group alkyl-O-alk- wherein “alk” is an alkylene group. In “lower alkoxyalkyl-”, each alkyl and alkylene is lower alkyl and alkylene, respectively.
- The terms “alkylthio-” refers to the group alkyl-S—.
- The term “alkylthioalkyl-” refers to the group alkyl-S-alk- wherein “alk” is an alkylene group. In “lower alkylthioalkyl-” each alkyl and alkylene is lower alkyl and alkylene, respectively.
- The term “alkoxycarbonyloxy-” refers to alkyl-O—C(O)—O—.
- The term “aryloxycarbonyloxy-” refers to aryl-O—C(O)—O—.
- The term “alkylthiocarbonyloxy-” refers to alkyl-S—C(O)—O—.
- The term “amido” refers to the NR2 group next to an acyl or sulfonyl group as in NR2—C(O)—, RC(O)—NR1—, NR2—S(═O)2— and RS(═O)2—NR1—, where R and R1 include —H, alkyl, aryl, aralkyl, and heterocycloalkyl.
- The term “carboxamido” refer to NR2—C(O)— and RC(O)—NR1—, where R and R1 include —H, alkyl, aryl, aralkyl, and heterocycloalkyl. The term does not include urea, —NR—C(O)—NR—.
- The terms “sulphonamido” or “sulfonamido” refer to NR2—S(═O)2— and RS(═O)2—NR1—, where R and R1 include —H, alkyl, aryl, aralkyl, and heterocycloalkyl. The term does not include sulfonylurea, —NR—S(═O)2—NR—.
- The term “carboxamidoalkylaryl” and “carboxamidoaryl” refers to an aryl-alk-NR1—C(O), and ar-NR1—C(O)-alk-, respectively where “ar” is aryl, “alk” is alkylene, R1 and R include H, alkyl, aryl, aralkyl, and heterocycloalkyl.
- The term “sulfonamidoalkylaryl” and “sulfonamidoaryl” refers to an aryl-alk-NR1—S(═O)2—, and ar-NR1—S(═O)2—, respectively where “ar” is aryl, “alk” is alkylene, R1 and R include —H, alkyl, aryl, aralkyl, and heterocycloalkyl.
- The term “hydroxyalkyl” refers to an alkyl group substituted with one —OH.
- The term “haloalkyl” refers to an alkyl group substituted with one halogen.
- The term “cyano” refers to —C≡N.
- The term “nitro” refers to —NO2.
- The term “acylalkyl” refers to an alkyl-C(O)-alk-, where “alk” is alkylene.
- The term “aminocarboxamidoalkyl-” refers to the group NR2—C(O)—N(R)-alk- wherein R is an alkyl group or H and “alk” is an alkylene group. “Lower aminocarboxamidoalkyl-” refers to such groups wherein “alk” is lower alkylene.
- The term “heteroarylalkyl” refers to an alkylene group substituted with a heteroaryl group.
- The term “perhalo” refers to groups wherein every C—H bond has been replaced with a C-halo bond on an aliphatic or aryl group. Suitable perhaloalkyl groups include —CF3 and —CFCl2.
-
- wherein:
- R14 is independently selected from the group consisting of H and NH2; and X is selected from the group consisting of NH2, NHCH3, N(CH3)2, OCH3, SCH3, OH, and SH.
- The phrase “therapeutically effective amount” means an amount of a compound or a combination of compounds that ameliorates, attenuates or eliminates one or more of the symptoms of a particular disease or condition or prevents, modifies, or delays the onset of one or more of the symptoms of a particular disease or condition.
- The term “pharmaceutically acceptable salt” includes salts of compounds of Formula I and its prodrugs derived from the combination of a compound of this invention and an organic or inorganic acid or base. Suitable acids include acetic acid, adipic acid, benzenesulfonic acid, (+)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptane-1-methanesulfonic acid, citric acid, 1,2-ethanedisulfonic acid, dodecyl sulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glucuronic acid, hippuric acid, hydrochloride hemiethanolic acid, HBr, HCl, HI, 2-hydroxyethanesulfonic acid, lactic acid, lactobionic acid, maleic acid, methanesulfonic acid, methylbromide acid, methyl sulfuric acid, 2-naphthalenesulfonic acid, nitric acid, oleic acid, 4,4′-methylenebis[3-hydroxy-2-naphthalenecarboxylic acid], phosphoric acid, polygalacturonic acid, stearic acid, succinic acid, sulfuric acid, sulfosalicylic acid, tannic acid, tartaric acid, terphthalic acid, and p-toluenesulfonic acid.
- The term “naturally-occurring L-amino acid” refers to those amino acids routinely found as components of proteinaceous molecules in nature, including alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine, glycine, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartic acid, glutamic acid, lysine, arginine and histidine. In one aspect, this term is intended to encompass L-amino acids having only the amine and carboxylic acid as charged functional groups, i.e., alanine, valine, leucine, isoleucine, proline, phenylalanine, tryptophan, methionine, glycine, serine, threonine, cysteine and tyrosine. In another aspect they are alanine, valine, leucine, isoleucine, proline, phenylalanine, and glycine. In a further aspect, it is valine.
- The term “patient” refers to an animal being treated including a mammal, such as a dog, a cat, a cow, a horse, a sheep, and a human. Another aspect includes a mammal, both male and female.
- The term “prodrug” as used herein refers to any compound that when administered to a biological system generates a biologically active compound as a result of spontaneous chemical reaction(s), enzyme catalyzed chemical reaction(s), and/or metabolic chemical reaction(s), or a combination of each. Standard prodrugs are formed using groups attached to functionality, e.g. HO—, HS—, HOOC—, R2N—, associated with the drug, that cleave in vivo. Standard prodrugs include but are not limited to carboxylate esters where the group is alkyl, aryl, aralkyl, acyloxyalkyl, alkoxycarbonyloxyalkyl as well as esters of hydroxyl, thiol and amines where the group attached is an acyl group, an alkoxycarbonyl, aminocarbonyl, phosphate or sulfate. The groups illustrated are exemplary, not exhaustive, and one skilled in the art could prepare other known varieties of prodrugs. Such prodrugs of the compounds of Formula I fall within this scope. Prodrugs must undergo some form of a chemical transformation to produce the compound that is biologically active or is a precursor of the biologically active compound. In some cases, the prodrug is biologically active, usually less than the drug itself, and serves to improve drug efficacy or safety through improved oral bioavailability, pharmacodynamic half-life, etc. Prodrug forms of compounds may be utilized, for example, to improve bioavailability, improve subject acceptability such as by masking or reducing unpleasant characteristics such as bitter taste or gastrointestinal irritability, alter solubility such as for intravenous use, provide for prolonged or sustained release or delivery, improve ease of formulation, or provide site-specific delivery of the compound. Prodrugs are described in The Organic Chemistry of Drug Design and Drug Action, by Richard B. Silverman, Academic Press, San Diego, 1992. Chapter 8: “Prodrugs and Drug delivery Systems” pp. 352-401; Design of Prodrugs, edited by H. Bundgaard, Elsevier Science, Amsterdam, 1985; Design of Biopharmaceutical Properties through Prodrugs and Analogs, Ed. by E. B. Roche, American Pharmaceutical Association, Washington, 1977; and Drug Delivery Systems, ed. by R. L. Juliano, Oxford Univ. Press, Oxford, 1980.
- The term “prodrug” herein also includes but is not limited to esterase cleavable prodrugs of the 2′ and 3′-hydroxy groups of compounds of Formula I (Anastasi et al., Curr. Med. Chem., 2003, 10, 1825). Standard groups include acyl and alkoxycarbonyl groups, and esters of natural L-amino acid derivatives (Perry, et al., Drugs, 1996, 52, 754). Also included is a cyclic carbonate derivative formed by carbonylation of the 2′ and 3′-hydroxy groups, which upon activation by esterase activity in vivo results in compounds of Formula I.
- In the case of bases, “prodrugs” are preferred at the 6-position of purine analogs. Such substitution may include H, halogen, amino, acetoxy or azido groups. Hydrogen substituted prodrugs at the 6-position of guanosine analogs undergo oxidation in vivo by aldehyde oxidase or xanthine oxidase to give the required functionality (Rashidi et al., Drug Metab. Dispos. 1997, 25, 805). While esterases unmask acetoxy groups, amine and halogen substituents are known to be substrates for deaminases. 6-Azido substituted compounds are also known to give the corresponding amino derivatives by the action of reductases (Koudriakova, et al., J. Med Chem., 1996, 39, 4676).
-
-
- has a plane of symmetry running through the phosphorus-oxygen double bond when V=W and V and W are either both pointing up or both pointing down.
-
-
- As shown above together V and Z are connected via 4 additional atoms.
-
- As shown above together W and W′ are connected via an additional 2 atoms.
- The structure above has V=aryl, and a spiro-fused cyclopropyl group for W and W′.
-
- The carbon attached to V must have a C—H bond. The carbon attached to Z must also have a C—H bond.
- The term “cis” stereochemistry refers to the spatial relationship of the V group and the substituent attached to the phosphorus atom via an exocyclic single bond on the six membered 2-oxo-phosphorinane ring. The structures A and B below show two possible cis-isomers of 2- and 4- substituted 2-oxo-phosphorinane. Structure A shows cis-isomer of (2S, 4R)-configuration whereas structure B shows cis-isomer of (2R, 4S)-configuration.
- The term “trans” stereochemistry refers to the spatial relationship of the V group and the substituent attached to the phosphorus atom via an exocyclic single bond on the six membered 2-oxo-phosphorinane ring. The structures C and D below show two possible trans-isomers of 2- and 4-substituted 2-oxo-phosphorinane. Structure C shows trans-isomer of (2S, 4S)— configuration whereas structure D shows trans-isomer of (2R, 4R)-configuration.
- The term “percent enantiomeric excess (% ee)” refers to optical purity. It is obtained by using the following formula:
- where [R] is the amount of the R isomer and [S] is the amount of the S isomer. This formula provides the % ee when R is the dominant isomer.
- The term “enantioenriched” or “enantiomerically enriched” refers to a sample of a chiral compound that consists of more of one enantiomer than the other. The extent to which a sample is enantiomerically enriched is quantitated by the enantiomeric ratio or the enantiomeric excess.
- The term “liver” refers to liver organ.
- The term “enhancing” refers to increasing or improving a specific property.
- The term “liver specificity” refers to the ratio:
as measured in animals treated with the drug or a prodrug. The ratio can be determined by measuring tissue levels at a specific time or may represent an AUC based on values measured at three or more time points. - The term “increased or enhanced liver specificity” refers to an increase in the liver specificity ratio in animals treated with the prodrug relative to animals treated with the parent drug.
- The term “enhanced oral bioavailability” refers to an increase of at least 50% of the absorption of the dose of the parent drug. In an additional aspect the increase in oral bioavailability of the prodrug (compared to the parent drug) is at least 100%, that is a doubling of the absorption. Measurement of oral bioavailability usually refers to measurements of the prodrug, drug, or drug metabolite in blood, plasma, tissues, or urine following oral administration compared to measurements following parenteral administration.
- The term “therapeutic index” refers to the ratio of the dose of a drug or prodrug that produces a therapeutically beneficial response relative to the dose that produces an undesired response such as death, an elevation of markers that are indicative of toxicity, and/or pharmacological side effects.
- The term “sustained delivery” refers to an increase in the period in which there is a prolongation of therapeutically-effective drug levels due to the presence of the prodrug.
- The term “bypassing drug resistance” refers to the loss or partial loss of therapeutic effectiveness of a drug (drug resistance) due to changes in the biochemical pathways and cellular activities important for producing and maintaining the biological activity of the drug and the ability of an agent to bypass this resistance through the use of alternative pathways or the failure of the agent to induce changes that tend to resistance.
- The terms “treating” or “treatment” of a disease includes inhibiting the disease (slowing or arresting its development), providing relief from the symptoms or side-effects of the disease (including palliative treatment), and relieving the disease (causing regression of the disease).
-
- wherein:
-
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- W and W′ are independently selected from the group consisting of —R2, optionally substituted monocyclic aryl, and optionally substituted monocyclic heteroaryl;
- Z is selected from the group consisting of halogen, —CN, —COR5, —CONR4 2, —CO2R5, —SO2R5, —SO2NR4 2, —OR4, —SR4, —R4, —NR4 2, —OCOR5, —OCO2R5, —SCOR5, —SCO2R5, —NHCOR4, —NHCO2R5, —(CH2)p—OR6, and —(CH2)p—SR6; or
- together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
- together W and W′ are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms;
- R2 is selected from the group consisting of R3 and hydrogen;
- R3 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R4 is selected from the group consisting of R3 and hydrogen;
- R5 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R6 is selected from the group consisting of hydrogen, and lower acyl;
- R12 is selected from the group consisting of hydrogen, and lower acyl; and
- p is an integer 2 or 3;
- or pharmaceutically acceptable prodrugs or salts thereof.
-
- wherein:
-
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- W and W′ are independently selected from the group consisting of —R2, optionally substituted monocyclic aryl, and optionally substituted monocyclic heteroaryl;
- Z is selected from the group consisting of halogen, —CN, —COR5, —CONR4 2, —CO2R5, —SO2R5, —SO2NR4 2, —OR4, —SR4, —R4, —NR4 2, —OCOR5, —OCO2R5, —SCOR5, —SCO2R5, —NHCOR4, —NHCO2R5, —(CH2)p—OR6, and —(CH2)p—SR6; or
- together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
- together W and W′ are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms;
- R2 is selected from the group consisting of R3 and hydrogen;
- R3 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R4 is selected from the group consisting of R5 and hydrogen;
- R5 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R6 is selected from the group consisting of hydrogen, and lower acyl;
- R12 is selected from the group consisting of hydrogen, and lower acyl; and
- p is an integer 2 or 3;
- or pharmaceutically acceptable prodrugs or salts thereof.
-
- wherein:
-
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- W and W′ are independently selected from the group consisting of —R2, optionally substituted monocyclic aryl, and optionally substituted monocyclic heteroaryl;
- Z is selected from the group consisting of halogen, —CN, —COR5, —CONR4 2, —CO2R5, —SO2R5, —SO2NR4 2, —OR4, —SR4, —R4, —NR4 2, —OCOR5, —OCO2R5, —SCOR5, —SCO2R5, —NHCOR4, —NHCO2R5, —(CH2)p—OR6, and —(CH2)p—SR6; or
- together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
- together W and W′ are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms;
- R2 is selected from the group consisting of R3 and hydrogen;
- R3 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R4 is selected from the group consisting of R5 and hydrogen;
- R5 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R6 is selected from the group consisting of hydrogen, and lower acyl;
- R12 is selected from the group consisting of hydrogen, and lower acyl; and
- p is an integer 2 or 3;
- or pharmaceutically acceptable prodrugs or salts thereof.
-
- wherein:
-
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- W and W′ are independently selected from the group consisting of —R2, optionally substituted monocyclic aryl, and optionally substituted monocyclic heteroaryl;
- Z is selected from the group consisting of halogen, —CN, —COR5, —CONR4 2, —CO2R5, —SO2R5, —SO2NR4 2, —OR4, —SR4, —R4, —NR4 2, —OCOR5, —OCO2R5, —SCOR5, —SCO2R5, —NHCOR4, —NHCO2R5, —(CH2)p—OR6, and —(CH2)p—SR6; or
- together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
- together W and W′ are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms;
- R2 is selected from the group consisting of R3 and hydrogen;
- R3 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R4 is selected from the group consisting of R5 and hydrogen;
- R5 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R6 is selected from the group consisting of hydrogen, and lower acyl;
- R12 is selected from the group consisting of hydrogen, and lower acyl; and
- p is an integer 2 or 3;
- or pharmaceutically acceptable prodrugs or salts thereof.
-
- wherein:
-
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- W and W′ are independently selected from the group consisting of —R2, optionally substituted monocyclic aryl, and optionally substituted monocyclic heteroaryl;
- Z is selected from the group consisting of halogen, —CN, —COR5, —CONR4 2, —CO2R5, —SO2R5, —SO2NR4 2, —OR4, —SR4, —R4, —NR4 2, —OCOR5, —OCO2R5, —SCOR5, —SCO2R5, —NHCOR4, —NHCO2R5, —(CH2)p—OR6, and —(CH2)p—SR6; or
- together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
- together W and W′ are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms;
- R2 is selected from the group consisting of R3 and hydrogen;
- R3 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R4 is selected from the group consisting of R5 and hydrogen;
- R5 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
- R6 is selected from the group consisting of hydrogen, and lower acyl;
- R12 is selected from the group consisting of hydrogen, and lower acyl; and
- p is an integer 2 or 3;
- or pharmaceutically acceptable prodrugs or salts thereof.
- In one aspect, V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of halogen, C1-C6 alkyl, —CF3, —OR3, —OR12, —COR3, —CO2R3, —NR3 2, —NR12 2, —CO2NR2 2, —SR3, —SO2R3, —SO2NR2 2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of halogen, C1-C6 alkyl, —CF3, —OR3, —OR12, —COR3, —CO2R3, —NR3 2, NR12 2, —CO2NR2 2, —SO2R3, —SO2NR2 2 and —CN, and wherein said monocyclic heteroaryl and substituted monocyclic heteroaryl has 1-2 heteroatoms that are independently selected from the group consisting of N, O, and S with the provisos that
- a) when there are two heteroatoms and one is O, then the other can not be O or S, and
- b) when there are two heteroatoms and one is S, then the other can not be O or S; or
- together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; and R3 is C1-C6 alkyl.
- In another aspect, V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN and wherein said monocyclic heteroaryl and substituted monocyclic heteroaryl has 1-2 heteroatoms that are independently selected from the group consisting of N, O, and S with the provisos that
- a) when there are two heteroatoms and one is O, then the other can not be O or S, and
- b) when there are two heteroatoms and one is S, then the other can not be O or S; or
- together V and Z are connected via an additional 4 atoms to form a 6-membered ring that is fused to a phenyl or substituted phenyl at the beta and gamma position to the O attached to the phosphorus.
- In yet another aspect, V is selected from the group consisting of phenyl; substituted phenyl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; pyridyl; substituted pyridyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; furanyl; substituted furanyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; thienyl; and substituted thienyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3.
- In a further aspect, V is selected from the group consisting of phenyl, 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-bromo-4-fluorophenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl. In another aspect, V is selected from the group consisting of 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-pyridyl, and 4-pyridyl.
- In another aspect, V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OH, —OMe, —NH2, —NMe2, —OEt, —COOH, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN; monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OH, —OMe, —NH2, —NMe2, —OEt, —COOH, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN; and wherein said monocyclic heteroaryl and substituted monocyclic heteroaryl has 1-2 heteroatoms that are independently selected from the group consisting of N, O, and S with the provisos that
- a) when there are two heteroatoms and one is O, then the other can not be O or S, and
- b) when there are two heteroatoms and one is S, then the other can not be O or S; or
- together V and Z are connected via an additional 4 atoms to form a 6-membered ring that is fused to a phenyl or substituted phenyl at the beta and gamma position to the O attached to the phosphorus.
- In one aspect, Z is selected from the group consisting of —H, —OMe, —OEt, phenyl, C1-C3 alkyl, —NR4 2, —SR4, —(CH2)p—OR6, —(CH2)p—SR6 and —OCOR5; R4 is C1-C4 alkyl; R5 is selected from the group consisting of C1-C4 alkyl, monocyclic aryl, and monocyclic aralkyl; and R6 is C1-C4 acyl. In a further aspect, Z is selected from the group consisting of —H, —OMe, —OEt, and phenyl.
- In an additional aspect, W and W′ are independently selected from the group consisting of —H, C1-C6 alkyl, and phenyl; or together W and W′ are connected via an additional 2-5 atoms to form a cyclic group. In yet another aspect, W and W′ are independently selected from the group consisting of —H, methyl, and V, or W and W′ are each methyl, with the proviso that when W is V, then W′ is H.
- In one aspect, V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- W and W′ are independently selected from the group consisting of —H, methyl, and V, or W and W′ are each methyl, with the proviso that when W is V, then W′ is H;
- Z is selected from the group consisting of —H, —OMe, —OEt, phenyl, C1-C3 alkyl, —NR4 2, —SR4, —(CH2)p—OR6, —(CH2)p—SR6 and —OCOR5; or
- together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
- together W and W′ are connected via an additional 2-5 atoms to form a cyclic group; and
- R4 is C1-C4 alkyl; R5 is selected from the group consisting of C1-C4 alkyl, monocyclic aryl, and monocyclic aralkyl; and R6 is C1-C4 acyl.
- In another aspect, V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of halogen, C1-C6 alkyl, —CF3, —OR3, —OR12, —COR3, —CO2R3, —NR3 2, —NR12 2, —CO2NR2 2, —SR3, —SO2R3, —SO2NR2 2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of halogen, C1-C6 alkyl, —CF3, —OR3, —OR12, —COR3, —CO2R3, —NR3 2, —NR12 2, —CO2NR2 2, —SR3, —SO2R3, —SO2NR2 2 and —CN, and wherein said monocyclic heteroaryl and substituted monocyclic heteroaryl has 1-2 heteroatoms that are independently selected from the group consisting of N, O, and S with the provisos that
- a) when there are two heteroatoms and one is O, then the other can not be O or S, and
- b) when there are two heteroatoms and one is S, then the other can not be O or S; or
- W and W′ are independently selected from the group consisting of —H, methyl, and V, or W and W′ are each methyl, with the proviso that when W is V, then W′ is H;
- Z is selected from the group consisting of —H, —OMe, —OEt, phenyl, C1-C3 alkyl, —NR4 2, —SR4, —(CH2)p—OR6, —(CH2)p—SR6 and —OCOR5; or
- together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
- together W and W′ are connected via an additional 2-5 atoms to form a cyclic group; and
- R3 is C1-C6 alkyl; R4 is C1-C4 alkyl; R5 is selected from the group consisting of C1-C4 alkyl, monocyclic aryl, and monocyclic aralkyl; and R6 is C1-C4 acyl.
- In a further aspect, V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN, and wherein said monocyclic heteroaryl and substituted monocyclic heteroaryl has 1-2 heteroatoms that are independently selected from the group consisting of N, O, and S with the provisos that
- a) when there are two heteroatoms and one is O, then the other can not be O or S; and
- b) when there are two heteroatoms and one is S, then the other can not be O or S; or
- W and W′ are independently selected from the group consisting of —H, methyl, and V, or W and W′ are each methyl, with the proviso that when W is V, then W′ is H;
- Z is selected from the group consisting of —H, —OMe, —OEt, phenyl, C1-C3 alkyl, —NR4 2, —SR4, —(CH2)p—OR6, —(CH2)p—SR6 and —OCOR5; or
- together V and Z are connected via an additional 4 atoms to form a 6-membered ring that is fused to a phenyl or substituted phenyl at the beta and gamma position to the O attached to the phosphorus; or
- together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
- together W and W′ are connected via an additional 2-5 atoms to form a cyclic group; and
- R4 is C1-C4 alkyl; R5 is selected from the group consisting of C1-C4 alkyl, monocyclic aryl, and monocyclic aralkyl; and R6 is C1-C4 acyl.
- In yet another aspect, V is selected from the group consisting of phenyl; substituted phenyl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; pyridyl; substituted pyridyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; furanyl; substituted furanyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; thienyl; and substituted thienyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3;
- W and W′ are independently selected from the group consisting of —H, methyl, and V, or W and W′ are each methyl, with the proviso that when W is V, then W′ is H;
- Z is selected from the group consisting of —H, —OMe, —OEt, phenyl, C1-C3 alkyl, —NR4 2, —SR4, —(CH2)p—OR6, —(CH2)p—SR6 and —OCOR5; or
- together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
- together W and W′ are connected via an additional 2-5 atoms to form a cyclic group; and
- R4 is C1-C4 alkyl; R5 is selected from the group consisting of C1-C4 alkyl, monocyclic aryl, and monocyclic aralkyl; and R6 is C1-C4 acyl.
- In a further aspect, V is selected from the group consisting of phenyl, 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-bromo-4-fluorophenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl; and
- Z is selected from the group consisting of —H, OMe, OEt, and phenyl; and
- W and W′ are independently selected from the group consisting of —H and phenyl, or W and W′ are each methyl.
- In one aspect, Z, W, and W′ are each —H. In another aspect, V and W are the same and each is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl.
-
- V is selected from the group consisting of 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, and 4-pyridyl; and Z, W, and W′ are each —H.
-
- V is selected from the group consisting of 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, and 4-pyridyl; and Z, W, and W′ are each —H.
-
- V is selected from the group consisting of 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, and 4-pyridyl; and Z, W, and W′ are each —H.
-
- V is selected from the group consisting of 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, and 4-pyridyl; and Z, W, and W′ are each —H.
-
- wherein:
- V and the 5′oxymethylene group of the ribose sugar moiety are cis to one another
-
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl; or pharmaceutically acceptable prodrugs or salts thereof.
-
- wherein:
- V and the 5′oxymethylene group of the ribose sugar moiety are cis to one another;
-
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl; or pharmaceutically acceptable prodrugs or salts thereof.
- In an additional aspect, V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of halogen, C1-C6 alkyl, —CF3, —OR3, —OR12, —COR3, —CO2R3, —NR3 2, —NR12 2, —CO2NR2 2, —SR3, —SO2R3, —SO2NR2 2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of halogen, C1-C6 alkyl, —CF3, —OR3, —OR12, —COR3, —CO2R3, —NR3 2, —NR12 2, —CO2NR2 2, —SR3, —SO2R3, —SO2NR2 2 and —CN, and wherein said monocyclic heteroaryl and substituted monocyclic heteroaryl has 1-2 heteroatoms that are independently selected from the group consisting of N, O, and S with the provisos that
- a) when there are two heteroatoms and one is O, then the other can not be O or S, and
- b) when there are two heteroatoms and one is S, then the other can not be O or S; and R3 is C1-C6 alkyl.
- In a further aspect, V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN and wherein said monocyclic heteroaryl and substituted monocyclic heteroaryl has 1-2 heteroatoms that are independently selected from the group consisting of N, O, and S with the provisos that
- a) when there are two heteroatoms and one is O, then the other can not be O or S, and
- b) when there are two heteroatoms and one is S, then the other can not be O or S; or
- together V and Z are connected via an additional 4 atoms to form a 6-membered ring that is fused to a phenyl or substituted phenyl at the beta and gamma position to the O attached to the phosphorus.
- In an additional aspect, V is selected from the group consisting of phenyl; substituted phenyl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; pyridyl; substituted pyridyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; furanyl; substituted furanyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; thienyl; and substituted thienyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3.
- In yet another aspect, V is selected from the group consisting of phenyl, 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-bromo-4-fluorophenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl. In another aspect, V is selected from the group consisting of 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-pyridyl, and 4-pyridyl.
-
- wherein:
-
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- W and W′ are independently selected from the group consisting of —H, methyl, and V, or W and W′ are each methyl, with the proviso that when W is V, then W′ is H;
- Z is selected from the group consisting of —H, —OMe, —OEt, phenyl, C1-C3 alkyl, —NR4 2, —SR4, —(CH2)p—OR6, —(CH2)p—SR6 and —OCOR5; or
- together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
- together W and W′ are connected via an additional 2-5 atoms to form a cyclic group;
- R4 is C1-C4 alkyl;
- R5 is selected from the group consisting of C1-C4 alkyl, monocyclic aryl, and monocyclic aralkyl; and
- R6 is C1-C4 acyl;
- R7 and R8 are independently selected from the group consisting of hydrogen, C1-C4 acyl, C1-C4 alkoxycarbonyl, and a naturally-occurring L-amino acid connected via its carbonyl group to form an ester; or
- together R7 and R8 form a cyclic carbonate;
- R9 is selected from the group consisting of amino, azido, —N═CHN(R4)2, —NHC(O)R4, and —NHC(O)OR4; and
- R10 is selected from the group consisting of OR6, halogen, and H.
-
- wherein:
-
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- W and W′ are independently selected from the group consisting of —H, methyl, and V, or W and W′ are each methyl, with the proviso that when W is V, then W′ is H;
- Z is selected from the group consisting of —H, —OMe, —OEt, phenyl, C1-C3 alkyl, —NR4 2, —SR4, —(CH2)p—OR6, —(CH2)p—SR6 and —OCOR5; or
- together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
- together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
- together W and W′ are connected via an additional 2-5 atoms to form a cyclic group;
- R4 is C1-C4 alkyl;
- R5 is selected from the group consisting of C1-C4 alkyl, monocyclic aryl, and monocyclic aralkyl; and
- R6 is C1-C4 acyl;
- R7 and R8 are independently selected from the group consisting of hydrogen, C1-C4 acyl, C1-C4 alkoxycarbonyl, and a naturally-occurring L-amino acid connected via its carbonyl group to form an ester; or
- together R7 and R9 form a cyclic carbonate; and
- R10 is selected from the group consisting of OR4, OR6, halogen, and H.
-
- wherein:
- V and the 5′oxymethylene group of the ribose sugar moiety are cis to one another;
-
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- R4 is C1-C4 alkyl;
- R6 is C1-C4 acyl;
- R7 and R8 are independently selected from the group consisting of hydrogen, C1-C4 acyl, C1-C4 alkoxycarbonyl, and a naturally-occurring L-amino acid connected via its carbonyl group to form an ester; or
- together R7 and R8 form a cyclic carbonate;
- R9 is selected from the group consisting of amino, azido, —N═CHN(R4)2, —NHC(O)R4, and —NHC(O)OR4; and
- R10 is selected from the group consisting of OR6, halogen, and H.
- In one aspect, V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN. In another aspect, V is selected from the group consisting of phenyl, 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-bromo-4-fluorophenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.
-
- wherein:
- V and the 5′oxymethylene group of the ribose sugar moiety are cis to one another;
-
- V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
- R4 is C1-C4 alkyl;
- R6 is C1-C4 acyl;
- R7 and R8 are independently selected from the group consisting of hydrogen, C1-C4 acyl, C1-C4 alkoxycarbonyl, and a naturally-occurring L-amino acid connected via its carbonyl group to form an ester; or
- together R7 and R8 form a cyclic carbonate; and
- R10 is selected from the group consisting of OR4, OR6, NH2, NHR4, halogen, and H.
- In one aspect, V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN. In another aspect, V is selected from the group consisting of phenyl, 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-bromo-4-fluorophenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.
-
- wherein X is selected from the group consisting of NH2, NHCH3, N(CH3)2, OCH3, and SCH3;
- Y and Y′ are independently O or NH;
- V, W, and W′ are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkaryl, each of which is optionally substituted; and
- Z is hydrogen, CHWOH, CHWOCOW′, SW, or CH2aryl.
-
-
- X is selected from the group consisting of NH2, NHCH3, N(CH3)2, OCH3, SCH3, OH, and SH;
- Y and Y′ are independently O or NH;
- R14 is independently selected from the group consisting of H and NH2;
- the heterocyclic base may be further substituted at any position on the heterocyclic base with a substituent of a molecular weight of less than 150 and selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, aryl, alkaryl, cycloalkyl, acyl, and alkoxy, and wherein said substituents may be coupled to the 6-position of the heterocyclic base via a carbon, sulfur, oxygen, or selenium;
- V, W, and W′ are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkaryl, each of which is optionally substituted; and
- Z is hydrogen, CHWOH, CHWOCOW′, SW, or CH2aryl.
-
-
- In another aspect, X is NH2.
-
-
-
-
-
- In another aspect of the invention the compounds of this invention have R-stereochemistry at the V-attached carbon and have S-stereochemistry at the phosphorus center. In another aspect of the invention the compounds of this invention have S-stereochemistry at the V-attached carbon and have R-stereochemistry at the phosphorus center.
- In one aspect the following compounds are included in the invention but the compounds are not limited to these illustrative compounds.
- The following prodrugs are preferred compounds of the invention. The compounds are shown without depiction of stereochemistry since the compounds are biologically active as the diastereomeric mixture or as a single stereoisomer. Compounds named in Table 1 are designated by numbers assigned to the variables of formula using the following convention: M1.V.L1.L2. M1 is a variable that represents nucleosides of Formula I which are attached via 5′-hydroxyl group that is phosphorylated with a group P(O)(O—CH(V)CH2CH2—O) to make compounds of Formula VI. V is an aryl or heteroaryl group that has 2 substituents, L1 and L2, at the designated positions. V may have additional substituents.
Variable M1:
Variable V: Group V1 - 1) 2-(L1)-3(L2)-phenyl
- 2) 2-(L1)-4(L2)-phenyl
- 3) 2-(L1)-5(L2)-phenyl
- 4) 2-(L1)-6(L2)-phenyl
- 5) 3-(L1)-4(L2)-phenyl
- 6) 3-(L1)-5(L2)-phenyl
- 7) 3-(L1)-6(L2)-phenyl
- 8) 2-(L1)-6(L2)-3-chlorophenyl
- 9) 4-(L1)-5(L2)-3-chlorophenyl
- Variable V: Group V2
- 1) 2-(L1)-3(L2)-4-pyridyl
- 2) 2-(L1)-5(L2)-4-pyridyl
- 3) 2-(L1)-6(L2)-4-pyridyl
- 4) 3-(L1)-5(L2)-4-pyridyl
- 5) 3-(L1)-6(L2)-4-pyridyl
- 6) 2-(L1)-4(L2)-3-pyridyl
- 7) 2-(L1)-5(L2)-3-pyridyl
- 8) 2-(L1)-6(L2)-3-pyridyl
- 9) 4-(L1)-5(L2)-3-pyridyl
- Variable V: Group V3
- 1) 4-(L1)-6(L2)-3-pyridyl
- 2) 5-(L1)-6(L2)-3-pyridyl
- 3) 3-(L1)-4(L2)-2-pyridyl
- 4) 3-(L1)-5(L2)-2-pyridyl
- 5) 3-(L1)-6(L2)-2-pyridyl
- 6) 4-(L1)-5(L2)-2-pyridyl
- 7) 4-(L1)-6(L2)-2-pyridyl
- 8) 3-(L1)-4(L2)-2-thienyl
- 9) 3-(L1)-4(L2)-2-furanyl
- Variable L1
- 1) hydrogen
- 2) chloro
- 3) bromo
- 4) fluoro
- 5) methyl
- 6) trifluoromethyl
- 7) methoxy
- 8) dimethylamino
- 9) cyano
- Variable L2
- 1) hydrogen
- 2) chloro
- 3) bromo
- 4) fluoro
- 5) methyl
- 6) trifluoromethyl
- 7) methoxy
- 8) dimethylamino
- 9) cyano
- Preferred compounds are compounds listed in Table 1 using variables M1 and V1 and L1 and L2 listed in that order. For example, compound 1.3.6.7 represents structure 1 of variable M1, i.e., 7-deaza-2′-methyl adenosine; structure 3 of group V1, i.e., 2-(L1)-5-(L2) phenyl; structure 6 of variable L1, i.e., trifluoromethyl; and structure 7 of variable L2, i.e., methoxy. The compound 1.3.6.7. therefore is 7-deaza-2′-methyladenosine with the P(O)(O—CH(V)CH2CH2O) attached to the 5′-primary hydroxyl group being {[1-(2-trifluoromethyl-5-methoxyphenyl)-1,3-propyl]phosphoryl.
- Preferred compounds are also compounds listed in Table 1 using variables M1 and V2 wherein the four digit number represents M1.V2.L1.L2.
- Preferred compounds are also compounds listed in Table 1 using variables M1 and V3 wherein the four digit number represents M1.V3.L1.L2.
TABLE 1 1.1.1.1 1.1.1.2 1.1.1.3 1.1.1.4 1.1.1.5 1.1.1.6 1.1.1.7 1.1.1.8 1.1.1.9 1.1.2.1 1.1.2.2 1.1.2.3 1.1.2.4 1.1.2.5 1.1.2.6 1.1.2.7 1.1.2.8 1.1.2.9 1.1.3.1 1.1.3.2 1.1.3.3 1.1.3.4 1.1.3.5 1.1.3.6 1.1.3.7 1.1.3.8 1.1.3.9 1.1.4.1 1.1.4.2 1.1.4.3 1.1.4.4 1.1.4.5 1.1.4.6 1.1.4.7 1.1.4.8 1.1.4.9 1.1.5.1 1.1.5.2 1.1.5.3 1.1.5.4 1.1.5.5 1.1.5.6 1.1.5.7 1.1.5.8 1.1.5.9 1.1.6.1 1.1.6.2 1.1.6.3 1.1.6.4 1.1.6.5 1.1.6.6 1.1.6.7 1.1.6.8 1.1.6.9 1.1.7.1 1.1.7.2 1.1.7.3 1.1.7.4 1.1.7.5 1.1.7.6 1.1.7.7 1.1.7.8 1.1.7.9 1.1.8.1 1.1.8.2 1.1.8.3 1.1.8.4 1.1.8.5 1.1.8.6 1.1.8.7 1.1.8.8 1.1.8.9 1.1.9.1 1.1.9.2 1.1.9.3 1.1.9.4 1.1.9.5 1.1.9.6 1.1.9.7 1.1.9.8 1.1.9.9 1.2.1.1 1.2.1.2 1.2.1.3 1.2.1.4 1.2.1.5 1.2.1.6 1.2.1.7 1.2.1.8 1.2.1.9 1.2.2.1 1.2.2.2 1.2.2.3 1.2.2.4 1.2.2.5 1.2.2.6 1.2.2.7 1.2.2.8 1.2.2.9 1.2.3.1 1.2.3.2 1.2.3.3 1.2.3.4 1.2.3.5 1.2.3.6 1.2.3.7 1.2.3.8 1.2.3.9 1.2.4.1 1.2.4.2 1.2.4.3 1.2.4.4 1.2.4.5 1.2.4.6 1.2.4.7 1.2.4.8 1.2.4.9 1.2.5.1 1.2.5.2 1.2.5.3 1.2.5.4 1.2.5.5 1.2.5.6 1.2.5.7 1.2.5.8 1.2.5.9 1.2.6.1 1.2.6.2 1.2.6.3 1.2.6.4 1.2.6.5 1.2.6.6 1.2.6.7 1.2.6.8 1.2.6.9 1.2.7.1 1.2.7.2 1.2.7.3 1.2.7.4 1.2.7.5 1.2.7.6 1.2.7.7 1.2.7.8 1.2.7.9 1.2.8.1 1.2.8.2 1.2.8.3 1.2.8.4 1.2.8.5 1.2.8.6 1.2.8.7 1.2.8.8 1.2.8.9 1.2.9.1 1.2.9.2 1.2.9.3 1.2.9.4 1.2.9.5 1.2.9.6 1.2.9.7 1.2.9.8 1.2.9.9 1.3.1.1 1.3.1.2 1.3.1.3 1.3.1.4 1.3.1.5 1.3.1.6 1.3.1.7 1.3.1.8 1.3.1.9 1.3.2.1 1.3.2.2 1.3.2.3 1.3.2.4 1.3.2.5 1.3.2.6 1.3.2.7 1.3.2.8 1.3.2.9 1.3.3.1 1.3.3.2 1.3.3.3 1.3.3.4 1.3.3.5 1.3.3.6 1.3.3.7 1.3.3.8 1.3.3.9 1.3.4.1 1.3.4.2 1.3.4.3 1.3.4.4 1.3.4.5 1.3.4.6 1.3.4.7 1.3.4.8 1.3.4.9 1.3.5.1 1.3.5.2 1.3.5.3 1.3.5.4 1.3.5.5 1.3.5.6 1.3.5.7 1.3.5.8 1.3.5.9 1.3.6.1 1.3.6.2 1.3.6.3 1.3.6.4 1.3.6.5 1.3.6.6 1.3.6.7 1.3.6.8 1.3.6.9 1.3.7.1 1.3.7.2 1.3.7.3 1.3.7.4 1.3.7.5 1.3.7.6 1.3.7.7 1.3.7.8 1.3.7.9 1.3.8.1 1.3.8.2 1.3.8.3 1.3.8.4 1.3.8.5 1.3.8.6 1.3.8.7 1.3.8.8 1.3.8.9 1.3.9.1 1.3.9.2 1.3.9.3 1.3.9.4 1.3.9.5 1.3.9.6 1.3.9.7 1.3.9.8 1.3.9.9 1.4.1.1 1.4.1.2 1.4.1.3 1.4.1.4 1.4.1.5 1.4.1.6 1.4.1.7 1.4.1.8 1.4.1.9 1.4.2.1 1.4.2.2 1.4.2.3 1.4.2.4 1.4.2.5 1.4.2.6 1.4.2.7 1.4.2.8 1.4.2.9 1.4.3.1 1.4.3.2 1.4.3.3 1.4.3.4 1.4.3.5 1.4.3.6 1.4.3.7 1.4.3.8 1.4.3.9 1.4.4.1 1.4.4.2 1.4.4.3 1.4.4.4 1.4.4.5 1.4.4.6 1.4.4.7 1.4.4.8 1.4.4.9 1.4.5.1 1.4.5.2 1.4.5.3 1.4.5.4 1.4.5.5 1.4.5.6 1.4.5.7 1.4.5.8 1.4.5.9 1.4.6.1 1.4.6.2 1.4.6.3 1.4.6.4 1.4.6.5 1.4.6.6 1.4.6.7 1.4.6.8 1.4.6.9 1.4.7.1 1.4.7.2 1.4.7.3 1.4.7.4 1.4.7.5 1.4.7.6 1.4.7.7 1.4.7.8 1.4.7.9 1.4.8.1 1.4.8.2 1.4.8.3 1.4.8.4 1.4.8.5 1.4.8.6 1.4.8.7 1.4.8.8 1.4.8.9 1.4.9.1 1.4.9.2 1.4.9.3 1.4.9.4 1.4.9.5 1.4.9.6 1.4.9.7 1.4.9.8 1.4.9.9 1.5.1.1 1.5.1.2 1.5.1.3 1.5.1.4 1.5.1.5 1.5.1.6 1.5.1.7 1.5.1.8 1.5.1.9 1.5.2.1 1.5.2.2 1.5.2.3 1.5.2.4 1.5.2.5 1.5.2.6 1.5.2.7 1.5.2.8 1.5.2.9 1.5.3.1 1.5.3.2 1.5.3.3 1.5.3.4 1.5.3.5 1.5.3.6 1.5.3.7 1.5.3.8 1.5.3.9 1.5.4.1 1.5.4.2 1.5.4.3 1.5.4.4 1.5.4.5 1.5.4.6 1.5.4.7 1.5.4.8 1.5.4.9 1.5.5.1 1.5.5.2 1.5.5.3 1.5.5.4 1.5.5.5 1.5.5.6 1.5.5.7 1.5.5.8 1.5.5.9 1.5.6.1 1.5.6.2 1.5.6.3 1.5.6.4 1.5.6.5 1.5.6.6 1.5.6.7 1.5.6.8 1.5.6.9 1.5.7.1 1.5.7.2 1.5.7.3 1.5.7.4 1.5.7.5 1.5.7.6 1.5.7.7 1.5.7.8 1.5.7.9 1.5.8.1 1.5.8.2 1.5.8.3 1.5.8.4 1.5.8.5 1.5.8.6 1.5.8.7 1.5.8.8 1.5.8.9 1.5.9.1 1.5.9.2 1.5.9.3 1.5.9.4 1.5.9.5 1.5.9.6 1.5.9.7 1.5.9.8 1.5.9.9 1.6.1.1 1.6.1.2 1.6.1.3 1.6.1.4 1.6.1.5 1.6.1.6 1.6.1.7 1.6.1.8 1.6.1.9 1.6.2.1 1.6.2.2 1.6.2.3 1.6.2.4 1.6.2.5 1.6.2.6 1.6.2.7 1.6.2.8 1.6.2.9 1.6.3.1 1.6.3.2 1.6.3.3 1.6.3.4 1.6.3.5 1.6.3.6 1.6.3.7 1.6.3.8 1.6.3.9 1.6.4.1 1.6.4.2 1.6.4.3 1.6.4.4 1.6.4.5 1.6.4.6 1.6.4.7 1.6.4.8 1.6.4.9 1.6.5.1 1.6.5.2 1.6.5.3 1.6.5.4 1.6.5.5 1.6.5.6 1.6.5.7 1.6.5.8 1.6.5.9 1.6.6.1 1.6.6.2 1.6.6.3 1.6.6.4 1.6.6.5 1.6.6.6 1.6.6.7 1.6.6.8 1.6.6.9 1.6.7.1 1.6.7.2 1.6.7.3 1.6.7.4 1.6.7.5 1.6.7.6 1.6.7.7 1.6.7.8 1.6.7.9 1.6.8.1 1.6.8.2 1.6.8.3 1.6.8.4 1.6.8.5 1.6.8.6 1.6.8.7 1.6.8.8 1.6.8.9 1.6.9.1 1.6.9.2 1.6.9.3 1.6.9.4 1.6.9.5 1.6.9.6 1.6.9.7 1.6.9.8 1.6.9.9 1.7.1.1 1.7.1.2 1.7.1.3 1.7.1.4 1.7.1.5 1.7.1.6 1.7.1.7 1.7.1.8 1.7.1.9 1.7.2.1 1.7.2.2 1.7.2.3 1.7.2.4 1.7.2.5 1.7.2.6 1.7.2.7 1.7.2.8 1.7.2.9 1.7.3.1 1.7.3.2 1.7.3.3 1.7.3.4 1.7.3.5 1.7.3.6 1.7.3.7 1.7.3.8 1.7.3.9 1.7.4.1 1.7.4.2 1.7.4.3 1.7.4.4 1.7.4.5 1.7.4.6 1.7.4.7 1.7.4.8 1.7.4.9 1.7.5.1 1.7.5.2 1.7.5.3 1.7.5.4 1.7.5.5 1.7.5.6 1.7.5.7 1.7.5.8 1.7.5.9 1.7.6.1 1.7.6.2 1.7.6.3 1.7.6.4 1.7.6.5 1.7.6.6 1.7.6.7 1.7.6.8 1.7.6.9 1.7.7.1 1.7.7.2 1.7.7.3 1.7.7.4 1.7.7.5 1.7.7.6 1.7.7.7 1.7.7.8 1.7.7.9 1.7.8.1 1.7.8.2 1.7.8.3 1.7.8.4 1.7.8.5 1.7.8.6 1.7.8.7 1.7.8.8 1.7.8.9 1.7.9.1 1.7.9.2 1.7.9.3 1.7.9.4 1.7.9.5 1.7.9.6 1.7.9.7 1.7.9.8 1.7.9.9 1.8.1.1 1.8.1.2 1.8.1.3 1.8.1.4 1.8.1.5 1.8.1.6 1.8.1.7 1.8.1.8 1.8.1.9 1.8.2.1 1.8.2.2 1.8.2.3 1.8.2.4 1.8.2.5 1.8.2.6 1.8.2.7 1.8.2.8 1.8.2.9 1.8.3.1 1.8.3.2 1.8.3.3 1.8.3.4 1.8.3.5 1.8.3.6 1.8.3.7 1.8.3.8 1.8.3.9 1.8.4.1 1.8.4.2 1.8.4.3 1.8.4.4 1.8.4.5 1.8.4.6 1.8.4.7 1.8.4.8 1.8.4.9 1.8.5.1 1.8.5.2 1.8.5.3 1.8.5.4 1.8.5.5 1.8.5.6 1.8.5.7 1.8.5.8 1.8.5.9 1.8.6.1 1.8.6.2 1.8.6.3 1.8.6.4 1.8.6.5 1.8.6.6 1.8.6.7 1.8.6.8 1.8.6.9 1.8.7.1 1.8.7.2 1.8.7.3 1.8.7.4 1.8.7.5 1.8.7.6 1.8.7.7 1.8.7.8 1.8.7.9 1.8.8.1 1.8.8.2 1.8.8.3 1.8.8.4 1.8.8.5 1.8.8.6 1.8.8.7 1.8.8.8 1.8.8.9 1.8.9.1 1.8.9.2 1.8.9.3 1.8.9.4 1.8.9.5 1.8.9.6 1.8.9.7 1.8.9.8 1.8.9.9 1.9.1.1 1.9.1.2 1.9.1.3 1.9.1.4 1.9.1.5 1.9.1.6 1.9.1.7 1.9.1.8 1.9.1.9 1.9.2.1 1.9.2.2 1.9.2.3 1.9.2.4 1.9.2.5 1.9.2.6 1.9.2.7 1.9.2.8 1.9.2.9 1.9.3.1 1.9.3.2 1.9.3.3 1.9.3.4 1.9.3.5 1.9.3.6 1.9.3.7 1.9.3.8 1.9.3.9 1.9.4.1 1.9.4.2 1.9.4.3 1.9.4.4 1.9.4.5 1.9.4.6 1.9.4.7 1.9.4.8 1.9.4.9 1.9.5.1 1.9.5.2 1.9.5.3 1.9.5.4 1.9.5.5 1.9.5.6 1.9.5.7 1.9.5.8 1.9.5.9 1.9.6.1 1.9.6.2 1.9.6.3 1.9.6.4 1.9.6.5 1.9.6.6 1.9.6.7 1.9.6.8 1.9.6.9 1.9.7.1 1.9.7.2 1.9.7.3 1.9.7.4 1.9.7.5 1.9.7.6 1.9.7.7 1.9.7.8 1.9.7.9 1.9.8.1 1.9.8.2 1.9.8.3 1.9.8.4 1.9.8.5 1.9.8.6 1.9.8.7 1.9.8.8 1.9.8.9 1.9.9.1 1.9.9.2 1.9.9.3 1.9.9.4 1.9.9.5 1.9.9.6 1.9.9.7 1.9.9.8 1.9.9.9 2.1.1.1 2.1.1.2 2.1.1.3 2.1.1.4 2.1.1.5 2.1.1.6 2.1.1.7 2.1.1.8 2.1.1.9 2.1.2.1 2.1.2.2 2.1.2.3 2.1.2.4 2.1.2.5 2.1.2.6 2.1.2.7 2.1.2.8 2.1.2.9 2.1.3.1 2.1.3.2 2.1.3.3 2.1.3.4 2.1.3.5 2.1.3.6 2.1.3.7 2.1.3.8 2.1.3.9 2.1.4.1 2.1.4.2 2.1.4.3 2.1.4.4 2.1.4.5 2.1.4.6 2.1.4.7 2.1.4.8 2.1.4.9 2.1.5.1 2.1.5.2 2.1.5.3 2.1.5.4 2.1.5.5 2.1.5.6 2.1.5.7 2.1.5.8 2.1.5.9 2.1.6.1 2.1.6.2 2.1.6.3 2.1.6.4 2.1.6.5 2.1.6.6 2.1.6.7 2.1.6.8 2.1.6.9 2.1.7.1 2.1.7.2 2.1.7.3 2.1.7.4 2.1.7.5 2.1.7.6 2.1.7.7 2.1.7.8 2.1.7.9 2.1.8.1 2.1.8.2 2.1.8.3 2.1.8.4 2.1.8.5 2.1.8.6 2.1.8.7 2.1.8.8 2.1.8.9 2.1.9.1 2.1.9.2 2.1.9.3 2.1.9.4 2.1.9.5 2.1.9.6 2.1.9.7 2.1.9.8 2.1.9.9 2.2.1.1 2.2.1.2 2.2.1.3 2.2.1.4 2.2.1.5 2.2.1.6 2.2.1.7 2.2.1.8 2.2.1.9 2.2.2.1 2.2.2.2 2.2.2.3 2.2.2.4 2.2.5.2 2.2.6.2 2.2.7.2 2.2.3.8 2.2.2.9 2.2.3.1 2.2.3.2 2.2.3.3 2.2.3.4 2.2.3.5 2.3.6.2 2.3.7.2 2.3.8.2 2.2.3.9 2.2.4.1 2.2.4.2 2.2.4.3 2.2.4.4 2.2.4.5 2.2.4.6 2.4.7.2 2.2.4.8 2.2.4.9 2.2.5.1 2.2.5.2 2.2.5.3 2.2.5.4 2.2.5.5 2.2.5.6 2.2.5.7 2.2.5.8 2.2.5.9 2.2.6.1 2.2.6.2 2.2.6.3 2.2.6.4 2.2.6.5 2.2.6.6 2.2.6.7 2.2.6.8 2.2.6.9 2.2.7.1 2.2.7.2 2.2.7.3 2.2.7.4 2.2.7.5 2.2.7.6 2.2.7.7 2.2.7.8 2.2.7.9 2.2.8.1 2.2.8.2 2.2.8.3 2.2.8.4 2.2.8.5 2.2.8.6 2.2.8.7 2.2.8.8 2.2.8.9 2.2.9.1 2.2.9.2 2.2.9.3 2.2.9.4 2.2.9.5 2.2.9.6 2.2.9.7 2.2.9.8 2.2.9.9 2.3.1.1 2.3.1.2 2.3.1.3 2.3.1.4 2.3.1.5 2.3.1.6 2.3.1.7 2.3.1.8 2.3.1.9 2.3.2.1 2.3.2.2 2.3.2.3 2.3.2.4 2.3.2.5 2.3.2.6 2.3.2.7 2.3.2.8 2.3.2.9 2.3.3.1 2.3.3.2 2.3.3.3 2.3.3.4 2.3.3.5 2.3.3.6 2.3.3.7 2.3.3.8 2.3.3.9 2.3.4.1 2.3.4.2 2.3.4.3 2.3.4.4 2.3.4.5 2.3.4.6 2.3.4.7 2.3.4.8 2.3.4.9 2.3.5.1 2.3.5.2 2.3.5.3 2.3.5.4 2.3.5.5 2.3.5.6 2.3.5.7 2.3.5.8 2.3.5.9 2.3.6.1 2.3.6.2 2.3.6.3 2.3.6.4 2.3.6.5 2.3.6.6 2.3.6.7 2.3.6.8 2.3.6.9 2.3.7.1 2.3.7.2 2.3.7.3 2.3.7.4 2.3.7.5 2.3.7.6 2.3.7.7 2.3.7.8 2.3.7.9 2.3.8.1 2.3.8.2 2.3.8.3 2.3.8.4 2.3.8.5 2.3.8.6 2.3.8.7 2.3.8.8 2.3.8.9 2.3.9.1 2.3.9.2 2.3.9.3 2.3.9.4 2.3.9.5 2.3.9.6 2.3.9.7 2.3.9.8 2.3.9.9 2.4.1.1 2.4.1.2 2.4.1.3 2.4.1.4 2.4.1.5 2.4.1.6 2.4.1.7 2.4.1.8 2.4.1.9 2.4.2.1 2.4.2.2 2.4.2.3 2.4.2.4 2.4.2.5 2.4.2.6 2.4.2.7 2.4.2.8 2.4.2.9 2.4.3.1 2.4.3.2 2.4.3.3 2.4.3.4 2.4.3.5 2.4.3.6 2.4.3.7 2.4.3.8 2.4.3.9 2.4.4.1 2.4.4.2 2.4.4.3 2.4.4.4 2.4.4.5 2.4.4.6 2.4.4.7 2.4.4.8 2.4.4.9 2.4.5.1 2.4.5.2 2.4.5.3 2.4.5.4 2.4.5.5 2.4.5.6 2.4.5.7 2.4.5.8 2.4.5.9 2.4.6.1 2.4.6.2 2.4.6.3 2.4.6.4 2.4.6.5 2.4.6.6 2.4.6.7 2.4.6.8 2.4.6.9 2.4.7.1 2.4.7.2 2.4.7.3 2.4.7.4 2.4.7.5 2.4.7.6 2.4.7.7 2.4.7.8 2.4.7.9 2.4.8.1 2.4.8.2 2.4.8.3 2.4.8.4 2.4.8.5 2.4.8.6 2.4.8.7 2.4.8.8 2.4.8.9 2.4.9.1 2.4.9.2 2.4.9.3 2.4.9.4 2.4.9.5 2.4.9.6 2.4.9.7 2.4.9.8 2.4.9.9 2.5.1.1 2.5.1.2 2.5.1.3 2.5.1.4 2.5.1.5 2.5.1.6 2.5.1.7 2.5.1.8 2.5.1.9 2.5.2.1 2.5.2.2 2.5.2.3 2.5.2.4 2.5.2.5 2.5.2.6 2.5.2.7 2.5.2.8 2.5.2.9 2.5.3.1 2.5.3.2 2.5.3.3 2.5.3.4 2.5.3.5 2.5.3.6 2.5.3.7 2.5.3.8 2.5.3.9 2.5.4.1 2.5.4.2 2.5.4.3 2.5.4.4 2.5.4.5 2.5.4.6 2.5.4.7 2.5.4.8 2.5.4.9 2.5.5.1 2.5.5.2 2.5.5.3 2.5.5.4 2.5.5.5 2.5.5.6 2.5.5.7 2.5.5.8 2.5.5.9 2.5.6.1 2.5.6.2 2.5.6.3 2.5.6.4 2.5.6.5 2.5.6.6 2.5.6.7 2.5.6.8 2.5.6.9 2.5.7.1 2.5.7.2 2.5.7.3 2.5.7.4 2.5.7.5 2.5.7.6 2.5.7.7 2.5.7.8 2.5.7.9 2.5.8.1 2.5.8.2 2.5.8.3 2.5.8.4 2.5.8.5 2.5.8.6 2.5.8.7 2.5.8.8 2.5.8.9 2.5.9.1 2.5.9.2 2.5.9.3 2.5.9.4 2.5.9.5 2.5.9.6 2.5.9.7 2.5.9.8 2.5.9.9 2.6.1.1 2.6.1.2 2.6.1.3 2.6.1.4 2.6.1.5 2.6.1.6 2.6.1.7 2.6.1.8 2.6.1.9 2.6.2.1 2.6.2.2 2.6.2.3 2.6.2.4 2.6.2.5 2.6.2.6 2.6.2.7 2.6.2.8 2.6.2.9 2.6.3.1 2.6.3.2 2.6.3.3 2.6.3.4 2.6.3.5 2.6.3.6 2.6.3.7 2.6.3.8 2.6.3.9 2.6.4.1 2.6.4.2 2.6.4.3 2.6.4.4 2.6.4.5 2.6.4.6 2.6.4.7 2.6.4.8 2.6.4.9 2.6.5.1 2.6.5.2 2.6.5.3 2.6.5.4 2.6.5.5 2.6.5.6 2.6.5.7 2.6.5.8 2.6.5.9 2.6.6.1 2.6.6.2 2.6.6.3 2.6.6.4 2.6.6.5 2.6.6.6 2.6.6.7 2.6.6.8 2.6.6.9 2.6.7.1 2.6.7.2 2.6.7.3 2.6.7.4 2.6.7.5 2.6.7.6 2.6.7.7 2.6.7.8 2.6.7.9 2.6.8.1 2.6.8.2 2.6.8.3 2.6.8.4 2.6.8.5 2.6.8.6 2.6.8.7 2.6.8.8 2.6.8.9 2.6.9.1 2.6.9.2 2.6.9.3 2.6.9.4 2.6.9.5 2.6.9.6 2.6.9.7 2.6.9.8 2.6.9.9 2.7.1.1 2.7.1.2 2.7.1.3 2.7.1.4 2.7.1.5 2.7.1.6 2.7.1.7 2.7.1.8 2.7.1.9 2.7.2.1 2.7.2.2 2.7.2.3 2.7.2.4 2.7.2.5 2.7.2.6 2.7.2.7 2.7.2.8 2.7.2.9 2.7.3.1 2.7.3.2 2.7.3.3 2.7.3.4 2.7.3.5 2.7.3.6 2.7.3.7 2.7.3.8 2.7.3.9 2.7.4.1 2.7.4.2 2.7.4.3 2.7.4.4 2.7.4.5 2.7.4.6 2.7.4.7 2.7.4.8 2.7.4.9 2.7.5.1 2.7.5.2 2.7.5.3 2.7.5.4 2.7.5.5 2.7.5.6 2.7.5.7 2.7.5.8 2.7.5.9 2.7.6.1 2.7.6.2 2.7.6.3 2.7.6.4 2.7.6.5 2.7.6.6 2.7.6.7 2.7.6.8 2.7.6.9 2.7.7.1 2.7.7.2 2.7.7.3 2.7.7.4 2.7.7.5 2.7.7.6 2.7.7.7 2.7.7.8 2.7.7.9 2.7.8.1 2.7.8.2 2.7.8.3 2.7.8.4 2.7.8.5 2.7.8.6 2.7.8.7 2.7.8.8 2.7.8.9 2.7.9.1 2.7.9.2 2.7.9.3 2.7.9.4 2.7.9.5 2.7.9.6 2.7.9.7 2.7.9.8 2.7.9.9 2.8.1.1 2.8.1.2 2.8.1.3 2.8.1.4 2.8.1.5 2.8.1.6 2.8.1.7 2.8.1.8 2.8.1.9 2.8.2.1 2.8.2.2 2.8.2.3 2.8.2.4 2.8.2.5 2.8.2.6 2.8.2.7 2.8.2.8 2.8.2.9 2.8.3.1 2.8.3.2 2.8.3.3 2.8.3.4 2.8.3.5 2.8.3.6 2.8.3.7 2.8.3.8 2.8.3.9 2.8.4.1 2.8.4.2 2.8.4.3 2.8.4.4 2.8.4.5 2.8.4.6 2.8.4.7 2.8.4.8 2.8.4.9 2.8.5.1 2.8.5.2 2.8.5.3 2.8.5.4 2.8.5.5 2.8.5.6 2.8.5.7 2.8.5.8 2.8.5.9 2.8.6.1 2.8.6.2 2.8.6.3 2.8.6.4 2.8.6.5 2.8.6.6 2.8.6.7 2.8.6.8 2.8.6.9 2.8.7.1 2.8.7.2 2.8.7.3 2.8.7.4 2.8.7.5 2.8.7.6 2.8.7.7 2.8.7.8 2.8.7.9 2.8.8.1 2.8.8.2 2.8.8.3 2.8.8.4 2.8.8.5 2.8.8.6 2.8.8.7 2.8.8.8 2.8.8.9 2.8.9.1 2.8.9.2 2.8.9.3 2.8.9.4 2.8.9.5 2.8.9.6 2.8.9.7 2.8.9.8 2.8.9.9 2.9.1.1 2.9.1.2 2.9.1.3 2.9.1.4 2.9.1.5 2.9.1.6 2.9.1.7 2.9.1.8 2.9.1.9 2.9.2.1 2.9.2.2 2.9.2.3 2.9.2.4 2.9.2.5 2.9.2.6 2.9.2.7 2.9.2.8 2.9.2.9 2.9.3.1 2.9.3.2 2.9.3.3 2.9.3.4 2.9.3.5 2.9.3.6 2.9.3.7 2.9.3.8 2.9.3.9 2.9.4.1 2.9.4.2 2.9.4.3 2.9.4.4 2.9.4.5 2.9.4.6 2.9.4.7 2.9.4.8 2.9.4.9 2.9.5.1 2.9.5.2 2.9.5.3 2.9.5.4 2.9.5.5 2.9.5.6 2.9.5.7 2.9.5.8 2.9.5.9 2.9.6.1 2.9.6.2 2.9.6.3 2.9.6.4 2.9.6.5 2.9.6.6 2.9.6.7 2.9.6.8 2.9.6.9 2.9.7.1 2.9.7.2 2.9.7.3 2.9.7.4 2.9.7.5 2.9.7.6 2.9.7.7 2.9.7.8 2.9.7.9 2.9.8.1 2.9.8.2 2.9.8.3 2.9.8.4 2.9.8.5 2.9.8.6 2.9.8.7 2.9.8.8 2.9.8.9 2.9.9.1 2.9.9.2 2.9.9.3 2.9.9.4 2.9.9.5 2.9.9.6 2.9.9.7 2.9.9.8 2.9.9.9 3.1.1.1 3.1.1.2 3.1.1.3 3.1.1.4 3.1.1.5 3.1.1.6 3.1.1.7 3.1.1.8 3.1.1.9 3.1.2.1 3.1.2.2 3.1.2.3 3.1.2.4 3.1.2.5 3.1.2.6 3.1.2.7 3.1.2.8 3.1.2.9 3.1.3.1 3.1.3.2 3.1.3.3 3.1.3.4 3.1.3.5 3.1.3.6 3.1.3.7 3.1.3.8 3.1.3.9 3.1.4.1 3.1.4.2 3.1.4.3 3.1.4.4 3.1.4.5 3.1.4.6 3.1.4.7 3.1.4.8 3.1.4.9 3.1.5.1 3.1.5.2 3.1.5.3 3.1.5.4 3.1.5.5 3.1.5.6 3.1.5.7 3.1.5.8 3.1.5.9 3.1.6.1 3.1.6.2 3.1.6.3 3.1.6.4 3.1.6.5 3.1.6.6 3.1.6.7 3.1.6.8 3.1.6.9 3.1.7.1 3.1.7.2 3.1.7.3 3.1.7.4 3.1.7.5 3.1.7.6 3.1.7.7 3.1.7.8 3.1.7.9 3.1.8.1 3.1.8.2 3.1.8.3 3.1.8.4 3.1.8.5 3.1.8.6 3.1.8.7 3.1.8.8 3.1.8.9 3.1.9.1 3.1.9.2 3.1.9.3 3.1.9.4 3.1.9.5 3.1.9.6 3.1.9.7 3.1.9.8 3.1.9.9 3.2.1.1 3.2.1.2 3.2.1.3 3.2.1.4 3.2.1.5 3.2.1.6 3.2.1.7 3.2.1.8 3.2.1.9 3.2.2.1 3.2.2.2 3.2.2.3 3.2.2.4 3.2.2.5 3.2.2.6 3.2.2.7 3.2.2.8 3.2.2.9 3.2.3.1 3.2.3.2 3.2.3.3 3.2.3.4 3.2.3.5 3.2.3.6 3.2.3.7 3.2.3.8 3.2.3.9 3.2.4.1 3.2.4.2 3.2.4.3 3.2.4.4 3.2.4.5 3.2.4.6 3.2.4.7 3.2.4.8 3.2.4.9 3.2.5.1 3.2.5.2 3.2.5.3 3.2.5.4 3.2.5.5 3.2.5.6 3.2.5.7 3.2.5.8 3.2.5.9 3.2.6.1 3.2.6.2 3.2.6.3 3.2.6.4 3.2.6.5 3.2.6.6 3.2.6.7 3.2.6.8 3.2.6.9 3.2.7.1 3.2.7.2 3.2.7.3 3.2.7.4 3.2.7.5 3.2.7.6 3.2.7.7 3.2.7.8 3.2.7.9 3.2.8.1 3.2.8.2 3.2.8.3 3.2.8.4 3.2.8.5 3.2.8.6 3.2.8.7 3.2.8.8 3.2.8.9 3.2.9.1 3.2.9.2 3.2.9.3 3.2.9.4 3.2.9.5 3.2.9.6 3.2.9.7 3.2.9.8 3.2.9.9 3.3.1.1 3.3.1.2 3.3.1.3 3.3.1.4 3.3.1.5 3.3.1.6 3.3.1.7 3.3.1.8 3.3.1.9 3.3.2.1 3.3.2.2 3.3.2.3 3.3.2.4 3.3.2.5 3.3.2.6 3.3.2.7 3.3.2.8 3.3.2.9 3.3.3.1 3.3.3.2 3.3.3.3 3.3.3.4 3.3.3.5 3.3.3.6 3.3.3.7 3.3.3.8 3.3.3.9 3.3.4.1 3.3.4.2 3.3.4.3 3.3.4.4 3.3.4.5 3.3.4.6 3.3.4.7 3.3.4.8 3.3.4.9 3.3.5.1 3.3.5.2 3.3.5.3 3.3.5.4 3.3.5.5 3.3.5.6 3.3.5.7 3.3.5.8 3.3.5.9 3.3.6.1 3.3.6.2 3.3.6.3 3.3.6.4 3.3.6.5 3.3.6.6 3.3.6.7 3.3.6.8 3.3.6.9 3.3.7.1 3.3.7.2 3.3.7.3 3.3.7.4 3.3.7.5 3.3.7.6 3.3.7.7 3.3.7.8 3.3.7.9 3.3.8.1 3.3.8.2 3.3.8.3 3.3.8.4 3.3.8.5 3.3.8.6 3.3.8.7 3.3.8.8 3.3.8.9 3.9.1.3 3.9.2.3 3.9.3.3 3.3.9.4 3.3.9.5 3.3.9.6 3.3.9.7 3.3.9.8 3.3.9.9 3.4.1.1 3.4.1.2 3.4.1.3 3.4.1.4 3.4.1.5 3.4.1.6 3.4.1.7 3.4.1.8 3.4.1.9 3.4.2.1 3.4.2.2 3.4.2.3 3.4.2.4 3.4.2.5 3.4.2.6 3.4.2.7 3.4.2.8 3.4.2.9 3.4.3.1 3.4.3.2 3.4.3.3 3.4.3.4 3.4.3.5 3.4.3.6 3.4.3.7 3.4.3.8 3.4.3.9 3.4.4.1 3.4.4.2 3.4.4.3 3.4.4.4 3.4.4.5 3.4.4.6 3.4.4.7 3.4.4.8 3.4.4.9 3.4.5.1 3.4.5.2 3.4.5.3 3.4.5.4 3.4.5.5 3.4.5.6 3.4.5.7 3.4.5.8 3.4.5.9 3.4.6.1 3.4.6.2 3.4.6.3 3.4.6.4 3.4.6.5 3.4.6.6 3.4.6.7 3.4.6.8 3.4.6.9 3.4.7.1 3.4.7.2 3.4.7.3 3.4.7.4 3.4.7.5 3.4.7.6 3.4.7.7 3.4.7.8 3.4.7.9 3.4.8.1 3.4.8.2 3.4.8.3 3.4.8.4 3.4.8.5 3.4.8.6 3.4.8.7 3.4.8.8 3.4.8.9 3.4.9.1 3.4.9.2 3.4.9.3 3.4.9.4 3.4.9.5 3.4.9.6 3.4.9.7 3.4.9.8 3.4.9.9 3.5.1.1 3.5.1.2 3.5.1.3 3.5.1.4 3.5.1.5 3.5.1.6 3.5.1.7 3.5.1.8 3.5.1.9 3.5.2.1 3.5.2.2 3.5.2.3 3.5.2.4 3.5.2.5 3.5.2.6 3.5.2.7 3.5.2.8 3.5.2.9 3.5.3.1 3.5.3.2 3.5.3.3 3.5.3.4 3.5.3.5 3.5.3.6 3.5.3.7 3.5.3.8 3.5.3.9 3.5.4.1 3.5.4.2 3.5.4.3 3.5.4.4 3.5.4.5 3.5.4.6 3.5.4.7 3.5.4.8 3.5.4.9 3.5.5.1 3.5.5.2 3.5.5.3 3.5.5.4 3.5.5.5 3.5.5.6 3.5.5.7 3.5.5.8 3.5.5.9 3.5.6.1 3.5.6.2 3.5.6.3 3.5.6.4 3.5.6.5 3.5.6.6 3.5.6.7 3.5.6.8 3.5.6.9 3.5.7.1 3.5.7.2 3.5.7.3 3.5.7.4 3.5.7.5 3.5.7.6 3.5.7.7 3.5.7.8 3.5.7.9 3.5.8.1 3.5.8.2 3.5.8.3 3.5.8.4 3.5.8.5 3.5.8.6 3.5.8.7 3.5.8.8 3.5.8.9 3.5.9.1 3.5.9.2 3.5.9.3 3.5.9.4 3.5.9.5 3.5.9.6 3.5.9.7 3.5.9.8 3.5.9.9 3.6.1.1 3.6.1.2 3.6.1.3 3.6.1.4 3.6.1.5 3.6.1.6 3.6.1.7 3.6.1.8 3.6.1.9 3.6.2.1 3.6.2.2 3.6.2.3 3.6.2.4 3.6.2.5 3.6.2.6 3.6.2.7 3.6.2.8 3.6.2.9 3.6.3.1 3.6.3.2 3.6.3.3 3.6.3.4 3.6.3.5 3.6.3.6 3.6.3.7 3.6.3.8 3.6.3.9 3.6.4.1 3.6.4.2 3.6.4.3 3.6.4.4 3.6.4.5 3.6.4.6 3.6.4.7 3.6.4.8 3.6.4.9 3.6.5.1 3.6.5.2 3.6.5.3 3.6.5.4 3.6.5.5 3.6.5.6 3.6.5.7 3.6.5.8 3.6.5.9 3.6.6.1 3.6.6.2 3.6.6.3 3.6.6.4 3.6.6.5 3.6.6.6 3.6.6.7 3.6.6.8 3.6.6.9 3.6.7.1 3.6.7.2 3.6.7.3 3.6.7.4 3.6.7.5 3.6.7.6 3.6.7.7 3.6.7.8 3.6.7.9 3.6.8.1 3.6.8.2 3.6.8.3 3.6.8.4 3.6.8.5 3.6.8.6 3.6.8.7 3.6.8.8 3.6.8.9 3.6.9.1 3.6.9.2 3.6.9.3 3.6.9.4 3.6.9.5 3.6.9.6 3.6.9.7 3.6.9.8 3.6.9.9 3.7.1.1 3.7.1.2 3.7.1.3 3.7.1.4 3.7.1.5 3.7.1.6 3.7.1.7 3.7.1.8 3.7.1.9 3.7.2.1 3.7.2.2 3.7.2.3 3.7.2.4 3.7.2.5 3.7.2.6 3.7.2.7 3.7.2.8 3.7.2.9 3.7.3.1 3.7.3.2 3.7.3.3 3.7.3.4 3.7.3.5 3.7.3.6 3.7.3.7 3.7.3.8 3.7.3.9 3.7.4.1 3.7.4.2 3.7.4.3 3.7.4.4 3.7.4.5 3.7.4.6 3.7.4.7 3.7.4.8 3.7.4.9 3.7.5.1 3.7.5.2 3.7.5.3 3.7.5.4 3.7.5.5 3.7.5.6 3.7.5.7 3.7.5.8 3.7.5.9 3.7.6.1 3.7.6.2 3.7.6.3 3.7.6.4 3.7.6.5 3.7.6.6 3.7.6.7 3.7.6.8 3.7.6.9 3.7.7.1 3.7.7.2 3.7.7.3 3.7.7.4 3.7.7.5 3.7.7.6 3.7.7.7 3.7.7.8 3.7.7.9 3.7.8.1 3.7.8.2 3.7.8.3 3.7.8.4 3.7.8.5 3.7.8.6 3.7.8.7 3.7.8.8 3.7.8.9 3.7.9.1 3.7.9.2 3.7.9.3 3.7.9.4 3.7.9.5 3.7.9.6 3.7.9.7 3.7.9.8 3.7.9.9 3.8.1.1 3.8.1.2 3.8.1.3 3.8.1.4 3.8.1.5 3.8.1.6 3.8.1.7 3.8.1.8 3.8.1.9 3.8.2.1 3.8.2.2 3.8.2.3 3.8.2.4 3.8.2.5 3.8.2.6 3.8.2.7 3.8.2.8 3.8.2.9 3.8.3.1 3.8.3.2 3.8.3.3 3.8.3.4 3.8.3.5 3.8.3.6 3.8.3.7 3.8.3.8 3.8.3.9 3.8.4.1 3.8.4.2 3.8.4.3 3.8.4.4 3.8.4.5 3.8.4.6 3.8.4.7 3.8.4.8 3.8.4.9 3.8.5.1 3.8.5.2 3.8.5.3 3.8.5.4 3.8.5.5 3.8.5.6 3.8.5.7 3.8.5.8 3.8.5.9 3.8.6.1 3.8.6.2 3.8.6.3 3.8.6.4 3.8.6.5 3.8.6.6 3.8.6.7 3.8.6.8 3.8.6.9 3.8.7.1 3.8.7.2 3.8.7.3 3.8.7.4 3.8.7.5 3.8.7.6 3.8.7.7 3.8.7.8 3.8.7.9 3.8.8.1 3.8.8.2 3.8.8.3 3.8.8.4 3.8.8.5 3.8.8.6 3.8.8.7 3.8.8.8 3.8.8.9 3.8.9.1 3.8.9.2 3.8.9.3 3.8.9.4 3.8.9.5 3.8.9.6 3.8.9.7 3.8.9.8 3.8.9.9 3.9.1.1 3.9.1.2 3.9.1.3 3.9.1.4 3.9.1.5 3.9.1.6 3.9.1.7 3.9.1.8 3.9.1.9 3.9.2.1 3.9.2.2 3.9.2.3 3.9.2.4 3.9.2.5 3.9.2.6 3.9.2.7 3.9.2.8 3.9.2.9 3.9.3.1 3.9.3.2 3.9.3.3 3.9.3.4 3.9.3.5 3.9.3.6 3.9.3.7 3.9.3.8 3.9.3.9 3.9.4.1 3.9.4.2 3.9.4.3 3.9.4.4 3.9.4.5 3.9.4.6 3.9.4.7 3.9.4.8 3.9.4.9 3.9.5.1 3.9.5.2 3.9.5.3 3.9.5.4 3.9.5.5 3.9.5.6 3.9.5.7 3.9.5.8 3.9.5.9 3.9.6.1 3.9.6.2 3.9.6.3 3.9.6.4 3.9.6.5 3.9.6.6 3.9.6.7 3.9.6.8 3.9.6.9 3.9.7.1 3.9.7.2 3.9.7.3 3.9.7.4 3.9.7.5 3.9.7.6 3.9.7.7 3.9.7.8 3.9.7.9 3.9.8.1 3.9.8.2 3.9.8.3 3.9.8.4 3.9.8.5 3.9.8.6 3.9.8.7 3.9.8.8 3.9.8.9 3.9.9.1 3.9.9.2 3.9.9.3 3.9.9.4 3.9.9.5 3.9.9.6 3.9.9.7 3.9.9.8 3.9.9.9 4.1.1.1 4.1.1.2 4.1.1.3 4.1.1.4 4.1.1.5 4.1.1.6 4.1.1.7 4.1.1.8 4.1.1.9 4.1.2.1 4.1.2.2 4.1.2.3 4.1.2.4 4.1.2.5 4.1.2.6 4.1.2.7 4.1.2.8 4.1.2.9 4.1.3.1 4.1.3.2 4.1.3.3 4.1.3.4 4.1.3.5 4.1.3.6 4.1.3.7 4.1.3.8 4.1.3.9 4.1.4.1 4.1.4.2 4.1.4.3 4.1.4.4 4.1.4.5 4.1.4.6 4.1.4.7 4.1.4.8 4.1.4.9 4.1.5.1 4.1.5.2 4.1.5.3 4.1.5.4 4.1.5.5 4.1.5.6 4.1.5.7 4.1.5.8 4.1.5.9 4.1.6.1 4.1.6.2 4.1.6.3 4.1.6.4 4.1.6.5 4.1.6.6 4.1.6.7 4.1.6.8 4.1.6.9 4.1.7.1 4.1.7.2 4.1.7.3 4.1.7.4 4.1.7.5 4.1.7.6 4.1.7.7 4.1.7.8 4.1.7.9 4.1.8.1 4.1.8.2 4.1.8.3 4.1.8.4 4.1.8.5 4.1.8.6 4.1.8.7 4.1.8.8 4.1.8.9 4.1.9.1 4.1.9.2 4.1.9.3 4.1.9.4 4.1.9.5 4.1.9.6 4.1.9.7 4.1.9.8 4.1.9.9 4.2.1.1 4.2.1.2 4.2.1.3 4.2.1.4 4.2.1.5 4.2.1.6 4.2.1.7 4.2.1.8 4.2.1.9 4.2.2.1 4.2.2.2 4.2.2.3 4.2.2.4 4.2.2.5 4.2.2.6 4.2.2.7 4.2.2.8 4.2.2.9 4.2.3.1 4.2.3.2 4.2.3.3 4.2.3.4 4.2.3.5 4.2.3.6 4.2.3.7 4.2.3.8 4.2.3.9 4.2.4.1 4.2.4.2 4.2.4.3 4.2.4.4 4.2.4.5 4.2.4.6 4.2.4.7 4.2.4.8 4.2.4.9 4.2.5.1 4.2.5.2 4.2.5.3 4.2.5.4 4.2.5.5 4.2.5.6 4.2.5.7 4.2.5.8 4.2.5.9 4.2.6.1 4.2.6.2 4.2.6.3 4.2.6.4 4.2.6.5 4.2.6.6 4.2.6.7 4.2.6.8 4.2.6.9 4.2.7.1 4.2.7.2 4.2.7.3 4.2.7.4 4.2.7.5 4.2.7.6 4.2.7.7 4.2.7.8 4.2.7.9 4.2.8.1 4.2.8.2 4.2.8.3 4.2.8.4 4.2.8.5 4.2.8.6 4.2.8.7 4.2.8.8 4.2.8.9 4.2.9.1 4.2.9.2 4.2.9.3 4.2.9.4 4.2.9.5 4.2.9.6 4.2.9.7 4.2.9.8 4.2.9.9 4.3.1.1 4.3.1.2 4.3.1.3 4.3.1.4 4.3.1.5 4.3.1.6 4.3.1.7 4.3.1.8 4.3.1.9 4.3.2.1 4.3.2.2 4.3.2.3 4.3.2.4 4.3.2.5 4.3.2.6 4.3.2.7 4.3.2.8 4.3.2.9 4.3.3.1 4.3.3.2 4.3.3.3 4.3.3.4 4.3.3.5 4.3.3.6 4.3.3.7 4.3.3.8 4.3.3.9 4.3.4.1 4.3.4.2 4.3.4.3 4.3.4.4 4.3.4.5 4.3.4.6 4.3.4.7 4.3.4.8 4.3.4.9 4.3.5.1 4.3.5.2 4.3.5.3 4.3.5.4 4.3.5.5 4.3.5.6 4.3.5.7 4.3.5.8 4.3.5.9 4.3.6.1 4.3.6.2 4.3.6.3 4.3.6.4 4.3.6.5 4.3.6.6 4.3.6.7 4.3.6.8 4.3.6.9 4.3.7.1 4.3.7.2 4.3.7.3 4.3.7.4 4.3.7.5 4.3.7.6 4.3.7.7 4.3.7.8 4.3.7.9 4.3.8.1 4.3.8.2 4.3.8.3 4.3.8.4 4.3.8.5 4.3.8.6 4.3.8.7 4.3.8.8 4.3.8.9 4.3.9.1 4.3.9.2 4.3.9.3 4.3.9.4 4.3.9.5 4.3.9.6 4.3.9.7 4.3.9.8 4.3.9.9 4.4.1.1 4.4.1.2 4.4.1.3 4.4.1.4 4.4.1.5 4.4.1.6 4.4.1.7 4.4.1.8 4.4.1.9 4.4.2.1 4.4.2.2 4.4.2.3 4.4.2.4 4.4.2.5 4.4.2.6 4.4.2.7 4.4.2.8 4.4.2.9 4.4.3.1 4.4.3.2 4.4.3.3 4.4.3.4 4.4.3.5 4.4.3.6 4.4.3.7 4.4.3.8 4.4.3.9 4.4.4.1 4.4.4.2 4.4.4.3 4.4.4.4 4.4.4.5 4.4.4.6 4.4.4.7 4.4.4.8 4.4.4.9 4.4.5.1 4.4.5.2 4.4.5.3 4.4.5.4 4.4.5.5 4.4.5.6 4.4.5.7 4.4.5.8 4.4.5.9 4.4.6.1 4.4.6.2 4.4.6.3 4.4.6.4 4.4.6.5 4.4.6.6 4.4.6.7 4.4.6.8 4.4.6.9 4.4.7.1 4.4.7.2 4.4.7.3 4.4.7.4 4.4.7.5 4.4.7.6 4.4.7.7 4.4.7.8 4.4.7.9 4.4.8.1 4.4.8.2 4.4.8.3 4.4.8.4 4.4.8.5 4.4.8.6 4.4.8.7 4.4.8.8 4.4.8.9 4.4.9.1 4.4.9.2 4.4.9.3 4.4.9.4 4.4.9.5 4.4.9.6 4.4.9.7 4.4.9.8 4.4.9.9 4.5.1.1 4.5.1.2 4.5.1.3 4.5.1.4 4.5.1.5 4.5.1.6 4.5.1.7 4.5.1.8 4.5.1.9 4.5.2.1 4.5.2.2 4.5.2.3 4.5.2.4 4.5.2.5 4.5.2.6 4.5.2.7 4.5.2.8 4.5.2.9 4.5.3.1 4.5.3.2 4.5.3.3 4.5.3.4 4.5.3.5 4.5.3.6 4.5.3.7 4.5.3.8 4.5.3.9 4.5.4.1 4.5.4.2 4.5.4.3 4.5.4.4 4.5.4.5 4.5.4.6 4.5.4.7 4.5.4.8 4.5.4.9 4.5.5.1 4.5.5.2 4.5.5.3 4.5.5.4 4.5.5.5 4.5.5.6 4.5.5.7 4.5.5.8 4.5.5.9 4.5.6.1 4.5.6.2 4.5.6.3 4.5.6.4 4.5.6.5 4.5.6.6 4.5.6.7 4.5.6.8 4.5.6.9 4.5.7.1 4.5.7.2 4.5.7.3 4.5.7.4 4.5.7.5 4.5.7.6 4.5.7.7 4.5.7.8 4.5.7.9 4.5.8.1 4.5.8.2 4.5.8.3 4.5.8.4 4.5.8.5 4.5.8.6 4.5.8.7 4.5.8.8 4.5.8.9 4.5.9.1 4.5.9.2 4.5.9.3 4.5.9.4 4.5.9.5 4.5.9.6 4.5.9.7 4.5.9.8 4.5.9.9 4.6.1.1 4.6.1.2 4.6.1.3 4.6.1.4 4.6.1.5 4.6.1.6 4.6.1.7 4.6.1.8 4.6.1.9 4.6.2.1 4.6.2.2 4.6.2.3 4.6.2.4 4.6.2.5 4.6.2.6 4.6.2.7 4.6.2.8 4.6.2.9 4.6.3.1 4.6.3.2 4.6.3.3 4.6.3.4 4.6.3.5 4.6.3.6 4.6.3.7 4.6.3.8 4.6.3.9 4.6.4.1 4.6.4.2 4.6.4.3 4.6.4.4 4.6.4.5 4.6.4.6 4.6.4.7 4.6.4.8 4.6.4.9 4.6.5.1 4.6.5.2 4.6.5.3 4.6.5.4 4.6.5.5 4.6.5.6 4.6.5.7 4.6.5.8 4.6.5.9 4.6.6.1 4.6.6.2 4.6.6.3 4.6.6.4 4.6.6.5 4.6.6.6 4.6.6.7 4.6.6.8 4.6.6.9 4.6.7.1 4.6.7.2 4.6.7.3 4.6.7.4 4.6.7.5 4.6.7.6 4.6.7.7 4.6.7.8 4.6.7.9 4.6.8.1 4.6.8.2 4.6.8.3 4.6.8.4 4.6.8.5 4.6.8.6 4.6.8.7 4.6.8.8 4.6.8.9 4.6.9.1 4.6.9.2 4.6.9.3 4.6.9.4 4.6.9.5 4.6.9.6 4.6.9.7 4.6.9.8 4.6.9.9 4.7.1.1 4.7.1.2 4.7.1.3 4.7.1.4 4.7.1.5 4.7.1.6 4.7.1.7 4.7.1.8 4.7.1.9 4.7.2.1 4.7.2.2 4.7.2.3 4.7.2.4 4.7.2.5 4.7.2.6 4.7.2.7 4.7.2.8 4.7.2.9 4.7.3.1 4.7.3.2 4.7.3.3 4.7.3.4 4.7.3.5 4.7.3.6 4.7.3.7 4.7.3.8 4.7.3.9 4.7.4.1 4.7.4.2 4.7.4.3 4.7.4.4 4.7.4.5 4.7.4.6 4.7.4.7 4.7.4.8 4.7.4.9 4.7.5.1 4.7.5.2 4.7.5.3 4.7.5.4 4.7.5.5 4.7.5.6 4.7.5.7 4.7.5.8 4.7.5.9 4.7.6.1 4.7.6.2 4.7.6.3 4.7.6.4 4.7.6.5 4.7.6.6 4.7.6.7 4.7.6.8 4.7.6.9 4.7.7.1 4.7.7.2 4.7.7.3 4.7.7.4 4.7.7.5 4.7.7.6 4.7.7.7 4.7.7.8 4.7.7.9 4.7.8.1 4.7.8.2 4.7.8.3 4.7.8.4 4.7.8.5 4.7.8.6 4.7.8.7 4.7.8.8 4.7.8.9 4.7.9.1 4.7.9.2 4.7.9.3 4.7.9.4 4.7.9.5 4.7.9.6 4.7.9.7 4.7.9.8 4.7.9.9 4.8.1.1 4.8.1.2 4.8.1.3 4.8.1.4 4.8.1.5 4.8.1.6 4.8.1.7 4.8.1.8 4.8.1.9 4.8.2.1 4.8.2.2 4.8.2.3 4.8.2.4 4.8.2.5 4.8.2.6 4.8.2.7 4.8.2.8 4.8.2.9 4.8.3.1 4.8.3.2 4.8.3.3 4.8.3.4 4.8.3.5 4.8.3.6 4.8.3.7 4.8.3.8 4.8.3.9 4.8.4.1 4.8.4.2 4.8.4.3 4.8.4.4 4.8.4.5 4.8.4.6 4.8.4.7 4.8.4.8 4.8.4.9 4.8.5.1 4.8.5.2 4.8.5.3 4.8.5.4 4.8.5.5 4.8.5.6 4.8.5.7 4.8.5.8 4.8.5.9 4.8.6.1 4.8.6.2 4.8.6.3 4.8.6.4 4.8.6.5 4.8.6.6 4.8.6.7 4.8.6.8 4.8.6.9 4.8.7.1 4.8.7.2 4.8.7.3 4.8.7.4 4.8.7.5 4.8.7.6 4.8.7.7 4.8.7.8 4.8.7.9 4.8.8.1 4.8.8.2 4.8.8.3 4.8.8.4 4.8.8.5 4.8.8.6 4.8.8.7 4.8.8.8 4.8.8.9 4.8.9.1 4.8.9.2 4.8.9.3 4.8.9.4 4.8.9.5 4.8.9.6 4.8.9.7 4.8.9.8 4.8.9.9 4.9.1.1 4.9.1.2 4.9.1.3 4.9.1.4 4.9.1.5 4.9.1.6 4.9.1.7 4.9.1.8 4.9.1.9 4.9.2.1 4.9.2.2 4.9.2.3 4.9.2.4 4.9.2.5 4.9.2.6 4.9.2.7 4.9.2.8 4.9.2.9 4.9.3.1 4.9.3.2 4.9.3.3 4.9.3.4 4.9.3.5 4.9.3.6 4.9.3.7 4.9.3.8 4.9.3.9 4.9.4.1 4.9.4.2 4.9.4.3 4.9.4.4 4.9.4.5 4.9.4.6 4.9.4.7 4.9.4.8 4.9.4.9 4.9.5.1 4.9.5.2 4.9.5.3 4.9.5.4 4.9.5.5 4.9.5.6 4.9.5.7 4.9.5.8 4.9.5.9 4.9.6.1 4.9.6.2 4.9.6.3 4.9.6.4 4.9.6.5 4.9.6.6 4.9.6.7 4.9.6.8 4.9.6.9 4.9.7.1 4.9.7.2 4.9.7.3 4.9.7.4 4.9.7.5 4.9.7.6 4.9.7.7 4.9.7.8 4.9.7.9 4.9.8.1 4.9.8.2 4.9.8.3 4.9.8.4 4.9.8.5 4.9.8.6 4.9.8.7 4.9.8.8 4.9.8.9 4.9.9.1 4.9.9.2 4.9.9.3 4.9.9.4 4.9.9.5 4.9.9.6 4.9.9.7 4.9.9.8 4.9.9.9 - Another group of preferred compounds are named in Table 2 and designated by numbers assigned to the variables of Formula I using the following convention: M1.V/Z/W. The compounds are shown without depiction of stereochemistry since the compounds are biologically active as the diastereomeric mixture or as a single stereoisomer. M1 is a variable that represents nucleosides of Formula I which are attached via 5′-hydroxyl group that is phosphorylated with a group P(O)(O—CH(V)CH(Z)C(WW′)—O) to make compounds of Formula I.
- The structures for variable M1 are the same as described above.
- Variable V/Z/W: Group 1 of V/Z/W
-
-
- 1) V=3-chlorophenyl; Z=methyl; W=hydrogen
- 2) V=3,5-dichlorophenyl; Z=methyl; W=hydrogen
- 3) V=4-pyridyl; Z=methyl; W=hydrogen
- 4) V=3-chlorophenyl; Z=methoxy; W=hydrogen
- 5) V=3,5-dichlorophenyl; Z=methoxy; W=hydrogen
- 6) V=4-pyridyl; Z=methoxy; W=hydrogen
- 7) V=3-chlorophenyl; Z=hydrogen; W=3-chlorophenyl
- 8) V=3,5-dichlorophenyl; Z=hydrogen; W=3,5-dichlorophenyl
- 9) V=4-pyridyl; Z=hydrogen; W=4-pyridyl
Variable V/Z/W: Group 2 of V/Z/W - 1) V=3-chlorophenyl; Z=NHAc; W=hydrogen
- 2) V=3,5-dichlorophenyl; Z=NHAc; W=hydrogen
- 3) V=4-pyridyl; Z=NHAc; W=hydrogen
- 4) V=3-chlorophenyl; Z=hydrogen; W=methyl
- 5) V=3,5-dichlorophenyl; Z=hydrogen; W=methyl
- 6) V=4-pyridyl; Z=hydrogen; W=methyl
- 7) V=3-chlorophenyl; Z=acetoxy; W=hydrogen
- 8) V=3,5-dichlorophenyl; Z=acetoxy; W=hydrogen
- 9) V=4-pyridyl; Z=acetoxy; W=hydrogen
Variable V/Z/W: Group 3 of V/Z/W - 1) V=phenyl; Z=phenyl; W=hydrogen
- 2) V=phenyl; Z=—CH2—CH2— fused to phenyl at V to form a 6-membered ring; W=hydrogen
- 3) V=phenyl; Z=H; W=—CH2—CH2— fused to phenyl at V to form a 6-membered ring
- 4) V=phenyl; Z=H; W=W′=methyl
- 5) V=phenyl; Z=H; W and W′=—CH2—CH2—CH2—CH2— to form a 6-membered ring
- 6) V=phenyl; Z and W=—CH2—CH2—CH2—CH2— to form a 6-membered ring
- 7) V=3-chlorophenyl; Z=CH2CH2CH2OC(O)OCH3; W=hydrogen
- 8) V=3-chlorophenyl; Z=CH2CH2CH2SC(O)CH3; W=hydrogen
- 9) V=4-pyridyl; Z=CH2CH2CH2OC(O)OCH3; W=hydrogen
- 10) V=4-pyridyl; Z=CH2CH2CH2SC(O)CH3; W=hydrogen
- W′ is hydrogen when not specified.
- Preferred compounds are compounds listed in Table 2 using groups M1 and Group 1 of V/Z/W. For example, compound 1.3 represents structure 1 of group M1, i.e., 7-deaza-2′-methyl adenosine; and structure 3 of Group 1 of V/Z/W, i.e., V=4-pyridyl, Z=methyl and W=hydrogen. The compound 1.3 therefore is 7-deaza-2′-methyladenosine with the P(O)(O—CH(4-pyridyl)CH(CH3)CH2O) attached to the primary hydroxyl.
- Preferred compounds are also compounds listed in Table 2 using groups M1 and Group 2 of V/Z/W.
- Preferred compounds are also compounds listed in Table 2 using groups M1 and Group 3 of V/Z/W.
TABLE 2 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 4.9 - Preferred compounds are also compounds of Tables 1 and 2 of formulae VI-VIII where R7 is an L-valinyl group attached via a carbonyl and R7 and R8 form a 5-membered cyclic carbonate.
- Moreover, the compounds of the present invention can be used for inhibiting viral replication. In another aspect, the compounds of this invention can be used for inhibiting RNA-dependent RNA viral replication. In a further aspect, the compounds of this invention can be used for inhibiting HCV replication.
- In another aspect, the compounds of the present invention can be used for treating viral infections. In a further aspect, compounds of this invention can be used for treating RNA-dependent RNA viral infection. In another aspect, compounds of this invention can be used for treating HCV infection.
- In another aspect, the compounds of the present invention can be used for treating viral infections of the liver. In a further aspect, compounds of this invention can be used for treating RNA-dependent RNA viral infection in the liver. In another aspect, compounds of this invention can be used for treating HCV infection in the liver.
- In one aspect, inhibition of viral replication is measured in serum. Increased viral titer reduction is associated with decreased generation of viral mutants which are associated with drug resistance.
- In another aspect, the compounds of the present invention can be used for preventing the onset of symptoms associated with a viral infection.
- Activation of prodrugs of this invention results in the production of a nucleoside monophosphate (NMP). NMPs are frequently further phosphorylated inside the hepatocyte to the biologically active nucleoside triphosphate (NTP). Drug elimination from the hepatocyte typically entails degradation of phosphorylated metabolites back to a species capable of being transported out of the hepatocyte and into the blood for elimination by the kidney or into the bile for biliary excretion. Often with nucleoside-based drug the phophorylated metabolites are dephosphorylated to the uncharged nucleoside.
- Nucleosides that leak back into the systemic circulation result in systemic exposure. If the nucleoside is active systemically, e.g. through entry into virally infected cells and phosphorylation to the active species, escape of the nucleoside from the liver leads to biological activity outside of the liver (i.e. extrahepatic tissues, blood cells). In this case, prodrugs of the invention can be effective for treating diseases outside of the liver, e.g. viral infections. Since many nucleosides exhibit poor oral bioavailability due to breakdown in the gastrointestinal tract either enzymatically (e.g. deamination by adenosine deaminase) or chemically (e.g. acid instability), the prodrug can be used for oral drug delivery. Moreover, given that the prodrugs in some cases are broken down slowly relative to e.g. most ester based prodrugs, the prodrugs could advantageously result in slow, sustained systemic release of the nucleoside.
- In other cases, however, systemic exposure to the nucleoside can result in toxicity. This can be minimized by selecting nucleosides that are preferentially excreted through the bile or nucleosides that are unable to undergo phosphorylation in tissues or nucleosides that undergo rapid intrahepatic metabolism to a biologically inactive metabolite. Some enzymes in the hepatocyte are present that can degrade nucleosides and therefore minimize exposure (e.g. Phase I and Phase II enzymes). One example is adenosine deaminase, which can deaminate some adenosine-based nucleosides to produce the corresponding inosine analogue. Rapid intracellular deamination of the nucleoside following its dephosphorylation to the nucleoside limits systemic exposure to the nucleoside and diminishes the risk of toxicity.
- Methods described in Examples A-D were used to test activation of compounds of this invention. Methods used in Example E were used to evaluate the ability of compounds of the invention to generate NTPs.
- HCV replication in human liver tissue was evaluated as in Example F. Liver specificity of the prodrugs relative to the nucleosides was measured by methods in Example G.
- Tissue distribution can be determined according to methods in Example H. Oral bioavailability was determined by methods described in Example I. The susceptibility of nucleoside analogs to metabolism can be determined as in Example J.
- In one aspect of the present invention, the RNA-dependent RNA viral infection is a positive-sense single-stranded RNA-dependent viral infection. In another aspect, the positive-sense single-stranded RNA-dependent RNA viral infection is Flaviviridae viral infection or Picornaviridae viral infection. In a subclass of this class, the Picornaviridae viral infection is rhinovirus infection, poliovirus infection, or hepatitis A virus infection. In a second subclass of this class, the Flaviviridae viral infection is selected from the group consisting of hepatitis C virus infection, yellow fever virus infection, dengue virus infection, West Nile virus infection, Japanese encephalitis virus infection, Banzi virus infection, and bovine viral diarrhea virus infection. In a subclass of this subclass, the Flaviviridae viral infections hepatitis C virus infection.
- In a further aspect, compounds of the present invention can be used to enhance the oral bioavailability of the parent drug. In another aspect, compounds of the present invention can be used to enhance the oral bioavailability of the parent drug by at least 5%. In another aspect, compounds of the present invention can be used to enhance the oral bioavailability of the parent drug by at least 10%. In another aspect, oral bioavailability is enhanced by 50% compared to the parent drug administered orally. In a further aspect, the oral bioavailability is enhanced by at least 100%.
- In another aspect, compounds of the present invention can be used to increase the therapeutic index of a drug.
- In one aspect, compounds of the present invention can be used to bypass drug resistance.
- In another aspect, compounds of the present invention can be used to treat cancer.
- Formulations
- Compounds of the invention are administered in a total daily dose of 0.01 to 1000 mg/kg. In one aspect the range is about 0.1 mg/kg to about 100 mg/kg. In another aspect the range is 0.5 to 20 mg/kg. The dose may be administered in as many divided doses as is convenient.
- Compounds of this invention when used in combination with other antiviral agents may be administered as a daily dose or an appropriate fraction of the daily dose (e.g., bid). Administration of the prodrug may occur at or near the time in which the other antiviral is administered or at a different time. The compounds of this invention may be used in a multidrug regimen, also known as combination or ‘cocktail’ therapy, wherein, multiple agents may be administered together, may be administered separately at the same time or at different intervals, or administered sequentially. The compounds of this invention may be administered after a course of treatment by another agent, during a course of therapy with another agent, administered as part of a therapeutic regimen, or may be administered prior to therapy by another agent in a treatment program.
- For the purposes of this invention, the compounds may be administered by a variety of means including orally, parenterally, by inhalation spray, topically, or rectally in formulations containing pharmaceutically acceptable carriers, adjuvants and vehicles. The term parenteral as used here includes subcutaneous, intravenous, intramuscular, and intraarterial injections with a variety of infusion techniques. Intraarterial and intravenous injection as used herein includes administration through catheters. Intravenous administration is generally preferred.
- Pharmaceutically acceptable salts include acetate, adipate, besylate, bromide, camsylate, chloride, citrate, edisylate, estolate, fumarate, gluceptate, gluconate, glucuronate, hippurate, hyclate, hydrobromide, hydrochloride, iodide, isethionate, lactate, lactobionate, maleate, mesylate, methylbromide, methylsulfate, napsylate, nitrate, oleate, palmoate, phosphate, polygalacturonate, stearate, succinate, sulfate, sulfosalicylate, tannate, tartrate, terphthalate, tosylate, and triethiodide.
- Pharmaceutical compositions containing the active ingredient may be in any form suitable for the intended method of administration. When used for oral use for example, tablets, troches, lozenges, aqueous or oil suspensions, dispersible powders or granules, emulsions, hard or soft capsules, syrups or elixirs may be prepared. Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents including sweetening agents, flavoring agents, coloring agents and preserving agents, in order to provide a palatable preparation. Tablets containing the active ingredient in admixture with non-toxic pharmaceutically acceptable excipient which are suitable for manufacture of tablets are acceptable. These excipients may be, for example, inert diluents, such as calcium or sodium carbonate, lactose, calcium or sodium phosphate; granulating and disintegrating agents, such as maize starch, or alginic acid; binding agents, such as starch, gelatin or acacia; and lubricating agents, such as magnesium stearate, stearic acid or talc. Tablets may be uncoated or may be coated by known techniques including microencapsulation to delay disintegration and adsorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.
- Formulations for oral use may be also presented as hard gelatin capsules where the active ingredient is mixed with an inert solid diluent, for example calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.
- Aqueous suspensions of the invention contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients include a suspending agent, such as sodium carboxymethylcellulose, methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia, and dispersing or wetting agents such as a naturally occurring phosphatide (e.g., lecithin), a condensation product of an alkylene oxide with a fatty acid (e.g., polyoxyethylene stearate), a condensation product of ethylene oxide with a long chain aliphatic alcohol (e.g., heptadecaethyleneoxycetanol), a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (e.g., polyoxyethylene sorbitan monooleate). The aqueous suspension may also contain one or more preservatives such as ethyl or n-propyl p-hydroxy-benzoate, one or more coloring agents, one or more flavoring agents and one or more sweetening agents, such as sucrose or saccharin.
- Oil suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as arachid oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oral suspensions may contain a thickening agent, such as beeswax, hard paraffin or cetyl alcohol. Sweetening agents, such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
- Dispersible powders and granules of the invention suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those disclosed above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.
- The pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions. The oily phase may be a vegetable oil, such as olive oil or arachid oil, a mineral oil, such as liquid paraffin, or a mixture of these. Suitable emulsifying agents include naturally-occurring gums, such as gum acacia and gum tragacanth, naturally occurring phosphatides, such as soybean lecithin, esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate, and condensation products of these partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweetening and flavoring agents.
- Syrups and elixirs may be formulated with sweetening agents, such as glycerol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative, a flavoring or a coloring agent.
- The pharmaceutical compositions of the invention may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as a solution in 1,3-butane-diol or prepared as a lyophilized powder. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may conventionally be employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectables.
- The amount of active ingredient that may be combined with the carrier material to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. For example, a time-release formulation intended for oral administration to humans may contain 20 to 2000 μmol (approximately 10 to 1000 mg) of active material compounded with an appropriate and convenient amount of carrier material which may vary from about 5 to about 95% of the total compositions. It is preferred that the pharmaceutical composition be prepared which provides easily measurable amounts for administration. For example, an aqueous solution intended for intravenous infusion should contain from about 0.05 to about 50 μmol (approximately 0.025 to 25 mg) of the active ingredient per milliliter of solution in order that infusion of a suitable volume at a rate of about 30 mL/h can occur.
- As noted above, formulations of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution or a suspension in an aqueous or non-aqueous liquid; or as an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The active ingredient may also be administered as a bolus, electuary or paste.
- A tablet may be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free flowing form such as a powder or granules, optionally mixed with a binder (e.g., povidone, gelatin, hydroxypropylmethyl cellulose), lubricant, inert diluent, preservative, disintegrant (e.g., sodium starch glycolate, cross-linked povidone, cross-linked sodium carboxymethyl cellulose) surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of the powdered compound moistened with an inert liquid diluent. The tablets may optionally be coated or scored and may be formulated so as to provide slow or controlled release of the active ingredient therein using, for example, hydroxypropyl methylcellulose in varying proportions to provide the desired release profile. Tablets may optionally be provided with an enteric coating, to provide release in parts of the gut other than the stomach. This is particularly advantageous with the compounds of Formula I when such compounds are susceptible to acid hydrolysis.
- Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin, or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
- Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
- Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
- Formulations suitable for parenteral administration include aqueous and non-aqueous isotonic sterile injection solutions which may contain antioxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Injection solutions and suspensions may be prepared from sterile powders, granules and tablets of the kind previously described.
- Formulations suitable for parenteral administration may be administered in a continuous infusion manner via an indwelling pump or via a hospital bag. Continuous infusion includes the infusion by an external pump. The infusions may be done through a Hickman or PICC or any other suitable means of administering a formulation either parenterally or i.v.
- Preferred unit dosage formulations are those containing a daily dose or unit, daily sub-dose, or an appropriate fraction thereof, of a drug.
- It will be understood, however, that the specific dose level for any particular patient will depend on a variety of factors including the activity of the specific compound employed; the age, body weight, general health, sex and diet of the individual being treated; the time and route of administration; the rate of excretion; other drugs which have previously been administered; and the severity of the particular disease undergoing therapy, as is well understood by those skilled in the art.
- Another aspect of the present invention is concerned with a method of inhibiting HCV replication or treating HCV infection with a compound of the present invention in combination with one or more agents useful for treating HCV infection. Such agents active against HCV include, but are not limited to, ribavirin, levovirin, viramidine, thymosin alpha-1, interferon-β, interferon-α, pegylated interferon-α (peginterferon-α), a combination of interferon-α and ribavirin, a combination of peginterferon-α and ribavirin, a combination of interferon-α and levovirin, and a combination of peginterferon-α and levovirin. Interferon-α includes, but is not limited to, recombinant interferon-α2a (such as Roferon interferon available from Hoffmann-LaRoche, Nutley, N.J.), pegylated interferon-α2a (Pegasys™), interferon-α2b (such as Intron-A interferon available from Schering Corp., Kenilworth, N.J.), pegylated interferon-α2b (PegIntron™), a recombinant consensus interferon (such as interferon alphacon-1), and a purified interferon-α product. Amgen's recombinant consensus interferon has the brand name Infergen®. Levovirin is the L-enantiomer of ribavirin which has shown immunomodulatory activity similar to ribavirin. Viramidine is a liver-targeting prodrug analog of ribavirin disclosed in WO 01/60379 (assigned to ICN Pharmaceuticals). In accordance with this method of the present invention, the individual components of the combination can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms. The instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment, and the term “administering” is to be interpreted accordingly. It will be understood that the scope of combinations of the compounds of this invention with other agents useful for treating HCV infection includes in principle any combination with any pharmaceutical composition for treating HCV infection. When a compound of the present invention or a pharmaceutically acceptable salt thereof is used in combination with a second therapeutic agent active against HCV, the dose of each compound may be either the same as or different from the dose when the compound is used alone.
- Also included within the scope of the invention is a pharmaceutical composition comprising a compound of Formula I or prodrug or pharmaceutically acceptable salt thereof and at least one agent useful for treating a viral infection, particularly an HCV infection.
- For the treatment of HCV infection, the compounds of the present invention may also be administered in combination with an agent that is an inhibitor of HCV NS3 serine protease. HCV NS3 serine protease is an essential viral enzyme and has been described to be an excellent target for inhibition of HCV replication. Both substrate and non-substrate based inhibitors of HCV NS3 protease inhibitors are disclosed in WO 98/22496, WO 98/46630, WO 99/07733, WO 99/07734, WO 99/38888, WO 99/50230, WO 99/64442, WO 00/09543, WO 00/59929, GB-2337262, WO 02/48116, WO 02/48172, U.S. Pat. No. 6,323,180, and U.S. Pat. No. 6,410,531. Specific embodiments of NS3 protease inhibitors for combination with the compounds of the present invention are BILN 2061 (Boehringer Ingelheim) and VX-950/LY-570310. HCV NS3 protease as a target for the development of inhibitors of HCV replication and for the treatment of HCV infection is discussed in B. W. Dymock, “Emerging therapies for hepatitis C virus infection,” Emerging Drugs, 6: 13-42 (2001).
- Ribavirin, levovirin, and viramidine may exert their anti-HCV effects by modulating intracellular pools of guanine nucleotides via inhibition of the intracellular enzyme inosine monophosphate dehydrogenase (IMPDH). IMPDH is the rate-limiting enzyme on the biosynthetic route in de novo guanine nucleotide biosynthesis. Ribavirin is readily phosphorylated intracellularly and the monophosphate derivative is an inhibitor of IMPDH. Thus, inhibition of IMPDH represents another useful target for the discovery of inhibitors of HCV replication. Therefore, the compounds of the present invention may also be administered in combination with an inhibitor of IMPDH, such as VX-497 (merimepodib), which is disclosed in WO 97/41211 and WO 01/00622 (assigned to Vertex); another IMPDH inhibitor, such as that disclosed in WO 00/25780 (assigned to Bristol-Myers Squibb); or mycophenolate mofetil [see A. C. Allison and E. M. Eugui, Agents Action, 44 (Suppl.): 165 (1993)].
- For the treatment of HCV infection, the compounds of the present invention may also be administered in combination with the antiviral agent amantadine (1-aminoadamantane) and its hydrochloride salt [for a comprehensive description of this agent, see J. Kirschbaum, Anal. Profiles Drug Subs. 12: 1-36 (1983)].
- The compounds of the present invention may also be combined for the treatment of HCV infection with antiviral 1′-C, 2′-C-, or 3′-C-branched ribonucleosides disclosed in R. E. Harry-O'kuru, et al., J. Org. Chem., 62: 1754-1759 (1997); M. S. Wolfe, et al., Tetrahedron Lett., 36: 7611-7614 (1995); U.S. Pat. No. 3,480,613 (Nov. 25, 1969); International Publication Number WO 01/90121 (29 Nov. 2001); International Publication Number WO 01/92282 (6 Dec. 2001); and International Publication Number WO 02/32920 (25 Apr. 2002); the contents of each of which are incorporated by reference in their entirety. Such branched ribonucleosides include, but are not limited to, 2′-C-methylcytidine, 2′-C-methyluridine, 2′-C-methyladenosine, 2′-C-methylguanosine, and 9-(2-C-methyl-β-D-ribofuranosyl)-2,6-diaminopurine, and prodrugs thereof.
- The compounds of the present invention may also be combined for the treatment of HCV infection with other nucleosides having anti-HCV properties, such as those disclosed in WO 02/51425 (4 Jul. 2002), assigned to Mitsubishi Pharma Corp.; WO 01/79246, WO 02/32920 (25 Apr. 2002), and WO 02/48165 (20 Jun. 2002), assigned to Pharmasset, Ltd.; WO 01/68663 (20 Sep. 2001), assigned to ICN Pharmaceuticals; WO 99/43691 (2 Sep. 1999); WO 02/18404 (7 Mar. 2002), assigned to Hoffmann-LaRoche; U.S. 2002/0019363 (14 Feb. 2002); WO 02/057287 (25 Jul. 2002), assigned to Merck & Co. and Isis Pharmaceuticals; and WO 02/057425 (25 Jul. 2002), assigned to Merck & Co. and Isis Pharmaceuticals.
- The compounds of the present invention may also be combined for the treatment of HCV infection with non-nucleoside inhibitors of HCV polymerase such as those disclosed in WO 01/77091 (18 Oct. 2001), assigned to Tularik, Inc.; WO 01/47883 (5 Jul. 2001), assigned to Japan Tobacco, Inc.; WO 02/04425 (17 Jan. 2002), assigned to Boehringer Ingelheim; WO 02/06246 (24 Jan. 2002), assigned to Istituto di Ricerche di Biologia Moleculare P. Angeletti S. P. A.; and WO 02/20497 (3 Mar. 2002). WO 01/47883 discloses a large number of benzimidazole derivatives, such as JTK-003, which is claimed to be an orally active inhibitor of NS5B that is currently undergoing clinical evaluation.
- Synthesis of the 5′-nucleoside monophosphate (NMP) prodrugs of the present invention is organized into two sections: 1. synthesis of phosphorylation precursors; 2. synthesis of prodrugs via coupling of nucleosides and prodrug moiety.
- Synthesis of Phosphorylation Precursors:
- Synthesis of phosphorylation precursors is attained in two stages: 1. Synthesis of 1,3-diols and 2. Synthesis of phosphorylation precursor.
- Synthesis of 1,3-Diols:
- A variety of synthetic methods are known to prepare the following types of 1,3-diols: a) 1-substituted; b) 2-substituted; and c) 1,2- or 1,3-annulated in their racemic or enantioenriched form. The V, W, Z groups of Formula I can be introduced or modified either during synthesis of diols or after the synthesis of prodrugs.
- Synthesis of 1-(aryl)-Propane-1,3-Diols:
- The suitable methods to prepare 1,3-diols are divided into two types as following: 1) synthesis of racemic 1-(aryl)-propane-1,3-diols; 2) synthesis of enantioenriched 1-(aryl)-propane-1,3-diols.
- Synthesis of Racemic 1-(aryl)-Propane-1,3-Diol:
- 1,3-Dihydroxy compounds can be synthesized by several well-known methods from the literature. Substituted aromatic aldehydes are utilized to synthesize racemic 1-(aryl)propane-1,3-diols via addition of lithium enolate of alkyl acetate followed by ester reduction (path A) (Turner, J. Org. Chem. 55:4744 (1990)). Alternatively, aryl lithium or aryl Grignard additions to 1-hydroxy propan-3-al also give 1-(arylsubstituted)propane-1,3-diols (path B). This method will enable conversion of various substituted aryl halides to 1-(arylsubstituted)-1,3-propane diols (Coppi, et al., J. Org. Chem. 53:911 (1988)). Aryl halides can also be used to synthesize 1-substituted propane diols by Heck coupling of 1,3-diox-4-ene followed by reduction and hydrolysis (Sakamoto, et al., Tetrahedron Lett. 33:6845 (1992)). Pyridyl-, quinolyl-, isoquinolyl-propan-3-ol derivatives can be hydroxylated to 1-substituted-1,3-diols by N-oxide formation followed by rearrangement in the presence of acetic anhydride (path C) (Yamamoto, et al., Tetrahedron 37:1871 (1981)). A variety of aromatic aldehydes can also be converted to 1-substituted-1,3-diols by vinyl lithium or vinyl Grignard addition followed by hydroboration reaction (path D).
Synthesis of Enantioenriched 1-(aryl)-Propane-1,3-Diol: - A variety of known methods for resolution of secondary alcohols via chemical or enzymatic agents may be utilized for preparation of diol enantiomers (Harada, et al., Tetrahedron Lett. 28:4843 (1987)). Transition metal catalyzed hydrogenation of substituted 3-aryl-3-oxo-propionic acids or esters is an efficient method to prepare R- or S-isomers of beta hydroxy acids or esters in high enantiomeric purity (Comprehensive Asymmetric Catalysis, Jacobsen, E. N., Pfaltz, A., Yamamoto, H. (Eds), Springer, (1999); Asymmetric Catalysis in Organic Synthesis, Noyori, R., John Wiley, (1994)). These beta hydroxy acid or ester products can be further reduced to give required 1-(aryl)-propane-1,3-diols in high enantiomeric excess (ee). (path A). The β-keto acid or ester substrates for high pressure hydrogenation or hydrogen transfer reactions may be prepared by a variety of methods such as condensation of acetophenone with dimethylcarbonate in the presence of a base (Chu, et al., J. Het Chem. 22:1033 (1985)), by ester condensation (Turner, et al., J. Org. Chem. 54:4229 (1989)) or from aryl halides (Kobayashi, et al., Tetrahedron Lett. 27:4745 (1986)). Alternatively, 1,3-diols of high enantiomeric purity can be obtained by enantioselective borane reduction of β-hydroxyethyl aryl ketone derivatives or β-keto acid derivatives (path B) (Ramachandran, et al., Tetrahedron Lett. 38:761 (1997)). In another method, commercially available cinnamyl alcohols may be converted to epoxy alcohols under catalytic asymmetric epoxidation conditions. These epoxy alcohols are reduced by Red-Al to result in 1,3-diols with high ee's (path C) (Gao, et al., J. Org. Chem. 53:4081 (1980)). Enantioselective aldol condensation is another well-described method for synthesis of 1,3-oxygenated functionality with high ee's starting from aromatic aldehydes. (path D) (Mukaiyama, Org. React. 28:203 (1982)).
Synthesis of 2-Substituted 1,3-Diols: - Various 2-substituted-1,3-diols can be made from commercially available 2-(hydroxymethyl)-1,3-propane-diol. Pentaerythritol can be converted to triol via decarboxylation of diacid followed by reduction (path a) (Werle, et al., Liebigs. Ann. Chem., 1986, 944) or diol-monocarboxylic acid derivatives can also be obtained by decarboxylation under known conditions (Iwata, et. al., Tetrahedron Lett. 1987, 28, 3131). Nitrotriol is also known to give triol by reductive elimination (path b) (Latour, et. al., Synthesis, 1987, 8, 742). The triol can be derivatized by mono acylation or carbonate formation by treatment with alkanoyl chloride, or alkylchloroformate (path d) (Greene and Wuts, Protective groups in organic synthesis, John Wiley, New York, 1990). Aryl substitution can be affected by oxidation to aldehyde and aryl Grignard additions (path c). Aldehydes can also be converted to substituted amines by reductive animation reaction (path e).
Synthesis of cyclic-1,3-diols: - Compounds of Formula 1 where V-Z or V-W are fused by four carbons are made from cyclohexane diol derivatives. Commercially available cis, cis-1,3,5-cyclohexane-triol can be used as is or modified as described in case of 2-substituted propan-1,3-diols to give various analogues. These modifications can either be made before or after ester formation. Various 1,3-cyclohexane-diols can be made by Diels-Alder methodology using pyrone as diene (Posner, et. al., Tetrahedron Lett., 1991, 32, 5295). Cyclohexanediol derivatives are also made by nitrile oxide-olefin additions (Curran, et. al., J. Am. Chem. Soc., 1985, 107, 6023). Alternatively, cyclohexyl precursors are also made from commercially available quinic acid (Rao, et. al., Tetrahedron Lett., 1991, 32, 547.)
- Synthesis of Substituted 1,3-hydroxyamines and 1,3-diamines:
- A large number of synthetic methods are available for the preparation of substituted 1,3-hydroxyamines and 1,3-diamines due to the ubiquitous nature of these functionalities in naturally occurring compounds. Following are some of these methods organized into: 1. synthesis of substituted 1,3-hydroxy amines; 2. synthesis of substituted 1,3-diamines and 3. synthesis of chiral substituted 1,3-hydroxyamines and 1,3-diamines.
- Synthesis of Substituted 1,3-hydroxy Amines:
- 1,3-Diols described in the earlier section can be converted selectively to either hydroxy amines or to corresponding diamines by converting hydroxy functionality to a leaving group and treating with anhydrous ammonia or required primary or secondary amines (Corey, et al., Tetrahedron Lett., 1989, 30, 5207: Gao, et al., J. Org. Chem., 1988, 53, 4081). A similar transformation may also be achieved directly from alcohols under Mitsunobu type of reaction conditions (Hughes, D. L., Org. React., 1992, 42).
- A general synthetic procedure for 3-aryl-3-hydroxy-propan-1-amine type of prodrug moiety involves aldol type condensation of aryl esters with alkyl nitrites followed by reduction of resulting substituted benzoylacetonitrile (Shih et al., Heterocycles, 1986, 24, 1599). The procedure can also be adapted for formation of 2-substituted aminopropanols by using substituted alkylnitrile. In another approach, 3-aryl-3-amino-propan-1-ol type of prodrug groups are synthesized from aryl aldehydes by condensation of malonic acid in presence of ammonium acetate followed by reduction of resulting substituted β-amino acids. Both these methods enable to introduce wide variety of substitution of aryl group (Shih, et al., Heterocycles., 1978, 9, 1277). In an alternate approach, β-substituted organolithium compounds of 1-amino-1-aryl ethyl dianion generated from styrene type of compounds undergo addition with carbonyl compounds to give variety of W, W′ substitution by variation of the carbonyl compounds (Barluenga, et al., J. Org. Chem., 1979, 44, 4798).
- Synthesis of Substituted 1,3-diamines:
- Substituted 1,3-diamines are synthesized starting from a variety of substrates. Arylglutaronitriles can be transformed to 1-substituted diamines by hydrolysis to amide and Hofmann rearrangement conditions (Bertochio, et al., Bull. Soc. Chim. Fr, 1962, 1809). Whereas, malononitrile substitution will enable variety of Z substitution by electrophile introduction followed by hydride reduction to corresponding diamines. In another approach, cinnamaldehydes react with hydrazines or substituted hydrazines to give corresponding pyrazolines which upon catalytic hydrogenation result in substituted 1,3-diamines (Weinhardt, et al., J. Med. Chem., 1985, 28, 694). High trans-diastereoselectivity of 1,3-substitution is also attainable by aryl Grignard addition on to pyrazolines followed by reduction (Alexakis, et al., J. Org. Chem., 1992, 576, 4563). 1-Aryl-1,3-diaminopropanes are also prepared by diborane reduction of 3-amino-3-arylacrylonitriles which in turn are made from nitrile substituted aromatic compounds (Dornow, et al., Chem Ber., 1949, 82, 254). Reduction of 1,3-diimines obtained from corresponding 1,3-carbonyl compounds are another source of 1,3-diamine prodrug moiety which allows a wide variety of activating groups V and/or Z (Barluenga, et al., J. Org. Chem., 1983, 48, 2255).
- Synthesis of Chiral Substituted 1,3-hydroxyamines and 1,3-diamines:
- Enantiomerically pure 3-aryl-3-hydroxypropan-1-amines are synthesized by CBS enantioselective catalytic reaction of β-chloropropiophenone followed by displacement of halo group to make secondary or primary amines as required (Corey, et al., Tetrahedron Lett., 1989, 30, 5207). Chiral 3-aryl-3-amino propan-1-ol type of prodrug moiety may be obtained by 1,3-dipolar addition of chirally pure olefin and substituted nitrone of arylaldehyde followed by reduction of resulting isoxazolidine (Koizumi, et al., J. Org. Chem., 1982, 47, 4005). Chiral induction in 1,3-polar additions to form substituted isoxazolidines is also attained by chiral phosphine palladium complexes resulting in enantioselective formation of amino alcohols (Hori, et al., J. Org. Chem., 1999, 64, 5017). Alternatively, optically pure 1-aryl substituted amino alcohols are obtained by selective ring opening of corresponding chiral epoxy alcohols with desired amines (Canas et al., Tetrahedron Lett., 1991, 32, 6931).
- Several methods are known for diastereoselective synthesis of 1,3-disubstituted aminoalcohols. For example, treatment of (E)-N-cinnamyltrichloroacetamide with hypochlorous acid results in trans-dihydrooxazine which is readily hydrolysed to erythro-β-chloro-γ-hydroxy-γ-phenylpropanamine in high diastereoselectivity (Commercon et al., Tetrahedron Lett., 1990, 31, 3871). Diastereoselective formation of 1,3-aminoalcohols is also achieved by reductive amination of optically pure 3-hydroxy ketones (Haddad et al., Tetrahedron Lett., 1997, 38, 5981). In an alternate approach, 3-aminoketones are transformed to 1,3-disubstituted aminoalcohols in high stereoselectivity by a selective hydride reduction (Barluenga et al., J. Org. Chem., 1992, 57, 1219).
- Synthesis of Phosphorylation Precursors:
-
- Phosphorylation of 5′-alcohol is achieved using cyclic 1′,3′-propanyl esters of phosphorylating agents where the agent is in the P(III) oxidation state. One preferred phosphorylating agent is a chloro phospholane (L′=chloro). Cyclic chlorophospholanes are prepared under mild conditions by reaction of phosphorus trichloride with substituted 1,3-diols (Wissner, et al, J. Med. Chem., 1992, 35, 1650). Alternatively phosphoramidites can be used as the phosphorylating agent (Beaucage, et al., Tetrahedron, 1993, 49, 6123). Appropriately substituted phosphoramidites can be prepared by reacting cyclic chlorophospholanes with N,N-dialkylamine (Perich, et al., Aust. J. Chem., 1990, 43, 1623. Perich, et al, Synthesis, 1988, 2, 142) or by reaction of commercially available dialkylaminophosphorochloridate with substituted propane-1,3-diols.
Synthesis of P(V) Phosphorylation Precursors: - In general, synthesis of phosphate esters is achieved by coupling the alcohol with the corresponding activated phosphate precursor for example, Chlorophosphate (L′=chloro) condensation with 5′-hydroxy of nucleoside is a well known method for preparation of nucleoside phosphate monoesters. The activated precursor can be prepared by several well known methods. Chlorophosphates useful for synthesis of the prodrugs are prepared from the substituted-1,3-propanediol (Wissner, et al, J. Med. Chem., 1992, 35, 1650). Chlorophosphates are made by oxidation of the corresponding chlorophospholanes (Anderson, et al, J. Org. Chem., 1984, 49, 1304), which are obtained by reaction of the substituted diol with phosphorus trichloride. Alternatively, the chlorophosphate agent is made by treating substituted-1,3-diols with phosphorus oxychloride (Patois, et al, J. Chem. Soc. Perkin Trans. I, 1990, 1577). Chlorophosphate species may also be generated in situ from corresponding cyclic phosphites (Silverburg, et al., Tetrahedron Lett., 1996, 37, 771), which in turn can be either made from a chlorophospholane or phosphoramidate intermediate. Phosphorofluoridate intermediate prepared either from pyrophosphate or phosphoric acid may also act as precursor in preparation of cyclic prodrugs (Watanabe et al., Tetrahedron Lett., 1988, 29, 5763).
- Phosphoramidates (L′=NRR′) are also well-known intermediates for the synthesis of phosphate esters. Monoalkyl or dialkylphosphoramidate (Watanabe, et al, Chem Pharm Bull., 1990, 38, 562), triazolophosphoramidate (Yamakage, et al., Tetrahedron, 1989, 45, 5459) and pyrrolidinophosphoramidate (Nakayama, et al, J. Am. Chem. Soc., 1990, 112, 6936) are some of the known intermediates used for the preparation of phosphate esters. Another effective phosphorylating procedure is a metal catalyzed addition of cyclic chlorophosphate adduct of 2-oxazolone. This intermediate attains high selectivity in phosphorylation of primary hydroxy group in presence of secondary hydroxyl group (Nagamatsu, et al, Tetrahedron Lett., 1987, 28, 2375). These agents are obtained by reaction of a chlorophosphate with the amine or alternatively by formation of the corresponding phosphoramidite followed by oxidation.
Synthesis of Enantiomerically Enriched P(V) Phosphorylation Precursors: - The enantioenriched activated phosphorylating agent is synthesized by phosphorylation of an enantioenriched 1-(V)-1,3-propanediol with phosphorodichloridates of formula L—P(O)Cl2 in the presence of a base (Ferroni, et al., J. Org. Chem. 64(13), 4943 (1999)). Phosphorylation of an enantiomerically pure substituted diol with, for example, a commercially available phosphorodichloridate R—OP(O)Cl2, where RO is a leaving group, preferably aryl substituted with electron withdrawing groups, such as a nitro or a chloro, produces two diastereomeric intermediates. The relative configuration of the phosphorus atom is easily determined by comparison of the 31P NMR spectra. The chemical shift of the equatorial phosphoryloxy moiety (trans-isomer) is always more upfield than the one of the axial isomer (cis-isomer) (Verkade, et al, J. Org. Chem., 1977, 42, 1549). These diastereomers can be further equilibrated to give a trans-2,4-substituted phosphorylating agents in presence of a base such as triethyl amine or DBU. The equilibration to complete inversion of 2,4-cis-diastereomer is also achieved in presence of appropriately substituted sodium phenoxide. The equilibration step results in greater than 95% ee of the isolated trans-phosphorylating agent.
- Synthesis of Nucleosides.
- All nucleoside moieties of Formula I are well described in the literature. 2′-C-methyl-adenosine and 2′-C-methyl-guanosine analogs are made by Lewis acid catalyzed reactions of the persilylated base and 1′-acetate or benzoate sugar intermediate (Walton et al., J. Am. Chem. Soc., 1966, 88, 4524; Harry-O'Kuru et al., J. Org. Chem., 1997, 62, 1754, WO01/90121). The 7-deaza analogs are made as described earlier from 1′-bromo sugar intermediate via reaction of sodium salt of the bases (US2002-0147160A1 or WO02/057827). The glycosylation products are subjected to deprotection and amination via ammonolysis reaction.
- The nucleoside moieties and derivatives thereof of Formulae VI-VIII of the present invention may be synthesized by many well-established general methods described in the nucleoside literature. Several nucleosides analogs described herein are synthesized as illustrated in WO04/046331 and by the methods cited therein. These compounds of the present invention can also be made from a wide variety of commercial bases utilizing the 2′-methyl riboglycosylation precursor (US2002-0147160A1 or WO02/057827) via a range of well-known glycosylation reactions (Vorbruggen and Ruh-Pohlenz, Handbook of Nucleoside Synthesis, Wiley, New York, 2001). Furthermore, deaza and aza nucleoside analogs may be prepared utilizing the methods reported in the case of corresponding ribo-analogs by glycosylation with 2′-methyl glycosylation precursor (Robins, et al., Advances in Antiviral Drug Design, Vol. 1, p 39-85, De Clercq, ed., JAI Press, Greenwich, Conn., 1993). In addition, new base analogs of the nucleosides can be synthesized by modification of the available nucleosides or via synthesis of new bases followed by glycosylation (Chemistry of Nucleosides and Nucleotides, Vols. 1-3, Townsend, ed., Plenum, New York, 1988 and Nucleic Acid Chemistry, Vols. 1-4, Townsend and Tipson Eds., Wiley, New York, 1986).
- Synthesis of Prodrugs Via Coupling of Nucleosides and Prodrug Moiety.
- The following procedures on the preparation of prodrugs illustrate the general procedures used to prepare the NMP prodrugs. Prodrugs can be introduced at different stages of the synthesis. Most often they are made at a later stage, because of the general sensitivity of these groups to various reaction conditions. Optically pure prodrugs containing single isomer at phosphorus center are made by coupling of enantiomerically enriched activated phosphate intermediates.
- All the procedures described herein, where Y and Y′ are oxygen are also applicable for the preparation of the prodrugs where Y and and/or Y′ are NH by appropriate substitution or protection of nitrogen.
-
- Chlorophospholanes are used to phosphorylate alcohols on nucleosides in the presence of an organic base (e.g., triethylamine, pyridine). Alternatively, the phosphite can be obtained by coupling the nucleoside with a phosphoramidate in the presence of a coupling promoter such as tetrazole or benzimidazolium triflate (Hayakawa et al., J. Org. Chem., 1996, 61, 7996). Phosphite diastereomers may be isolated by column chromatography or crystallization (Wang, et al, Tetrahedron Lett, 1997, 38, 3797; Bentridge et al., J. Am. Chem. Soc., 1989, 111, 3981). Since condensation of alcohols with chlorophospholanes or phosphoramidites is an SN2(P) reaction, the product is expected to have an inverted configuration. This allows for the stereoselective synthesis of cyclic phosphites. Isomeric mixtures of phosphorylation reactions can also be equilibrated (e.g. thermal equilibration) to a more thermodynamically stable isomer.
- The resulting phosphites are subsequently oxidized to the corresponding phosphate prodrugs using an oxidant such as molecular oxygen or t-butylhydroperoxide (Meier et al., Bioorg, Med. Chem. Lett., 1997, 7, 1577). Oxidation of optically pure phosphites is expected to stereoselectively provide optically active prodrugs (Mikolajczyk, et al., J. Org. Chem., 1978, 43, 2132. Cullis, P. M. J. Chem. Soc., Chem Commun., 1984, 1510, Verfurth, et al., Chem. Ber., 1991, 129, 1627).
- Synthesis of Prodrugs Via P(V) Intermediates:
- For the synthesis of cis-prodrugs of Formula I, the prodrug moiety can be introduced at different stages of the synthesis. Most often the cyclic phosphates are introduced at a later stage, because of the general sensitivity of these groups to various reaction conditions. The synthesis can also proceed through using a protected or unprotected nucleoside or nucleoside analog depending on the reactivity of the functional groups present in the compound. Single stereoisomers of the cis-prodrugs can be made either by separation of the diastereoisomers/enantiomers by a combination of column chromatography and/or crystallization, or by enantiospecific or enantioselective synthesis using enantioenriched activated phosphate intermediates.
Synthesis of Enantiomerically Enriched Prodrugs:
wherein Q is N or CH; and L is H and M is NH2 or M is OH and L is NH2. - The general procedure for the phosphorylation of protected nucleosides is accomplished by reacting a suitably protected nucleoside with a base and reacting the alkoxide generated with the phosphorylating reagent. The protected nucleoside can be prepared by one skilled in the art using one of the many procedures described for the protection of nucleosides (Greene T. W., Protective Groups in Organic Chemistry, John Wiley & Sons, New York (1999)). The nucleoside is protected in such a way as to expose the hydroxyl group on which to add the phosphate group while protecting all the remaining hydroxyls and other functional groups on the nucleoside that may interfere with the phosphorylation step or lead to regioisomers. In one aspect, the protecting groups selected are resistant to strong bases, e.g., ethers, silyl ethers and ketals. In one aspect, the protecting groups are optionally substituted MOM ethers, MEM ethers, trialkylsilyl ethers and symmetrical ketals. In another aspect, the protecting groups are t-butyldimethylsilyl ether and isopropylidene. Further protection entails masking of the amino group of the base moiety, if present, so as to eliminate any acidic protons. In one aspect the selected N-protecting groups are selected from the groups of dialkyl formamidines, mono and dialkyl imines, mono and diaryl imines. In one aspect, the N-protecting groups are selected from the groups of dialkyl formamidines and mono-alkyl imine and mono aryl imine. In one aspect the mono-alkyl imine is benzylimine and the mono-aryl imine is phenylimine. In another aspect, the N-protecting group is a symmetrical dialkyl formamidine selected from the group of dimethyl formamidine and diethyl formamidine.
- Generation of the alkoxide of the exposed hydroxyl group on the suitably protected nucleoside is accomplished with a base in an aprotic solvent that is not base sensitive such as THF, dialkyl and cyclic formamides, ether, toluene and mixtures of those solvents. In one aspect, the solvents are DMF, DMA, DEF, N-methylpyrrolidinone, THF, and mixture of those solvents.
- Many different bases have been used for the phosphorylation of nucleosides and non-nucleoside compounds with cyclic and acyclic phosphorylating agents. For example trialkylamines such as triethylamine (Roodsari et al., J. Org. Chem. 64(21), 7727 (1999)) or N,N-diisopropylethylamine (Meek et al., J. Am. Chem. Soc. 110(7), 2317 (1988)); nitrogen containing heterocyclic amines such as pyridine (Hoefler et al., Tetrahedron 56(11), 1485 (2000)), N-methylimidazole (Vankayalapati et al., J. Chem. Soc. Perk T 1 14, 2187(2000)), 1,2,4-triazole (Takaku et al., Chem. Lett. (5), 699 (1986)) or imidazole (Dyatkina et al., Tetrahedron Lett. 35(13), 1961 (1994)); organometallic bases such as potassium t-butoxide (Postel et al., J. Carbohyd. Chem. 19(2), 171 (2000)), butyllithium (Torneiro et al., J. Org. Chem. 62(18), 6344 (1977)), t-butylmagnesium chloride (Hayakawa et al., Tetrahedron Lett. 28(20), 2259 (1987)) or LDA (Aleksiuk et al., J. Chem. Soc. Chem. Comm. (1), 11 (1993)); inorganic bases such as cesium fluoride (Takaku et al., Nippon Kagaku Kaishi (10), 1968 (1985)), sodium hydride (Hanaoka et al., Heterocycles 23(11), 2927 (1985)), sodium iodide (Stromberg et al., J. Nucleos. Nucleot. 6(5), 815 (1987)), iodine (Stromberg et al., J. Nucleos. Nucleot. 6(5), 815 (1987)) or sodium hydroxide (Attanasi et al., Phosphorus Sulfur 35(1-2), 63 (1988)); metals such as copper (Bhatia et al., Tetrahedron Lett. 28(3), 271 (1987)). However, no reaction or racemization at the phosphorus stereogenic center was observed when coupling of phosphorylating reagent was attempted using the previously described procedures. Especially, no reaction was observed with bases previously used with substituted cyclic phosphorylating agent to give the corresponding cyclic phosphate in high yield such as sodium hydride (Thuong et al., Bull. Soc. Chim. Fr. 667 (1974)), pyridine (Ayral-Kaloustian et al., Carbohydr. Res. 187(1991)), butyl-lithium (Hulst et al., Tetrahedron Lett. 1339 (1993)), DBU (Merckling et al., Tetrahedron Lett. 2217 (1996)), triethylamine (Hadvary et al., Helv. Chim. Acta, 1986, 69(8), 1862), N-methylimidazole (Li et al., Tetrahedron Lett. 6615 (2001)) or sodium methoxide (Gorenstein et al., J. Am. Chem. Soc. 5077 (1980)). It was found that the use of Grignard reagents promoted phosphorylation with minimal epimerization of the phosphorus center. In one aspect, Grignard reagents are alkyl and aryl Grignards. In another aspect, the Grignard reagents are t-butyl magnesium halides and phenyl magnesium halides. In another aspect, the Grignard reagents are t-butylmagnesium chloride and phenylmagnesium chloride.
- In another aspect magnesium alkoxides are used to generate the magnesium 5′-alkoxide of the nucleoside. In one aspect magnesium alkoxides are selected from the group of Mg(O-t-Bu)2, and Mg(O-iPr)2.
- The protected prodrugs generated as described above are then subjected to a deprotection step to remove all the protecting groups using one of the many methods known to those skilled in the art (Greene T. W., Protective Groups in Organic Chemistry, John Wiley & Sons, New York (1999)) and that are compatible with the stability of the phosphate prodrug. In one aspect, deprotection reagents include fluoride salts to remove silyl protecting groups, mineral or organic acids to remove acid labile protecting groups such as silyl and/or ketals and N-protecting groups, if present. In another aspect, reagents are tetrabutylammonium fluoride (TBAF), hydrochloric acid solutions and aqueous TFA solutions. Isolation and purification of the final prodrugs, as well as all intermediates, are accomplished by a combination of column chromatography and/or crystallization.
- The sequence provides methods to synthesize single isomers of compounds of Formula I. Due to the presence of a stereogenic center at the carbon where V is attached on the cyclic phosphate reagent, this carbon atom can have two distinct orientations, namely R or S. As such the trans-phosphate reagent prepared from a racemic diol can exist as either the S-trans or R-trans configuration and results in a S-cis and R-cis prodrug mixture. The reaction of the C′-S-trans-phosphate reagent generates the C′-S-cis-prodrug of the nucleoside while reaction with the C′-R-trans-phosphate reagent generates the C′-R-cis-prodrug.
- Synthesis of 6-, 2′-, and/or 3′-Substituted Prodrugs:
- Synthesis of 6-, 2′- and/or 3-′ substituted prodrugs of Formula II or III can be accomplished starting from compounds of Formula I. For example, selective 3′-acylation of nucleoside monophosphate cyclic prodrugs of Formula I may be achieved by several methods as described in the literature (Protective groups in organic synthesis, Greene and Wuts, John Wiley, New York, 1991). Additionally, selective 3′-acylation can be attained by various esterification methods in the presence of tertiary hydroxy functionality at the 2′-position without protection. Acylation may also be accomplished efficiently by utilizing amine protected amino acids as described earlier (WO 04/002422, Hanson et al., Bioorg. Med. Chem. 2000, 8, 2681) and the amine protective groups are removed under mild acidic conditions. 2′,3-Cyclic carbonate formation is another well-known transformation for ribofuranosyl nucleosides. Compounds of formula I undergo carbonate formation under neutral conditions to result in compounds of Formula II or III (Pankiewicz, et al., J. Org. Chem., 1985, 50, 3319).
- Prodrugs at 6-position may be prepared from the corresponding halo derivatives of the nucleosides. The prodrug substitution is made at the nucleoside stage (before 5′-prodrug formation) from the corresponding chloro or hydroxy functionalities in case of compounds of Formula II or III where R9 or R10 is substituted (e.g., N3, H, —COR). Synthesis of such nucleoside precursors are attained as described earlier (WO 02/057287). Preparation of these purine analogs by azido displacement (Aso et al., J. Chem Soc Perkin Trans II, 2000, 8 1637) or hydrogention (Freer et al., Tetrahedron, 2000, 56, 45) are well known methods. Subsequently, these prodrug functionality substituted nucleosides are transformed to corresponding monophosphate cyclic prodrugs of Formula II or III.
- Miscellaneous Methods:
- Coupling of activated phosphates with alcohols is accomplished in the presence of an organic base. For example, chlorophosphates synthesized as described in the earlier section react with an alcohol in the presence of a base such as pyridine or N-methylimidazole. In some cases phosphorylation is enhanced by in situ generation of iodophosphate from chlorophosphate (Stomberg, et al., Nucleosides & Nucleotides., 1987, 5: 815). Phosphorofluoridate intermediates have also been used in phosphorylation reactions in the presence of a base such as CsF or n-BuLi to generate cyclic prodrugs (Watanabe et al., Tetrahedron Lett., 1988, 29, 5763). Phosphoramidate intermediates are known to couple by transition metal catalysis (Nagamatsu, et al., Tetrahedron Lett., 1987, 28, 2375).
- Reaction of the optically pure diastereomer of phosphoramidate intermediate with the hydroxyl of nucleoside in the presence of an acid produces the optically pure phosphate prodrug by direct SN2(P) reaction (Nakayama, et al., J. Am. Chem. Soc., 1990, 112, 6936). Alternatively, reaction of the optically pure phosphate precursor with a fluoride source, preferably cesium fluoride or TBAF, produces the more reactive phosphorofluoridate which reacts with the hydroxyl of the nucleoside to give the optically pure prodrug by overall retention of configuration at the phosphorus atom (Ogilvie, et al., J. Am. Chem. Soc., 1977, 99, 1277).
- Prodrugs of Formula I are synthesized by reaction of the corresponding phosphodichloridate and an alcohol (Khamnei, et al., J. Med. Chem., 1996, 39: 4109). For example, the reaction of a phosphodichloridate with substituted 1,3-diols in the presence of base (such as pyridine and triethylamine) yields compounds of Formula I.
- Such reactive dichloridate intermediates can be prepared from the corresponding acids and the chlorinating agents such as thionyl chloride (Starrett, et al, J. Med. Chem., 1994, 1857), oxalyl chloride (Stowell, et al., Tetrahedron Lett., 1990, 31: 3261), and phosphorus pentachloride (Quast, et al., Synthesis, 1974, 490).
- Phosphorylation of an alcohol is also achieved under Mitsunobu reaction conditions using the cyclic 1′,3′-propanyl ester of phosphoric acid in the presence of triphenylphosphine and diethyl azodicarboxylate (Kimura et al., Bull. Chem. Soc. Jpn., 1979, 52, 1191). The procedure can be extended to prepare enantiomerically pure phosphates from the corresponding phosphoric acids. Phosphate prodrugs are also prepared from the free acid by Mitsunobu reactions (Mitsunobu, Synthesis, 1981, 1; Campbell, J. Org. Chem., 1992, 52: 6331), and other acid coupling reagents including, but not limited to, carbodiimides (Alexander, et al., Collect. Czech. Chem. Commun., 1994, 59: 1853; Casara, et al., Bioorg. Med. Chem. Lett., 1992, 2: 145; Ohashi, et al., Tetrahedron Lett., 1988, 29: 1189), and benzotriazolyloxytris-(dimethylamino)phosphonium salts (Campagne, et al., Tetrahedron Lett., 1993, 34: 6743). Cyclic-1,3-propanyl prodrugs of phosphates are also synthesized from NMP and substituted propane-1,3-diols using a coupling reagent such as 1,3-dicyclohexylcarbodiimide (DCC) in presence of a base (e.g., pyridine). Other carbodiimide based coupling agents such as 1,3-diisopropylcarbodiimide and the water soluble reagent, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) can also be utilized for the synthesis of cyclic prodrugs.
- Phosphate prodrugs can be prepared by an alkylation reaction between the phosphate corresponding tetrabutylammonium salts and substituted-1,3-diiodopropanes made from 1,3-diols (Farquhar, et al., Tetrahedron Lett., 1995 36, 655). Furthermore, phosphate prodrugs can be made by conversion of nucleoside to the dichloridate intermediate with phosphoryl chloride in presence of triethylphosphite and quenching with substituted-1,3-propanediols (Farquhar et al., J. Org. Chem., 1983, 26, 1153).
- Phosphorylation can also be achieved by making the mixed anhydride of the cyclic diester of phosphoric acid and a sulfonyl chloride, preferably 8-quinolinesulfonyl chloride, and reacting the hydroxyl of the nucleoside in the presence of a base, preferably N-methylimidazole (Takaku, et al., J. Org. Chem., 1982, 47, 4937). In addition, starting from an enantiomerically pure cyclic diester of a phosphoric acid, obtained by resolution (Wynberg, et al., J. Org. Chem., 1985, 50, 4508), one can obtain enantiomerically pure phosphates.
- The compounds used in this invention and their preparation can be understood further by the Examples, which illustrate some of the processes by which these compounds are prepared. These Examples should not however be construed as specifically limiting the invention, and variations of the compounds, now known or later developed, are considered to fall within the scope of the present invention as hereinafter claimed.
- Compounds of Formula I are prepared as outlined below. The TLC conditions given are utilizing plates of Analtech UNIPLATE, silica gel GHLF, scored 10×20 cm, 250 micron.
- To a solution of 2-furaldehyde (3 g, 31.2 mmol) in THF (60 mL) was added 1 M vinyl magnesium bromide in THF (34 mL) at 0° C. After stirring for an hour, a solution of 1 M BH3 THF complex in THF was added. The reaction was quenched with 3N NaOH (20 mL) and 30% hydrogen peroxide (10 mL) at 0° C. The organic fraction was separated and concentrated. The crude product was chromatographed by eluting with 5% methanol-dichloromethane to give 1-(2′-furyl)propane-1,3-diol (1 g).
- Step A: (J. Org. Chem. 22:589 (1957))
- To a solution of 3-(2′-pyridyl)propan-1-ol (10 g, 72.9 mmol) in acetic acid (75 mL) was added 30% hydrogen peroxide slowly. The reaction mixture was heated to 80° C. for 16 h. The reaction was concentrated under vacuum and the residue was dissolved in acetic anhydride (100 mL) and heated at 110° C. overnight. Acetic anhydride was evaporated upon completion of the reaction. Chromatography of the mixture by eluting with methanol-methylene chloride (1:9) resulted in 10.5 g of pure diacetate.
- Step B:
- To a solution of diacetate (5 g, 21.1 mmol) in methanol-water (3:1, 40 mL) was added potassium carbonate (14.6 g, 105.5 mmol). After stirring for 3 h at room temperature, the reaction mixture was concentrated. The residue was chromatographed by eluting with methanol-methylene chloride (1:9) to give 2.2 g of crystalline diol.
- Step A: (J. Org. Chem. 53:911 (1988))
- To a solution of oxalyl chloride (5.7 mL, 97 mmol) in dichloromethane (200 mL) at −78° C. was added dimethyl sulfoxide (9.2 mL, 130 mmol). The reaction mixture was stirred at −78° C. for 20 min before addition of 3-(benzyloxy)propan-1-ol (11 g, 65 mmol) in dichloromethane (25 mL). After an hour at −78° C., reaction was quenched with triethylamine (19 mL, 260 mmol) and warmed to room temperature. Work-up and column chromatography by elution with dichloromethane resulted in 8 g of 3-(benzyloxy)propan-1-al.
- Step B:
- To a solution of 3-(benzyloxy)propan-1-al (1 g, 6.1 mmol) in THF at 0° C. was added a 1 M solution of 4-fluorophenylmagnesium bromide in THF (6.7 mL, 6.7 mmol). The reaction was warmed to room temperature and stirred for 1 h. Work-up and column chromatography by elution with dichloromethane resulted in 0.7 g of alcohol.
- Step C:
- To a solution of benzyl ether (500 mg) in ethyl acetate (10 mL) was added 10% Pd(OH)2C (100 mg). The reaction was stirred under hydrogen gas for 16 h. The reaction mixture was filtered through Celite and concentrated. Chromatography of the residue by elution with ethyl acetate-dichloromethane (1:1) resulted in 340 mg of product.
- Step A: (J. Org. Chem. 55:4744 (1990))
- To a −78° C. solution of diisopropylamine (2 mmol) in THF (0.7 mL/mmol diisopropylamine) was slowly added n-butyllithium (2 mmol, 2.5 M solution in hexanes). The reaction was then stirred for 15 min at −78° C. before a solution of ethyl acetate (2 mmol) in THF (0.14 mL/mmol ethyl acetate) was slowly introduced. After stirring an additional 30 min at −78° C., a THF solution containing the aryl aldehyde (1.0 mmol in 0.28 mL THF) was added. The reaction was then stirred at −78° C. for 30 min, warmed to room temperature and stirred an additional 2 h. After aqueous work up (0.5 M HCl), the organic layer was concentrated to a crude oil (beta-hydroxyester).
- Step B:
- The crude hydroxyester was dissolved in ether (2.8 mL/mmol), cooled to ice bath temperature, and lithium aluminum hydride (3 mmol) was added batch wise. The reaction was stirred allowing the cooling bath to melt and the reaction to reach room temperature. After stirring overnight at room temperature, the reaction was cooled back to ice bath temperature and quenched with ethyl acetate. Aqueous work up (0.5 M HCl) afforded the crude diol, which was purified either by chromatography or distillation.
- 1-(3-bromophenyl)-1,3-propane diol was prepared as Example 4 and further derivatized as follows:
- A pressure vessel was charged with 1-(3-bromophenyl)-1,3-propanediol (2 g, 8.6 mmol), methanol (30 mL), triethylamine (5 mL) and bis(triphenylphosphine)palladium dichloride (0.36 g, 05 mmol). The sealed vessel was pressurize with carbon monoxide at 55 psi and heated at 85° C. for 24 h. The cooled vessel was opened and the reaction mixture was filtered through Celite and rinsed with methanol. The combined filtrates were concentrated under reduced pressure and the residue was purified by column chromatography (silica gel, hexanes/ethyl acetate 1/1) to afford the title compound (1.2 g)
- TLC: hexanes/ethyl acetate 2/8; Rf=0.5
- 1H NMR (CDCl3, Varian Gemini 200 MHz): 5.05-4.95 (m, 1H), 3.9 (s, 3H), 2-1.8 (m, 2H).
- 1-(4-bromophenyl)-1,3-propane diol was prepared as Example 4 and further derivatized as Example 4a.
- TLC: hexanes/ethyl acetate 3/7; Rf=0.35
- 1H NMR (CDCl3, Varian Gemini 200 MHz): 5.1-5 (m, 1H), 3.91 (s, 3H), 2.05-1.9 (m, 2H).
- Synthesis of Enantioenriched 1-(Aryl)-Propane-1,3-Diols:
- Racemic diols synthesized as in Examples 1-4 may be resolved to yield both enantiomers as described in the following procedure.
- Step A:
- To a solution of diol (1.0 mmol) in THF (1.0 ml) was added hexamethyldisilazane (2.1 mmol) followed by a catalytic amount of trimethylsilyltriflate (2-3 drops). After stirring at room temperature for 1 h, the reaction was diluted with hexane (4 mL) and subjected to Work up with ice-cold water. The resulting disilylether was either purified by chromatography or, if sufficiently pure, used crude in the next reaction.
- Step B:
- To a solution of disilylether (1.0 mmol) and (−)-menthone (1.1 mmol) in dichloromethane (2.0 ml) at −40° C., was slowly added trimethylsilyltriflate (0.11 mmol). The reaction was then kept at −50° to −60° C. for 48 h, at which time pyridine was added to quench the reaction. After warming to room temperature, the crude mixture was diluted with hexane (4.0 ml) and subjected to aqueous work up. The two ketals were separated by chromatography.
- Step C:
- The separated ketals were hydrolyzed by adding a catalytic amount of concentrated hydrochloric acid to a methanol (4.0 mmol) solution of each. After stirring overnight at room temperature, the methanol was removed under vacuum and the residue was subjected to aqueous work up. The resolved diols were further purified by either chromatography or distillation.
- Step A:
- To a dispersion of m-chloro-cinnamic acid (25 g, 137 mmol) in ethanol (275 mL) was added conc. sulfuric acid (8 mL) at room temperature. The reaction was refluxed overnight and concentrated. Ice-cold water was added to the crude and precipitated white solid was filtered and washed with cold water. The precipitate was dried under vacuum overnight to give 25 g of ester. (Rf=0.5 in dichloromethane on silica)
- Step B:
- To a solution of ethyl-m-chlorocinnamate (23 g, 109.5 mmol) in dichloromethane at −78° C. was added 1 M DIBAL-H in dichloromethane (229 mL, 229 mmol) dropwise over 1 h. The reaction was stirred at −78° C. for an additional 3 h. Ethylacetate was added to quench excess DIBAL-H and saturated aq. potassium sodium tartrate was added and the reaction was stirred at room temperature for 3 h. The organic layer was separated and salts were washed with ethyl acetate. The combined organic extracts were concentrated and distilled at 120° C./0.1 mm to give 14 g of pure allylic alcohol. (Rf=0.38 in 1:1 ethylacetate:hexane on silica)
- Step C:
- To a solution of m-chlorocinnamyl alcohol (5 g, 29.76 mmol) in dichloromethane (220 mL) was added activated 4 Å molecular sieves powder (2.5 g) and the mixture was cooled to −20° C. (+)-Diethyl tartrate (0.61 mL, 3.57 mmol) was added at −20° C. and stirred for 15 min before adding titanium tetraisopropoxide (0.87 g, 2.97 mmol). The reaction was stirred for additional 30 min and 5-6 M solution of t-butylhydroperoxide in heptane (10 mL, 60 mmol) was added dropwise while maintaining the internal temperature at −20 to −25° C. The mixture was stirred for an additional 3 h at −20° C. and a 10% sodium hydroxide in saturated aq. sodium chloride (7.5 mL) followed by ether (25 mL) were added. The reaction was warmed to 10° C. and stirred for 15 min before adding anhydrous magnesium sulfate (10 g) and Celite (1.5 g). The mixture was further stirred for additional 15 min, filtered and concentrated at 25° C. to give crude epoxy alcohol. (R=0.40 in 1:1 ethylacetate:hexane on silica)
- Step D:
- To a solution of crude m-chloroepoxycinnamyl alcohol obtained from earlier reaction in dimethoxyethane (300 mL) was added a 65% Red-Al solution in toluene (18.63 mL, 60 mmol) dropwise under nitrogen at 0° C. After stirring at room temperature for 3 h, the solution was diluted with ethyl acetate (400 mL) and quenched with aq. saturated sodium sulfate solution (50 mL). After stirring at room temperature for 30 min, the resulting white precipitate formed was filtered and washed with ethylacetate. The filtrate was dried and concentrated. The crude product was distilled at 125-130° C./0.1 mm to give 3.75 g of enantioenriched (R)-1-(3′-chlorophenyl)-1,3-dihydroxypropane. (Rf=0.40 in 1:1 ethylacetate:dichloromethane)
- Enantiomeric excesses were defined as diacetates (prepared by treatment of diols with acetic anhydride, triethylamine, cat.DMAP in dichloromethane) by HPLC ((S,S) Whelko-0, 250 cm×4.0 mm ID purchased from Regis).
- (R)-1-(3′-chlorophenyl)-1,3-dihydroxypropane: 91% ee
- (+)Diisopropyltartrate provided >96% ee in (R)-1-(3′-chlorophenyl)-1,3-dihydroxypropane.
- (S)-1-(3′-chlorophenyl)-1,3-dihydroxypropane was also prepared under identical conditions via asymmetric epoxidation and reduction protocol utilizing (−)-tartrate in similar yields. (S)-3-(3′-chlorophenyl)-1,3-dihydroxypropane was obtained with 79% ee.
- Step A: Preparation of Methyl 3-(3′-chlorophenyl)-3-oxo-propanoate:
- A 22 L, 3-neck round bottom flask was equipped with a mechanical stirrer, thermowell/thermometer and nitrogen inlet (bubbler in-line). The flask was flushed with nitrogen and charged sequentially with THF (6 L), potassium t-butoxide (1451 g), and THF (0.5 L). The resulting mixture was stirred at ambient temperature for 15 min. and a 20° C. water bath was applied. A 3 L round bottom flask was charged with 3′-chloroacetophenone (1000 g) and diethylcarbonate (1165 g), and the resulting yellow solution was added slowly to the stirred potassium t-butoxide solution, maintaining the temperature between 16 and 31° C. After the addition was complete (1 h, 10 min.), the cooling bath was removed and the solution was stirred for 1 h, 30 min. TLC indicated that the reaction was complete. A 5 gallon stationary separatory funnel was charged with ice water (4 L) and concentrated hydrochloric acid (1.3 L of 12 M solution). The dark red reaction solution was quenched into the aqueous acid and the mixture was stirred for 15 min. The layers were separated and the aqueous phase (lower) was extracted again with toluene (4 L). The combined organic extracts were washed with saturated brine (2×3 L, 10 min. stirring time each), dried (MgSO4), filtered and concentrated under reduced pressure to provide 1480 g of a brown oil. The oil was placed under high vacuum (10 torr) overnight to give 1427 g. The material was vacuum distilled (short path column, fraction cutter receiver) and the fraction at 108-128° C./1-0.5 torr was collected to provide 1273.9 g of a yellow oil. (Rf=0.36 in 20% ethyl acetate/hexanes).
Step B: Preparation of Methyl (S)-3-(3′-chlorophenyl)-3-hydroxypropionate: - A 12 L, 3-neck round bottom flask was equipped with a mechanical stirrer, thermometer, addition funnel (500 mL) and nitrogen inlet (bubbler in-line). The flask was flushed with nitrogen and charged with formic acid (292 mL, 350 g). Triethylamine (422 mL, 306 g) was charged to the addition funnel, then added slowly with stirring, maintaining the temperature less than 45° C. After the addition was complete (1 h, 30 min), the solution was stirred with the ice bath applied for 20 min., then at ambient temperature for an additional 1 h. The flask was charged sequentially with methyl 3-(3-chlorophenyl)-3-oxo-propanoate (1260 g), DMF (2.77 L including rinsing volume) and (S,S)-Ts-DPEN-Ru—Cl-(p-cymene) (3.77 g). The flask was equipped with a heating mantle and the addition funnel was replaced with a condenser (5 C circulating coolant for condenser). The stirred reaction solution was slowly heated to 60° C. (90 min. to attain 60° C.) and the contents were maintained at 60° C. for 4.25 h. HPLC indicated 3% starting material remained. The solution was stirred at 60° C. for an additional 8 h, then gradually cooled to ambient temperature overnight. HPLC indicated 0.5% starting material. A 5 gallon stationary separatory funnel was charged with water (10 L) and MTBE (1 L). The reaction solution was poured into the aqueous mixture and the reaction flask was rinsed into the separatory funnel with an additional 1 L of MTBE. The contents were stirred for several minutes and the layers were separated. The aqueous phase was extracted with additional MTBE (2×1 L), and the combined organic extracts were washed with brine (1 L), and concentrated under reduced pressure to provide 1334 g of a red oil. The oil was used without further purification for the next step.
- The crude hydroxyester (10 mg, 0.046 mmol) was dissolved in dichloromethane (1 mL). Acetic anhydride (22 μL, 0.23 mmol) and 4-(dimethylamino)pyridine (22 mg, 0.18 mmol) were added and the solution was stirred at ambient temperature for 15 min. The solution was diluted with dichloromethane (10 mL) and washed with 1 M hydrochloric acid (3×3 mL). The organic phase was dried (MgSO4), filtered and concentrated under reduced pressure. The residual oil was dissolved in methanol and analyzed by chiral HPLC (Zorbax Rx-C18, 250×4.6 mm; mobile phase: 65/35 (v/v) water/acetonitrile, isocratic; flow rate=1.5 mL/min; inj. volume=15 μL; UV detection at 220 nm. Retention times: Product=9.3 min, starting material=17.2 min). The hydroxyester was derivatized to the acetate for analysis by chiral HPLC and shown to give 91% ee. (HPLC conditions: Column: Pirkle covalent (S,S) Whelk-O 10/100 krom FEC, 250×4.6 mm; mobile phase: 70/30 (v/v) methanol/water, isocratic; flow rate: 1.5 mL/min; inj. volume=10 μL; UV detection at 220 nm. Retention times: S-hydroxyester (acetate)=9.6 min, R-hydroxyester (acetate)=7.3 min.)
- Step C: Preparation of (S)-3-(3′-chlorophenyl)-3-hydroxypropanoic Acid:
- To the crude hydroxyester in a 10 L rotary evaporator flask was added sodium hydroxide solution (2.5 L of 2 M solution). The resulting solution was stirred on the rotary evaporator at ambient pressure and temperature for 2 h. HPLC indicated 5% starting material still remained (HPLC conditions: Column: Zorbax Rx-C18, 250×4.6 mm; mobile phase: 65/35 (v/v) water/acetonitrile, isocratic; flow rate=1.5 mL/min; inj. volume=15 μL; UV detection at 220 nm. Retention times: Product=3.8 min, starting material=18.9 min.). The pH of the solution was 11 (wide range pH paper). Additional 2 M NaOH solution was added to adjust the pH to 14 (approx. 100 mL), and the solution was stirred for an additional 30 min. HPLC indicated the reaction was complete. The solution was transferred to a 5 gallon stationary separatory funnel and extracted with MTBE (2 L). The layers were separated and the organic extract was discarded. The aqueous phase was transferred back to the separatory funnel and acidified with 12 M HCl solution (600 mL). The mixture was extracted with MTBE (1×2 L, 2×1 L). The combined acidic organic extracts were dried (MgSO4), filtered and concentrated under reduced pressure to give 1262 g of a brown, oily semi-solid. The residue was slurried with ethyl acetate (1 L) and transferred to a 12 L, 3-neck round bottom flask equipped with a mechanical stirrer, heating mantle, condenser and thermometer. The stirred mixture was heated to dissolve all solids (28° C.) and the dark solution was cooled to 10° C. (a precipitate formed at 11° C.). The mixture was slowly diluted with hexanes (4 L over 1 h) and the resulting mixture was stirred at <10° C. for 2 h. The mixture was filtered and the collected solid was washed with cold 4/1 hexanes/ethyl acetate (1 L), and dried to constant weight (−30 in. Hg, 50° C., 4 h). Recovery=837 g of a beige solid. mp=94.5-95.5° C.
- A 50 mg sample of hydroxyacid was reduced to the diol with borane-THF (see Step D). The resulting crude diol was diacetylated (as described in Step B)) and analyzed by chiral HPLC. Retention times: S-diol (diacetate)=12.4 min, R-diol (diacetate)=8.8 min.) ee=98%
- A second crop of hydroxyacid was isolated. The filtrate from above was concentrated under reduced pressure to give 260 g of a brown sludge. The material was dissolved in ethyl acetate (250 mL) and the stirred dark solution was slowly diluted with hexanes (1000 mL) and the resulting mixture was stirred at ambient temperature overnight. The mixture was filtered and the collected solid was washed with 5/1 hexanes/ethyl acetate (200 mL), and dried to constant weight (−30 in. Hg, 50° C., 16 h). Recovery=134 g of a beige solid. ee=97%
Step D: Preparation of (S)-(−)-1-(3-chlorophenyl)-1,3-propanediol: - A 22 L, 3-neck round bottom flask was equipped with a mechanical stirrer, thermowell/thermometer and nitrogen inlet (outlet to bubbler). The flask was charged with 2 M borane-THF (3697 g, 4.2 L) and the stirred solution was cooled to 5° C. A solution of (S)-3-(3-chlorophenyl)-3-hydroxypropanoic acid (830 g) in THF (1245 mL) was prepared with stirring (slightly endothermic). The reaction flask was equipped with an addition funnel (1 L) and the hydroxyacid solution was slowly added to the stirred borane solution, maintaining the temperature ≦16° C. After the addition was complete (3 h), the mixture was stirred at ice bath temperature for 1.5 h. The reaction was quenched by careful addition of water (2.5 L). After the addition was complete (30 min), 3 M NaOH solution (3.3 L) was added (temperature increased to 35° C.) and the resulting mixture was stirred for an additional 20 min. (temperature=30° C.). The reaction mixture was transferred to a 5 gallon stationary separatory funnel and the layers were separated. The aqueous phase was extracted with MTBE (2.5 L) and the combined organic extracts (THF and MTBE) were washed with 20 wt % NaCl solution (2 L) and stirred with MgSO4 (830 g) for 30 min. The mixture was filtered through Celite and concentrated under reduced pressure to provide 735 g of a thick, brown oil.
- The oil was purified by vacuum distillation and the fraction at 135-140° C./0.2 mm Hg was collected to provide 712.2 g of a colorless oil.
- The diol was diacetylated and analyzed by chiral HPLC (e.e.=98%) (see Step B). Retention times: S-diol (diacetate)=12.4 min, R-diol (diacetate)=8.9 min. [α]D=−51.374 (5 mg/mL in CHCl3)
- Step A: Synthesis of Methyl 3-oxo-3-(pyridin-4-yl)-propanoate
- A 50 L, 3-neck flask was equipped with an overhead stirrer, heating mantle, and nitrogen inlet. The flask was charged with THF (8 L), potassium t-butoxide (5 kg, 44.6 mol), and THF (18 L). 4-Acetylpyridine (2.5 kg, 20.6 mol) was added, followed by dimethylcarbonate (3.75 L, 44.5 mol). The reaction mixture was stirred without heating for 2.5 h then with heating to 57-60° C. for 3 h. The heat was turned off and the mixture cooled slowly overnight (15 h). The mixture was filtered through a 45 cm Buchner funnel. The solid was returned to the 50 L flask and diluted with aqueous acetic acid (3 L acetic acid in 15 L of water). The mixture was extracted with MTBE (1×16 L, 1×12 L). The combined organic layers were washed with aqueous Na2CO3 (1750 g in 12.5 L water), saturated aqueous NaHCO3 (8 L), and brine (8 L) then dried over MgSO4 (500 g) overnight (15 h). The solution was filtered and the solvent removed by rotary evaporation to a mass of 6.4 kg. The resulting suspension was cooled in an ice bath with stirring for 2 h. The solid was collected by filtration, washed with MTBE (500 mL), and dried in a vacuum oven at 20° C. for 15 h, giving 2425 g of the keto ester as a pale yellow solid.
- The MTBE mother liquor was concentrated to approximately 1 L. The resulting suspension was cooled in an ice bath for 1 h. The solid was collected by filtration, washed with MTBE (2×150 mL), and dried in a vacuum oven to give 240 g of a second crop.
- TLC. Merck silica gel plates, 1:2 THF/hexane, UV lamp, Rf of SM=0.25, Rf of product=0.3.
-
- A 22 L, 3-neck round bottom flask was equipped with an overhead stirrer, thermowell/thermometer, addition funnel (1 L), and cooling vessel (empty). The flask was flushed with nitrogen, charged with formic acid (877 g) and cooled with an ice bath. Triethylamine (755 g) was charged to the addition funnel and added slowly over 50 min. to the stirred formic acid. After the addition was complete, the cooling bath was removed and the reaction solution was diluted with DMF (5.0 L). The ketoester (2648 g) was added in one portion, followed by an additional 0.5 L of DMF. The flask was equipped with a heating mantle and the stirred mixture was heated gradually to 16° C. to dissolve all solids. The catalyst (S,S)-Ts-DPEN-Ru—Cl-(p-cymene) (18.8 g) was added in one portion and the stirred mixture was heated to 55° C. over 1 h. The resulting dark solution was stirred at 55° C. for 16 h. TLC indicated the reaction was complete. The solvent was evaporated under reduced pressure (Buchi R152 rotary evaporator under high vacuum, bath temp=60° C.) to give 3574 g of a brown oil. The oil was dissolved in dichloromethane (10 L) and transferred to a 5 gal. stationary separatory funnel. The dark solution was washed with saturated sodium bicarbonate solution (3.0 L) and the aqueous phase was back extracted with dichloromethane (3.0 L). The combined dichloromethane extracts were dried over MgSO4 (300 g), filtered, and concentrated under reduced pressure to provide 3362 g of a brown oil.
- Column: Chiralpak AD, 0.46×25 cm; mobile phase=10:90, ethanol:hexane, isocratic; flow rate=1.5 mL/min; injection volume=10 μL UV detection at 254 nm.
- Retention times: R-hydroxy ester=19.9 min.
-
- S-hydroxy ester=21.7 min.
- Retention times: R-diol=14.2 min.
-
- S-diol=15.5 min
- Hydroxy Ester:
- 1H NMR (CDCl3): δ 2.73 (d, 2H, J=1.5 Hz), 3.73 (s, 3H), 4.35 (s, 1H), 5.11-5.19 (m, 1H), 7.31 (d, 2H, J=6.6 Hz), 8.53 (d, 2H, J=6.0 Hz)
- Merck silica gel 60 plates, 2.5×7.5 cm, 250 micron; UV lamp: 5% MeOH in CH2Cl2; Rf of S.M.=0.44, Rf of product=0.15.
-
- A 22 L, 4-neck round bottom flask was equipped with an overhead stirrer, thermowell/thermometer, addition funnel (2 L), condenser and cooling vessel (empty). The flask was flushed with nitrogen and charged sequentially with sodium borohydride (467 g, 12.3 mol), 1-butanol (9.0 L), and water (148 mL, 8.23 mol) The crude hydroxyester was dissolved in 1-butanol (1.0 L) and the solution was charged to the addition funnel. The solution was added over 3.25 h, using cooling as necessary to keep the temperature below 62° C. After addition was complete, the mixture was stirred for 0.5 h then the flask was equipped with a heating mantle and the stirred mixture was heated to 90° C. over 0.75 h. The mixture was stirred at 90-93° C. for 2.25 h, then cooled over 1.5 h to 28° C. The reaction mixture was quenched with aqueous potassium carbonate solution (10 wt/vol %, 6 L) and the mixture was stirred for 10 min. The layers were separated and the butanol phase was washed with aqueous potassium carbonate solution (10 wt/vol %, 2 L) and sodium chloride solution (15 wt/vol %, 2 L). The solvent was removed under reduced pressure (Buchi R152 rotary evaporator, high vacuum, bath temperature=60° C.) until a concentrated solution resulted and 10.5 L of distillate had been collected. Acetonitrile (3 L) was fed into the evaporator flask and the solvent was evaporated under reduced pressure. Acetonitrile (9 L) was again fed into the evaporator flask and the slurry was stirred (rotation on the rotary evaporator) at ˜60° C. (bath temperature=70° C., atmospheric pressure) for 15 min. The hot slurry was filtered through Celite 521 (250 g as a slurry in 1 L of acetonitrile was prepacked on a 24 cm Buchner funnel). The filtrate was partially concentrated under reduced pressure (5 L of distillate were collected) and the resulting slurry was heated at atmospheric pressure on the rotary evaporator to dissolve all solids (bath temp=65° C.). The heat source was turned off and the resulting solution was stirred on the rotary evaporator for 10 h, with gradual cooling to ambient temperature. The resulting mixture was filtered and the collected solid was washed with acetonitrile (2×200 mL) and dried to constant weight (−30 in. Hg, 55° C., 4 h), giving S-(−)-1-(4-pyridyl)-1,3-propanediol as a yellow solid weighing 496 g.
- Melting point=98-100° C.
- HPLC conditions:
- Column: Chiralpak AD, 0.46×25 cm; mobile phase=10:90, ethanol:hexane, isocratic; flow rate=1.5 mL/min; injection volume=10 μL UV detection at 254 nm.
-
- Retention times: R-diol=14.2 min.
- S-diol=15.5 min.
- Retention times: R-diol=14.2 min.
- Merck silica gel 60 plates, 2.5×7.5 cm, 250 micron; UV lamp; 15% MeOH in CH2Cl2; Rf of starting material=0.38, Rf of product=0.17, Rf of boron complex=0.26.
- Step A: Preparation of 3-(3-chlorophenyl)-3-oxo-propanoic Acid:
- A 12 L, 3-neck round bottom flask was equipped with a mechanical stirrer and addition funnel (2 L). The flask was flushed with nitrogen and charged with diisopropylamine (636 mL) and THF (1.80 L). A thermocouple probe was immersed in the reaction solution and the stirred contents were cooled to −20° C. n-Butyllithium (1.81 L of a 2.5 M solution in hexanes) was charged to the addition funnel and added slowly with stirring, maintaining the temperature between −20 and −28° C. After the addition was complete (30 min), the addition funnel was rinsed with hexanes (30 mL) and the stirred solution was cooled to −62° C. Trimethylsilyl acetate (300 g) was added slowly with stirring, maintaining the temperature <−60° C. After the addition was complete (30 min), the solution was stirred at −60° C. for 15 min. 3-Chlorobenzoyl chloride (295 mL) was added slowly with stirring, maintaining the temperature <−60° C. After the addition was complete (65 min), the cooling bath was removed and the reaction solution was stirred for 1.25 h, with gradual warming to 0° C. The reaction flask was cooled with an ice bath, then water (1.8 L) was added to the stirred solution. The reaction mixture was stirred for 10 min., then diluted with t-butyl methyl ether (1.0 L). The lower aqueous phase was separated and transferred to a 12 L, 3-neck round bottom flask equipped with a mechanical stirrer. t-Butyl methyl ether was added (1.8 L) and the stirred mixture was cooled to <10° C. (ice bath). Concentrated HCl solution (300 mL of 12 M solution) was added and the mixture was vigorously stirred. The layers were separated and aqueous phase was further acidified with con. HCl (30 mL) and extracted again with t-butyl methyl ether (1.0 L). The combined MTBE extracts were washed with brine (1 L), dried (MgSO4, 70 g), filtered and concentrated under reduced pressure to give 827 g of a yellow solid. The crude solid was slurried in hexanes (2.2 L) and transferred to a 5 L, 3-neck round bottom flask equipped with a mechanical stirrer. The mixture was stirred at <10° C. (ice bath) for 1 h, then filtered, washed with hexanes (4×100 mL) and dried to constant weight (−30 in. Hg, ambient temperature, 14 h). Recovery=309 g of a pale yellow powder.
Step B: Preparation of (S)-3-(3-chlorophenyl)-3-hydroxypropanoic Acid: - A 12 L, 3-neck round bottom flask was equipped with a mechanical stirrer and addition funnel (1 L). The flask was flushed with nitrogen and charged with 3-(3-chlorophenyl)-3-oxo-propanoic acid (275.5 g) and dichloromethane (2.2 L). A thermocouple probe was immersed in the reaction slurry and the stirred contents were cooled to −20° C. Triethylamine (211 mL) was added over 5 min. to the stirred slurry and all solids dissolved. A dichloromethane solution of (−)-β-chlorodiisopinocampheylborane (1.60 M, 1.04 L) was charged to the addition funnel, then added slowly with stirring, maintaining the temperature between −20 and −25° C. After the addition was complete (35 min), the solution was warmed to ice bath temperature (2-3° C.) and stirred for 4 h. Water (1.2 L) was added to the cloudy orange reaction mixture, followed by 3 M NaOH solution (1.44 L). The mixture was vigorously stirred for 5 min, then transferred to a separatory funnel. The layers were separated and the basic aqueous phase was washed with ethyl acetate (1.0 L). The aqueous phase was acidified with conc. HCl (300 mL) and extracted with ethyl acetate (2×1.3 L). The two acidic ethyl acetate extracts were combined, washed with brine (600 mL), dried (MgSO4, 130 g), filtered and concentrated under reduced pressure to provide 328 g of a yellow oil (the oil crystallized on standing). The solid was slurried in ethyl acetate (180 mL) and transferred to a 2 L, 3-neck round bottom flask, equipped with a mechanical stirrer. The stirred mixture was cooled to <10° C. (ice bath), then diluted with hexanes (800 mL). The resulting mixture was stirred at ice bath temperature for 4 h, then filtered. The collected solid was washed with 4:1 hexanes:ethyl acetate (3×50 mL) and dried to constant weight (−30 in. Hg, ambient temperature, 12 h). Recovery=207.5 g of a white powder.
Step C: Preparation of (S)-(−)-1-(3-chlorophenyl)-1,3-propanediol: - The compound was prepared as described in Example 7, Step D.
- The residue was dissolved in methanol (1 mL) and analyzed by chiral HPLC (see, Example 7; Step B). ee>98%.
- Step A:
- Beta-ketoester starting material was synthesized as described in Example 7, step A.
- Step B:
- A solution containing beta-ketoester (1 mmol) in either methanol or ethanol (5-10 mL/mmol ketoester) was degassed through several pump/vent (N2) cycles at room temperature. The degassed solution was moved into a glove bag and under an atmosphere of N2 was poured into a stainless steel bomb containing a stir bar and 1.0 mole % Ru-BINAP catalyst. The bomb was sealed, removed from the glove bag and purged with H2 prior to stirring 18-24 h at room temperature and 150 psi H2. After venting the hydrogen pressure, the bomb was opened and the reaction mixture was removed and concentrated. The crude beta-hydroxyester was used for hydrolysis.
- Step C:
- Crude beta-hydroxy ester was hydrolyzed as described in Example 7, step C.
- Step D:
- Optically active beta-hydroxy acid was reduced as described in Example 7, step D.
- Synthesis of Racemic Phosphorylating Agents:
-
- A solution of 1-(3-chlorophenyl)-1,3-propane diol (25 g, 134 mmol) and triethylamine (62.5 mL, 442 mmol) in THF was added to a solution of 4-nitrophenyl-phosphorodichloridate (37.7 g, 147 mmol) in THF at room temperature and the resulting solution was heated at reflux. After 2 h, TLC indicated complete consumption of the starting diol and formation of the cis and trans isomers in a 60/40 ratio (HPLC). The clear yellow solution was cooled to 30° C., sodium 4-nitrophenoxide (56 g, 402 mmol)) was added and the reaction mixture was heated at reflux. After 90 min. the reddish reaction mixture was cooled to room temperature and stirred at room temperature for 2 h then placed in the refrigerator overnight. The final ratio was determined by HPLC to be 96/4 trans/cis. The reaction mixture was quenched with a saturated solution of ammonium chloride and diluted with ethyl acetate. The layers were separated and the organics were washed 4 times with 0.3 N sodium hydroxide to remove the nitrophenol, then saturated sodium chloride and dried over sodium sulfate. The filtered solution was concentrated under reduced pressure and the resulting solid was recrystallized from ethyl acetate to give large off white needles (45 g, mp=115-116° C., purity 98 A %).
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: cis-isomer 5.6-5.8 (m, 1H), trans-isomer 5.5-5.69 (m, 1H).
- TLC conditions: Merck silica gel 60 F254 plates, 250 μm thickness; mobile phase=60/40 hexanes/ethyl acetate; Rf: diol=0.1, cis-phosphate=0.2, trans-phosphate=0.35.
- HPLC conditions: Column=Waters μ Bondapack C18 3.9×300 mm; mobile phase=40/60 acetonitrile/phosphate buffer pH 6.2; flow rate=1.4 mL/min; detection=UV @ 270 nm; retention times in min: cis-isomer=14.46, trans-isomer=16.66, 4-nitrophenol=4.14.
- Same as Example 11.1
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.6-5.8 (m, 1H)
- Same as Example 11.1
- TLC conditions: Merck silica gel 60 F254 plates, 250 μm thickness; mobile phase=50/50 hexanes/ethyl acetate; Rf: diol=0.1, cis-phosphate=0.25, trans-phosphate=0.4.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.7-5.5 (m, 1H)
- Same as Example 11.1 starting with 1-(4-methylphenyl)-1,3-propanediol
- TLC: 50/50 hexanes/ethyl acetate; Rf: cis-phosphate=0.25; trans-phosphate=0.35.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.65-5.5 (m, 1H)
- Same as Example 11.1 starting with 1-(3,5-dimethylphenyl)-1,3-propanediol
- TLC: 50/50 hexanes/ethyl acetate; Rf: cis-phosphate=0.2; trans-phosphate=0.3.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.6-5.45 (m, 1H)
- Same as Example 11.1 starting with 1-(3,5-dichlorophenyl)-1,3-propanediol
- TLC: 70/30 hexanes/ethyl acetate; Rf: cis-phosphate=0.3; trans-phosphate=0.5.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.85-5.7 (m, 1H)
- Same as Example 11.1 starting with 1-(pyrid-4-yl)-1,3-propanediol
- TLC: 95/5 dichloromethane/ethanol; Rf: trans-phosphate=0.35.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.7-5.55 (m, 1H)
- Same as Example 11.1 starting with 1-(3-methoxycarbonylphenyl)-1,3-propanediol
- TLC: 30/70 hexanes/ethyl acetate; Rf: cis-phosphate=0.5; trans-phosphate=0.6.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.7-5.6 (m, 1H)
- Same as Example 11.1 starting with 1-(4-methoxycarbonylphenyl)-1,3-propanediol
- TLC: 30/70 hexanes/ethyl acetate; Rf: cis-phosphate=0.35; trans-phosphate=0.5.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.7-5.6 (m, 1H)
- Same as Example 11.1 starting with 1-(5-bromopyrid-3-yl)-1,3-propanediol
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.8-5.65 (m, 1H)
- Same as Example 11.1 starting with 1-(2,3-dichlorophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and lithium hydride as in Example 13a.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 6-5.9 (m, 1H)
- Same as Example 11.1 starting with 1-(2,3,5-trichlorophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.9-5.7 (m, 1H)
- Same as Example 11.1 starting with 1-(2-chlorophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and lithium hydride as in Example 13a.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 6-5.9 (m, 1H)
- Same as Example 11.1 starting with 1-(3,5-dimethoxyphenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.55-5.45 (m, 1H), 3.3 (s, 6H)
- Same as Example 11.1 starting with 1-(2-bromophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13a.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.95-5.85 (m, 1H)
- Same as Example 11.1 starting with 1-(3-bromo-5-ethoxyphenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.9-5.75 (m, 1H), 4.04 (q, 2H), 1.39 (t, 3H).
- Same as Example 11.1 starting with 1-(2-trifluoromethylphenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 6-5.75 (m, 1H).
- Same as Example 11.1 starting with 1-(4-chlorophenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- TLC: hexanes/ethyl acetate 1/1; Rf: cis-phosphate=0.2; trans-phosphate=0.6.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.6-5.5 (m, 1H).
- Same as Example 11.1 starting with 1-(3-methylphenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- TLC: hexanes/ethyl acetate 6/4; Rf: cis-phosphate=0.2; trans-phosphate=0.5.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.65-5.5 (m, 1H).
- Same as Example 11.1 starting with 1-(4-fluorophenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- 1H NMR (DMSO-d6, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.78-5.85 (m, 1H).
- Same as Example 11.1 starting with 1-(2-fluorophenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- 1H NMR (DMSO-d6, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.9-6.1 (m, 1H).
- Same as Example 11.1 starting with 1-(3-fluorophenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- 1H NMR (DMSO-d6, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.8-5.9 (m, 1H).
- Same as Example 11.1 starting with 1-[4-(4-chlorophenoxy)phenyl]-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- 1H NMR (DMSO-d6, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.75-5.9 (m, 1H).
- Same as Example 11.1 starting with 1-(3-bromophenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- TLC: hexanes/ethyl acetate 1/1; Rf: cis-phosphate=0.25; trans-phosphate=0.5.
- 1H NMR (DMSO-d6, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.8-5.95 (m, 1H).
- Same as Example 11.1 starting with 1-(3,4-ethylenedioxyphenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- TLC: hexanes/ethyl acetate 1/1; Rf: trans-phosphate=0.6.
- 1H NMR (DMSO-d6, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.8-5.9 (m, 1H).
- Same as Example 11.1 starting with 1-(2-fluoro-4-chlorophenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- TLC: hexanes/ethyl acetate 1/1; Rf: trans-phosphate=0.7.
- 1H NMR (DMSO-d6, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.9-6 (m, 1H).
- Same as Example 11.1 starting with 1-(2,6-dichlorophenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- TLC: hexanes/ethyl acetate 1/1; Rf: trans-phosphate=0.65.
- 1H NMR (DMSO-d6, Varian Gemini 200 MHz): C′-proton: trans-isomer 6.2-6.4 (m, 1H).
- Same as Example 11.1 starting with 1-(2-fluoro-5-methoxyphenyl)-1,3-propanediol except that the trans-isomer was isolated from the cis/trans mixture without isomerization.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.8-5.95 (m, 1H), 3.8 (s, 3H).
- Same as Example 11.1 starting with 1-(3-fluoro-4-chlorophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.4-5.6 (m, 1H).
- Same as Example 11.1 starting with 1-(3-chloro-4-fluorophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.5-5.6 (m, 1H).
- Same as Example 11.1 starting with 1-(2-fluoro-5-bromophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.8-5.9 (m, 1H).
- Same as Example 11.1 starting with 1-(2,3,5,6-tetrafluorophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.9-6 (m, 1H).
- Same as Example 11.1 starting with 1-(2,3,6-trifluorophenyl)-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- 1H NMR (CDCl3, Varian Gemini 200 MHz): C′-proton: trans-isomer 5.9-6 (m, 1H).
- Same as Example 11.1 starting with 1(R)-(phenyl)-1,3-propanediol isolated by column without the isomerization.
- Rf=0.5 (50% EtOAc in Hexanes). mp 90-92° C. Anal calcd for C15H14ClO4P: C, 55.49; H, 4.35. Found: C, 55.64; H, 3.94.
- Same as Example 11.1 starting with 1(R)-(phenyl)-1,3-propanediol isolated by column without the isomerization.
- Rf=0.4 (50% EtOAc in Hexanes). mp 130-131° C. Anal calcd for C15H14NO6P: C, 53.74; H, 4.21; N, 4.18. Found: C, 53.86; H, 4.07; N, 4.00.
- Same as Example 11.1 starting with 1(S)-(phenyl)-1,3-propanediol.
- Rf=0.2 (5% EtOAc in CH2Cl2). mp 128-129° C. Anal calcd for C15H14NO6P: C, 53.74; H, 4.21; N, 4.18. Found: C, 53.69; H, 4.53; N, 4.23.
- Same as Example 11.1 starting with 1-(3-trifluoromethylphenyl)-1,3-propanediol.
- Rf=0.32(35% EtOAc in hexanes). mp 78-81° C. Anal calcd for C16H13F3NO6P: C, 47.66; H, 3.25; N, 3.47. Found: C, 47.69; H, 3.77; N, 3.52.
- Same as Example 11.1 starting with 1-(2,4-dichlorophenyl)-1,3-propanediol.
- Rf=0.32(35% EtOAc in hexanes). mp 154-157° C. Anal calcd for C15H12Cl2NO6P: C, 44.58; H, 2.99; N, 3.47. Found: C, 44.63; H, 3.07; N, 3.47.
- Same as Example 11.1 starting with 1-(3-bromo-4-fluorophenyl)-1,3-propanediol. Rf=0.2 (5% EtOAc in CH2Cl2). mp 108° C. Anal calcd for C15H12NO6BrFP: C, 41.69; H, 2.80; N, 3.24. Found: C, 41.90; H, 2.76; N, 3.05.
- Same as Example 11.1 starting with 1-(2-pyridyl)-1,3-propanediol. mp 99-102° C. Anal calcd for C14H13N2O6P: C, 50.01; H, 3.90; N, 8.33. Found: C, 49.84; H, 3.41; N, 8.14.
- Same as Example 11.1 starting with 1-(3,4-dichlorophenyl)-1,3-propanediol. Rf=0.15 (35% EtOAc in Hexanes). mp 126-129° C. Anal calcd for C15H12Cl2NO6P: C, 44.58; H, 2.99; N, 3.47. Found: C, 44.71; H, 3.49; N, 3.41.
- Same as Example 11.1 starting with 1-(4-tert-butylphenyl)-1,3-propanediol. Rf=0.20 (35% EtOAc in Hexanes). mp 108-111° C. Anal calcd for C19H22NO6P: C, 58.31; H, 5.67; N, 3.58. Found: C, 58.04; H, 5.67; N, 3.55.
- Same as Example 11.1 starting with 1-(3-thiophenyl)-1,3-propanediol. mp 94-96° C. Anal calcd for C13H12NO6PS: C, 45.75; H, 3.54; N, 4.10. Found: C, 45.65; H, 3.21; N, 4.24.
- Same as Example 11.1 starting with 1-(3-furanyl)-1,3-propanediol. mp 108-111° C. Anal calcd for C13H12NO7P: C, 48.01; H, 3.72; N, 4.31. Found: C, 48.06; H, 3.61; N, 4.26.
- Same as Example 11.1 starting with 1-(2-bromo-5-chlorophenyl)-1,3-propanediol. Rf=0.20 (5% MeOH in CH2Cl2). mp 105-106° C. Anal calcd for C15H12NO6BrClP: C, 40.16; H, 2.70; N, 3.12. Found: C, 39.97; H, 2.86; N, 3.06.
- Same as Example 11.1 starting with 1-(2,5-difluorophenyl)-1,3-propanediol. Rf=0.50 (50% EtOAc in Hexanes). mp 120-122° C. Anal calcd for C15H12F2NO6P: C, 48.53; H, 3.26; N, 3.77. Found: C, 48.46; H, 3.52; N, 3.87.
- Same as Example 11.1 starting with 1-(2,4-difluorophenyl)-1,3-propanediol. Rf=0.50 (50% EtOAc in Hexanes). mp 85-87° C. Anal calcd for C15H12F2NO6P: C, 48.53; H, 3.26; N, 3.77. Found: C, 48.82; H, 3.55; N, 3.84.
- Same as Example 11.1 starting with trans-1,3-diphenyl-1,3-propanediol (Yamamura, H., Araki, S., Tetrahedron, 1997, 53, 46, 15685-15690) without equilibration. Rf=0.29 (35% EtOAc in Hexanes). mp 118-121° C. Anal calcd for C21H18NO6P: C, 61.32; H, 4.41; N, 3.41. Found: C, 60.94; H, 4.44; N, 3.53.
- Same as Example 11.1 starting with cis-1,3-diphenyl-1,3-propanediol (Yamamura, H., Araki, S., Tetrahedron, 1997, 53, 46, 15685-15690) without equilibration. Rf=0.65 (5% EtOAc in CH2Cl2). mp 144-147° C. Anal calcd for C21H18NO6P: C, 61.32; H, 4.41; N, 3.41. Found: C, 61.21; H, 4.58; N, 3.36.
- Same as Example 11.1 starting with cis-1,3-diphenyl-1,3-propanediol (Yamamura, H., Araki, S., Tetrahedron, 1997, 53, 46, 15685-15690) without equilibration. Rf=0.3 (5% EtOAc in CH2Cl2). mp 135-138° C. Anal calcd for C21H18NO6P: C, 61.32; H, 4.41; N, 3.41. Found: C, 61.29; H, 4.77; N, 3.46.
- Same as Example 11.1 starting with cis-1,2-diphenyl-1,3-propanediol (Kristersson, P, Lindquist, K., Acta Chem. Scand. B 1980, 34, 3, 213-234) without equilibration. Rf=0.35 (5% EtOAc in CH2Cl2). mp 136-139° C. Anal calcd for C21H18NO6P: C, 61.32; H, 4.41; N, 3.41. Found: C, 60.95; H, 4.41; N, 3.82.
- Same as Example 11.1 starting with cis-1,2-diphenyl-1,3-propanediol (Kristersson, P, Lindquist, K., Acta Chem. Scand. B 1980, 34, 3, 213-234) without equilibration. Rf=0.65 (5% EtOAc in CH2Cl2). mp 176-178° C. Anal calcd for C21H18NO6P: C, 61.32; H, 4.41; N, 3.41. Found: C, 61.09; H, 4.46; N, 3.80.
- Step A:
- To a solution of diisopropylamine (58.4 g, 577 mmol) in dry ether (500 mL) at −78° C. under nitrogen was added n-BuLi (215 mL, 2.5 M in hexane, 538 mmol) over 30 min. The reaction was stirred for 10 min before addition of ethyl acetate (55 mL, 558 mmol) over a period 30 min. Freshly distilled benzaldehyde (47 mL, 443 mmol) in ether (50 mL) was slowly added over 30 min and the mixture was allowed to warm to room temperature. The reaction was quenched with saturated ammonium chloride (150 mL) at 0° C. The organic layer was washed, dried (anhydrous Na2SO4) and concentrated to give the crude addition product.
- Step B:
- To a solution of crude condensation product (10.6 g, 54.6 mmol) in dry ether at −78° C. was added MeMgBr (60 mL, 3.0 M in THF, 180 mmol). The mixture was allowed to warm to room temperature and stirred overnight. The reaction was quenched with ammonium chloride (50 mL) at 0° C. and diluted with EtOAc (350 mL). The organic layer was washed, dried (anhydrous Na2SO4) and concentrated. The crude product was purified by column chromatography (0-10% EtOAc in CH2Cl2) to give 3,3-dimethyl-1-phenyl-1,3-propanediol (7 g) as a pale yellow oil.
- Step C:
- Same as Example 11.1 starting with 3,3-dimethyl-1-phenyl-1,3-propanediol without equilibration. Rf=0.18 (35% EtOAc in hexanes). mp 131-133° C. Anal calcd for C17H18NO6P: C, 56.20; H, 4.99; N, 3.86. Found: C, 56.00; H, 5.03; N, 3.86.
- Step A:
- To a solution of lithium diisopropylamide (356 mmol) in THF (500 mL) at −78° C. was slowly added 2-methoxy-methyl acetate (38.8 mL, 392 mmol) via an addition funnel. The reaction was stirred at −78° C. for 30 min before 3-chlorobenzaldehyde (20.1 mL, 178 mmol) was added. The reaction was allowed to warm to room temperature and quenched with saturated aq NH4Cl (500 mL). The mixture was extracted with EtOAc (3×200 mL) and the combined organic extracts were washed with water and dried (anhydrous Na2SO4). The crude product was purified by column chromatography (5-50% EtOAc in hexanes) to yield 3-(3-chlorophenyl)-3-hydroxy-2-methoxy-methyl proprionate (39 g) as pale yellow oil.
- Step B:
- To a solution of the ester (39 g, 159 mmol) obtained from step A in ethanol (500 mL) was added sodiumborohydride (6.2 g, 159 mmol) in three portions, over 10 min. The reaction was refluxed for 3 h and the ethanol was evaporated under reduced pressure. The residue was dissolved in EtOAc (500 mL), washed with water and dried (anhydrous Na2SO4). The crude product was purified by column chromatography (1-5% MeOH—CH2Cl2) to give the diol (28 g) as colorless oil.
- Step C:
- To a solution of diol (28 g, 129 mmol) in acetone (250 mL) was added trimethyl orthoformate (10 mL) followed by p-toluenesulfonic acid (500 mg, 2.64 mmol) and the reaction was heated to reflux overnight. The reaction was cooled to room temperature and the acetone was removed under vacuum. The residue was dissolved in ethyl acetate and washed with NaHCO3, water and dried (anhydrous Na2SO4). The ketals were separated by column chromatography (5-10% EtOAc in hexanes) to give 1,2-cis (7.26 g) and 1,2-trans ketal (0.9 g) diastereomers.
- Step D:
- The 1,2-cis ketal (4.5 g, 17.5 mmol) was dissolved in 70% aq TFA (10 mL) and allowed to react overnight at room temperature. The reaction was diluted with acetonitrile (30 mL) and volatiles were removed under reduced pressure. The residue was dissolved in EtOAc (300 mL) and the organic layer was washed with saturated aq NaHCO3, water and dried (anhydrous Na2SO4). The crude product was purified by column chromatography (1-5% MeOH—CH2Cl2) to give 1,2-cis diol diastereomer (3.5 g).
- The 1,2-trans ketal diastereomer was also hydrolyzed following the above procedure to give 1,2-trans-diol diastereomer.
- Step E:
- 1,2-cis-diol diastereomer was subjected to phosphorylation using the procedure described in Example 11.1 without equilibration to give the following two isomers.
- 11.54: Rf=0.57 (5% EtOAc in CH2Cl2). mp 110-112° C. Anal calcd for C16H15NO7PCl: C, 48.08; H, 3.78; N, 3.50. Found: C, 48.35; H, 3.56; N, 3.69.
- 11.55: Rf=0.34 (5% EtOAc in CH2Cl2). mp 131-134° C. Anal calcd for C16H15NO7PCl 0.0.3H2O: C, 47.44; H, 3.88; N, 3.46. Found: C, 47.23; H, 4.01; N, 3.46.
- Phosphorus oxychloride (3.4 mL, 36.3 mmol) was added to a solution of 1-(3-chlorophenyl)-1,3-propanediol in dichloromethane at 0° C. followed by triethylamine (10.2 mL, 73 mmol). After 2 h, sodium 4-nitrophenoxide (10.63 g, 66 mmol) was added to the solution of cis/trans phosphorochloridate reagent and the orange reaction mixture was heated at reflux for 1 h. The cooled solution was partitioned with ethyl acetate and a saturated solution of ammonium chloride. The organics were separated and dried over sodium sulfate, filtered and concentrated under reduced pressure. The residue was taken up in THF, sodium 4-nitrophenoxide (10.63 g, 66 mmol) was added and the orange reaction mixture was heated to reflux for 3 h (HPLC, 95/5 trans/cis). The cooled solution was partitioned with ethyl acetate and a saturated solution of ammonium chloride. The organics were separated and washed with 0.3 N solution of sodium hydroxide and brine, dried over sodium sulfate and concentrated under reduced pressure. Recrystallization from ethyl acetate as in Example 10 gave the phosphate reagent.
- A cis/trans mixture of 4-(3-chlorophenyl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinanes was prepared as in Example 11, except that the cis and trans isomers were separated by column chromatography prior to the addition of 4-nitrophenol.
- Cis-4-(3-chlorophenyl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinane was isomerized to the trans isomer by adding a solution of the cis-isomer to a solution of 4-nitrophenoxide prepared with the following bases.
- Lithium hydride (19.4 mg, 2.44 mmol) was added to a solution of 4-nitrophenol in THF at room temperature. The yellow solution was stirred at room temperature for 30 min. A solution of cis-4-(3-chlorophenyl)-2-(4-nitrophenoxy)-2-oxo-1,3,2-dioxaphosphorinane (300 mg, 0.813 mmol) in THF was added to the solution of lithium 4-nitrophenoxide. The orange reaction mixture was stirred a room temperature. After 5 h the ratio was 92.9/5.4 trans/cis (HPLC determination).
- Same as above using triethylamine instead of lithium hydride. After 20 h the trans/cis ratio was 90.8/5.3.
- Same as above using DBU instead of lithium hydride. After 3 h the trans/cis ratio was 90.8/5.3.
- Synthesis of Enantioenriched Phosphorylating Agents
-
- A solution of (+)-(R)-1-(3-chlorophenyl)-1,3-propanediol (3 g, 16.1 mmol) and triethylamine (6.03 ml, 59.6 mmol) in THF (80 mL) was added dropwise to a solution of 4-nitrophenoxyphosphorodichloridate (7.63 g, 29.8 mmol) in 150 mL of THF at 0° C. After about 2 h, the starting diol was consumed, with the formation of two isomeric 4-nitophenylphosphates, and additional triethylamine (8.31 mL) followed by of 4-nitrophenol (8.29 g, 59.6 mmol) were added. The reaction mixture was stirred overnight. The solvent was evaporated under reduced pressure and the residue was partitioned between ethyl acetate and water. The organic phase was washed (0.4 M NaOH, water and sat'd NaCl solution) and dried over MgSO4. Concentration and chromatography of the residue using 30% ethyl acetate in hexanes yielded 4.213 g of the desired product.
- HNMR (200 MHz, CDCl3): 8.26 (2H, d, J=9.7 Hz), 7.2-7.5 (6H, m), 5.56 (1H, apparent d, J=11.7 Hz), 4.4-4.7 (2H, m), 2.2-2.6 (1H, m), 2.0-2.2 (1H, m).
- mp: 114-115° C. [α]D=+91.71. Elemental Analysis: Calculated for C15H13NO6ClP: C, 48.73; H, 3.54; N, 3.79. Found: C, 48.44; H, 3.20; N, 3.65
-
- In a similar manner, from 3.116 g of (−)-(S)-1-(3-chlorophenyl)-1,3-propane diol was obtained 4.492 g of the desired phosphate.
- HNMR (200 MHz, CDCl3): 8.26 (2H, d, J=9.7 Hz), 7.2-7.5 (6H, m), 5.56 (1H, apparent d, J=11.7 Hz), 4.4-4.7 (2H, m), 2.2-2.6 (1H, m), 2.02-2.2 (1H, m).
- mp: 114-115° C. [α]D=−91.71. Elemental Analysis: Calculated for C15H13NO6ClP: C, 48.73; H, 3.54; N, 3.79. Found: C, 48.61; H, 3.36; N, 3.66.
- Same as Example 11.1 starting with S-(−)-1-phenyl-1,3-propanediol except that the isomerization was conducted with 4-nitrophenol and triethylamine as in Example 13b.
- TLC: hexanes/ethyl acetate 4/1); Rf=0.4
- 1H NMR (DMSO-d6, Varian Gemini 300 MHz): C′-proton: trans-isomer 5.85-5.75 (m, 1H).
-
- A 12 L round bottom flask equipped with an overhead stirrer and nitrogen inlet was charged with (S)-(−)-1-(pyrid-4-yl)-1,3-propanediol (1.2 kg, 7.83 mol) and pyridine (6 L) The mixture was vigorously stirred at room temperature for 0.5 h until all the solids had dissolved. Meanwhile, a 22 L, 3-neck flask was equipped with an overhead stirrer, thermocouple, cooling bath, and nitrogen inlet. This vessel was charged with 4-nitrophenyl phosphorodichloridate (2.01 kg, 7.83 mol) and pyridine (6 L). The resulting mixture was cooled to 3.3° C. After the diol was completely dissolved (0.5 h), triethylamine (190 mL, 1.36 mol) was added and the slightly cloudy, yellow-brown solution was transferred in portions to a 2 L addition funnel on the 22 L flask. The solution was added to the cold phosphorodichloridate solution over 3.25 h. After the addition was complete, the cooling bath was drained and stirring was continued for 3 h. During this time, a 50 L, 3-neck flask was equipped with an overhead stirrer, thermocouple, addition funnel, cooling bath (ice water) and nitrogen inlet. This flask was then charged with sodium hydride (180 g, 4.5 mol) and THF (1 L) and the addition funnel was charged with a solution of 4-nitrophenol (817 g, 5.87 mol) in THF (1 L). The nitrophenol solution was slowly added to the cold suspension of sodium hydride. After the addition was complete, the resulting bright orange suspension was stirred at room temperature for 1 h. After the diol-dichloridate reaction was judged complete the dark suspension was subjected to vacuum filtration. The glassware and filter cake (triethylamine-HCl) were rinsed with THF (1 L) and the combined filtrate and rinse were poured into the orange, sodium 4-nitrophenoxide suspension. The resulting mixture was then heated at 40° C. for 3.5 h at which time the heating mantle was turned off and the reaction was stirred an additional 11 h at room temperature. The crude reaction mixture was concentrated on a rotary evaporator at 45-50° C. at reduced pressure (oil pump). The resulting thick, black, foamy tar was dissolved in 1.5 M aq HCl (12 L) and ethyl acetate (8 L). The mixture was transferred to a 12.5-gallon separatory funnel, stirred 10 min, and the phases separated. The ethyl acetate layer was washed with an additional 1.3 L of 1.5 M aq HCl. To the combined aqueous layers was added dichloromethane (8 L) and the vigorously stirred mixture was carefully neutralized with solid sodium bicarbonate. The layers were separated and the aqueous layer was extracted with dichloromethane (8 L). The combined organic layers were dried over magnesium sulfate (600 g) and filtered. The solution was concentrated on a rotary evaporator until most of the solvent was removed and a thick suspension resulted. 2-Propanol (5 L) was added and evaporation continued until 4 L of distillate were collected. 2-Propanol (3 L) was added and evaporation continued until 3 L of distillate were collected. The thick slurry was diluted with 2-propanol (2 L) and the mixture stirred with cooling (ice bath) for 1 h. The solid was collected by filtration, washed with 2-propanol (2 L), and dried in a vacuum oven (−30 in. Hg, 55° C., 18 h) to a constant weight of 1.86 kg.
- mp 140-142° C.
- Specific Rotation=−80.350 (c=1.0, MeOH); ee=99+% trans
- HPLC conditions:
- Column: Chiralpak AD, 0.46×25 cm; mobile phase=50:50, 2-propanol:hexane, isocratic; flow rate=1.0 mL/min; injection volume=10 μL UV detection at 254 nm.
- The cis/trans equilibration was monitored by HPLC. Stopped at 92% trans, 6.6% cis, r.t.=trans isomer 6.9 min. and cis isomer 10.9 min.
- 1HNMR (DMSO-d6): δ=2.23-2.29 (m, 2H), 4.56-4.71 (m, 2H), 5.88-5.95 (m, 1H), 7.44 (d, 2H, J=5.8 Hz), 7.59 (d, 2H, J=9.2 Hz), 8.34 (d, 2H, J=9.4 Hz), 8.63 (d, 2H J=5.8 Hz)
- A 1 liter 3-neck round bottom flask was equipped with a mechanical stirrer, addition funnel, a thermometer and a N2 inlet. The flask is charged with S-(−)-1-(pyrid-4-yl)-propane-1,3-diol (25 g, 163.4 mmol) and ethyl acetate (250 mL) and the resulting suspension was treated slowly with a 4N HCl solution in dioxane (43 mL, 176 mmol) over a period of 15 min. After stirring for 30 min at room temperature, 4-nitrophenylphosphorodichloridate (41.81 g, 163.4 mmol) was added as a solid as quickly as possible under a positive flow of N2. The internal temperature of the reaction mixture was adjusted to −10° C. with the help of a dry ice-acetone cooling bath. A solution of triethylamine (79 mL, 572 mmol) in ethyl acetate (100 mL) was added maintaining the reaction temperature at <−5° C. Thirty minutes after the complete addition of the triethylamine solution, the cooling bath was removed and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was filtered to remove triethylamine-hydrochloride salt, which is washed with ethyl acetate (3×30 mL) until the filtrate shows only faint absorption. The filtrate was evaporated down to a volume of 150-175 mL under reduced pressure. 4-nitrophenol (7.5 g, 54.3 mmol) and triethylamine (9 mL) were added to the concentrated solution and the resulting orange reaction mixture was stirred at room temperature for 24 h. The solid formed in the reaction mixture was collected by filtration, washed with ethyl acetate (2×25 mL) and methyl t-butyl ether (25 mL) and dried under vacuum at 55° C. to give 31.96 g of the desired product. Same analytical data as Example 14a.
-
- To a solution of 4-amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine (US2002-0147160A1, WO 02/057827) (10 g, 0.356 mol) in anhydrous acetone (145 mL) and anhydrous DMF (35 mL) were added p-toluene sulfonic acid monohydrate (33.8 g, 0.18 moles) and triethyl orthoformate (31.2 mL, 28.5 moles) at room temperature. The reaction was warmed to ˜80° C. and allowed to stir for 3 h under nitrogen. The mixture was evaporated under reduced pressure. The oily residue was purified by column chromatography (5% MeOH in CH2Cl2) to give the isopropylidene derivative (8.6 g) as a white solid.
- Step B:
- To a solution of 2′,3′-O-isopropylidene-4-amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine (0.094 g, 0.29 mmol) in DMF (1.5 mL) was added t-butyl magnesium chloride and stirred under nitrogen for 30 min. The reaction mixture was then cooled to −55° C. and the phosphorylating agent (whose preparation is described in example 11.1) (0.13 g, 0.35 mmol) in DMF (1.5 mL) was added dropwise. The reaction was allowed to warm to room temperature and stirred under nitrogen for 2 h. The mixture was evaporated under reduced pressure and purified by chromatography (5% MeOH in CH2Cl2) to yield 0.070 g of the 2′,3′-O-isopropylidene protected prodrug as a yellow solid.
- Step C:
- The prodrug (0.15 g, 0.27 mmol) obtained from the above step was dissolved in pre-cooled 75% TFA/H2O (20 mL) and allowed to stir at 0° C. for 2 h. The reaction mixture was evaporated under reduced pressure. The crude product was purified by flash chromatography (1% aq.NH4OH in 10% MeOH in CH2Cl2) to give 0.142 g of the title compound as an off-white solid.
- Rf=0.40 (10% MeOH in CH2Cl2). mp 138-141° C. Anal calcd for C21H24ClN4O7P.0.4 CH2Cl2: C, 47.18; H, 4.59; N, 10.28. Found: C, 46.97; H, 4.59; N, 10.11.
- The following examples were synthesized as described in steps A-C of example 16.1, utilizing the phosphorylating agents of examples 1-15.
-
- Rf=0.35 (10% MeOH in CH2Cl2). mp 145-148° C. Anal Calcd for C21H23N4O7F2P.1.35H2O.1.0 CF3CO2H: C, 42.45; H, 4.14; N, 8.62. Found: C, 42.18; H, 3.77; N, 8.42.
-
- Rf=0.30 (10% MeOH in CH2Cl2). mp 128-130° C. Anal Calcd for C21H23N4O7FClP.2H2O.1.9CF3CO2H: C, 38.11; H, 3.73; N, 7.17. Found: C, 38.04; H, 3.28; N, 7.02.
-
- Rf=0.40 (10% MeOH in CH2Cl2). mp 140-142° C. Anal Calcd for C23H29N4O7P.1H2O.0.4 CF3CO2H: C, 50.32; N, 5.57; N, 9.86. Found: C, 50.38; H, 5.12; N, 9.96.
-
- Rf=0.45 (10% MeOH in CH2Cl2). mp 135-138° C. Anal Calcd for C21H24ClN4O7P.0.2H2O.0.4 CH2Cl2: C, 46.87; H, 4.63; N, 10.22. Found: C, 47.02; H, 4.25; N, 9.99.
-
- Rf=0.45 (10% MeOH in CH2Cl2). mp 125-128° C. Anal Calcd for C21H24N4O7ClP.1.6 CH3SO3H.1.0H2O: C, 39.76; H, 4.78; N, 8.21; S, 7.52. Found: C, 39.39; H, 4.30; N, 8.30; S, 7.96.
-
- Rf=0.40 (15% MeOH in CH2Cl2-1% NH4OH). mp 183-185° C. Anal Calcd for C20H24N5O7P. 1.6H2O: C, 47.45; H, 5.42; N, 13.83. Found: C, 47.78; H, 5.47; N, 13.77.
-
- Rf=0.15 (10% MeOH in CH2Cl2). Anal Calcd for C21H24FN4O7P. 0.3 H2O: C, 50.46; H, 4.96; N, 11.21. Found: C, 50.63; H, 5.35; N, 10.94.
-
- Rf=0.48 (15% MeOH in CH2Cl2-1% NH4OH). Anal Calcd for C21H24BrN4O7P. 0.5 H2O: C, 44.70; H, 4.47; N, 9.93. Found: C, 44.58; H, 4.52; N, 9.56.
-
- Rf=0.15 (10% MeOH in CH2Cl2). mp 132-135° C. Anal Calcd for C21H24BrN4O7P. 0.5 H2O: C, 44.7; H, 4.47; N, 9.93. Found: C, 44.73; H, 4.69; N, 9.82.
-
- Rf=0.35 (10% MeOH in EtOAc) mp 132-135° C. Anal Calcd for C20H23N5O7BrP. 0.5 H2O. 0.5 EtOAc: C, 43.36; H, 4.63; N, 11.49.
- Found: C, 43.37; H, 4.80; N, 11.16.
-
- Rf=0.42 (15% MeOH in CH2Cl2-1% NH4OH). mp 115-118° C. Anal Calcd for C21H25N4O7P. 0.4 EtOAc. 1.0 H2O: C, 51.25; H, 5.75; N, 10.58. Found: C, 51.07; H, 5.88; N, 10.35.
-
- Rf=0.45 (10% MeOH in CH2Cl2). mp 174-177° C. Anal Calcd for C29H30F3N4O9P.1.75 H2O: C, 49.90; H, 4.48; N, 8.03. Found: C, 49.68; H, 4.82; N, 8.1.
-
- Rf=0.48 (10% MeOH in CH2Cl2). mp 187-190° C. Anal Calcd for C21H24ClN4O7P. H2O. 0.2 DMF: C, 47.72; H, 5.05; N, 10.77. Found: C, 47.66; H, 5.02; N, 10.96.
-
- Rf=0.48 (15% MeOH in CH2Cl2-1% NH4OH). Anal Calcd for C21H23BrFN4O7P. 1.3H2O: C,42.27; H, 4.32; N, 9.39. Found: C, 42.26; H, 4.03; N, 9.36.
-
- Rf=0.20 (10% MeOH in CH2Cl2). mp 140-143° C. Anal Calcd for C27H29N4O7P.1.25 H2O.CF3CO2H: C, 50.55; H, 4.75; N, 8.13. Found: C, 50.25; H, 4.88; N, 7.99.
-
- Rf=0.15 (10% MeOH in CH2Cl2). mp 130-134° C. Anal Calcd for C23H23N4O7P. 0.6 H2O: C, 44.33; H, 3.91; N, 8.99. Found: C, 44.29; H, 4.13; N, 8.98.
-
- Rf=0.48 (15% MeOH in CH2C2-1% NH4OH). mp>220° C. Anal Calcd for C27H29N4O7P.0.9 H2O: C, 57.02; H, 5.46; N, 9.85. Found: C, 57.55; H, 5.97; N, 9.88.
-
- Rf=0.3 (10% MeOH in EtOAc). mp 116-120° C. Anal Calcd for C20H23N5O7BrP.1 H2O. 0.6 EtOAc: C, 42.90; H, 4.79; N, 11.17 Found: C, 42.90; H, 4.42; N, 10.82.
-
- Rf=0.15 (10% MeOH in CH2Cl2). mp 184-188° C. Anal Calcd for C22H24F3N4O7P. 0.6 H2O: C, 47.59; H, 4.57; N, 10.09. Found: C, 47.46; H, 4.96; N, 10.10.
-
- Rf=0.15 (10% MeOH in CH2Cl2). mp 120-124° C. Anal Calcd for C21H23Cl2N4O7P.0.5 H2O: C, 45.50; H, 4.36; N, 10.11. Found: C, 45.32; H, 4.58; N, 10.26.
-
- Rf=0.75 (15% MeOH in CH2Cl2-1% NH4OH). mp 160-163° C. Anal Calcd for C27H29N4O7P.1.2 H2O: C, 56.48; H, 5.51; N, 9.76. Found: C, 56.34; H, 5.75; N, 9.71.
-
- Rf=0.25 (10% MeOH in CH2Cl2). mp 116-120° C. Anal Calcd for C22H26N4O8PCl.1.75 H2O.1.5 CF3CO2H: C, 40.39; H, 4.20; N, 7.54. Found: C, 39.95; H, 3.85; N, 7.38.
-
- Rf=0.30 (10% MeOH in CH2Cl2). mp 140-143° C. Anal Calcd for C22H26N4O8PCl.2.5 H2O.2.2 CF3CO2H: C, 37.89; H, 4.00; N, 6.70. Found: C, 37.73; H, 3.61; N, 6.85.
-
- Rf=0.3 (10% MeOH in CH2Cl2). mp 193-196° C. Anal Calcd for C21H23N4O7PClBr.1.75 H2O.1 CF3CO2H: C, 37.57; H, 3.77; N, 7.62. Found: C, 37.20; H, 3.49; N, 7.36.
-
- Rf=0.3 (10% MeOH in CH2Cl2). mp 182-185° C. Anal Calcd for C21H23N4O7Cl2P.0.3 MeOH0.0.5 H2O: C, 45.37; H, 4.50; N, 9.93. Found: C, 45.36; H, 4.18; N, 9.58.
-
- Rf=0.35 (10% MeOH in CH2Cl2). mp 135-140° C. Anal Calcd for C21H23N4O7F2P.1.0 H2O: C, 47.55; H, 4.75; N, 10.56. Found: C, 47.29; H, 4.51; N, 10.28.
-
- Rf=0.45 (10% MeOH in CH2Cl2). mp 126-128° C. Anal Calcd for C21H24ClN4O7P.1.0 H2O: C, 47.69; H, 4.96; N, 1059. Found: C, 47.31; H, 4.77; N, 10.3.
-
- Rf=0.5 (10% MeOH in CH2Cl2). mp 115-120° C. Anal Calcd for C22H24F3N4O7P.1.0 H2O.1.0 CF3CO2H: C, 42.61; H, 4.02; N, 8.28. Found: C, 42.78; H, 4.07; N, 8.27.
-
- Rf=0.3 (20% MeOH in EtOAc). mp 132-136° C. Anal Calcd for C20H24N5O7P.0.03 H2O.0.7 CH2Cl2: C, 46.52; H, 4.79; N, 13.14. Found: C, 46.13; H, 4.39; N, 13.50.
-
- Rf=0.35 (10% MeOH in EtOAc). mp 122-125° C. Anal Calcd for C21H23N4O7FBrP.0.2 CF3CO2H: C, 43.12; H, 3.92; N, 9.40. Found: C, 42.82; H, 3.76; N, 9.57.
-
- Rf=0.30 (10% MeOH in EtOAc). mp 134-138° C. Anal Calcd for C20H24N5O7P.1.5 H2O: C, 47.62; H, 5.40; N, 13.88. Found: C, 47.89; H, 5.08; N, 13.97.
-
- Rf=0.50 (10% MeOH in CH2Cl2). mp 88-90° C. Anal Calcd for C20H24N5O7P.2.3 H2O.1.3 CF3CO2H: C, 40.69; H, 4.52; N, 10.50. Found: C, 40.38; H, 4.86; N, 10.90.
-
- Rf=0.30 (10% MeOH in CH2Cl2). mp 177-180° C. Anal Calcd for C21H25N4O7P. 0.1 EtOAc. 0.2 CF3CO2H: C, 51.54; H, 5.16; N, 11.03. Found: C, 51.92; H, 4.78; N, 10.75.
-
- Rf=0.45 (10% MeOH in CH2Cl2). mp 182-184° C. Anal Calcd for C21H24N4O7ClP.2.0 H2O.2.9 CF3CO2H: C, 36.68; H, 3.55; N, 6.38. Found: C, 36.33; H, 3.35; N, 6.44.
-
- Rf=0.5 (10% MeOH in CH2Cl2). mp 177-180° C. Anal Calcd for C21H23F2N4O7P.1.9 H2O.1.1CF3CO2H: C, 41.46; H, 4.18; N, 8.34. Found: C, 42.07; H, 4.02; N, 8.68.
-
- Rf=0.4 (10% MeOH in CH2Cl2). mp 80-85° C. Anal Calcd for C22H26N4O8FP.0.4 H2O.2.0 CF3CO2H: C, 41.11; H, 3.82; N, 7.37. Found: C, 41.13; H, 3.50; N, 7.54.
-
- Rf=0.46 (15% MeOH in CH2Cl2). mp 138-141° C. Anal Calcd for C21H23ClFN4O7P. 0.3 H2O. 0.9 CF3CO2H: C, 43.00; H, 3.88; N, 8.80. Found: C, 42.73; H, 4.21; N, 8.55.
-
- Rf=0.48 (15% MeOH in CH2Cl2-1% NH4OH). mp 101-103° C. Anal Calcd for C21H24FN4O7P. 1.5 H2O: C, 48.37; H, 5.22; N, 10.74. Found: C, 48.70; H, 5.47; N, 10.43.
-
- Rf=0.42 (15% MeOH in CH2Cl2-1% NH4OH). Anal Calcd for C22H24N5O7P. 2 H2O. 0.1 CF3CO2H: C, 48.58; H, 5.16; N, 12.76. Found: C, 48.86; H, 5.51; N, 12.70.
-
- Rf=0.45 (10% MeOH in CH2Cl2). mp 145-148° C. Anal Calcd for C21H24N4O7PCl.0.7 CH2Cl2.1.2 CF3CO2H: C, 40.93; H, 3.79; N, 7.92; F, 9.67.
- Found: C, 40.43; H, 3.77; N, 8.22; F, 9.47.
-
- Rf=0.24 (15% MeOH in CH2Cl2-1% NH4OH). mp 110-113° C. Anal Calcd for C25H31N4O7P. 2.0 H2O: C, 53.00; H, 6.23; N, 9.89. Found: C, 53.03; H, 5.93; N, 9.91.
-
- Rf=0.51 (15% MeOH in CH2Cl2-1% NH4OH). mp 157-160° C. Anal Calcd for C22H24N5O7P. 2.5H2O: C, 48.35; H, 5.35; N, 12.82. Found: C, 48.50; H, 5.72; N, 12.77.
- The parent nucleoside 2-amino-7-(2-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidin-4(3H)-one was synthesized as described in US2002-0147160A1 and WO 02/057827.
- The nucleoside was converted to corresponding prodrug following the procedures as in steps A, B and C of Example 16.
- The following examples were synthesized as described steps A-C.
-
- Rf=0.30 (10% MeOH in CH2Cl2). Anal calcd for C21H24ClN4O8P.1.2 CF3CO2NH4.1.0 CF3CO2H: C, 38.22; H, 3.76; N, 9.13. Found: C, 37.93; N, 3.80; N, 9.40.
-
- Rf=0.15 (10% MeOH in CH2Cl2). mp 175° C. Anal Calcd for C21H24ClN4O8P.0.5H2O: C, 47.07; H, 4.70; N, 10.46. Found: C, 46.73; H, 4.90; N, 10.16.
-
- Rf=0.41 (15% MeOH in CH2Cl2-1% NH4OH). Anal Calcd for C21H23BrFN4O8P. 0.5 H2O. 0.2 CF3CO2H: C, 41.38; H, 3.93; N, 9.02. Found: C, 41.60; H, 4.32; N, 8.77.
-
- Rf=0.38 (15% MeOH in CH2Cl2-1% NH4OH). mp 142-145° C. Anal Calcd for C21H24N4O8P. 0.7H2O. 0.9 CF3CO2H: C, 39.89; H, 3.86; N, 8.16. Found: C, 39.53; H, 3.65; N, 8.43.
-
- Rf=0.45 (20% MeOH in CH2Cl2. Anal Calcd for C21H23N4O8FClP. 1.4 H2O: C, 44.24, H, 4.78; N, 9.83. Found: C, 43.77; H, 4.78; N, 10.31.
-
- Rf=0.35 (20% MeOH in CH2Cl2). mp 170-173° C. Anal Calcd for C21H23F2N4O8P.2.0 H2O.0.4 CF3CO2NH4: C, 42.45; H, 4.67; N, 9.99. Found: C, 42.28; H, 4.76 N, 9.96.
-
- Rf=0.25 (15% MeOH in CH2Cl2-1% NH4OH). Anal Calcd for C21H24ClN4O8P. 1.25 H2O. 0.2 CF3CO2H: C, 44.92; H, 4.70; N, 9.79. Found: C, 44.93; H, 5.09; N, 10.08.
-
- Rf=0.4 (15% MeOH in CH2Cl2). mp 180-190° C. Anal Calcd for C20H24N5O8P.1.3 CF3CO2H.0.3 CH2Cl2: C, 41.23; H, 3.91; N, 10.50. Found: C, 40.96; H, 3.46; N, 11.05.
-
- Rf=0.4 (10% MeOH in CH2Cl2). mp 185-188° C. Anal Calcd for C22H24N4O8F3P.0.8 CF3CO2H: C, 43.50; H, 3.84; N, 8.60. Found: C, 43.55; H, 3.97; N, 8.98.
-
- Rf=0.50 (15% MeOH in CH2Cl2). mp 170-180° C.
-
- Rf=0.30 (10% MeOH in CH2Cl2) mp 182-185° C. Anal Calcd for C21H23N4O8F2P.0.3 EtOAc. 0.2 CF3CO2H: C, 46.99; H, 4.47; N, 9.70. Found: C, 47.26; H, 4.32; N, 9.46.
-
- Rf=0.35 (10% MeOH in CH2Cl2). mp 177-180° C. Anal Calcd for C21H23N4O8C12P.0.1 EtOAc 0.0.2 CF3CO2H. C, 44.16; H, 4.08; N, 9.45. Found: C, 44.33; H, 4.44; N, 9.18.
-
- Rf=0.21 (15% MeOH in CH2Cl2-1% NH4OH). mp 138-141° C. Anal Calcd for C20H24N5O8P. 2.2 H2O: C, 45.07; H, 5.33; N, 13.14. Found: C, 45.12; H, 5.40; N, 12.89.
-
- Rf=0.25 (10% MeOH in CH2Cl2). mp 170° C. Anal Calcd for C21H24FN4O8P.1.5 H2O: C, 46.93; H, 5.06; N,10.42. Found: C, 46.92; H, 5.12; N, 10.44.
-
- Rf=0.25 (10% MeOH in CH2Cl2). mp 175-179° C. Anal Calcd for C21H23BrFN4O8P. 0.5 H2O. 0.5 EtOAc: C, 43.01; H, 4.39; N, 8.72. Found: C, 43.03; H, 4.49; N, 8.49.
-
- Rf=0.30 (10% MeOH in CH2Cl2) mp 128-133° C. Anal Calcd for C21H25N4O8P. 1.1 H2O.0.3 CF3CO2H: C, 47.48; H, 5.07; N, 10.25. Found: C, 47.61; H, 5.36; N, 9.91.
-
- Rf=0.45 (20% MeOH in CH2Cl2). mp 187-190° C. Anal Calcd for C27H29N4O8P.2 H2O.1.3 CF3CO2H: C, 47.23; H, 4.59; N, 7.44. Found: C, 46.83; H, 4.33; N, 7.31.
-
- Rf=0.40 (20% MeOH in CH2Cl2). mp 192-194° C. Anal Calcd for C23H29N4O8P.2.0 H2O.1.0 CF3CO2H: C, 44.78; H, 5.11; N, 8.36. Found: C, 44.40; H, 4.67; N, 8.22.
-
- Rf=0.30 (20% MeOH in CH2Cl2). mp 148-151° C. Anal Calcd for C22H26N4O9ClP.1.0 H2O: C, 45.96; H, 4.91; N, 9.75. Found: C, 46.03; H, 4.80; N, 9.64.
-
- Rf=0.5 (10% MeOH in CH2Cl2). mp 215-220° C. Anal Calcd for C21H23N4O8F2P.1.0 H2O.1.0 CF3CO2H: C, 41.83; H, 3.97; N, 8.48. Found: C, 41.70; H, 3.77; N, 8.50.
-
- Rf=0.15 (10% MeOH in CH2Cl2). mp 180° C. Anal Calcd for C21H24BrN4O8P.1.1 H2O: C, 42.67; H, 4.47; N, 9.48. Found: C, 42.51; H, 4.60; N, 9.58.
-
- Rf=0.30 (10% MeOH in CH2Cl2). mp 192-195° C. Anal Calcd for C21H23N4O8Cl2P.0.2 CF3CO2H. 0.2 EtOAc: C, 44.31; H, 4.15; N, 9.31. Found: C, 44.40; H, 3.94; N, 9.21.
-
- Rf=0.15 (10% MeOH in CH2Cl2) mp 155-175° C. Anal Calcd for C23H23F6N4O8P.0.6 H2O: C, 43.22; H, 3.82; N, 8.76. Found: C, 43.08; H, 4.03; N, 8.94.
-
- Rf=0.15 (10% MeOH in CH2Cl2). mp 145-165° C. Anal Calcd for C22H24F3N4O8P.1 H2O: C, 45.68; H, 4.53; N, 9.69. Found: C, 45.31; H, 4.88; N, 9.71.
-
- Rf=0.15 (10% MeOH in CH2Cl2) mp 175° C. Anal Calcd for C21H23C12N4O8P.1H2O: C, 43.54; H, 4.35; N, 9.67. Found: C, 43.32; H, 4.35; N, 9.55.
-
- Rf=0.3 (10% MeOH in CH2Cl2) mp 185-189° C. Anal Calcd for C20H23N5O8BrP 0.1.5 CF3CO2H: C, 37.16; H, 3.32; N, 9.42. Found: C, 37.23; H, 3.44; N, 9.33.
-
- Rf=0.15 (10% MeOH in CH2Cl2); Anal Calcd for C20H24N5O8P.1 H2O.0.4 EtOAc: C, 47.46; H, 5.38; N, 12.81. Found: C, 47.40; H, 5.17; N, 12.78.
-
- 2′-C-methyl adenosine was made as described in WO01/90121.
- Step A:
- General procedure for synthesis of cyclic phosphoramidites from substituted diols:
- To a solution of commercially available diisopropyl phosphoramidous dichloride (1 mmol) in THF (5 mL) was added 1,3-diol (1 mmol) and triethylamine (4 mmol) in THF (5 mL) at −78° C. over 30 min. The reaction was slowly warmed to room temperature and left stirring overnight. Reaction mixture was filtered to remove salts and filtrate was concentrated to give crude product. Silica gel column chromatography provided pure cyclic diisopropyl phosphoramidite of 1,3-diol.
- Step B:
- General procedure for nucleoside-cyclic phosphoramidite coupling and oxidation:
- (J. Org. Chem., 1996, 61, 7996)
- To a solution of nucleoside (1 mmol) and cyclic phosphoramidite (1 mmol) in DMF (10 mL) was added benzimidazolium triflate (1 mmol). The reaction was stirred for 30 min at room temperature. The mixture was cooled to −40° C. before addition of t-butylhydro peroxide (2 mmol) and left at room temperature overnight. Concentration under reduced pressure and chromatography of crude product resulted in pure cyclic propyl prodrug.
- Rf=0.46 (12% MeOH in CH2Cl2). mp 153° C. Anal calcd for C20H23ClN5O7P: C, 46.93; H, 4.53; N, 13.63. Found: C, 47.06; H, 4.36; N, 13.68.
-
- 2′-C-Methyl guanosine was made as described in WO01/90121.
- The nucleoside was converted to corresponding prodrug following the procedures as in steps A, B and C of Example 16.
- Rf=0.35 (25% MeOH in CH2Cl2). mp>230° C. Anal calcd for C20H23ClN5O8P: C, 45.51; H, 4.39; N, 13.27. Found: C, 45.89; H, 4.44; N, 13.23.
-
- The compound was synthesized in a similar sequence as Example 19 using the phosphorylating agent whose preparation is described in Example 14.
- Rf=0.35 (20% MeOH in CH2Cl2). mp>180° C. Anal calcd for C20H23N5O8ClP.1.0 H2O.0.8 CF3CO2H: C,40.72; H, 4.08; N, 10.99. Found: C, 40.43; N, 4.41; N, 11.34.
- 2′-C-methyl adenosine was made as described in WO01/90121.
- The nucleoside was converted to corresponding prodrug following the procedures as in steps A, B and C of Example 16.
- trans-phosphorylating agents utilized in step B are synthesized by the procedures as described in examples 1-15.
-
- Rf=0.3 (5% MeOH in EtOAc). mp 125-128° C. Anal calcd for C20H23ClN5O7P.1.7 CF3CO2H: C, 39.83; H, 3.53; N, 9.92. Found: C, 39.52; H, 3.46; N, 10.21.
-
- Rf=0.43 (15% MeOH in CH2Cl2-1% NH4OH). mp 153-156° C. Anal calcd for C21H23N6O7P.1.1 H2O: C, 48.30; H, 4.86; N, 16.09. Found: C, 48.53; H, 5.11; N, 15.75.
-
- Rf=0.60 (15% MeOH in CH2Cl2-1% NH4OH). mp 75-78° C. Anal calcd for C20H22F2N5O7P.0.3 CH2Cl2: C, 45.25; H, 4.23; N, 13.00. Found: C, 45.07; H, 3.94; N, 12.69.
-
- Rf=0.65 (15% MeOH in CH2Cl2-1% NH4OH). mp 120-123° C. Anal calcd for C20H22F2N5O7P.1.5 H2O.0.1 C6H14: C, 45.07; H, 4.85; N, 12.76. Found: C, 45.04; H, 5.25; N, 12.59.
-
- Rf=0.55 (15% MeOH in CH2Cl2-1% NH4OH). Anal calcd for C19H23N6O7P.2.5H2O: C, 43.60; H, 5.39; N, 16.06. Found: C, 43.35; H, 5.54; N, 16.05.
-
- Rf=0.5 (10% MeOH in CH2Cl2). mp 108-110° C. Anal calcd for C20H23N5O7BrP.1.5 H2O.0.4 CF3CO2H: C, 39.72; H, 4.23; N, 11.14. Found: C, 39.44; H, 4.55; N, 11.18.
-
- Rf=0.4 (10% MeOH in CH2Cl2). mp 118-120° C. Anal calcd for C19H23N6O7P.2.0 H2O.1.0 CF3CO2H: C, 40.14; H, 4.49; N, 13.37. Found: C, 40.36; H, 4.92; N, 13.63.
-
- Rf=0.3 (10% MeOH in CH2Cl2). mp 185-187° C. Anal calcd for C21H26N5O9PS.0.6 H2O.0.6 CF3CO2H: C, 42.01; H, 4.41; N, 11.03. Found: C, 41.93; H, 4.73; N, 10.97.
-
- Rf=0.2 (10% MeOH in EtOAc). mp 137-140° C. Anal calcd for C19H23N6O7P.1.5 H2O.0.4 EtOAc. C, 45.76; H, 15.54; N, 5.44. Found: C, 45.88; H, 15.19; N, 5.09.
- To a solution of 5′-substituted cyclic propyl prodrug (0.3 mmol) in pyridine (3 mL) was added acetic anhydride (0.6 mL) at 0° C. The reaction was left at 0° C. for 18 h. Excess acetic anhydride was quenched with ethanol (3 mL). The mixture was concentrated and azeotroped with additional ethanol (2×5 mL). The crude residue was chromatographed to get pure monoacetylated compound as a solid.
-
- Rf=0.35 (15% MeOH in CH2Cl2). mp 182-185° C. Anal calcd for C22H26N5O8P.1.5 H2O.0.2 CH2Cl2: C, 47.32; H, 5.56; N, 12.43. Found: C, 47.19; H, 4.78; N, 12.09.
-
- Rf=0.35 (10% MeOH in CH2Cl2). mp 90-93° C. Anal calcd for C23H26N4O8ClP.1.0.H2O: C, 48.39; H, 4.94; N, 9.81. Found: C, 48.79; H, 4.85; N, 9.91.
- To a solution of 5′-substituted cyclic propyl prodrug (0.25 mmol) in DMF (2.5 mL) was added carbonyl diimidazole (CDI) (0.5 mmol) at 0° C. The reaction was warmed to room temperature and stirred for 4 h. Solvent was removed under reduced pressure and the crude product was chromatographed to give 2′,3′-carbonate as a solid.
-
- Rf=0.45 (10% MeOH in CH2Cl2). mp 127-130° C. Anal calcd for C22H22N4O8PCl.1.0 H2O: C, 47.62; H, 4.36; N, 10.10. Found: C, 47.94; H, 4.10; N, 10.13.
-
- Rf=0.4 (20% MeOH in CH2Cl2). mp 192-195° C. Anal calcd for C21H22N5O8P.1.0 H2O: C, 48.37; H, 4.64; N, 13.43. Found: C, 48.41; H, 4.39; N, 13.60.
- 5′-substituted cyclic prodrug (16.5) was made as described in example 16.
- Step A:
- To a solution of BOC-L-Val (217 mg, 1.0 mmol) in THF (5 mL) was added carbonyl diimidazole (CDI) (162 mg, 1 mmol). The reaction was warmed to 50° C. and allowed to stir for 1 h. The resulting mixture was added to a solution of 5′-substituted cyclic prodrug (16.5) (0.50 mmol) in DMF (3 mL) followed by triethylamine (1.5 mL) and 4-dimethylamino pyridine (6 mg, 0.05 mmol). The reaction was heated at 80° C. for 3 h. The reaction mixture was concentrated under reduced pressure and the crude was extracted with 10% MeOH—CH2Cl2. The organic extract was washed with water, dried and concentrated. The crude residue was chromatographed by eluting with 5%-10% MeOH—CH2Cl2 to give 3′-BOC-L-Val adduct of 5′-cyclic propyl prodrug (200 mg).
- Step B:
- The BOC protected prodrug (200 mg) was dissolved in pre-cooled 70% aqueous trifluoroacetic acid (10 mL) at 0° C. The reaction was stirred at 0° C. for 3 h. The mixture was concentrated under reduced pressure and azeotroped with ethanol (2×5 mL). The crude residue was chromatographed by eluting with 5%-20% MeOH in CH2Cl2 to give the BOC deprotected prodrug (140 mg).
- Rf=0.35 (15% MeOH in CH2Cl2). mp 132-135° C.
- Anal calcd for C26H33N5O8ClP.2.3 CF3CO2H.2.1 H2O: C, 40.38; H, 4.37; N, 7.70. Found: C, 39.94; H, 3.93; N, 7.48.
- 4-Chloro-7-(2′-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine was prepared as described in WO 02/057287.
- Step A:
- To a solution of 4-chloro-7-(2′-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine (162 mg, 0.54 mmol) in DMF (5 mL) was added sodium azide (70 mg, 1.08 mmol) at room temperature. The reaction was heated to 60° C. and stirred for 18 h. The mixture was concentrated and chromatographed by eluting with CH2Cl2 to 5% MeOH—CH2Cl2 to give the azido substitution product (102 mg).
-
- Rf=0.4 (5% MeOH in CH2Cl2). mp 179-180° C. Anal calcd for C12H14N6O4: C, 47.06; H, 4.61; N, 27.44. Found: C, 46.97; H, 4.71; N, 27.28.
- Step B:
- 5′-substituted monophosphate cyclic prodrug of 4-Azido-7-(2′-C-methyl-beta-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine is made as described in Example 16.
- Examples of use of the method of the invention include the following. It will be understood that these examples are exemplary and that the method of the invention is not limited solely to these examples.
- For the purposes of clarity and brevity, chemical compounds are referred to as synthetic example numbers in the biological examples below.
- The prodrug analogues were tested for activation in rat liver microsomes by means of a prodrug byproduct capture assay.
- Methods:
- Prodrugs were tested for activation by liver microsomes isolated from rats induced with dexamethasone to enhance CYP3A4 activity (Human Biologics Inc., Phoenix Ariz.). The study was performed at 2 mg/mL rat liver microsomes, 100 mM KH2PO4, 10 mM glutathione, 25 μM or 250 μM compound, and 2 mM NADPH for 0-7.5 min. in an Eppendorf Thermomixer 5436 at 37° C., speed 6. The reactions were initiated by addition of NADPH following a 2-min. preincubation. Reactions were quenched with 60% methanol at 0, 2.5, 5, and 7.5 min. L-Glutamyl-L-(S-(3-oxo-3-(3-chlorophenyl)propyl)cysteinylglycine, a glutathione adduct of the by-product of prodrug activation, 3-chlorophenyl vinyl ketone, was quantified following extraction of the reaction with 1.5 volumes of methanol. The extracted samples were centrifuged at 14,000 rpm in an Eppendorf microfuge and the supernatant analyzed by HPLC for L-glutamyl-L-(S-(3-oxo-3-(3-chlorophenyl)propyl)cysteinylglycine content. Spiked L-glutamyl-L-(S-(3-oxo-3-(3-chlorophenyl)propyl)cysteinylglycine standards (1-30 μM) were prepared in 2 mg/mL microsomes under reaction conditions and then quenched and processed in an identical fashion to unknown samples. For HPLC analysis, the loading mobile phase buffer (Buffer A) consisted of a 9:1 ratio (v/v) of 20 mM potassium phosphate, pH 6.2 and acetonitrile. Extract (100 μL) was injected onto a Beckman Ultrasphere ODS column (4.6×250 mM, part #235329). The column was eluted with a gradient to 60% acetonitrile. The elution of L-glutamyl-L-(S-(3-oxo-3-(3-chlorophenyl)propyl)cysteinylglycine (retention time 10.4 min.) was monitored at 245 nm.
- Results:
-
Activation (250 μM) Compound (nmol/mg/min) 18 4.7 16.5 0.24 17.2 0.397
Conclusion: - Formation of product, L-glutamyl-L-(S-(3-oxo-3-(3-chlorophenyl)propyl) cysteinylglycine indicated activation of Compound 18 prodrug at a rate of 4.7 nmol/mg/min.
- Prodrug analogues were tested for activation to NMP in reactions catalyzed by the microsomal fraction of rat liver.
- Methods:
- Prodrugs were tested for activation by liver microsomes isolated from rats induced with dexamethasone to enhance CYP3A4 activity (Human Biologics Inc., Phoenix Ariz.). Reactions were conducted in 0.1 M KH2PO4, pH 7.4, in the presence of 2 mM NADPH and liver microsomes (1 mg/mL). Reaction mixtures were incubated for 5 min. in an Eppendorf Thermomixer 5436 (37° C., speed 6). Reactions were terminated by the addition of 1.5 volumes of methanol. The resulting extracts were clarified by centrifugation at 14,000 rpm in an Eppendorf microfuge (20 min.). The supernatants (200 μL) were evaporated under vacuum and heat to dryness. The dried residue was reconstituted with 200 μL of water and the mixture was centrifuged for 10 min at 14,000 rpm. A mixture of 35 μL aliquot of supernatant and 35 μL of mobile phase A (20 mM N—N-dimethylhexylamine and 10 mM propionic acid in 20% methanol) was analyzed by LC-MS/MS (Applied Biosystems, API 4000) equipped with an Agilent 1100 binary pump and a LEAP injector. NMP was detected by using MS/MS mode (M−/78.8) and quantified based on comparison to a standard of lamivudine monophosphate.
- Results:
-
Activation (250 μM) Compound (nmol/mg/min) 16.2 0.158 16.3 0.159 16.4 0.020 16.5 0.195 16.7 0.365 17.2 1.764 16.8 0.160 16.9 0.126 16.10 0.077 16.11 0.142 16.12 0.070 16.13 0.001 16.14 0.082 16.15 0.215 16.16 0.070 16.17 0.006 16.18 0.058 16.19 0.213 16.20 0.063 16.21 0.040 16.22 0.081 16.23 0.001 16.24 0.004 16.25 0.068 16.26 0.256 16.27 0.286 16.28 0.121 17.3 1.119 16.29 0.172 17.4 0.862 17.5 1.173 17.6 1.758 16.30 0.108 16.31 0.217 16.32 0.186 17.7 0.761 17.8 0.264 17.9 0.488 17.10 1.033 17.11 1.996 17.12 0.918 17.13 1.039 17.14 1.636 17.15 0.969 17.16 0.863 17.18 0.095 17.20 1.091 17.21 0.623 17.22 0.599 17.23 0.094 17.24 0.240 - The prodrug analogues are tested for activation in human liver microsomes.
- Methods:
- Human liver microsomes are purchased from In Vitro Technologies (IVT1032). The study is performed at 2 mg/mL human liver microsomes, 100 mM KH2PO4, 10 mM glutathione, 25 μM or 250 μM compound, and 2 mM NADPH for 0-7.5 min. in an Eppendorf Thermomixer 5436 at 37° C., speed 6. The reactions are initiated by addition of NADPH following a 2-min. preincubation. Reactions are quenched with 60% methanol at 0, 2.5, 5, and 7.5 min. L-Glutamyl-L-(S-(3-oxo-3-(3-chlorophenyl)propyl)cysteinylglycine, a glutathione adduct of the by-product of prodrug activation, 3-chlorophenyl vinyl ketone, is quantified following extraction of the reaction with 1.5 volumes of methanol. The extracted samples are centrifuged at 14,000 rpm in an Eppendorf microfuge and the supernatant analyzed by HPLC for L-glutamyl-L-(S-(3-oxo-3-(3-chlorophenyl)propyl)cysteinylglycine content. Spiked L-glutamyl-L-(S-(3-oxo-3-(3-chlorophenyl)propyl)cysteinylglycine standards (1-30 μM) are prepared in 2 mg/mL microsomes under reaction conditions and then quenched and processed in an identical fashion to unknown samples. For HPLC analysis, the loading mobile phase buffer (Buffer A) consists of a 9:1 ratio (v/v) of 20 mM potassium phosphate, pH 6.2 and acetonitrile. Extract (100 μL) is injected onto a Beckman Ultrasphere ODS column (4.6×250 mM, part #235329). The column is eluted with a gradient to 60% acetonitrile. The elution of L-glutamyl-L-(S-(3-oxo-3-(3-chlorophenyl)propyl)cysteinylglycine (retention time 10.4 min.) is monitored at 245 nm.
- Conclusion:
- Formation of product, L-glutamyl-L-(S-(3-oxo-3-(3-chlorophenyl)propyl) cysteinylglycine indicates the prodrugs are activated in vitro in human liver microsomes.
- Prodrug analogues were tested for activation to NMP in reactions catalyzed by the microsomal fraction of human liver.
- Methods:
- Prodrugs were tested for activation by human liver microsomes purchased from In Vitro Technologies (IVT1032) Reactions were conducted in 0.1 M KH2PO4, pH 7.4, in the presence of 2 mM NADPH and liver microsomes (1 mg/mL). Reaction mixtures were incubated for 5 min. in an Eppendorf Thermomixer 5436 (37° C., speed 6). Reactions were terminated by the addition of 1.5 volumes of methanol. The resulting extracts were clarified by centrifugation at 14,000 rpm in an Eppendorf microfuge (20 min.). The supernatants (200 μL) were evaporated under vacuum and heated to dryness. The dried residue was reconstituted with 200 μL of water and the mixture was centrifuged for 10 min at 14,000 rpm.
- A mixture of 35 μL aliquot of supernatant and 35 μL of mobile phase A (20 mM N—N-dimethylhexylamine and 10 mM propionic acid in 20% methanol) was analyzed by LC-MS/MS (Applied Biosystems, API 4000) equipped with an Agilent 1100 binary pump and a LEAP injector. NMP was detected by using MS/MS mode (M−/78.8) and quantified based on comparison to a standard of lamivudine monophosphate.
- Results:
-
Activation (250 μM) Compound (nmol/mg/min) 16.2 0.301 16.3 0.162 16.4 0.049 16.5 0.463 16.7 0.213 17.2 2.040 16.8 0.436 16.9 0.316 16.10 0.241 16.11 0.100 16.12 0.394 16.13 0.002 16.14 0.282 16.15 0.335 16.16 0.075 16.17 0.021 16.18 0.044 16.19 0.171 16.20 0.137 16.21 0.043 16.22 0.077 16.23 0.013 16.24 0.031 16.25 0.242 16.26 0.223 16.27 0.455 16.28 0.293 17.3 1.677 17.4 1.324 17.5 0.952 17.6 2.086 16.30 0.037 16.31 0.138 16.32 0.074 17.7 1.024 17.8 0.322 17.9 0.314 17.10 0.626 17.11 1.439 17.12 0.750 17.13 0.499 17.14 1.164 17.15 0.733 17.16 0.497 17.18 0.085 17.20 1.381 17.21 0.626 17.22 0.484 17.23 0.089 17.24 0.455 - Nucleoside analogues and their prodrugs were evaluated for their ability to generate NTPs in freshly isolated rat hepatocytes. It is generally accepted that the NTP form of a nucleoside is the active antiviral agent.
- Methods:
- Hepatocytes were prepared from fed Sprague-Dawley rats (250-300 g) according to the procedure of Berry and Friend (Berry, M. N. Friend, D. S., J. Cell Biol. 43:506-520 (1969)) as modified by Groen (Groen, A. K. et al., Eur. J. Biochem 122:87-93 (1982)). Hepatocytes (20 mg/mL wet weight, >85% trypan blue viability) were incubated at 37° C. in 2 mL of Krebs-bicarbonate buffer containing 20 mM glucose, and 1 mg/mL BSA for 2 h in the presence of 1-250 μM nucleoside or prodrug (from 25 mM stock solutions in DMSO). Following the incubation, 1600 μL aliquot of the cell suspension was centrifuged and 300 μL of acetonitrile was added to the pellet, vortexed and sonicated until the pellet broke down. Then 200 μL of water was added to make a 60% acetonitrile solution. After 10 min centrifugation at 14,000 rpm, the resulting supernatant was transferred to a new vial and evaporated to near dryness in a Savant SpeedVac Plus at room temperature. The dried residue was reconstituted with 200 μL of water and the mixture was centrifuged for 10 min at 14,000 rpm. A mixture of 35 μL aliquot of supernatant and 35 μL of mobile phase A (20 mM N—N-dimethylhexylamine and 10 mM propionic acid in 20% methanol) was analyzed by LC-MS/MS (Applied Biosystems, API 4000) equipped with an Agilent 1100 binary pump and a LEAP injector. NTP was detected by using MS/MS mode (M−/78.8) and quantified based on comparison to a standard of lamivudine triphosphate.
- Results:
- Following the incubation of 25 μM or 250 μM nucleosides and prodrugs with primary rat hepatocytes, NTP formation observed over the course of 2 h was measured as nmol/g.
NTP formation from NTP formation from 25 μM compound 250 μM compound Compound (nmol/g) (nmol/g) 2′-C- 193 798 methyladenosine 2′-C- 1.3 4.7 methylguanosine 19 13.8 56.7 18 51.8 16.1 85 160 19 130.9 16.2 130.3 16.3 102.6 16.4 55.0 16.7 347.7 17.2 4.2 16.8 160.6 16.9 115.1 16.10 17.6 16.11 63.2 16.12 18.3 16.13 3.4 16.14 18.6 16.15 34.5 16.16 6.3 16.17 7.2 16.18 13.8 16.19 70.1 16.20 19.4 16.21 10.2 16.22 10.9 16.23 2.7 16.24 4.4 16.25 22.5 16.26 58.5 16.27 63.9 16.28 19.8 17.3 2.2 16.29 14.1 17.4 3.1 17.5 2.0 17.6 3.5 16.30 36.7 16.31 16.5 16.32 49.5 17.7 1.3 17.8 1.6 17.9 2.0 17.10 2.1 17.11 3.4 17.12 1.9 17.13 3.8 17.14 4.0 17.15 1.8 17.16 1.5 17.17 0.2 17.18 4.1 17.19 0.1 17.20 2.1 17.21 1.2 17.22 1.8 17.23 0.3 17.24 3.9
Conclusion: - Compounds of this invention showed an ability to generate NTP in freshly isolated rat hepatocytes.
- Inhibition of HCV replication in human liver tissue was evaluated using the following assay.
- Methods:
- Procurement:
- Liver from a brain-dead HCV antibody-positive human patient was perfused with ice-cold Viaspan (Dupont Pharmaceutical) preservation solution and received on ice in Viaspan.
- Precision-cut liver slices of ˜200-250 μm thickness and 8 cm diameter were prepared and cultured in Waymouth's cell culture medium (Gibco, Inc.) that was supplemented with 10% fetal bovine serum and 10 mL/L Fungi-Bact at 37° C., and gassed with carbogen (95% O2, 5% CO2) at 0.75 liters/min. Tissue slices were maintained in culture for 72 h. Cell culture medium containing test compound in solution was changed on a daily basis.
- At appropriate times of liver slice incubation, liver slices and medium were collected for analysis of HCV RNA (tissue and medium) and nucleotide levels (NTP). All collected media and tissue slices were maintained in liquid N2 until analysis.
- Medium and tissue samples were analyzed for HCV RNA levels according to published procedures (Bonacini et. al., 1999) which utilize an automated, multicycle, polymerase chain reaction (PCR)-based technique. This assay has a lower limit of detection for HCV RNA of 100 viral copies/ml.
- Analysis of Tissue NTPs:
- Frozen liver slices were disrupted by using a combination of ultrasound probe sonication, Branson Sonifier 450 (Branson Ultrasonics, Danbury, Conn.) and homogenization using a Dounce conical pestle in 200 μls of 10% (v/v) perchloric acid (PCA). After a 5 min centrifugation at 2,500×g, the supernatants were neutralized using 3 M KOH/3 M KHCO3 and mixed thoroughly. The neutralized samples were centrifuged at 2,500 g for 5 min and NTP levels were determined by ion exchange phase HPLC (Hewlett Packard 1050) using a Whatman Partisil 5 SAX (5 μm, 4.6×250 mm) column. Samples (50 μL) were injected onto the column in 70% 10 mM ammonium phosphate buffer and 30% 1 M ammonium phosphate buffer, both at pH 3.5 and containing 6% ethanol. Nucleoside triphosphates were eluted from the column using a linear gradient to 80% 1 M ammonium phosphate pH 3.5/6% ethanol buffer, at a flow rate of 1.25 mL/min and detected by UV absorbance (254 nm).
- Results:
- HCV RNA levels present in the liver slice culture media decreased from the levels present in control, untreated slices following incubation with 2′-C-methylguanosine and compound 19.
Log10 decrease Log10 decrease in viral RNA in viral RNA Concentration of from control at 48-72 h from control at 48-72 h Compound following treatment with 2′- following treatment with (μM) C-methylguanosine compound 19 0.25 0.51 1.27 1 — 1.61 2.5 1.74 1.70 25 1.48 1.72
Conclusion: - Treatment of HCV-infected human liver slices with 2′-C-methylguanosine or compound 19 for 72 h decreased the amount of HCV RNA released into the culture medium from 48-72 h. Treatment with the prodrug, compound 19 was more effective than treatment with the nucleoside, 2′-C-methylguanosine, at lowering viral RNA production in the culture medium.
- The liver specificity of the compound 19 prodrug was compared relative to the parent nucleoside, 2′-C-methylguanosine, and for compound 21.1 prodrug relative to its parent nucleoside, 2′-C-methyladenosine, by measuring the generation of NTP in the liver compared to nucleoside in the plasma.
- Methods:
- Compound 19 or 2′-C-methylguanosine were administered intraperitoneally to C57BL/6 mice at a dose of 30 mg/kg based on nucleoside equivalents (30 mg/kg 2′-C-methylguanosine and 53.27 mg/kg compound 19). Compound 21.1 or 2′-C-methyladenosine were administered intravenously to C57BL/6 mice at dose of about 5.5 mg/kg nucleoside equivalents (5.5 mg/kg 2′-C-methyladenosine and 10 mg/kg compound 21.1). Plasma concentrations of 2′-C-methylguanosine, compound 19, 2′-C-methyladenosine, and compound 21.1 were determined by HPLC-UV and the liver concentrations of the 5′-triphosphate of 2′-C-methylguanosine and 2′-C-methyladenosine were measured by LC-MS using the standard ion-pairing chromatography method for triphosphate as described in Example E. Conventional SAX HPLC-UV could not differentiate between endogenous GTP and 2′-C-methylguanosine triphosphate. Since an authentic standard of 2′-C-methylguanosine triphosphate was not available, the liver concentrations of the nucleotide were approximated as described in Example E.
- Results:
- Liver targeting of compound 19 as the triphosphate of 2′-C-methylguanosine and of compound 21.1 as the triphosphate of 2′-C-methyladenosine were clearly demonstrated with the prodrugs. The relative liver NTP AUC values, plasma nucleoside AUC values, the liver targeting ratio (liver/plasma), and the fold-improvement with the prodrugs are summarized in the table below. Compound 19 showed a 30-fold prodrug improvement of liver targeting over free nucleoside. Compound 21.1 showed a greater than 32-fold prodrug improvement of liver targeting over free nucleoside, which was below the limit of quantitation in the plasma following dosing of compound 21.1.
Liver Plasma Targeting Liver Nucleoside Index Prodrug Nucleoside NTP AUC AUC (Liver/ Improvement [Prodrug] (nmol * h/g) (μM * h) Plasma) (Fold) 2′-C- 64 73.7 0.87 — methylguanosine 19 485 18.5 26.2 30 2′-C- 119 26.8 4.4 — methyladenosine 21.1 502 <3.6 >141.4 >32 - The liver specificity of prodrugs are compared relative to their parent nucleoside analog inhibitors in liver and other organs that could be targets of toxicity.
- Methods:
- Nucleoside analogues and their prodrugs are administered at 30 mg/kg (in terms of nucleoside equivalents) to fasted rats by oral gavage. Plasma concentrations of nucleoside and prodrug are determined by HPLC-UV, as described in Example J, and the liver, skeletal muscle, cardiac, kidney, small intestine, and other organ concentrations of the 5′-triphosphate of the nucleoside are measured by LC-MS using the standard ion-pairing chromatography method for triphosphate as described in Example E.
- Results:
- The results demonstrate the liver targeting of the nucleoside analog prodrugs and provide evidence for improved safety of the prodrugs over that of the nucleosides alone. This can occur solely by the liver targeting provided by the prodrug or by additional liver metabolism of nucleoside derived following dephosphorylation of the nucleoside monophosphate. In the latter case, the nucleoside can escape from the liver into the periphery leading to exposure of other tissues to the nucleoside and potential extrahepatic toxicity. The release of nucleoside from the liver can be reduced by metabolism of the nucleoside monophosphate or the nucleoside in the liver cell, e.g. the breakdown of adenosine-based nucleoside monophosphates to inosine via adenylate deaminase and nucleotidase, or the breakdown of adenosine-based nucleoside to inosine and hypoxanthine by adenosine deaminase and purine nucleoside phosphorylase, respectively.
- The oral bioavailability (OBAV) of the nucleoside analogues and their prodrugs were evaluated in the normal male rat.
- Methods:
- The compounds were solubilized in a suitable vehicle for intravenous and oral administration. The OBAV was assessed by calculating the ratio of the AUC values of the liver organ concentration-time profile of NTP following oral and i.v. or i.p. administration of 30 mg/kg (in terms of nucleoside equivalents) of the compound to groups of four rats. Liver organ samples were taken at 20 min and 1, 3, 5, 8, 12, and 24 h following dosing. Liver organ concentrations of NTP were determined as determined by LC-MS/MS (Example E) or HPLC (Example F) analysis.
- Results:
-
Compound % F 16.32 31.7 - The susceptibility of the purine nucleoside analogues to metabolism is assessed in rat liver S9 fraction or isolated rat hepatocytes.
- Methods: Purine nucleoside analogues (100 μM) (e.g., 2′-C-methyladenosine) are incubated in rat liver S9 fraction or with isolated rat hepatocytes at 37° C. The reactions are terminated at time points up to 2 h and then deproteinized by extraction with 60% acetonitrile. Following centrifugation, the supernatants are evaporated to dryness and the resulting residues are reconstituted with aqueous mobile phase. These samples are analyzed for potential metabolites by a single HPLC system equipped with a diode array detector. Nucleosides (e.g., 2′-C-methylinosine) and bases (e.g., hypoxanthine) are separated and quantified on a Beckman Ultrasphere C-18 reverse phase column (4.5×250 mm) using a gradient of Buffer A (100 mM potassium phosphate pH 6) and Buffer B (25% v/v methanol) at a flow rate of 1.5 mL/min. The column is developed over 40 min using a nonlinear gradient of 0% Buffer B to 100% Buffer B (% pump Buffer B=100×(time [min]/40)3) and monitored by UV absorbance at 260 nm. Metabolites are identified by coelution with authentic standards and/or UV spectrum matching.
- Results: The susceptibility of the purine nucleoside analogues to metabolism is dependent upon the type and location of the structural modification of the congener. The inclusion of certain pharmacophores (such as the 2′-C-methyl group of 2′-C-methyladenosine] leads to increased resistance to metabolism by purine salvage pathway enzymes [such as adenosine deaminase and purine nucleoside phosphorylase).1
1Eldrup A B, Allerson C R, Bennett C F, et al. (2004) J. Med. Chem. 47(9):2283-2295, “Structure-activity relationship of purine ribonucleotides for inhibition of hepatitis C virus RNA-dependent RNA polymerase.”
Claims (46)
1. A compound of Formula I:
wherein:
B is selected from the group consisting of
V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
W and W′ are independently selected from the group consisting of —R2, optionally substituted monocyclic aryl, and optionally substituted monocyclic heteroaryl;
Z is selected from the group consisting of halogen, —CN, —COR5, —CONR4 2, —CO2R5, —SO2R5, —SO2NR4 2, —OR4, —SR4, —R4, —NR4 2, —OCOR5, —OCO2R5, —SCOR5, —SCO2R5, —NHCOR4, —NHCO2R5, —(CH2)p—OR6, and —(CH2)p—SR6; or
together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
together W and W′ are connected via an additional 2-5 atoms to form a cyclic group, optionally containing 0-2 heteroatoms;
R2 is selected from the group consisting of R3 and hydrogen;
R3 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
R4 is selected from the group consisting of R3 and hydrogen;
R5 is selected from the group consisting of alkyl, aryl, heterocycloalkyl, and aralkyl;
R6 is selected from the group consisting of hydrogen, and lower acyl;
R12 is selected from the group consisting of hydrogen, and lower acyl; and
p is an integer 2 or 3;
or a pharmaceutically acceptable salt thereof.
4. (canceled)
5. A compound of Formula II:
wherein:
B is selected from the group consisting of:
V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
W and W′ are independently selected from the group consisting of —H, methyl, and V, or W and W′ are each methyl, with the proviso that when W is V, then W′ is H;
Z is selected from the group consisting of —H, —OMe, —OEt, phenyl, C1-C3 alkyl, —NR4 2, —SR4, —(CH2)p—OR6, —(CH2)p—SR6 and —OCOR5; or
together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
together W and W′ are connected via an additional 2-5 atoms to form a cyclic group;
R4 is C1-C4 alkyl;
R5 is selected from the group consisting of C1-C4 alkyl, monocyclic aryl, and monocyclic aralkyl; and
R6 is C1-C4 acyl;
R7 and R8 are independently selected from the group consisting of hydrogen, C1-C4 acyl, C1-C4 alkoxycarbonyl, and a naturally-occurring L-amino acid connected via its carbonyl group to form an ester; or
together R7 and R8 form a cyclic carbonate;
R9 is selected from the group consisting of amino, azido, —N═CHN(R4)2, —NHC(O)R4, and —NHC(O)OR4; and
R10 is selected from the group consisting of OR6, halogen, and H;
or a pharmaceutically acceptable salt thereof.
6. The compound of claim 1 , wherein:
V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of halogen, C1-C6 alkyl, —CF3, —OR3, —OR12, —COR3, —CO2R3, —NR3 2, —NR12 2, —CO2NR2 2, —SR3, —SO2R3, —SO2NR2 2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of halogen, C1-C6 alkyl, —CF3, —OR3, —OR12, —COR3, —CO2R3, —NR3 2, —NR12 2, —CO2NR2 2, —SR3, —SO2R3, —SO2NR2 2 and —CN, and wherein said monocyclic heteroaryl and substituted monocyclic heteroaryl has 1-2 heteroatoms that are independently selected from the group consisting of N, O, and S with the provisos that
a) when there are two heteroatoms and one is O, then the other can not be O or S, and
b) when there are two heteroatoms and one is S, then the other can not be O or S; or
together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; and
R3 is C1-C6 alkyl.
7. The compound of claim 6 wherein:
V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN and wherein said monocyclic heteroaryl and substituted monocyclic heteroaryl has 1-2 heteroatoms that are independently selected from the group consisting of N, O, and S with the provisos that
a) when there are two heteroatoms and one is O, then the other can not be O or S, and
b) when there are two heteroatoms and one is S, then the other can not be O or S; or
together V and Z are connected via an additional 4 atoms to form a 6-membered ring that is fused to a phenyl or substituted phenyl at the beta and gamma position to the O attached to the phosphorus.
8. The compound of claim 7 wherein V is selected from the group consisting of phenyl; substituted phenyl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; pyridyl; substituted pyridyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; furanyl; substituted furanyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; thienyl; and substituted thienyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3.
9. The compound of claim 8 wherein V is selected from the group consisting of phenyl, 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-bromo-4-fluorophenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.
10. The compound of claim 9 wherein V is selected from the group consisting of 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-pyridyl, and 4-pyridyl.
11. The compound of claim 1 wherein Z is selected from the group consisting of —H, —OMe, —OEt, phenyl, C1-C3 alkyl, —NR4 2, —SR4, —(CH2)p—OR6, —(CH2)p—SR6 and —OCOR5;
R4 is C1-C4 alkyl;
R5 is selected from the group consisting of C1-C4 alkyl, monocyclic aryl, and monocyclic aralkyl; and
R6 is C1-C4 acyl.
12. The compound of claim 11 wherein Z is selected from the group consisting of —H, —OMe, —OEt, and phenyl.
13. The compound of claim 1 wherein:
W and W′ are independently selected from the group consisting of —H, C1-C6 alkyl, and phenyl; or
together W and W′ are connected via an additional 2-5 atoms to form a cyclic group.
14. The compound of claim 1 wherein W and W′ are independently selected from the group consisting of —H, methyl, and V, or W and W′ are each methyl, with the proviso that when W is V, then W′ is H.
15. The compound of claim 1 wherein:
V is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl;
W and W′ are independently selected from the group consisting of —H, methyl, and V, or W and W′ are each methyl, with the proviso that when W is V, then W′ is H;
Z is selected from the group consisting of —H, —OMe, —OEt, phenyl, C1-C3 alkyl, —NR4 2, —SR4, —(CH2)p—OR6, —(CH2)p—SR6 and —OCOR5; or
together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; or
together Z and W are connected via an additional 3-5 atoms to form a cyclic group, optionally containing one heteroatom; or
together W and W′ are connected via an additional 2-5 atoms to form a cyclic group; and
R4 is C1-C4 alkyl;
R5 is selected from the group consisting of C1-C4 alkyl, monocyclic aryl, and monocyclic aralkyl; and
R6 is C1-C4 acyl.
16. The compound of claim 15 wherein:
V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of halogen, C1-C6 alkyl, —CF3, —OR3, —OR12, —COR3, —CO2R3, —NR3 2, —NR12 2, —CO2NR2 2, —SR3, —SO2R3, —SO2NR2 2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of halogen, C1-C6 alkyl, —CF3, —OR3, —OR12, —COR3, —CO2R3, —NR3 2, —NR12 2, —CO2NR2 2, —SR3, —SO2R3, —SO2NR2 2 and —CN, and wherein said monocyclic heteroaryl and substituted monocyclic heteroaryl has 1-2 heteroatoms that are independently selected from the group consisting of N, O, and S with the provisos that
a) when there are two heteroatoms and one is O, then the other can not be O or S, and
b) when there are two heteroatoms and one is S, then the other can not be O or S; or
together V and Z are connected via an additional 3-5 atoms to form a cyclic group, optionally containing 1 heteroatom, that is fused to an aryl group at the beta and gamma position to the O attached to the phosphorus; and
R3 is C1-C6 alkyl.
17. The compound of claim 16 wherein:
V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN, and wherein said monocyclic heteroaryl and substituted monocyclic heteroaryl has 1-2 heteroatoms that are independently selected from the group consisting of N, O, and S with the provisos that
a) when there are two heteroatoms and one is O, then the other can not be O or S; and
b) when there are two heteroatoms and one is S, then the other can not be O or S; or
together V and Z are connected via an additional 4 atoms to form a 6-membered ring that is fused to a phenyl or substituted phenyl at the beta and gamma position to the O attached to the phosphorus.
18. The compound of claim 17 wherein V is selected from the group consisting of phenyl; substituted phenyl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; pyridyl; substituted pyridyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; furanyl; substituted furanyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; thienyl; and substituted thienyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3.
19. The compound of claim 1 wherein:
V is selected from the group consisting of phenyl, 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-bromo-4-fluorophenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl; and
Z is selected from the group consisting of —H, OMe, OEt, and phenyl; and
W and W′ are independently selected from the group consisting of —H and phenyl, or W and W′ are each methyl.
20. The compound of claim 1 wherein Z, W, and W′ are each —H.
21. The compound of claim 1 wherein V and W are the same and each is selected from the group consisting of optionally substituted monocyclic aryl and optionally substituted monocyclic heteroaryl.
26-28. (canceled)
31. The compound of claim 30 wherein V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN.
32. The compound of claim 31 wherein V is selected from the group consisting of phenyl, 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-bromo-4-fluorophenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.
33. The compound of claim 32 wherein said compound has R-stereochemistry at the V-attached carbon and has S-stereochemistry at the phosphorus center.
34. The compound of claim 32 wherein said compound has S-stereochemistry at the V-attached carbon and has R-stereochemistry at the phosphorus center.
35. The compound of claim 29 wherein V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of halogen, C1-C6 alkyl, —CF3, —OR3, —OR12, —COR3, —CO2R3, —NR3 2, —NR12 2, —CO2NR2 2, —SR3, —SO2R3, —SO2NR2 2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of halogen, C1-C6 alkyl, —CF3, —OR3, —OR12, —COR3, CO2R3, —NR3 2, —NR12 2, —CO2NR2 2, —SR3, —SO2R3, —SO2NR2 2 and —CN, and wherein said monocyclic heteroaryl and substituted monocyclic heteroaryl has 1-2 heteroatoms that are independently selected from the group consisting of N, O, and S with the provisos that
a) when there are two heteroatoms and one is O, then the other can not be O or S, and
b) when there are two heteroatoms and one is S, then the other can not be O or S; and
R3 is C1-C6 alkyl.
36. The compound of claim 35 wherein V is selected from the group consisting of phenyl, substituted phenyl with 1-3 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN, monocyclic heteroaryl, and substituted monocyclic heteroaryl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, —CF3, —COCH3, —OMe, —NMe2, —OEt, —CO2t-butyl, —CO2NH2, —SMe, —SO2Me, —SO2NH2 and —CN and wherein said monocyclic heteroaryl and substituted monocyclic heteroaryl has 1-2 heteroatoms that are independently selected from the group consisting of N, O, and S with the provisos that
a) when there are two heteroatoms and one is O, then the other can not be O or S, and
b) when there are two heteroatoms and one is S, then the other can not be O or S; or
together V and Z are connected via an additional 4 atoms to form a 6-membered ring that is fused to a phenyl or substituted phenyl at the beta and gamma position to the O attached to the phosphorus.
37. The compound of claim 36 wherein V is selected from the group consisting of phenyl; substituted phenyl with 1-2 substituents independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; pyridyl; substituted pyridyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; furanyl; substituted furanyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3; thienyl; and substituted thienyl with 1 substituent independently selected from the group consisting of —Cl, —Br, —F, C1-C3 alkyl, and —CF3.
38. The compound of claim 37 wherein V is selected from the group consisting of phenyl, 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-bromo-4-fluorophenyl, 2-pyridyl, 3-pyridyl, and 4-pyridyl.
39. The compound of claim 38 wherein V is selected from the group consisting of 3-chlorophenyl, 3-bromophenyl, 2-bromophenyl, 3,5-dichlorophenyl, 3-pyridyl, and 4-pyridyl.
40. The compound of claim 29 wherein said compound has R-stereochemistry at the V-attached carbon and has S-stereochemistry at the phosphorus center.
41. The compound of claim 29 wherein said compound has S-stereochemistry at the V-attached carbon and has R-stereochemistry at the phosphorus center.
42. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.
43. A pharmaceutical composition comprising a pharmaceutically effective amount of a compound of claim 5 and a pharmaceutically acceptable carrier.
44-101. (canceled)
102. A compound of Formula VII:
wherein B is selected from the group consisting of:
X is selected from the group consisting of NH2, NHCH3, N(CH3)2, OCH3, SCH3, OH, and SH;
Y and Y′ are independently O or NH;
R14 is independently selected from the group consisting of H and NH2;
the heterocyclic base B may be further substituted at any position on the heterocyclic base B with a substituent of a molecular weight of less than 150 and selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, aryl, alkaryl, cycloalkyl, acyl, and alkoxy, and wherein said substituents may be coupled to the 6-position of the heterocyclic base via a carbon, sulfur, oxygen, or selenium;
V, W, and W′ are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, alkaryl, each of which is optionally substituted; and
Z is hydrogen, CHWOH, CHWOCOW′, SW, or CH2aryl.
103-104. (canceled)
106. The compound of claim 105 wherein X is NH2.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/593,381 US20070179114A1 (en) | 2004-02-13 | 2006-11-06 | Novel 2'-C methyl nucleoside derivatives |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54474304P | 2004-02-13 | 2004-02-13 | |
US10/903,215 US20050182252A1 (en) | 2004-02-13 | 2004-07-29 | Novel 2'-C-methyl nucleoside derivatives |
US11/593,381 US20070179114A1 (en) | 2004-02-13 | 2006-11-06 | Novel 2'-C methyl nucleoside derivatives |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/903,215 Division US20050182252A1 (en) | 2004-02-13 | 2004-07-29 | Novel 2'-C-methyl nucleoside derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070179114A1 true US20070179114A1 (en) | 2007-08-02 |
Family
ID=34841195
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/903,215 Abandoned US20050182252A1 (en) | 2004-02-13 | 2004-07-29 | Novel 2'-C-methyl nucleoside derivatives |
US11/572,785 Abandoned US20090131370A1 (en) | 2004-02-13 | 2005-07-29 | Novel Nucleoside Derivatives |
US11/589,363 Active 2024-11-06 US7666855B2 (en) | 2004-02-13 | 2006-10-30 | 2′-C-methyl nucleoside derivatives |
US11/593,381 Abandoned US20070179114A1 (en) | 2004-02-13 | 2006-11-06 | Novel 2'-C methyl nucleoside derivatives |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/903,215 Abandoned US20050182252A1 (en) | 2004-02-13 | 2004-07-29 | Novel 2'-C-methyl nucleoside derivatives |
US11/572,785 Abandoned US20090131370A1 (en) | 2004-02-13 | 2005-07-29 | Novel Nucleoside Derivatives |
US11/589,363 Active 2024-11-06 US7666855B2 (en) | 2004-02-13 | 2006-10-30 | 2′-C-methyl nucleoside derivatives |
Country Status (5)
Country | Link |
---|---|
US (4) | US20050182252A1 (en) |
EP (1) | EP1720556A4 (en) |
JP (1) | JP2007522237A (en) |
BR (1) | BRPI0507675A (en) |
WO (1) | WO2005084192A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100022468A1 (en) * | 2006-12-20 | 2010-01-28 | Malte Meppen | Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection |
US20100035835A1 (en) * | 2007-01-05 | 2010-02-11 | Frank Narjes | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
US20140356325A1 (en) * | 2012-01-12 | 2014-12-04 | Ligand Pharmaceuticals Incorporated | Novel 2'-c-methyl nucleoside derivative compounds |
WO2015123352A1 (en) * | 2014-02-13 | 2015-08-20 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
US9994600B2 (en) | 2014-07-02 | 2018-06-12 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7200970B2 (en) * | 2004-02-09 | 2007-04-10 | Trim-Tex, Inc. | Combination comprising vertical wall, horizontal ceiling, and crown molding member having planar portion, intermediate portion, and mounting flange |
US20050182252A1 (en) * | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
WO2006065335A2 (en) * | 2004-10-21 | 2006-06-22 | Merck & Co., Inc. | Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of rna-dependent rna viral infection |
WO2006104945A2 (en) | 2005-03-29 | 2006-10-05 | Biocryst Pharmaceuticals, Inc. | Hepatitis c therapies |
US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
MX2009007333A (en) | 2007-01-12 | 2009-08-31 | Biocryst Pharm Inc | Antiviral nucleoside analogs. |
TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
WO2010036407A2 (en) | 2008-05-15 | 2010-04-01 | Biocryst Pharmaceuticals, Inc. | Antiviral nucleoside analogs |
TW201004632A (en) * | 2008-07-02 | 2010-02-01 | Idenix Pharmaceuticals Inc | Compounds and pharmaceutical compositions for the treatment of viral infections |
WO2011123586A1 (en) | 2010-04-01 | 2011-10-06 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
CA2843324A1 (en) | 2011-03-31 | 2012-11-15 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
US9326991B2 (en) | 2012-09-14 | 2016-05-03 | Ligand Pharmaceuticals, Inc. | Nucleotide prodrug compounds and use |
US9676809B2 (en) | 2013-11-22 | 2017-06-13 | Ligand Pharmaceuticals Incorporated | Derivatives of uridine 5′-cyclophosphate useful to treat hepatitis C viral infections |
AU2016229966B2 (en) | 2015-03-06 | 2018-09-27 | Atea Pharmaceuticals, Inc. | Beta-D-2'-deoxy-2'alpha-fluoro-2'-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment |
EP4088725A1 (en) | 2016-09-07 | 2022-11-16 | ATEA Pharmaceuticals, Inc. | 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family |
CN106518942B (en) * | 2016-10-24 | 2019-04-19 | 银杏树药业(苏州)有限公司 | For treating the Novel ring phosphide of HCV infection |
CN112351799A (en) | 2018-04-10 | 2021-02-09 | 阿堤亚制药公司 | Treatment of HCV infected patients with cirrhosis |
US10874687B1 (en) | 2020-02-27 | 2020-12-29 | Atea Pharmaceuticals, Inc. | Highly active compounds against COVID-19 |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3018302A (en) * | 1956-12-20 | 1962-01-23 | Asta Werke Ag Chem Fab | Novel cyclic phosphoric acid ester amides, and the production thereof |
US5506347A (en) * | 1993-02-03 | 1996-04-09 | Gensia, Inc. | Lyxofuranosyl analogues of adenosine |
US5514798A (en) * | 1993-06-02 | 1996-05-07 | Gilead Sciences, Inc. | Method and cyclic carbonates for nucleotide analogues |
US5763596A (en) * | 1989-09-15 | 1998-06-09 | Metabasis Therapeutics, Inc. | C-4' modified adenosine kinase inhibitors |
US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
US20030225277A1 (en) * | 2002-05-13 | 2003-12-04 | Kopcho Joseph J. | Process for preparation of cyclic prodrugs of PMEA and PMPA |
US20030229225A1 (en) * | 2002-05-13 | 2003-12-11 | Reddy K. Raja | Novel phosphonic acid based prodrugs of PMEA and its analogues |
US20030236216A1 (en) * | 2001-06-12 | 2003-12-25 | Devos Rene Robert | 4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication |
US20040006007A1 (en) * | 2001-09-28 | 2004-01-08 | Gilles Gosselin | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides |
US20040063658A1 (en) * | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
US20040092476A1 (en) * | 2002-10-31 | 2004-05-13 | Serge Boyer | Novel cytarabine monophosphate prodrugs |
US6752981B1 (en) * | 1999-09-08 | 2004-06-22 | Metabasis Therapeutics, Inc. | Prodrugs for liver specific drug delivery |
US20040147464A1 (en) * | 2002-09-30 | 2004-07-29 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
US6777395B2 (en) * | 2001-01-22 | 2004-08-17 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase of hepatitis C virus |
US6864244B2 (en) * | 2002-12-09 | 2005-03-08 | Roche Palo Alto Llc | Anhydrous crystalline 1-[4(S)-azido-2(S),3(R)-dihydroxy-4-(hydroxymethyl)-1(R)-cyclopentyl]cytosine hemisulfate as useful as an antiviral agent |
US20050090463A1 (en) * | 2003-10-27 | 2005-04-28 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US20050107312A1 (en) * | 2003-10-27 | 2005-05-19 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US6914054B2 (en) * | 2000-05-23 | 2005-07-05 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus |
US20050182252A1 (en) * | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
US7163929B2 (en) * | 2000-05-26 | 2007-01-16 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL187439B1 (en) | 1996-01-23 | 2004-07-30 | Icn Pharmaceuticals | Modulation of cytokin th 1/th 2 expression by means of ribavirin and ribavirin analoques in t lymphocytes |
US6128582A (en) | 1996-04-30 | 2000-10-03 | Vertex Pharmaceuticals Incorporated | Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
BR9714349A (en) | 1996-10-16 | 2000-11-14 | Icn Pharmaceuticals | Purine L-nucleosides, their analogues and their uses |
AU738170B2 (en) | 1996-10-16 | 2001-09-13 | Icn Pharmaceuticals, Inc. | Monocyclic L-nucleosides, analogs and uses thereof |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
KR20000069028A (en) | 1996-11-19 | 2000-11-25 | 와트 씨 데이빗, 해리 에이 루스제 | Multivalent salts of pyridostigmine and related compounds |
HU0000769A (en) | 1996-12-27 | 2000-07-28 | G-rich oligo aptamers and methods of modulating an immune response | |
KR20000070167A (en) | 1997-01-14 | 2000-11-25 | 와트 씨 데이빗, 해리 에이 루스제 | Cytokine related treatments of disease |
SE9700792L (en) | 1997-03-06 | 1998-02-23 | Carlo Castro | Back lubricant for lubricating skin cream on a human body |
GB9707659D0 (en) | 1997-04-16 | 1997-06-04 | Peptide Therapeutics Ltd | Hepatitis C NS3 Protease inhibitors |
AU735601B2 (en) | 1997-06-30 | 2001-07-12 | Icn Pharmaceuticals, Inc. | Method of producing tiazofurin and other C-nucleosides |
IL121413A (en) | 1997-07-28 | 2000-10-31 | Green Cloud Ltd | Method for reducing the accumulation of precipitates and impurities on ultrasonic transducers |
ES2234144T3 (en) | 1997-08-11 | 2005-06-16 | Boehringer Ingelheim (Canada) Ltd. | ANALOGS OF INHIBITING PEPTIDES OF HEPATITIS C. |
PT1003775E (en) | 1997-08-11 | 2005-07-29 | Boehringer Ingelheim Ca Ltd | HEPATITIS C INHIBITING PEPTIDES |
WO1999036074A1 (en) | 1998-01-15 | 1999-07-22 | Icn Pharmaceuticals, Inc. | Use of 8-cl-camp in prevention of restenosis of arterial walls |
CN100349913C (en) | 1998-02-25 | 2007-11-21 | 埃莫里大学 | 2' -fluoro nucleosides |
EP1060182B1 (en) * | 1998-03-06 | 2012-12-19 | Metabasis Therapeutics, Inc. | Novel prodrugs for phosphorus-containing compounds |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
JP4690545B2 (en) | 1998-03-31 | 2011-06-01 | バーテックス ファーマシューティカルズ インコーポレイテッド | Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease |
BR9911596A (en) | 1998-05-26 | 2001-10-02 | Icn Pharmaceuticals | Nucleosides having bicyclic sugar portion |
GB9812523D0 (en) | 1998-06-10 | 1998-08-05 | Angeletti P Ist Richerche Bio | Peptide inhibitors of hepatitis c virus ns3 protease |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US6045638A (en) | 1998-10-09 | 2000-04-04 | Atlantic Research Corporation | Monopropellant and propellant compositions including mono and polyaminoguanidine dinitrate |
AU764479B2 (en) | 1998-10-29 | 2003-08-21 | Bristol-Myers Squibb Company | Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme |
EP1146883A4 (en) | 1999-01-29 | 2004-11-24 | Icn Pharmaceuticals | Modulation of immune response by ribavirin |
UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
ES2200902T3 (en) | 1999-06-25 | 2004-03-16 | Vertex Pharmaceuticals Incorporated | IMPDH INHIBITING CARBAMATE PROPHARMS. |
SK1772002A3 (en) | 1999-08-27 | 2002-10-08 | Icn Pharmaceuticals | Nucleoside analog, method of change of cytokine secreting from a cell and method for inhibiting the growth of hyperproliferative cells |
US6518253B1 (en) | 1999-11-19 | 2003-02-11 | Robert Tam | Treatment of viral infections using the L-isomer of ribavirin |
WO2001045642A2 (en) | 1999-12-13 | 2001-06-28 | Icn Pharmaceuticals, Inc. | Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease |
SI20976A (en) | 1999-12-23 | 2003-02-28 | Icn Pharmaceuticals, Inc. | Compositions and methods for l-nucleosides, l-nucleotides, and their analogs |
SK13752001A3 (en) | 1999-12-27 | 2002-07-02 | Japan Tobacco, Inc. | Fused-ring compounds and use thereof as drugs |
US6495677B1 (en) | 2000-02-15 | 2002-12-17 | Kanda S. Ramasamy | Nucleoside compounds |
US6455508B1 (en) | 2000-02-15 | 2002-09-24 | Kanda S. Ramasamy | Methods for treating diseases with tirazole and pyrrolo-pyrimidine ribofuranosyl nucleosides |
WO2001077091A2 (en) | 2000-04-05 | 2001-10-18 | Tularik Inc. | Ns5b hcv polymerase inhibitors |
CA2404639A1 (en) | 2000-04-13 | 2001-10-25 | Pharmasset, Ltd. | 3'-or 2'-hydroxymethyl substituted nucleoside derivatives for treatment of hepatitis virus infections |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
UA72612C2 (en) | 2000-07-06 | 2005-03-15 | Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells | |
GB0017676D0 (en) | 2000-07-19 | 2000-09-06 | Angeletti P Ist Richerche Bio | Inhibitors of viral polymerase |
KR20030040415A (en) | 2000-08-22 | 2003-05-22 | 리버팜 인크. | Improved specificity in treatment of diseases |
RU2003102607A (en) | 2000-08-22 | 2004-07-27 | Рибафарм Инк. (US) | METHODS FOR DELIVERY OF MEDICINE TO HEPATOCYTES AND TREATMENT OF FLAVIVIRUS INFECTIONS |
US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
WO2002020497A1 (en) | 2000-09-01 | 2002-03-14 | Shionogi & Co., Ltd. | Compounds having anti-hepatitis c virus effect |
BR0114837A (en) | 2000-10-18 | 2006-05-09 | Pharmasset Ltd | modified nucleosides for treatment of viral infections and abnormal cell proliferation |
ATE430166T1 (en) | 2000-12-12 | 2009-05-15 | Schering Corp | DIARYL REST COMPRISING PEPTIDES AS INHIBITORS OF THE NS-3 SERINE PROTEASES OF HEPATITIS C VIRUS |
AU2002230763A1 (en) | 2000-12-13 | 2008-01-03 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
JP2005502580A (en) | 2000-12-15 | 2005-01-27 | フアーマセツト・リミテツド | Antiviral drugs for the treatment of flavivirus infection |
WO2002051425A1 (en) | 2000-12-26 | 2002-07-04 | Mitsubishi Pharma Corporation | Remedies for hepatitis c |
JP2005509591A (en) | 2001-06-15 | 2005-04-14 | リバファーム・インコーポレイテッド | Nucleoside vaccine adjuvant |
GB2378524A (en) | 2001-08-08 | 2003-02-12 | Bookham Technology Plc | Intergrated optic device |
GB0119369D0 (en) | 2001-08-08 | 2001-10-03 | Bookham Technology Plc | Optic system |
WO2003026675A1 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside |
US20030072451A1 (en) | 2001-10-16 | 2003-04-17 | Pimentel Roberto J. | Method and apparatus for securely transferring wireless data |
JPWO2003034709A1 (en) | 2001-10-17 | 2005-02-10 | ナルテック株式会社 | Decompression method and data processing apparatus |
WO2003037908A1 (en) | 2001-10-31 | 2003-05-08 | Ribapharm Inc. | Antiviral combination therapy and compositions |
AU2002357876A1 (en) | 2001-12-17 | 2003-06-30 | Ribapharm Inc. | Nucleoside analog libraries and compounds |
AU2002359732A1 (en) | 2001-12-17 | 2003-06-30 | Ribapharm Inc. | Substituted purine nucleoside libraries and compounds by solid-phase combinatorial strategies |
WO2003051899A1 (en) | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Deazapurine nucleoside libraries and compounds |
WO2003052053A2 (en) | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Nucleoside libraries and compounds by mcc combinatorial strategies on solid support |
WO2003051896A1 (en) | 2001-12-17 | 2003-06-26 | Ribapharm Inc. | Cytidine libraries and compounds synthesized by solid-phase combinatorial strategies |
AU2002353164A1 (en) | 2001-12-17 | 2003-06-30 | Ribapharm Inc. | Unusual nucleoside libraries, compounds, and preferred uses as antiviral and anticancer agents |
US7261704B2 (en) | 2001-12-28 | 2007-08-28 | Terumo Kabushiki Kaisha | Syringe |
WO2003062256A1 (en) | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents |
EP1572705A2 (en) * | 2002-01-17 | 2005-09-14 | Ribapharm, Inc. | Sugar modified nucleosides as viral replication inhibitors |
AU2003209045B2 (en) * | 2002-02-13 | 2006-12-14 | Isis Pharmaceuticals, Inc. | Methods of inhibiting orthopoxvirus replication with nucleoside compounds |
WO2004003138A2 (en) * | 2002-06-27 | 2004-01-08 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
MXPA04012779A (en) | 2002-06-28 | 2005-08-19 | Idenix Cayman Ltd | 2' and 3'-nucleoside prodrugs for treating flaviviridae infections. |
AU2003248748A1 (en) | 2002-06-28 | 2004-01-19 | Idenix (Cayman) Limited | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
AP2005003212A0 (en) | 2002-06-28 | 2005-03-31 | Centre Nat Rech Scient | Modified 2' and 3' nucleoside prodrugs for treating flaviviridae infections. |
JP2005533108A (en) * | 2002-07-16 | 2005-11-04 | メルク エンド カムパニー インコーポレーテッド | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
WO2004013300A2 (en) | 2002-08-01 | 2004-02-12 | Pharmasset Inc. | Compounds with the bicyclo[4.2.1]nonane system for the treatment of flaviviridae infections |
AU2003298658A1 (en) | 2002-11-15 | 2004-06-15 | Idenix (Cayman) Limited | 2'-branched nucleosides and flaviviridae mutation |
TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
RS54573B1 (en) | 2003-10-14 | 2016-06-30 | F. Hoffmann-La Roche Ltd | Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication |
-
2004
- 2004-07-29 US US10/903,215 patent/US20050182252A1/en not_active Abandoned
-
2005
- 2005-02-14 BR BRPI0507675-7A patent/BRPI0507675A/en not_active IP Right Cessation
- 2005-02-14 JP JP2006553282A patent/JP2007522237A/en active Pending
- 2005-02-14 EP EP05750052A patent/EP1720556A4/en not_active Withdrawn
- 2005-02-14 WO PCT/US2005/004447 patent/WO2005084192A2/en active Application Filing
- 2005-07-29 US US11/572,785 patent/US20090131370A1/en not_active Abandoned
-
2006
- 2006-10-30 US US11/589,363 patent/US7666855B2/en active Active
- 2006-11-06 US US11/593,381 patent/US20070179114A1/en not_active Abandoned
Patent Citations (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3018302A (en) * | 1956-12-20 | 1962-01-23 | Asta Werke Ag Chem Fab | Novel cyclic phosphoric acid ester amides, and the production thereof |
US5763596A (en) * | 1989-09-15 | 1998-06-09 | Metabasis Therapeutics, Inc. | C-4' modified adenosine kinase inhibitors |
US5506347A (en) * | 1993-02-03 | 1996-04-09 | Gensia, Inc. | Lyxofuranosyl analogues of adenosine |
US5514798A (en) * | 1993-06-02 | 1996-05-07 | Gilead Sciences, Inc. | Method and cyclic carbonates for nucleotide analogues |
US5686629A (en) * | 1993-06-02 | 1997-11-11 | Gilead Sciences, Inc. | Method and cyclic carbonates for nucleotide analogues |
US6312662B1 (en) * | 1998-03-06 | 2001-11-06 | Metabasis Therapeutics, Inc. | Prodrugs phosphorus-containing compounds |
US6752981B1 (en) * | 1999-09-08 | 2004-06-22 | Metabasis Therapeutics, Inc. | Prodrugs for liver specific drug delivery |
US6914054B2 (en) * | 2000-05-23 | 2005-07-05 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus |
US7163929B2 (en) * | 2000-05-26 | 2007-01-16 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating flaviviruses and pestiviruses |
US6777395B2 (en) * | 2001-01-22 | 2004-08-17 | Merck & Co., Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase of hepatitis C virus |
US20030236216A1 (en) * | 2001-06-12 | 2003-12-25 | Devos Rene Robert | 4'-substituted nucleoside derivatives as inhibitors of HCV RNA replication |
US6784166B2 (en) * | 2001-06-12 | 2004-08-31 | Syntex (U.S.A.) Llc | 4′-substituted nucleoside derivatives as inhibitors of HCV RNA replication. |
US20040006007A1 (en) * | 2001-09-28 | 2004-01-08 | Gilles Gosselin | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides |
US7138376B2 (en) * | 2001-09-28 | 2006-11-21 | Idenix Pharmaceuticals, Inc. | Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides |
US20040063658A1 (en) * | 2002-05-06 | 2004-04-01 | Roberts Christopher Don | Nucleoside derivatives for treating hepatitis C virus infection |
US20030229225A1 (en) * | 2002-05-13 | 2003-12-11 | Reddy K. Raja | Novel phosphonic acid based prodrugs of PMEA and its analogues |
US20030225277A1 (en) * | 2002-05-13 | 2003-12-04 | Kopcho Joseph J. | Process for preparation of cyclic prodrugs of PMEA and PMPA |
US7214668B2 (en) * | 2002-05-13 | 2007-05-08 | Metabasis Therapeutics, Inc. | Phosphonic acid based prodrugs of PMEA and its analogues |
US7193081B2 (en) * | 2002-05-13 | 2007-03-20 | Metabasis Therapeutics, Inc. | Process for preparation of cyclic prodrugs of PMEA and PMPA |
US7425547B2 (en) * | 2002-09-30 | 2008-09-16 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
US20040147464A1 (en) * | 2002-09-30 | 2004-07-29 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis C virus infection |
US7151092B2 (en) * | 2002-10-31 | 2006-12-19 | Metabasis Therapeutics, Inc. | Cytarabine monophosphate prodrugs |
US20040092476A1 (en) * | 2002-10-31 | 2004-05-13 | Serge Boyer | Novel cytarabine monophosphate prodrugs |
US7148349B2 (en) * | 2002-10-31 | 2006-12-12 | Metabasis Therapeutics, Inc. | Cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs |
US20040192651A1 (en) * | 2002-10-31 | 2004-09-30 | Reddy K Raja | Novel cyclic phosphate diesters of 1,3-propane-1-aryl diols and their use in preparing prodrugs |
US6864244B2 (en) * | 2002-12-09 | 2005-03-08 | Roche Palo Alto Llc | Anhydrous crystalline 1-[4(S)-azido-2(S),3(R)-dihydroxy-4-(hydroxymethyl)-1(R)-cyclopentyl]cytosine hemisulfate as useful as an antiviral agent |
US7144868B2 (en) * | 2003-10-27 | 2006-12-05 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US7157434B2 (en) * | 2003-10-27 | 2007-01-02 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US20050107312A1 (en) * | 2003-10-27 | 2005-05-19 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US20050090463A1 (en) * | 2003-10-27 | 2005-04-28 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
US20050182252A1 (en) * | 2004-02-13 | 2005-08-18 | Reddy K. R. | Novel 2'-C-methyl nucleoside derivatives |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100022468A1 (en) * | 2006-12-20 | 2010-01-28 | Malte Meppen | Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection |
US8148349B2 (en) | 2006-12-20 | 2012-04-03 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection |
US20100035835A1 (en) * | 2007-01-05 | 2010-02-11 | Frank Narjes | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection |
US8071568B2 (en) | 2007-01-05 | 2011-12-06 | Merck Sharp & Dohme Corp. | Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection |
US20140356325A1 (en) * | 2012-01-12 | 2014-12-04 | Ligand Pharmaceuticals Incorporated | Novel 2'-c-methyl nucleoside derivative compounds |
WO2015123352A1 (en) * | 2014-02-13 | 2015-08-20 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and their uses |
CN106061984A (en) * | 2014-02-13 | 2016-10-26 | 配体药物公司 | Prodrug compounds and their uses |
US10449210B2 (en) | 2014-02-13 | 2019-10-22 | Ligand Pharmaceuticals Inc. | Prodrug compounds and their uses |
US11278559B2 (en) | 2014-02-13 | 2022-03-22 | Ligand Pharmaceuticals Incorporated | Prodrug compounds and their uses |
US9994600B2 (en) | 2014-07-02 | 2018-06-12 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses therof |
US10150788B2 (en) | 2014-07-02 | 2018-12-11 | Ligand Pharmaceuticals, Inc. | Prodrug compounds and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
EP1720556A2 (en) | 2006-11-15 |
WO2005084192A3 (en) | 2006-05-11 |
US20070042989A1 (en) | 2007-02-22 |
BRPI0507675A (en) | 2007-07-17 |
WO2005084192A2 (en) | 2005-09-15 |
JP2007522237A (en) | 2007-08-09 |
EP1720556A4 (en) | 2012-05-09 |
US7666855B2 (en) | 2010-02-23 |
US20050182252A1 (en) | 2005-08-18 |
US20090131370A1 (en) | 2009-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7666855B2 (en) | 2′-C-methyl nucleoside derivatives | |
US20090118223A1 (en) | Novel 2'-c-methyl and 4'c-methyl nucleoside derivatives | |
JP2008508319A (en) | Novel nucleoside derivatives | |
KR101759369B1 (en) | Stereoselective synthesis of phosphorus containing actives | |
JP5046219B2 (en) | Novel cyclic phosphodiester of 1,3-propane-1-aryldiol and its use in prodrugs | |
EP2223927B1 (en) | Salts of a phosphonic acid based prodrug of PMEA | |
EP3186244B1 (en) | Dioxolane analogues of uridine for the treatment of cancer | |
JP6776273B2 (en) | Β-D-2'-deoxy-2'-α-fluoro-2'-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment | |
US20140356325A1 (en) | Novel 2'-c-methyl nucleoside derivative compounds | |
JP2009526850A (en) | Nucleoside aryl phosphoramidates for treating RNA-dependent RNA viral infections | |
JP2012501999A (en) | Nucleoside derivatives as inhibitors of viral polymerases. | |
JP2022068329A (en) | 2'-substituted-n6-substituted purine nucleotides for rna virus treatment | |
CN101252839A (en) | Novel 2'-C-methyl and 4'-C-methyl nucleoside derivatives | |
EP1905778A2 (en) | Novel 2'-C-methyl nucleoside derivatives | |
CN1997377A (en) | Novel 2'-C methyl nucleoside derivatives | |
Reddy et al. | Stereoselective Synthesis of PSI-352938: A β-D-20-Deoxy-20-r-fluoro-20-β-C-methyl-30, 50-cyclic Phosphate Nucleotide Prodrug for the Treatment of HCV |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MERCK & CO., INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OLSEN, DAVID B.;MACCOSS, MALCOLM;REEL/FRAME:020129/0099;SIGNING DATES FROM 20070330 TO 20070402 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |